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Abstract 
This is a brief overview of principles, views and methods, of the Kanban System for the pharmacy of a general hospital. The 
main goal is the reduction of stores managed by the pharmacy, as well as improvement of the mode of operation. Solutions to 
problems, such as inadequate storage space, the delay in serving patients or clinics and the expiration of various 
pharmaceutical formulations, stored for so long time, are provided. The philosophy behind the Kanban procurement System and 
specifically its applicability to a pharmacy underperforming in terms of efficiency, in Greece, are described. Based on the 
analysis of stock requirement, item stock prices and demand, it is concluded that a significant percentage of the stocked drugs 
can be procured using the Kanban System. Significant cost savings and operational advantages following the Kanban System 
will take place. The challenging endeavor is the analysis, design and application of a system that supports the proposed 
procurement method. Hospital pharmacies in Greece and in other countries that face an economic crisis may largely benefit 
after using the Kanban System. 
HJNM 2015; 18(Suppl1); 4-10                                                                Published on line: 12 December 2015 
 
 
 
Introduction 
 
ospital is a complex intricate organization comprises providers, therapies, physical location, technology and 
innovation that require continuous improvement towards providing what patient wants quickly, efficiently, and with 
little waste. The complex procedures of a Greek General Hospital is the objective of this paper focusing on the 
application of lean management systematically in the hospital pharmacy, as Lean Hospital is considered a common 
practice in health care organizations in USA and other countries [11]. Observing the activities that take place on the value 
stream of processes, identifying the root causes of the non-value adding activities such as tremendous allocation of 
resources (people, technology, shared information), overworked staff, inefficient processes and bad service, the health 
care organization lead to a lean topos health provider [9]. 
The hospital that was studied is accountable for over budgeted costs for medications during 2013 since Greece 
is facing economic crisis and it is characterized as red hospital of Greek health care system that need help from Hellenic 
republic, government and Ministry of Health. The director of hospital pharmacy has to report and explain to the Greek 
authorities for the over budgeting spent for medications in year 2013. The goal of this study was the application of Kanban 
System estimating Kanban quantities and reallocating the budget cost for medications and consumable health material 
efficiently enough to overcome the deficit. This system helps in achieving a stable working environment in the battlefield 
of competitiveness at the lower overall cost while the Lean Hospital has the best chances to win the battle of surviving, 
making strategic inventory management a reality. 
The scope of this paper is the drastic reduce of excessive overall inventory in the pharmacy storage with aim to 
do the work faster, with fewer mistakes in a clear, standardized working environment that contributes significantly to 
constant improvement of healthcare delivery. The Kanban System has the capacity to deal with wasteful steps and non-
adding activities in sector of care processes in a number of dimensions namely medical assessment errors, wrong drugs, 
adverse drug reaction and mainly reduce of excess supply that leads to medications and health material stored but not 
used and must be disposed of, reducing additional costs. The waste of excess inventory that has no intended use in 
immediate future results in overstocked medications on the floor of pharmacy using multiple locations for storage and 
multiple suppliers as it is shown in Figure 1. 
The Kanban is a systematic way based on ABC-XYZ analysis of stock requirement, item stock prices and 
demand, proving that a significant percentage of the stocked drugs can be procured as it aligns the patient’s demand with 
supply chain and attacking inventory issues. It seems the only strategy, by all accounts, for this Greek general hospital 
that is fraught with problems and lack of sustainability under the current circumstances of economic crisis.  
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Figure 1. Overstocked medications in the pharmacy, multiple locations and multiple suppliers 
 
Review of lean management 
 
The paper highlights the adapting of Toyota Production System (TPS) idea to healthcare delivery services. The principles 
of this system contribute with concept, technology solutions and processes that lead to produce cars with low cost, best 
quality, short lead time and elimination of waste [10]. The lean management is synonymous to TPS since it uses less of 
everything (effort, parts, space, time, equipment) compared to other manufacturing production systems adding value from 
the customer’s point of view. Value is considered any specifications and procedures of production system that the end 
consumer is ready to pay for. Waste or muda is the non-adding value activities or services that do not add value to 
customer’s experience, is anything other than using minimum resources for achieving higher efficiency and accelerating 
momentum [7, 8] and do not contribute directly to the society. 
The lean management was the development of scientific management that was first best evidenced from 
Frederick Winslow Taylor [4] and Henry Ford [5]. During 1940, Taiichi Ohnov [6] identifies that defects of production 
system in automobile manufacturing was the result of stock on hand that lead to dead costly capital, increased storage 
space and defective products. Toyota Motor Corporation achieved long-term success, after decades, undergoing 
continuous iterative learning circles that serve as foundation of development. The overall goal was adding value to the 
end-product and elimination of all forms of waste that was based on Plan-Do-Check-Act circles of W. Edwards Deming 
(Figure 2) with its roots in lean thinking to pursue perfection [1]. 
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                 Figure 2. The Deming cycle 
 
Kanban Systems 
 
Kanban System 
Primary technique of JIT (just-in-time) systems is the Kanban that is used for delivering services just as and when they 
are needed that requires the complete integration of collaboration between suppliers and hospital pharmacy as a supply 
chain in order to respect the actual consumption rates of medications and build procedures to supply the pharmacy 
according the hospital needs and no more. The word “Kanban”, in Japanese, stands for card and signal. The card is the 
green signal for store to forward medications from supplier to pharmacy on requirement bases. The card writes on part 
description, part number, quantity, lead time and location of supply and consumption (Figure 3). The card is placed on a 
designer box/container which moves from the pharmacy to the store that contains the kanban quantity of every 
medication or consumable health material. 
 
 
 
Figure 3. The Kanban Card 
 
Kanban quantity 
Primary role in Kanban Systems has the estimation of kanban quantity of every product that will be contained in every box 
respectively. The Kanban function is (1): 
 
 
 
 
 
 
Dc: Daily capacity of product based on demand 
Q: The quantity spent 
R: The replenishment time in hours according to strategy 
S: Shifts per day in pharmacy 
H: The replenishment time in hours 
P: Parts contained in the package from the supplier 
 
 
The replenishment via Supermarket 
The storage in Kanban System is called supermarket. In this phase of replenishment cycle, the existing inventory cover 
the needs for a certain period based on true patient’s needs, values and preferences rather than forecast of prediction. 
The demand in health care according to NHS institute for Innovation and Improvement is mostly predictable with a range 
[3]. The production line is informed through kanban signal that need to produce a specific medicine from suppliers and a 
central storage place. If, for example, the container of medicine A is spent in the workflow then the pharmacist will transfer 
the empty container in supermarket (storage) for replenishment. In this place, the pharmacist reaches the box with A 
medicine and transfers the card from the empty box to the full one. The card is placed on the empty box that was taken 
previously from supermarket. The replenishment using cards smoothes the value stream with work, health material and 
information as much as possible with minimal interruptions and align the supply of services with patient’s demand. The 
value stream means mapping and dividing the activities within the process as far as these activities provide value. The 
empty containers of supermarket are collected and transferred for replenishment by the pharmacist according to pull 
 Kanban quantity 
* *
= 1
* *
Dc Q R
H S P
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system that was aforementioned. The full containers are stored by the pharmacist in supermarket while the production 
lines follow the FIFO (First In-First Out). 
 
 
Forms of Kanban 
Usually, two types of Kanban applied in corporations. The application is not restricted since the organization can establish 
its own signal for replenishment. The most widespread is single card - double container and fetch - batch card. 
 
 
System of single card 
The card sets the beginning of workflow according to current conditions (for example card or optical signal alerts for 
stockout). Medicines are only provided upstream when the patient downstream requests for health care [2].  The order of 
doctor’s prescription sets the beginning of medicine delivery. One card is placed in every container box. The box contains 
the quantity of a specific medicine that covers a specific time frame according to strategic inventory management (Table 
I). When the box is empty, the card is moved to the place of replenishment while the box is moved to the supermarket. 
When the supplier full the box again, the card is placed on it until it will empty again and the cycle is repeated when the 
pharmacist receive the full box with the card on it. 
 
System of two cards 
The system consists of two containers in the place of pharmacy. If the work station is available then the pharmacist 
begins the activity described in the production card described in a special box. The card informs the pharmacist about the 
medicines that are needed. The pharmacist searches the medicines in the supermarket. Every code has a traffic card. If 
the medicines are available, removes the traffic cards and place them on a special box. If not, then he goes back to the 
box of production cards and takes the next one. When he finds the production card and the available medicines he 
completes the production activity and the production card is placed on the place that transfers the medicines to the 
clinics. The two cards is the one fetch card that alerts for bringing medicines from supermarket while the batch or 
production card alerts for collection of medicines for box that are needed in the clinic. 
 
 
The general hospital-case study 
 
Structure of General Hospital 
The General Hospital that was studied has 3 sectors: Medical, Nursing and Administration. Taking account the staff data, 
it is calculated that planned permanent posts are 542, the covered posts are 343 while the empty are 199 (Diagram 1). So 
the hospital in order to complete its staff should employ 542 overall employers in the 3 sectors while now has 343. In 
medical sector, the planned permanent posts are 93 while the covered are 73. In nursing, there exist 241 planned 
permanent posts while the covered are 165. In administration, the planned permanent posts are 34 while the covered are 
27. 
 
37%
63%
Empty
Covered
 
Diagram 1. Empty and covered posts according staff data. 
 
Design of Kanban System for a hospital pharmacy  
 
ABC-XYZ analysis 
According to ABC-XYZ analysis, inventory levels will be accurately calculated based on Kanban codes of medicine and 
health material while afterwards Kanban quantity is calculated based on the analysis of stock requirement, item stock 
prices and demand. The medicines’ codes used by the pharmacy were segmented and prioritized in different segments 
were 835 and consumable health materials were 401. The analysis was applied separately for medicines and 
consumable health material. The medicines were divided in 3 categories. The codes classified “A” are expensive 
(represent 5%-10% of the codes that correspond to 60%-80% of the overall inventory), B includes less expensive 
(represent 10%-30% of codes that correspond to 10%-30% of the overall inventory) and on C are the cheapest ones 
(represent 60%-85% of codes that correspond to remaining 5%-15% of the overall inventory). X classifies medicines with 
high/stable demand, Y mediocre while on Z the low demand. The codes included in X with big X are suitable for Kanban 
while as X getting smaller, the kanban ability decreases (Figure 4). The medicines in AZ are not suitable for Kanban.  
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There exist codes that pharmacist have to decide whether to include them or no in Kanban System. 
 
 
 
 
Figure 4. ABY-XYZ analysis. 
 
Strategic inventory manegement-systems approach  
Many organizations apply the ABC-XYZ analysis in order to prioritize the levels of inventory. After the level of inventory is 
defined, they can optimally allocate their resources. Therefore, the companies set goals according to the segments such 
as policy in entitlement time in 2 days for “A” codes. One of the biggest advantages of this method is that is easily 
understood and establish a control mechanism for the control of inventory levels over the segments and the strategy is 
shown in Table 1 that propose the management for every code and the replenishment time according to volatility. By 
comparing the replenishment time with inventory on hand, pharmacist can quickly identify which codes are over 
entitlement that leads to excessive inventory and which are under entitlement that result in stock out. 
 
 
 
Table 1. ABC classification 
 
 
 
 
Calculating the kanban quantity 
Comparing the results of ABC-XYZ analysis, the author reaches the conclusion that 46,9% of medication codes that are 
managed by the pharmacy can be included in the Kanban System while the 53,1% are unsuitable (Table 2). 
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Table 2. The results of ABC-XYZ analysis based on the data for consumption of medications during 2013 
 
  
 
Conclusion 
 
The application of lean principles can be achieved easily without additional resources and offers multiple benefits in a 
health organization such as a General Hospital. Summarizing the advantages of the pharmacy that applies Kanban 
System as the one was studied are the following: 
1) Reducing overall costs of hospital 
2) Allocating resources and strategic management of inventory 
3) Reducing waste 
4) Quick and accurate service of patients 
5) Reducing needs of storage space for stock 
6) Reducing medications and health material stored but not used and must be disposed of 
7) Reducing waste of time due to ill-formed or deficient prescription or waiting for servicing in the pharmacy due to 
inventory in the floor 
 
The author concludes that majority of pharmaceutical mistakes are caused by faulty conditions that lead people 
to make errors and not to prevent them. The commitment to Kanban System culture, techniques and lean health care 
philosophy should start from the very top management of the organization. In other words, it should be a part of the 
organizational strategy to improve patient care that involves internal and external customers of the system such as 
patients, society, public and private insurers, ancillary support staff that provide clinical and non-clinical healthcare 
services and third parties in healthcare system and of course of authorities. 
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Abstract 
Background: Rest tremor (RT), a tremor that occurs in a body part that is completely supported against gravity, is together with 
rigidity and bradykinesia among the core features of Parkinson’s disease (PD). In addition to classical RT, many PD patients 
also have action tremor (AT) occurring during sustained postures or voluntary movement. Earlier studies showed a good 
correlation between striatal dopamine transporter (DAT) binding, measured with [
123
I] FP-CIT SPET and bradykinesia. By 
contrast, neither rigidity nor rest tremor seems to be closely related to the degree of dopaminergic denervation as measured by 
DAT imaging. Little is known about the relationship, if any, between the severity of action tremor and striatal DAT binding. 
Subjects and Methods: A cross-sectional study was conducted in 94 patients (57 men and 37 women) with Parkinson’s disease 
staging 1-2 on the Hoehn-Yahr scale. Data on the severity of action tremor and other motor signs were collected using the 
Unified Parkinson’s Disease Rating Scale part III. DAT imaging was performed after injection of 111-185MBq of 
123
I-FP-CIT. 
Images were visualized on Workstation Xeleris 3.0 (GE Healthcare) and reconstructed with dedicated software by a nuclear 
physician blinded about the clinical information of patients. Spearman correlation coefficient was performed to evaluate the 
relationship between putamen DAT binding and severity of bradykinesia, severity of rigidity, RT and AT respectively. 
Multivariable logistic regression analysis was used to assess the association between age, sex, disease duration, and levodopa 
equivalent daily dose and investigated variables after adjusting for possible confounders. Results: In this group of patients with 
early PD, DAT binding in the putamen significantly correlated with the severity of bradykinesia (Spearman r=-0.35, P<0.001) but 
not with the severity of rigidity (Spearman r=0.02, P=0.8), RT (Spearman r=0.05, P=0.6), or AT (Spearman r=-0.03, P=0.7). The 
findings were confirmed by multivariable regression analysis adjusted by age, sex, disease duration, and levodopa equivalent 
daily dose. Conclusion: Our study confirms the good correlation between putamen DAT binding and bradykinesia and the lack of 
correlation between putamen DAT binding and rigidity/RT.  In addition, we failed to found any significant correlation between 
putamen DAT binding and severity of action tremor, which suggests a contribution of non-dopaminergic mechanisms to its 
pathophysiology. 
HJNM 2015; 18(Suppl1); 11-16                                                                Published on line: 12 December 2015 
 
 
Introduction 
      
arkinson’s disease (PD) is a progressive neurodegenerative disease that is mainly characterized by bradykinesia, 
rigidity, rest tremor (RT), and postural instability. In addition to classical RT, many PD patients also have action 
tremor (AT) occurring during sustained postures or voluntary movement. These motor abnormalities reflect at least 
in part neurodegeneration in the substantia nigra pars compacta with secondary dopamine decrease in the striatum. In 
the early stages of PD, dopamine decrease is more evident in the putamen nucleus.  
Dopamine transporter (DAT) single photon emission computed tomography (SPET) imaging has been 
extensively used as objective in vivo marker of nigrostriatal neuron loss in PD showing a widespread reduced striatal 
uptake which is greater in putamen than in caudate. Severity of bradykinesia is correlated with DAT uptake both in the 
caudate and putamen whereas rigidity and RT have sometimes been found to be related to putamen uptake alone [1-7]. It 
is worth noting that most studies assessing the relationship between DAT uptake and tremor in PD did not distinguish 
between RT and AT [3, 4, 7, 8, 9]. In this study, therefore, we assessed in a large sample of PD patients the relationship 
between striatal DAT uptake and severity of RT and AT, separately. 
 
 
Materials and Methods 
 
Patients and Clinical Assessment  
P 
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During a 4-years period (2009-2012) DAT SPET with [
123
I]FP-CIT (
123
I-ioflupane, DaTSCAN; GE Healthcare) was 
performed in 114 patients suffering from Parkinsonian Syndromes referred to our Movement Disorder Centre. Among 
these patients, 94 had a final diagnosis of (Idiopathic) Parkinson disease according with the United Kingdom Parkinson's 
Disease Society Brain Bank criteria [10]. Patients with imaging findings indicative of basal ganglia lesions, or with other 
causes of parkinsonism were excluded. Information on relevant demographic and clinical data as well as on DAT uptake 
was collected. At the time of the DAT SPET study, a clinical examination during off conditions (at least 12 hours after 
stopping medication) was conducted by one experienced  neurologist using the Unified Parkinson’s Disease Rating Scale 
(UPDRS part III) to assess motor clinical signs (RT and AT included) [11], and the Hoehn and Yahr (HY) scale to assess 
the disease stage [12]. For the purpose of the study, only patients with early PD staging (1-2 on the Hoehn-Yahr scale) 
entered into the study; UPDRS motor subscores for rest tremor (items 20), action tremor (item 21), rigidity (item 22), and 
bradykinesia (items 23-26) were analyzed. The study was approved by our ethics committee and informed consent was 
provided by all subjects. 
 
DAT SPET procedure and data processing 
DAT SPET imaging was performed in all subjects 3 hours after injection of 111-185MBq of [
123
I]FP-CIT using a dual-head 
gamma camera (Infinia, GE Healthcare, Waukesha, Wisconsin, USA) equipped with parallel-hole, low-energy high-
resolution collimators. SPET studies were acquired using the following parameters: 128x128 matrix, rotation of 360°, 60 
views, 6° view angle, 45s for projection. Slice thickness was 3.68mm. Acquisition time was 22min; total brain counts >1 
million were achieved in all examinations. Reconstruction was performed by filtered back-projection with a Butterworth 
filter (cut-off frequency: 0.3cycles/cm, 10
th
 order) to produce transaxial slices that were attenuation corrected. Attenuation 
correction was performed according to Chang method (attenuation coefficient: 0.12cm), after manually drawing an ellipse 
around the head contour [13].
 
System spatial resolution (full width at half-maximum) at a radius of rotation of 15.9cm was 
11mm as reported elsewhere [14, 15]. For analysis of DAT striatal uptake, slices were reoriented to be parallel to the 
canthomeatal line and two transverse slices representing the most intense striatal binding were summed. A standard 
region of interest (ROI) template, constructed according to a stereotactic atlas and including fixed regions for caudate 
nucleus, putamen, whole striatum, and occipital cortex, was placed bilaterally on the combined image, as described 
previously [16]. Estimates of specific striatal binding were made by subtracting occipital counts (nonspecific binding) from 
total striatal counts. The ratio of specific to non-specific striatal [
123
I]FP-CIT binding was then calculated dividing the 
specific striatal uptake by the occipital uptake. These binding ratios were also used to calculate comparable ones for 
caudate nucleus and putamen. An example of DAT SPET imaging is showed in Figure 1. 
 
 
 
 
Figure 1. Transaxial images of DAT SPET with [
123
I] FP-CIT: A. PD patient with action tremor and normal DAT 
uptake in basal ganglia; B. PD patient with bradykinesia and significant reduction of putamen DAT uptake. 
 
 
Statistical analysis 
Statistical analysis was performed using the Stata 11.0 package (Stata Corporation, College Station, TX). Data were 
expressed as mean±SD unless otherwise indicated. Spearman correlation coefficient was calculated to evaluate the 
relationship between caudate and putamen DAT binding (averaged on both hemispheres) and severity of motor signs. 
Multivariable logistic regression analysis was used to adjust correlation analysis for possible confounders like age, sex, 
disease duration, and levodopa equivalent daily dose and investigated variables after adjusting. Statistical significance 
was set at the 0.05 level. 
 
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 13 
Results 
 
Demographic and clinical information on PD patients and control subjects are reported in Table 1. There was a significant 
relationship between caudate and putamen DAT uptake and age at study time (caudate: rho=-0.4, P<0.001; putamen: 
rho=-0.2, P=0.04), whereas no relationship was observed between both caudate or putamen DAT uptake and PD 
duration (caudate: rho=0.07, P=0.5; putamen: rho=-0.14, P=0.17).  
 
 
Table 1. Demographic and clinical features of the study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAT uptake in the putamen inversely correlated with the HY staging (rho=-0.36, P<0.001), UPDRS part III total 
score (rho=-0.3, P=0.01) and UPDRS-III bradykinesia score (rho=-0.35, P<0.001) (Figure 2). Whereas no correlation was 
found with the severity of rigidity (rho=0.02, P=0.8), RT (rho=0.05, P=0.6), and AT (rho=-0.03, P=0.7) as illustrated in 
Figure 3, Figure 4 and Figure 5, respectively. Likewise no relationships were found between caudate DAT uptake and 
severity of rigidity, RT or AT. 
 
 
 
 
Figure 2. Comparison between putamen DAT binding and UPDRS-III bradykinesia score: statistically significant inverse  
correlation is found. 
 
 
n. of patients 94 
Sex, f/m 37/57 
Age, years (mean±SD) 62.3±10 
Age at disease onset, years (mean±SD) 60±10.4 
Disease duration, years (mean±SD) 2.3±1.8 
Levodopa equivalent daily dose, mg (mean±SD) 257±179 
n. of patients with tremor 71 
n. of patients with rest tremor 60 
n. of patients with action tremor 39 
n. of patients with both rest and action tremor 28 
UPDRS-III total score 20.6±9.1 
UPDRS-III bradykinesia score 8.8±4.8 
UPDRS-III total tremor score 2.1±2 
UPDRS-III rest tremor score 1.6±1.5 
UPDRS-III action tremor score 0.6±0.8 
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Figure 3. Comparison between putamen DAT binding and UPDRS-III rigidity score: no statistically significant  
correlation is found. 
 
 
 
 
 
Figure 4. Comparison between putamen DAT binding and UPDRS-III rest tremor score: no statistically significant  
correlation is found. 
 
 
Multivariable linear regression analysis adjusted by age, sex, disease duration, and levodopa equivalent daily 
dose confirmed the significant correlation between the putamen DAT uptake and the UPDRS-III bradykinesia score 
(adjusted RC, -0.02; P=0.01) as well as the lack of correlation with either RT or AT. 
 
Discussion 
 
Imaging of the dopaminergic system with DAT SPET is a widespread tool in clinical practice to confirm or exclude 
nigrostriatal neuron loss in patients with suspicious of PD; DAT SPET imaging distinguishes patients with PD from normal 
subjects even in early disease in fact significant DAT changes may precede the onset of clinical symptoms [17-19]. 
Earlier cross-sectional DAT imaging studies [1-7] as well as the present study, show good inverse correlation between 
putamen DAT binding and the main clinical indicators of disease severity and disability as UPDRS part III total score and 
HY stage. In line with previous reports, [1-7] our study confirmed the result of a close association between lower putamen 
with the [
123
I]FP-CIT DAT SPET uptake and a more severe bradykinesia on the UPDRS-III, a cardinal symptom in PD 
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Figure 5. Comparison between putamen DAT binding and UPDRS-III action tremor score: no statistically significant  
correlation is found. 
 
 
that has been shown to better correlate to the degree of nigral cell loss; similarly, the lack of correlation between putamen 
DAT uptake and the severity scores of rigidity, RT and AT we found in our patients with early PD replicated the findings of 
several prior studies where these motor symptoms did correlate neither caudate nor putamen uptake [3, 6, 20].  
A clinical classification of tremors syndromes in PD have been extensively accepted [21] and included either rest 
or action tremor, with several manifestation of AT being closely linked to rest tremor. However, the origins of both rest and 
action tremor in PD remain unclear. Over the two past decades, both pathological findings [22] and studies with PET [23-
26] and SPET [1, 3, 4, 6, 20] have raised the hypothesis that dopamine deficiency may not be completely responsible for 
development of tremor in PD. Indeed, different neuronal networks are thought to be involved in triggering and modulation 
of tremor including basal ganglia and thalamus-motor cortex-cerebellum circuits [27, 28], with possible different roles of 
the aforementioned anatomical structures for RT or AT.  
 
 
Conclusion 
 
The results of our study confirming the good correlation between putamen DAT binding and bradykinesia and the lack of 
correlation between putamen DAT binding and rigidity/RT/AT are in line with previous observation assuming involvement 
of dopamine in the pathogenesis of bradykinesia rather than rigidity/tremor.  The lack of correlation between putamen 
DAT uptake and both RT and AT would add to the evidence suggesting that the two forms of tremor may be manifestation 
of the same abnormality.  
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Abstract 
Objective: Spondylodiscitis is characterized by infection involving the intervertebral disc and adjacent vertebrae. It can occur 
anywhere in the vertebral column but more commonly involves lumbar spine. Our aim was to evaluate the usefulness of 
18
F-
FDG PET/CT to detect the early response to antibiotic therapy in patients affected by infectious spondylodiscitis and to compare 
the role of 
18
F-FDG PET/CT and MRI in post-treatment evaluation. Materials and Methods: 15 patients (12M, 3F), with mean age 
65±13 years old, with typical clinical symptoms of Infectious Spondylodiscitis (pain, fever and increase of inflammatory indexes) 
and confirmed by blood culture or vertebral biopsy underwent within three day-interval a 
18
F-FDG PET/CT and Magnetic 
Resonance (MR) at “baseline” and after antibiotic therapy. Semiquantitative parameters at 
18
F-FDG PET/CT “baseline” SUV 
max1, MTV1 and TLG1 and after therapy SUV max2, MTV2 and TLG2 of involved vertebrae were calculated. Follow-up period 
of at least three months was available for all patients. T-student test for paired groups was performed to compare baseline and 
after therapy 
18
F-FDG PET/CT semiquantitative parameters. Results: According to 
18
F-FDG PET/CT parameters all patients 
showed a response to antibiotic therapy. All patients were positive at “baseline” MRI of the spine, while at follow-up, 7/15 
patients showed MR signs of infection and were considered “positive” and 8/15 showed resolution of infectious condition and, 
therefore they were considered “negative”. A statistical significant difference between 
18
F-FDG PET/CT “baseline” and after 
antibiotic therapy was found for all semiquantitative parameters: SUV max (t=5.8, P=0.01); MTV (t=5.17, P=0.001); TLG (t=5,26, 
P=0,001). The comparison between the “baseline” and “after treatment” 
18
F-FDG semiquantitative parameters showed a 
significant reduction of all parameters. This reduction was relevant also in patients with positive post-treatment MRI. This can be 
probably related to the tissue remodeling in the very immediate phase post-treatment, resulted positive at MRI and negative at 
18
F-FDG PET/CT. Clinical follow-up of at least three months confirmed these results. Conclusions: 
18
F-FDG PET/CT is useful to 
detect the early response to antibiotic therapy in patients affected by infectious spondylodiscitis. 
18
F-FDG PET/CT 
semiquantitative parameters provide critical diagnostic information of the infectious process. 
18
F-FDG PET/CT should be 
considered as first-line exam in the early post-treatment evaluation of spondylodiscitis while MR should be preferred for delayed 
assessment. 
HJNM 2015; 18(Suppl1); 17-22                                                                Published on line: 12 December 2015 
 
 
Introduction 
      
he spondylodiscitis are rare but serious diseases, difficult to diagnose and manage. The spine infections may 
involve disc, bone and paravertebral tissues. The peak incidence is in patients under 20 years of age and between 
50 and 70 years of age [1]. The increased incidence of spondylodiscitis in the last years [2] may also be due to an 
improvement in diagnostic sensitivity [3]. 
An increase in the prevalence of vertebral osteomyelitis with Staphylococcus aureus septicemia is reported in 
literature [3, 4]. In other reports the increase of spondylodiscitis cases is attributed to intravenous drug use, diabetes 
mellitus, long term steroid use, to the rise in health-care-associated infections [5], chronic renal or liver diseases, increase 
of the immunosuppressed subjects, ageing population [2] and, especially, spinal surgery [6]. 
The most commonly found pathogen responsible for spondylodiscitis is Staphylococcus Aureus. The range 
described in different studies varies from 20% to 84% [1]. Coagulase-negative staphylococci, Streptococcus species, 
Pseudomonas aeruginosa, Escherichia coli, and fungi such as Candida albicans are also regularly found [7]. Tuberculous 
spondylodiscitis is rare, but is a serious clinical for the neurological complication and severe vertebral deformity [8]. 
Lumbar vertebrae are most frequently affected in spondylodiscitis, followed by the thoracic and the cervical area. 
In a significant number of cases a multifocal involvement may be observed. 
The diagnosis is usually late due to nonspecific nature of symptoms (back pain, fever, nausea, and weight loss). 
It is based on clinical, laboratory and radiological features (blood cultures, MRI scans and vertebral biopsies) [1]. 
MRI is considered the modality of choice for the radiological diagnosis of spondylodiscitis. It has a reported sensitivity of 
96%, specificity of 93% and accuracy of 94% [9]. 
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is showing promise as sensitive 
T 
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modality in detecting not only malignant tumors, but also inflammatory diseases [10, 11]. Evidence in the scientific 
literature shows a expanding role of 
18
F-FDG PET/CT  as clinical utility beyond the remit of cancer imaging, with 
applications in a diverse group of non-oncological conditions that include suspected infection and inflammation central 
nervous system disorders (e.g., dementia), and cardiovascular disease (e.g., cardiac sarcoidosis) [12, 13]. 
It can effectively distinguish infection from degenerative changes even when magnetic resonance imaging (MRI) 
is inconclusive [14]. 
The aim of this retrospective study was to evaluate the role of 
18
F-FDG semiquantitative parameters at diagnosis 
and after antibiotic therapy and to compare these semiquantitative parameters with MRI scan results in post-treatment 
assessment in early prediction of response to therapy in patients affected by infective haematogenous spondylodiscitis. 
 
 
Materials and Methods 
 
Patients 
Thirty two consecutive patients with suspected haematogenous infective spondylodiscitis were selected from our 
database.  
Patient inclusion criteria were: clinical symptoms suggestive of active infection of the spine (fever, back pain); 
increase of inflammatory indexes (ESR and/or CRP); infection diagnosed by microbiological documentation in cultures of 
image-guided spinal puncture fluid or blood; contrast-enhanced MRI and 
18
F-FDG PET/CT before the start of therapy and 
after antibiotic therapy (after 6 weeks); the interval between MRI and 
18
F-FDG PET/CT was within 3 days. 
Ten patients were excluded because they did not perform a microbiological culture, seven patients were 
excluded because they did not undergo the second MRI scan. 
So, 15 patients were included. Of these patients 12 were male and 3 female. Mean age of this study population 
was 65±13 years. 
We considered as gold standard the clinical-laboratory follow-up of at least 3 months after the end of treatment. 
 
18
F-FDG PET/CT 
Whole-body 
18
F-FDG PET/CT was carried out using standard procedures. Scans were performed using a hybrid PET/CT 
scanner (Discovery STE, General Electric Healthcare Milwaukee, WI, USA) with a full-ring PET scanner with bismuth 
germinate crystals and a low-dosehelical CT scanner (16 slice). Patients fasted for 6h before PET acquisition. Blood 
glucose levels were required to be less than 140mg/dl before intravenous injection of 3.7MBq/kg of 
18
F-FDG. 
After intravenous injection using a venous line patients remained in a quiet room for approximately 60min.  
During acquisitions, patients were positioned supine with their arms raised above the head. Whole-body PET data were 
acquired in 3D mode and for 3min per bed position. The total duration of the examination from the hip to the head was 
approximately 20min.  
The PET/CT exam was considered positive for infection when 
18
F-FDG uptake was higher than bone marrow 
uptake in adjacent vertebras and/or soft tissue uptake. 
 
Contrast-enhanced MRI 
MRI examinations of the spine were acquired with a 1.5T scanner (ACHIEVA, Philips Healthcare) with a dedicated array 
spine coil. The scanning of cervical, thoracic, and/or lumbar spine was performed. The MRI scan protocol consisted of T1-
weighted, TSE, T2 and STIR. The T1-weighted sagittal, axial and coronal scans were performed after contrast agent 
administration in all patientsin free breathing except for the chest and abdomen, obtained with breath-hold. 
The total duration of the examination was 20-25 minutes without considering post-processing. The reconstructed 
images in the coronal plane for each station were merged to obtain coronal whole-body images. The same acquisition 
and processing procedure was performed at baseline MRI (MRI1) and after therapy MRI (MRI2). 
MRI findings were considered indicative of spondylodiscitis decreased signal intensity from disc and adjacent 
vertebral bodies on T1-weighted images, increased signal intensity on T2-weighted images (due to oedema) and loss of 
endplate definition on T1 weighting. The Gadolinium enhancement of discs, vertebrae and surrounding soft tissues helps 
to differentiate infective lesions from degenerative changes (Modic type 1 abnormalities) or neoplasms [9]. 
 
Image Analysis 
An experienced nuclear medicine physicians reviewed all 
18
F-FDG PET/CT images on a dedicated workstation (GE 
Advantage 4.3). Metabolic and volumetric parameters were measured using MultiVol CONF PETCT software (GE 
Healthcare, Milwaukee, WI, USA). Semi-quantitative parameters, maximum standardized uptake value (SUV max), 
metabolic tumor volume (MTV) and Total Lesion Glycolysis (TLG), were calculated at 
18
F-FDG PET/CT “baseline” (SUV 
max1, MTV1 and TLG1) and after therapy (SUV max2, MTV2 and TLG2). 
The software provides a delineated VOI using an isocontour threshold method based on the SUV. 
To collect the metabolic tumor volume (MTV) and total lesion glycolysis (TLG) a fixed threshold value of 40% of 
the SUVmax uptake was used to determine lesion margins automatically, according to the previously published method of 
Larson et al and Lee [15, 16]. 
TLG was obtained by multiplying the SUVmean by the number of voxels. 
 
Statistical analysis 
To compare baseline and after therapy 
18
F-FDG PET/CT semi-quantitative parameters was used at-Student test for 
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paired groups. A P value of less than 0.05 was considered statistically significant. 
 
Results 
 
Details of the findings are shown in Table 1. 10/15 patients (67%) had an infection in the lumbar intervertebral discs, 4/15 
patients (27%) in the thoracic discs and one patients (6%) in L5-S1. 
 
Table 1. Individual data of 15 patients, imaging findings and 18F-FDG PET/CT semiquantitative parameter value at the 
baseline and at the end of treatment. 
 
The etiology diagnosis were obtained in 7/15 patients (47%) from blood cultures and in 8/15 patients (53%) from 
vertebral biopsy. The cause of infection was identified as S. aureus in 4 patients, coagulase-negative staphylococci in 3 
patients, Gram-negative bacteria in 4 patients, and tuberculosis infection in 4 patients. 
According to 
18
F-FDG PET/CT semiquantitative parameters all patients responded to the therapy. 
At baseline 
18
F-FDG PET/CT, the SUVmax1 ranged from 3.0 to 9.8 (mean 5.55±1.80), the MTV1 ranged from 
4.72 to 86.26cm
3
 (mean 40.69±24.52cm3), the TLG1 ranged from 17634.4 to 258691.1 (mean 109253.6±62508.2). 
After 6 weeks of antibiotic therapy, the SUVmax2 ranged from 1.7 to 5.4 (mean 3.11±0.93), the MTV2 ranged 
from 4.18 to 58.17cm
3
 (mean 22.5±14.05cm3), the TLG2 ranged from 12424.4 to 101188.8 (mean 41392.4±25324.9). 
All patients were positive at MRI1, while at MRI2, 7/15 patients showed signs of infection and were considered 
“positive” and 8/15 showed resolution of infectious condition and were considered “negative”. 
A statistical significant difference between 
18
F-FDG PET/CT “baseline” and after antibiotic therapy was found for 
all semiquantitative parameters: SUVmax (t=5.8, P=0.01); MTV (t=5.17, P=0.001); TLG (t=5,26, P=0,001). The 
comparison between the “baseline” and “after treatment” 18F-FDG semiquantitative parameters showed a significant 
reduction of all parameters.  
The findings of the comparison of the 
18
F-FDG PET/CT semiquantitative parameters to MRI2 are reported in 
Table 2. The reduction of 
18
F-FDG PET/CT semiquantitative parameters was relevant not only in the group “negative” 
MRI2, but also in the group MRI positive. 
Table 2. Comparative features between 18F-FDG PET/CT semiquantitative parameters to MRI2 results 
MRI2 
(After therapy) 
Differences between 
18
F-FDG PET/CT 
Semiquantitative 
parameters 
Mean±SD t-student P<0,05 
Resolution 
SUVmax1-SUVmax2 
MTV1-MTV2 (cm
3
) 
TLG1-TLG2 
2.96±1.84 
21.47±12.72 
94624.65±47923.51 
4.55 
4.77 
5.58 
0.003 
0.002 
0.001 
Persistence 
SUVmax1-SUVmax2 
MTV1-MTV2 (cm
3
) 
TLG1-TLG2 
1.84±1.21 
14.44±14.62 
37274±33009.69 
4.03 
2.61 
2.988 
0.007 
0.04 
0.024 
Patient 
n. 
Age Sex 
Microbiologic 
diagnosis 
Etiology Site 
MRI 1 
results 
MRI  
results 
SUVmax1 SUVmax2 
MTV1 
(cm
3
) 
MTV2 
(cm
3
) 
TLG1 TLG2 
1 63 M 
Blood 
Culture 
S.Aureus 
L1-
L2 
Positive Persistence 7.0 3.1 24.18 12.18  77957.3 44636.5 
2 74 M 
Vertebral 
biopsy 
M. 
Tuberculosis 
L3-
L4 
Positive Resolution 5.8 3.6 43.50  17.09  131569.7 39861.9 
3 76 M 
Blood 
Culture 
E. Coli 
L3-
L4 
Positive Resolution 5.3 3.7 17.75  6.06  48647.7 12424.4 
4 50 M 
Vertebral 
biopsy 
Brucella spp 
L5-
S1 
Positive Resolution 6.4 3.8 40.88  24.13  133456.2 47200.0 
5 80 M 
Blood 
Culture 
S.Aureus 
T9-
T10 
Positive Resolution 4.1 2.0 84.62  41.66  187562.6 53619.5 
6 78 M 
Blood 
Culture 
S. 
Epidermidis+ 
S. Capitis 
L2-
L3 
Positive Persistence 4.7 2.8 29.61 19.07 69150.5 36143.3 
7 38 M 
Vertebral 
biopsy 
S. 
Epidermidis 
L3-
L4 
Positive Resolution 9.8 3.1 26.04  10.83  142290.3 16877.8 
8 83 F 
Blood 
Culture 
S.Aureus 
L3-
L4 
Positive Persistence 4.0 3.4 45.16  25.62  97736.5 53341.9 
9 74 F 
Blood 
Culture 
E. Coli 
T11-
T12 
Positive Resolution 7.2 2.4 42.76  13.86  127647.7 19192.7 
10 66 M 
Blood 
Culture 
Brucella spp 
L5-
S1 
Positive Persistence 3.6 2.7 31.59  22.64  58606.4 33509.0 
11 65 M 
Blood 
Culture 
M. 
Tuberculosis 
T4-
T5 
Positive Resolution 3.0 1.7 25.94  24.21  40137.6 22640.6 
12 70 F 
Vertebral 
biopsy 
M. 
Tuberculosis 
L3-
L4 
Positive Persistence 6.9 3.9 28.07  23.32  99690.3 84943.9 
13 54 M 
Vertebral 
biopsy 
M. 
Tuberculosis 
L2-
L3 
Positive Persistence 6.4 5.4 4.72  4.18  17634.4 13233.5 
14 65 M 
Blood 
Culture 
S.Aureus 
L3-
L4 
Positive Resolution 5.5 3.1 86.26  58.17  258691.1 101188.8 
15 75 M 
Blood 
Culture 
S. 
Epidermidis+ 
S. Schleiferi 
L5-
S1 
Positive Persistence 3.6 2.0 79.26  34.52  148025.9 42072.4 
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Clinical symptoms resolved within 2 to 6 weeks. CRP and ESR returned to normal values in all patients within 3 
months of follow-up. According the clinical-laboratory resolution, all patients were considered responders to therapy. 
 
 
Discussion 
 
In recent years the role of 
18
F-FDG-PET/CT in inflammatory and infectious diseases, besides cancer is growing since it 
has been useful in cases of fever of unknown origin, vasculitis, infected prostheses, osteomyelitis, sarcoidosis, fungal 
infections and rheumatoid arthritis [10, 12, 17]. 
The accumulation of 
18
F-FDG in these diseases is based on glucose uptake in activated leukocytes, because the 
higher present of glucose transporter (GLUT) proteins on cell membrane [18]. 
In the evaluation of suspected spondylodiscitis, MRI imaging is currently the gold standard imaging technique, for 
its high sensitivity, for the excellent anatomical information without the use of ionizing radiations [19]. There are situations 
where MRI can be less helpful for diagnosing infection because of its lower specificity [20], such as in the presence of 
fractures and spinal implants [21] or when the suspected spondylodiscitis is associated to Modic type or arthro-
degenerative changes [22]. 
The role of 
18
F-FDG PET/CT for the diagnosis of spondylodiscitis was described in several studies [14, 23, 24].  
Albert et al [24] reported in a study of 11 patients with Modic type 1 changes (above and below herniated 
disc/discs) in lumbar spine, no increased in 
18
F-FDG metabolism in any vertebra or disc. Ohtori et al [25] evaluated the 
utility of 
18
F-FDG-PET for the diagnosis of pyogenic spondylitis in 18 patients. They reported a high sensitivity and 
specificity in detecting infection, and recommended 
18
F-FDG-PET for distinguishing between common Modic change and 
spinal infection. 
Two reviews [23, 26] evaluated the role 
18
F-FDG PET/CT in diagnosis of spinal infections, in comparison with 
conventional radionuclide imaging test (bone scan, radiolabeled leukocyte scan and gallium scan), morphological 
imaging (CT, MRI) and clinical-laboratory evidence of disease. Thy concluded 
18
F-FDG PET/CT is very promising 
alternative to other procedures, especially in presence of implants. 
Recently Fuster et al. [27] compared 
18
F-FDG PET/CT and MRI in diagnosis of haematogenous spondylodiscitis in 26 
patients, calculating SUV max in an area surrounding the lesion suspected of infection. They concluded that 
18
F-FDG 
PET/CT and the quantification with SUVmax are useful in the evaluation of suspected spondylodiscitis and especially in 
patients in whom MRI is suggestive of infection but no soft-tissue involvement is present.  
In our study, in accordance with literature, positive findings on 
18
F-FDG PET/CT scans and the semiquantitative 
parameters correlated to positive MRI scans at baseline evaluation in all patients. 
Up to date, the literature data about the role of 
18
F-FDG PET/CT in the therapy follow-up in spine infections and 
inflammatory diseases are few [10]. Nanni et al. [28] evaluated the role of 
18
F-FDG PET/CT in the early prediction of 
response to therapy in comparison to CRP serum levels in patients affected by haematogenous spondylodiscitis. 
They concluded the delta-SUVmax had higher sensitivity for the early identification of responders. 
Our data demonstrate that 
18
F-FDG PET/CT semiquantitative parameters (SUVmax, but also MTV and TLG) are 
useful to demonstrate the response to the antibiotic treatment (Figure 1). The difference between baseline and post-
treatment values of all these semiquantitative parameters resulted statistically significant. 
Another important finding of our study regards the positive MRI2 group. In these 7/15 patients a statistically 
significant reduction of all semiquantitative parameters (SUVmax, MTV and TLG) was observed despite an unchanged 
MRI2 results. In these patients, MRI results were inconclusive, due to tissue remodeling or edema of paravertebral tissue 
or degenerative spine diseases in the early post-treatment period (Figure 2). 
To the best of our knowledge, our study is the first one that evaluated the role of 
18
F-FDG PET/CT 
semiquantitative parameters to detect and to prove the antibiotic therapy efficacy in infectious spondylodiscitis, 
demonstrating a significant reduction of SUVmax, MTV e TLG. It’s the first time that the efficacy of therapy was correlated 
to the decrease of MTV and TLG. 
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Figure 1. MRI and PET/CT imaging in a 38 years old patient with back pain, fever and S. Epidermidis infection of the  
lumbar spine confirmed by positive microbiology culture of the vertebral biopsy. (A): baseline lumbar MRI, sagittal  
image showed oedema in the intervertebral disc between L1 and L2, confirmed by fused PET/CT scans (B). After three  
mounts of therapy, both scans (C, D) showed spondylodiscitis in resolution. 
 
 
 
 
 
               Figure 2. MRI and PET/CT imaging before and after therapy of 71 years old patients with M.tubercolosis infection,   
                confirmed by by positive microbiology culture of the vertebral biopsy. (A) Sagitta MRI images of lumbosacral spine    
                showed pathological signal in L3-L4 intervertebral disc with vertebral collapse. (B): 
18
F-FDG PET/CT “baseline” image  
                showed pathological uptake in L3-L4 intervertebral disc (SUV max 6.9 MTV 29.19cm
3
, TLG: 94051.7). (C): MRI scans  
                after therapy confirmed finding of spondylodiscitis between L3-L4 with vertebral collapse. (D): The 
18
F-FDG PET/CT  
                showed a reduction of uptake into the intervertebral disc between L3-L4 (SUV max 3.6 MTV 18.31cm
3
, TLG: 42419.4) 
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Conclusion 
 
18
F-FDG PET/CT is useful to detect the early response to antibiotic therapy in spondylodiscitis. Semiquantitative 
parameters provide additional information about the spine infection status, so 
18
F-FDG PET/CT may be considered a 
complementary method to MRI for detecting and monitoring therapy. 
 
The authors declare that they have no conflicts of interest. 
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Abstract 
Objective: This study aims to evaluate the diagnostic efficacy of 
99m
Tc-HMPAO-labeled white blood cells scintigraphy (RL-WBC 
scan) in a variety of infectious processes. Despite the technical difficulties of labeling WBCs without altering their 
viability/pathophysiologic integrity and the lengthy imaging procedure, the RL-WBC scan has gained an evolving role in the 
detection of occult infection. Methods: Retrospective review of 66 patient files (34 males and 32 females) that underwent this 
functional imaging test from September 2013 until September 2015. Their mean age was 58.39±18.63 (range: 11-84) years. 
Twenty seven of them were investigated for fever of unknown origin, 6 with suspicion of inflammatory bowel disease, 9 with 
aneurysm of celiac artery before or after abdominal endovascular aortic repair, 6 with joint prostheses, 5 with diabetic 
angiopathy, and 13 had rather undefined symptoms. Results: The mean labeling yield of the leukocytes with the lipophilic 
complex 
99m
Tc-HMPAO was 57.4±8.6. The RL-WBC scan was positive in 39/66 patients, including 16/27 patients with fever of 
unknown origin and 8/9 patients with aortic aneurysm/graft infection. It showed expected/suspected localization of radioactivity 
in 23 patients, whereas 11 of them had equivocal signs of infection. In 16 patients, a significant change in patients’ management 
was conferred, as non-suspected locations of inflammatory process were detected, based on early functional alterations derived 
from leukocyte recruitment. Conclusion: The RL-WBC scan (i) is extremely useful in the diagnosis of perigraft tissue infection 
and osteomyelitis (except for spine) with high rate of sensitivity and specificity (≈90%) when timely used, and (ii) may provide 
valuable information in patients with fever of unknown origin, inflammatory bowel disease or vague symptoms. False positive 
results have been noticed mainly due to artifacts, co-existent skeletal lesions or in the early postoperative course because of the 
nonspecific radionuclide uptake in the healing tissue. On the other hand, false negative results may appear in delayed aortic 
graft infection, etc. Difficulties arise in the discrimination between infection and sterile inflammatory lesions accompanying 
atheromatosis or grafts/prostheses. Our experience shows that there should take place a closer co-operation between nuclear 
medicine physicians and clinicians to ensure the rational selection of the patients that would benefit from this complex diagnostic 
procedure, in order to get the optimal results concerning in vivo inflammation/abscess visualization. 
HJNM 2015; 18(Suppl1); 23-28                                                                Published on line: 12 December 2015 
 
 
Introduction 
      
n clinical setting, the distinction between inflammation and infection is an important step towards their optimal 
management, as they arise from different pathophysiologic pathways. Inflammation is the response of the organism to 
a pathogen or tissue injury that may be caused by physical, chemical or immunological agents or even by radiation. It 
is characterized by local hyperemia, pain, and edema or swelling. An infection is caused by an exogenous pathogen 
(such as bacteria, viruses or fungi and etc.), has signs and symptoms such as fever, pain, loss of appetite, general 
malaise and abnormal laboratory results. It is often accompanied by an acute inflammation that may last for hours or days 
and is usually resolved without residual lesions [1]. 
The acute inflammation lasts for a short duration (8-10 days) and neutrophils are the predominant cells mediating 
cellular immunity, whereas chronic inflammation may last from few weeks to many years, is usually accompanied by late 
complications and it is characterized by reduction in the number of neutrophils and an increased infiltration of 
macrophages, lymphocytes, plasma cells and fibroblasts [1, 2]. 
The potential imaging targets in infection and acute inflammation are (i) the pathogens (bacteria, fungi), (ii) the 
activated endothelial cells and the involved cytokines and mediators in these processes, (iii) the macromolecules that 
accumulate in inflamed tissues due to the increased vascular permeability and, (iv) the polymorphonuclear cells 
(leukocytes, granulocytes) that migrate to the injured tissue. 
The need for detection and assessment of the different pathobiochemical conditions involved in infectious and 
I 
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inflammatory processes has led into the application of radiopharmaceuticals which may selectively localize in inflamed or 
infected tissues [3, 4]. Their physical characteristics, recommended administered activity, time of imaging, and common 
clinical uses will described later. 
 
The available radiopharmaceuticals for imaging infections and acute inflammation are:  
 
Acute inflammation  
67
Ga-
68
Ga-citrate, 
99m
Tc/
99m
Tc-SnF2/
111
In/
18
F-FDG/
64
Cu-labeled WBC, 
99m
Tc-labeled MoAb (LeuTech, leukoscan, 
scintimun), 
99m
Tc/
111
In-HIG, 
99m
Tc-nanocolloids, 
18
F-FDG, 
123
I-IL-1ra, 
99m
Tc-IL-8, 
99m
Tc-P483H, 
99m
Tc-EP1-HNE2, 
99m
Tc-a-
E-selectin, 
99m
Tc-DMP444, 
99m
Tc-chemotactic peptides, 
99m
Tc-PEG-liposomes 
 
For Bacterial infection  
99m
Tc/
18
F-ubiquitidin 29-41, 
99m
Tc-human neutrophils peptide 1-3, 
99m
Tc-bacteriophage, 
99m
Tc/
111
In-biotin, 
99m
Tc-PAMA4, 
99m
Tc/
18
F-ciprofloxacin (Infecton), 
99m
Tc-alafosfalin, 
99m
Tc-cefoperazone, 
99m
Tc-ceftixozime, 
99m
Tc-ceftriaxone, 
99m
Tc-
cefuroxime, 
99m
Tc-kanamycin, 
99m
Tc-isoniazid, 
99m
Tc-lomefloxacin, 
99m
Tc-ofloxacin, 
99m
Tc-moxifloxacin, 
99m
Tc-
nitrofurantoin, 
99m
Tc-norfloxacin, 
99m
Tc-pefloxacin, 
99m
Tc-rifampicin, 
99m
Tc-sitafloxacin, 
99m
Tc-sparafloxacin, 
99m
Tc-
gatifloxacin, 
99m
Tc-cefepime, 
18
F-fluoroacetamidoglucopyranose 
 
For Fungal infection  
99m
Tc-fluconazole, 
123
I-chitinase, 
99m
Tc-CBP21, 
99m
Tc-hLF 1-11 
 
Radiological imaging procedures such as ultrasonography, X-ray, computed tomography (CT) and magnetic 
resonance imaging (MRI) have shown variable sensitivity, but they exhibit suboptimal specificity for infections especially 
during the early phase whereas there are no changes in the relevant anatomic structures. As they are all morphologic 
imaging tests, they cannot detect the preceding functional disturbances and pathobiologic alterations [5-7]. Nuclear 
medicine techniques are very important in the evaluation of patients with suspected infection. By adding substantial 
physiological information to these patients, the source of infection can often be localized and treated effectively. 
The most primitive radioisotope for detection of infection is 
67
Ga-citrate. It is transported either in ionic form or 
bound to transferrin, binds to the transferrin receptor (CD71), and may leak through the vascular epithelium at the site of 
infection, where it is then bound to lactoferrin. Another mechanism of uptake may be based on the production of 
siderophores by microorganisms grown in a low-iron environment. Siderophores have a binding affinity for both iron and 
gallium; because of a lack of freely available iron, 
67
Ga citrate may be transported directly into the cell in its place. Is 
mainly used for the study of chronic osteomyelitis, in which gallium imaging has shown better results than leukocyte 
scanning. In immunocompromised patients, it is the exam of choice for detecting opportunistic respiratory tract infections. 
It could also be helpful for scintigraphic imaging of FUO patients, due to its diagnostic potential for both acute and chronic 
inflammatory conditions and neoplasms. Unfortunately it has several disadvantages, like the long physical half-life (78 
hours), low specificity due to physiological bowel excretion and accumulation in malignant tissues, high and multiple 
energy gamma radiation causing high radiation absorbed doses to the patients and staff. These disadvantages and the 
development of newer radiopharmaceuticals have resulted in the replacement of 
67
Ga-scintigraphy with radiolabeled 
leukocytes in the majority of infectious diseases. 
The role of 
99m
Tc-methylenediphosphonate (MDP) bone scintigraphy in infection imaging is limited to diagnosing 
osteomyelitis. Tracer uptake depends on blood flow (increased vascularity and permeability) and the rate of new bone 
formation. Three phase bone scanning with 
99m
Tc-MDP is commonly used for diagnosing osteomyelitis. The test is highly 
sensitive and can be positive as early as 2 days after the onset of symptoms. Its role in the evaluation of painful joint 
replacement has been extensively investigated. The overall accuracy of 
99m
Tc-MDP scan in assessing the painful 
prosthetic joint is about 50%-70%, rather suboptimal to be clinically useful, except perhaps as a screening test, or in 
conjunction with other radionuclide studies like gallium or labeled leukocyte imaging. 
18
F-FDG is a positron emitter with a half-life of 110min. FDG is transported through the cellular membrane by 
glucose transporter proteins and is subsequently phosphorylated to [
18
F]2΄-FDG-6 phosphate by the hexokinase enzyme. 
FDG may accumulate not only in malignant tissues but also in inflammatory processes. The use of 
18
F-FDG-PET in 
infections is limited to spondylodiscitis, FUO, vascular graft infections and vasculitis, but has also important value in 
various inflammatory diseases, such as sarcoidosis. The imaging of bacteria still needs some clarification. 
The aforementioned mechanisms are obviously complementary steps in the inflammatory processes, thus 
putting forward the research for more specific and delineating approaches. The white blood cells (WBC) labeled with 
99m
Tc-HMPAO or 
111
In-oxine can be considered as the gold standard nuclear imaging technique for the diagnosis of 
infections in the bone and soft tissue, except for spondylodiscitis [8, 9]. These autologous leukocytes are characterized by 
high specificity, because they only accumulate as a result of active migration into the inflamed tissues. After injection, 
they show rapid clearance from the lungs and blood pool, with progressive migration into the spleen, liver, bone marrow 
and the sites of infection where a neutrophilic infiltrate predominates. Radiolabeled WBCs first adhere to the vascular 
endothelium and then migrate toward the infected area through the endothelium and basal membrane, thus representing 
a specific indicator for leukocytic infiltration. 
The primary clinical indications for radiolabeled leukocytes include inflammatory bowel diseases, osteomyelitis, 
and the follow-up of patients with infections of vascular and orthopedic prostheses and soft tissue infections. In fever of 
unknown origin (FUO), its application has been associated with high sensitivity and specificity values. The reported 
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diagnostic accuracy for prosthetic joint infections and acute osteomyelitis is approximately 90% [10-12]. Besides, it has 
shown high sensitivity (82%-100%) and specificity (75%-100%) in the diagnosis of vascular graft infections. Some studies 
have shown lower rates for sensitivity and specificity and this discrepancy may partly be related to different interpretation 
criteria and different image acquisition protocols [11, 12]. Therefore the Infection Committee of the European Association 
of Nuclear Medicine (EANM) has recently published worldwide standardized guidelines that maintain the strength of 
clinical use of WBC scintigraphy, the practical aspects, indications, safety and quality control procedures of the technique 
[13, 14]. Technetium 99m is an agent avidly forming complexes with polymorphonuclear leukocytes that migrate by 
chemotaxis to the inflammatory sites. It provides lower radiation exposure as well as superior imaging quality and 
consequently higher sensitivity and specificity for acute infections compared to Indium-111.  
The procedure may simplify the differentiation of normal postoperative changes from infection and is useful for 
diagnosing vascular graft infection. In inflammatory bowel disease, the WBC imaging is useful for initial screening, 
monitoring treatment response and detecting recurrent disease. Labeled leukocyte imaging, combined with bone marrow 
scintigraphy accurately diagnoses complicated osteomyelitis [15, 16]. 
Despite the technical difficulties of labeling WBCs without altering their viability or/and pathophysiologic integrity 
and the lengthy imaging procedure, the 
99m
Tc-HMPAO-WBC scan has gained an evolving role in the detection of occult 
infection. 
 
 
Materials and Methods 
 
Data from 66 patients who were referred for 
99m
Tc-HMPAO-labelled WBC scintigraphy, in a 2 year period (September 
2013-September 2015) in our hospital were included in this retrospective study. We analyzed various clinical conditions 
such as fever of unknown origin (FUO), diabetic angiopathy, suspected osteomyelitis, suspected prosthesis infection, 
suspected inflammatory bowel disease (IBD), suspected endovascular graft infection and/or other with rather undefined 
symptoms. All patients had already undergone extensive investigation with clinical examination, detailed laboratory blood 
tests and imaging studies with negative, indeterminate or equivocal results. 
In vitro labeling was performed according to the guidelines for the labeling of leucocytes with 
99m
Tc-HMPAO of 
the European Association of Nuclear Medicine. Strict aseptic conditions were taken for the labeling procedure using only 
sterile reagents, disposable plastic-ware, sterile gloves, cap and masks. The labeling of WBC was performed in a laminar 
flow cabinet in order to prevent contamination and moreover only one patient labeling was performed at a time in order to 
prevent possible cross-contamination 
Collection of blood, isolation of cell-free plasma and isolation of granulocytes were initially performed. 
Approximately 40 to 55mL of patient’s blood were collected into a syringe fitted with a 20 gauge needle that contained 6-
8ml of Acid Citrate Dextrose Solution (ACD). Blood withdrawal was smooth and slow in order to avoid the production of 
bubbles or foaming. Erythrocytes were removed by erythrocyte sedimentation by maintaining the blood in the upright 
position for about 30-60min. Next, the leukocytes were separated from the platelets by centrifugation (7min) and the 
leukocyte “pellet” was removed and washed. 99mTc-HMPAO (Ceretec; GE Healthcare, Little Chalfont, UK) was prepared 
with freshly eluted 
99m
Tc-pertechnetate. After radiolabeling, leukocytes underwent incubation. Mean labeling yield was 
almost 57%. 
99m
Tc-HMPAO-labeled WBC was finally injected into the patient not later than 1 hour after labeling. Quality 
controls included visual inspection before reinjection of 
99m
Tc-HMPAO-labeled WBC, routine control of labeling efficiency 
and in vivo lung uptake. Radiolabeling procedure usually lasted 2-3 hours. 
In more than half of the patients, whole body scan performed acquiring planar (static) images at 4h (18/66), 6h 
(19/66) and 24h (29/66) p.i. The usual dose was 12mCi (444MBq) 
99m
Tc-HMPAO. All images were acquired on a SPET 
gamma camera system (PHILIPS AXIS) with low-energy general purposes collimators with the energy window centered 
at the 140KeV photopeak of 
99m
Tc using a width of 15% and using a 256x256 matrix. 
 
Results 
 
Thirty four of our patients were men and 32 were women, with a mean age of almost 58 years. Twenty seven of them 
were investigated for fever of unknown origin (FUO), 6 with suspicion of inflammatory bowel disease (IBD), 9 with 
abdominal aortic aneurysm (AAA), 6 with joint prostheses, 5 with diabetic angiopathy while 13 had rather undefined 
symptoms. 
Thirty nine out of 66 patients who were investigated had positive findings. Sixteen out 27 patients who presented 
with FUO and 8 out of 9 patients who presented with aortic aneurysm had positive findings. The scan showed 
expected/suspected localization of radioactivity in 23 out of 39 patients whereas in almost 41% of the patients with 
positive findings, inflammatory process was detected in non suspected locations. 
One location of inflammatory process was detected in 16 patients, 2 locations in 15 patients, 3 locations in 6 
patients and more than 3 locations in 2 patients. Leucocyte scan results led to management change in 16 patients. 
Further investigation was proposed to 15 patients, while in 8 of them another radionuclide method was performed to 
improve the accuracy of the diagnosis. 
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Discussion 
 
Nuclear medicine imaging techniques are considered extremely useful and effective in the detection, diagnosis and 
evaluation of infections and inflammations. Many radiopharmaceuticals are used worldwide in everyday medical practice 
for the investigation of infectious and inflammatory diseases, such as 
99m
Tc MDP, 
67
Ga Citrate, 
111
In leukocytes, 
99m
Tc-
HMPAO, 
18
FDG etc [4]. The selection of a radiopharmaceutical is determined by the balance between the advantages 
and disadvantages and the particular accuracy, specificity and sensitivity of each clinical application (Table 1). 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Considering these facts, the scintigraphy with 
99m
Tc-HMPAO-leukocytes may be assessed as the best nuclear 
medicine imaging modality option in a large variety of infectious processes. Although it is a time-and effort-consuming 
test, it is relatively cheap, readily available, and its application has been associated with remarkable percentages of 
sensitivity and specificity. In addition it is well known that technetium provides the most ideal characteristics for gamma 
camera imaging [17, 18]. The 
99m
Tc-HMPAO-WBC scan is considered to be the gold standard nuclear imaging technique 
for osteomyelitis and soft tissue infections. It is also characterized by high accuracy for prosthetic joint infections, arterial 
graft infections, inflammatory bowel diseases and conditions related with fever of unknown origin [4, 19, 20, 21, 22, 23, 
24, 25]. 
             Osteomyelitis refers to inflammation of bone caused by an infectious agent, typically bacterial. The 
99m
Tc-
HMPAO-WBC scintigraphy is commonly used for the diagnosis of acute osteomyelitis especially when equivocal or 
indeterminate clinical and radiological signs exist. Three phase bone scanning with 
99m
Tc-MDP shows high sensitivity for 
the detection of osteomyelitis, but it lacks specificity in cases with recent trauma or surgical intervention, other underlying 
bone lesions and complicated or occult infection. The combination of 
99m
Tc-MDP scan and 
99m
Tc-HMPAO-WBC scan 
enhances the diagnostic value in the above mentioned cases [2, 26]. 
The increasing number of patients with hip or knee arthroplasty and consequently the increased incidence of 
prostheses’ infection set a perplexing clinical problem, difficult to diagnose and handle. Long term success of 
arthroplasties has reached a percentage of 90%, but infections do occur with an incidence of 2%-5%. Larikka et al. 
reported sensitivity of 87.5% and specificity of 77% for 
99m
Tc-HMPAO-WBC imaging of knee arthroplasty infections. For 
hip arthroplasties the reported sensitivity and specificity are 89% and 75% respectively [27, 28, 29, 32]. In our study, 
99m
Tc-HMPAO-WBC scan essentially helped in the diagnosis of 6 out of 7 patients with infected arthroplasty. 
The main causes of FUO are infections, inflammations, malignancies and autoimmune diseases. Despite 
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thorough clinical, laboratory and imaging investigation, the underlying cause may be difficult to determine. 
99m
Tc-HMPAO-
WBC scan may provide essential information regarding the detection of infection focus leading to appropriate 
management of the patient. We have demonstrated the presence of scintigraphic findings highly indicative of the cause of 
FUO in 16 out of 27 patients (59.25%). As several causes of FUO are not usually associated with neutrophil infiltration, 
the test proves helpful in 25%-50% of the cases (Figures 1, 2) [30].  
Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of the digestive tract. 
99m
Tc-
HMPAO-WBC scan has been successfully applied to elucidate the location of the lesions, to evaluate their response to 
treatment and to detect early reoccurrence; however its role remains to be established [17, 21, 31]. 
             Prosthetic vascular grafts may be complicated by infections in 1-5% of patients. The early management of grafts 
infections represents a crucial matter due to the associated very high morbidity and mortality rates. 
99m
Tc-HMPAO-WBC 
scan offers significant diagnostic value for the diagnosis of prosthetic vascular graft infection with high accuracy (~95%) 
[20, 24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
Conclusively, the RL-WBC scan (i) is extremely useful in the diagnosis of perigraft tissue infection and osteomyelitis 
(except for spine) with high rate of sensitivity and specificity (≈90%) when timely used, and (ii) may provide valuable 
information in patients with fever of unknown origin, inflammatory bowel disease or vague symptoms. False positive 
results have been noticed mainly due to artifacts, co-existent skeletal lesions or in the early postoperative course because 
of the nonspecific radionuclide uptake in the healing tissue. On the other hand, false negative results may appear in 
delayed aortic graft infection, etc. Difficulties arise in the discrimination between infection and sterile inflammatory lesions 
accompanying atheromatosis or grafts/prostheses. The triggering of several signaling pathways may lead to sterile 
inflammation. Its pathophysiology has recently started being elucidated and its diagnosis is still largely up to clinical 
suspicion. As neutrophils are one of the first cellular mediators of sterile inflammation forming clusters at the site of injury 
and propagate the sequential inflammatory process, 
99m
Tc-HMPAO radiolabeled leucocytes scintigraphy cannot provide a 
definite discrimination between sterile and infectious inflammation. In addition to this, no other imaging studies provide 
clear differential diagnosis for such clinical setting. Molecular methods (such as the expression of certain genes or PCR 
determination of the relative amounts of plasma mitochondrial and bacterial DNA), have shown promising results 
indicating the presence of sterile inflammation. This crucial distinction may lead to novel therapeutic approaches that will 
dampen inflammation at the injury site without disabling systemic innate immune pathways affording protection against 
Figure 1. An 11 years old boy with FUO. Ophthalmological 
evaluation revealed iridocyclitis. Findings from colonoscopy 
and bone scan were normal. Abdomen CT showed thickening 
of ileum wall which was an indicator of local inflammation. The 
presence of enlarged lymph nodes in the area of the proximal 
ascending colon set the suspicion for lymphoma. From the 
first hour until the completion of the study a diffuse mildly and 
inhomogeneously increased concentration of the radiolabeled 
autologous WBC at the area of ileum and proximal ascending 
colon can be observed.   
 
Figure 2. A 79 years old female with FUO, pemphigus with a 
recent onset, Parkinson disease, diabetes mellitus and by-
pass history. Four blood cultures showed infection from S. 
aureus. Whole body scan performed in 1h, 4h and 20h p.i. 
The increased concentration of the radiolabeled WBC in the 
pelvis bilaterally just above the bladder and also at the 6th 
thoracic vertebrae, set the suspicion of infection. The 
concentration at the left hip was attributed to radioinfection. 
ved.   
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infection Our experience shows that there should take place a closer co-operation between nuclear medicine physicians 
and clinicians to ensure the rational selection of the patients that would benefit from this complex diagnostic procedure, in 
order to get the optimal results concerning in vivo inflammation/abscess visualization. 
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Abstract 
Objective: To report the anatomical and functional results of intravitreal injections of aflibercept (Eylea) (A-IVI) for the treatment 
of naïve eyes with neovascular age-related macular degeneration (nv-AMD). Subjects and Methods: This retrospective, one-
center, non-comparative chart review included 26 treatment naïve eyes with nv-AMD of 26 patients (14 male) with a mean age of 
80.5 (range 63-91) who had a complete follow-up of 14 months. The morphological analysis included spectral domain optical 
coherence tomography and fundus fluorescein angiography, while the functional assessment included logarithm of the minimum 
angle of resolution (LogMAR) best correct visual acuity (BCVA). The timing of the follow-up was: baseline, 3, 6, and 14 months. 
All patients received 8 A-IVI according to the protocol (first 3 consecutive monthly A-IVI, followed by bi-monthly retreatment for 
the first year, regardless of disease activity as per local guidelines). Statistical analysis was performed using 
ANOVA. Improvement of visual acuity more than 15 letters was considered as ‘improvement’, less than 5 letters as ‘stable’ and 
any letter loss as ‘worsening’. Results: Mean±standard deviation LogMAR visual acuity improved from 0.26±0.15 at presentation 
to 0.14±0.20 at the final follow-up of 14 months (P=0.02). BCVA was stable in 23.1%, improved in 61.5% (16 eyes) worsened in 
15.4%. A mean pretreatment central macular thickness of 409μm reduced significantly to 229μm at month 14 (P<0.02). The 
OCT of eyes with worsened BCVA showed resolution of retinal fluid but presence of subretinal fibrosis. No adverse events were 
attributed to aflibercept. Conclusions: Patients who had a worsening in visual acuity were found to have longer duration of 
symptoms prior to treatment and presence of geographic atrophy, and/or subretinal haemorrhage and/or subretinal fibrosis at 
baseline. From our experience, with 14 months follow-up, A-IVI is an effective treatment for treatment naïve patients with nv-
AMD. Our real world results were similar to pivotal trials. 
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Introduction 
      
ge-related macular degeneration (AMD) is a chronic progressive condition associated with ageing, characterised 
by central vision loss that may lead to irreversible vision loss if left untreated or sub optimally managed [1-3]. It is 
characteristically a disease of individuals >50 years of age and is the leading cause of visual loss in developed 
countries. In the United States, it is estimated that approximately 6% of individuals 65-74 years of age, and 20% of those 
older than 75 years of age are affected with AMD [4]. The annual UK incidence of wet neovascular AMD (nv-AMD) is 
estimated to be 39,700 with 103.1 new cases per 100,000 adult population per year [5]. Non-modifiable risk factors for 
AMD are include age and genetic Modifiable risk factors include cigarette smoking, high body mass index and low-level 
dietary antioxidants [6]. 
 With an ageing population, vision loss from AMD is expected to increase [7]. AMD can be classified into one of 
two general subgroups: early AMD which is mainly characterised by drusen and retinal pigment epithelium (RPE) 
changes; and late AMD, which is characterised by geographic atrophy of the RPE (dry AMD) and nv-AMD [1]. The dry 
form of AMD is more prevalent, accounting for approximately 90% of all AMD cases, and is often characterized by a slow 
degeneration of the macula resulting in atrophy of the central retina with gradual vision loss over a period of years. By 
contrast, nv-AMD, although less prevalent, commonly causes sudden, often substantial, loss of central vision and is 
responsible for most cases of severe loss of visual acuity in this disease [3]. Dry AMD is characterised by soft drusen, 
RPE atrophy, geographic outer retinal atrophy and loss of choriocapillaris, [6] while nv-AMD is characterised by fluid, 
haemorrhage, RPE detachment and exudates. For dry AMD there is lack of effective therapy, whereas v-AMD can be 
effectively treated with anti-angiogenic therapies [6]. Without treatment the natural history of nv-AMD is macular scarring 
and visual loss [3]. Patterns of choroidal neovascularization in common forms of wet AMD include occult CNV in >85% of 
cases and classic CNV in around 12%. Rarer forms include idiopathic polypoidal choroidal vasculopathy (IPCV) and 
A 
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retinal angiomatous proliferation (RAP) [6, 8-9].  
Nv-AMD results when abnormal blood vessels (neovascularization) proliferate under and/or within the retina. 
These blood vessels leak blood and fluid into the retina, which results in rapid vision loss. The end stage of the disease is 
scarring with irreversible destruction of the central retina. The current FDA approved pharmacologic therapies for nv-AMD 
target and inhibit vascular endothelial growth factor (VEGF). VEGF is an endothelial cell survival factor and a mitogen. 
Endothelial cells are a key component of neovascular tissue. All approved anti-VEGF agents for wet AMD are 
administered by intravitreal injection. These include ranibizumab (Lucentis), aflibercept (Eylea), and pegaptanib sodium 
(Macugen) [10-13].  
In addition, although not licenced by the FDA for the treatment of n-v AMD, the anti-VEGF agent Avastin 
(bevacizumab) is currently used to treat the ~50% of eyes with nv-AMD in the United States. A multicenter, prospective, 
randomized trial, funded by the US National Eye Institute, “The Comparison of Age-Related Macular Degeneration 
Treatments Trials” (CATT) demonstrated that monthly dosing with Avastin 1.25mg (0.05mL) was non-inferior to monthly 
dosing of Lucentis for eyes with nv AMD [14].   
Avastin, Lucentis, and Eylea, on average, all improve the visual outcomes in eyes with nv AMD. The primary 
mechanism of action of these anti-VEGF agents is to decrease the intraretinal and subretinal fluid associated with 
abnormal blood vessels. 
Aflibercept, also known as VEGF Trap-Eye is the first fully human intravitreal fusion protein. Key binding domains 
of VEGF-R1 and VEGF-R2 are fused for tight binding affinity for both VEGF-A isomers and placental growth factor (PIGF) 
[15-16]. Two dual-domain arms are used for one aflibercept molecule to mimic the natural receptor pairing necessary for 
growth factor signalling. The Fc portion of IgG1 is fused to the dual-domain arms resulting in the engineered molecule of 
aflibercept. Aflibercept binds both VEGF-A and PIGF with an affinity higher than their natural receptors [15-16].  
View 1 and 2 were phase III trials comparing aflibercept to ranibizumab and showed that aflibercept 2mg every 8 weeks 
produced non-inferior efficacy results to monthly ranibizumab, that persistent to 96 weeks. The proportion of fluid-free 
eyes was similar in all groups at both 52 weeks and this benefit remained at 96 weeks. Aflibercept was well-tolerated and 
had a similar profile to ranibizumab for ocular treatment-emergent and injection-related adverse events, and for systemic 
non-ocular adverse events [12].  
In the first 12 months, aflibercept 2mg in 50 microlitres can be given every two months with no requirement for 
monitoring between injections, following three monthly induction injections [12].  
The aim of the present study was to report the morpho-functional results of intravitreal injection of aflibercept (Eylea) for 
nv-AMD, and compare these to those published in the pivotal trials. 
 
 
Method 
 
We retrospectively reviewed the charts of 26 consecutive patients who underwent treatment with A-IVI for nv-AMD. All 
eyes included were treatment naïve. 
The morphological analyses included spectral-domain optical coherence tomography (SD-OCT) and fluorescein 
angiography (FA), while the functional assessment included logarithm of the minimum angle of resolution (LogMAR) best 
corrected visual acuity (BCVA). For each individual case, permission to treat was also obtained from the Chair of the 
Hospital's Drug and Therapeutics Committee. Ethical approval was not required to retrospectively report this 
interventional case series. 
Patients were treated under topical anaesthesia. Eyes were prepared using povidone iodine, surgical draping, 
and placement of an eyelid speculum. Each eye received a single, pars plana intravitreal injection of 2mg of aflibercept.  
All patients received 8 A-IVI according to the protocol (first 3 consecutive monthly A-IVI, followed by bimonthly 
retreatment for the first year, regardless of disease activity as per local guidelines). 
Baseline FA and serial SD-OCT scans (Spectralis, Heidelberg Engineering, Heidelberg, Germany) were read in 
a masked fashion to quantify the central retinal thickness (CRT). Follow up was at baseline, months 1, 2, 3 and then 
every 2 months for the first 14 months.   
Statistical analysis was performed using ANOVA. P-values<0.05 were considered significant. We examined 26 
eyes of 26 patients, including 14 males and 12 females with mean age of 80.5 (range 63 to 91). 
Endpoint was the proportion of patients maintaining vision (defining as losing <15 letters on an ETDRS chart at 14 
months. 
 
 
Results 
 
At the end of the follow-up, 61.5% (16 eyes) had improved the BCVA, 23.1% remained stable and 15.4% had a 
worsening of BCVA (P-value <0.02%). Mean±standard deviation LogMAR BCVA improved from 0.26±0.15 at presen-
tation to 0.14±0.20 at the final follow-up of 14 months (P=0.02). 
All the patients had a reduction of the central macular thickness at month 12 (P-value<0.02%). Mean central 
macular thickness (decreased from 409±154 microns to 229±122μm (P-value<0.02%). 
In the eyes with a worsening of the VA at the end of the follow-up (15.4%) there were retinal scars evident on the 
OCT, but the macula was dry. 
Visual acuity worsening in 15.4% of eyes was found to be related to either the acute appearance of sub-retinal or 
sub-RPE haemorrhage or to late stage of disease at the time of observation due to structural damage of the fovea from 
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the development of subfoveal scarring formation, geographic atrophy and/or fovea-involving exudation. 
 
Discussion 
 
A broad range of trials have investigated the efficacy and safety of ranibizumab, aflibercept and bevacizumab in n-v AMD 
and similar outcomes were reported [10-12, 14].  
The one-year results of intravitreal injection of aflibercept showed that the majority of patients had improvement 
or stabilisation of BCVA from baseline. Visual acuity worsening in 15.4% of eyes was found to be related to either the 
acute appearance of sub-retinal or sub-RPE haemorrhage or to late stage of disease at the time of observation due to 
structural damage of the fovea from the development of subfoveal scarring formation, geographic atrophy and / or fovea-
involving exudation. 
The eyes with the most favourable visual outcome had early diagnosis and treatment of their disease. 
In our study mean (±standard deviation) LogMAR visual acuity improved from 0.26±0.15 at presentation to 
0.14±0.20 at the final follow-up of 14 months (P=0.02).  
One of the limitations of our study is that our sample is small and we cannot generate our results, which however 
seem to be consistent with pivotal VIEW 1 and VIEW 2 trials.  
In VIEW 1 and VIEW 2, all 4 methods of treatment led to excellent and statistically equivalent visual outcomes, 
with each of the 4 arms achieving a mean of 8.3 to 9.3 letters of visual gain at the 1-year primary endpoint [12]. 
From an anatomical perspective, a slightly different result was observed. Specifically, analysis of central macular 
thickness (CMT) by OCT in the aflibercept 2mg arm in which patients were treated every 2 months revealed a “saw-tooth 
pattern” after the initial 3 monthly doses: CMT transiently increased at the end of the 2-month interval and then decreased 
upon retreatment, a phenomenon also observed in CLEAR-IT 2, the phase 2 study of aflibercept [17]. 
These observations suggest that aflibercept’s maximal anti-VEGF biological activity may not last a full 8 weeks in 
all patients. Nonetheless, secondary analyses of the data indicate that eyes receiving aflibercept monthly and every other 
month after 3 loading doses were 52% and 38% more likely, respectively, to demonstrate no macular edema at any point 
during the first 52 weeks compared with monthly ranibizumab (P<0.01).  
 
 
Conclusions 
 
In conclusion, patients with n-v AMD treated with intravitreal aflibercept resulted in stabilised vision and improved 
anatomic outcomes, while allowing injection intervals to be extended. From our experience, with 12 months follow-up, 
intravitreal injection of aflibercept showed to have promising outcomes for treatment naive patients with n-v AMD. A long 
term follow-up would be useful to evaluate the stability of this treatment. 
 
Comparison of 
18
F-FDG PET/CT and MDCT 
Aflibercept is an extremely effective anti-VEGF medication in the management of neovascular AMD. Many patients 
treated with aflibercept will require more than every-other-month dosing to achieve and maintain maximal retinal 
deturgescence. Still other antiangiogenic agents, including inhibitors of platelet derived growth factor (PDGF), are being 
actively investigated, and future advances will likely continue to improve patients’ vision and reduce their treatment 
burden. 
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Abstract 
Objective: To study real world outcomes of ranibizumab (Lucentis) intravitreal injection in diabetic macular oedema (DMO). 
Subjects and Methods: We included 100 patients with DMO. Those who had optical coherence tomography central retinal 
thickness (CRT) of 400μm or more (Group 1) underwent combination treatment with ranibizumab and macular LASER, while 
those with CRT less than 400μm (Group 2) had LASER monotherapy. The primary outcome measure was change in best 
corrected visual acuity (BCVA) from baseline. Secondary outcomes were change of CRT from baseline, the number of 
intravitreal injections in group one during the first and second year of follow-up and the proportion of LASER sessions in both 
groups at 2 years follow-up. Patients’ lipid profile was compared to the presence and extent of macular hard exudates, quantified 
using masked readers and image analysis software. Results: Group 1 showed better outcomes in terms of BCVA and CRT 
compared to Group 2 during the two-year follow-up period. The mean number of ranibizumab intravitreal injections in Group 1 
was reduced from 3.86 (standard deviation±1.37) in the first year to 2.02 in the second year. At 2 years, Group 1 had a higher 
proportion of individuals that had undergone 3 macular LASER treatments (4% Group 1, 28% Group 2). The presence of hard 
exudates was associated with higher total cholesterol (P=0.004 and P=0.041 group 1 and 2 respectively) and with higher low 
density lipoprotein (LDL) cholesterol (P=0.01 and P=0.045 respectively). The size of hard exudates was associated with higher 
total cholesterol (P=0.02 and P=0.03 respectively) and with higher LDL cholesterol (P=0.003 and P=0.01 respectively). Neither 
high density lipoprotein (HDL) cholesterol, nor triglycerides were related to the presence or size of hard exudates. No serious 
adverse events were attributed to either LASER or ranibizumab. Conclusions: Combination treatment of intravitreal ranibizumab 
injections and macular LASER appears safe and effective over two years. The need for injection declines over time. There is an 
association between higher levels of serum total and LDL cholesterol and the presence and the extent of hard exudates. 
HJNM 2015; 18(Suppl1); 33-41                                                                Published on line: 12 December 2015 
 
 
Introduction 
      
he prevalence of diabetes in the United Kingdom is projected to increase from nearly three million adults in 2013 [1] 
to around 5 million people by 2025 [2]. Together, diabetic retinopathy (DR) and maculopathy represent the second 
most common cause of certifiable blindness among working-age adults in England and Wales [3].  
The visual acuity in diabetic patients is most commonly compromised because of the complications of retinal 
neovascularization and/or the occurrence of diabetic maculopathy, either in the form of ischaemic maculopathy, DMO or a 
combination of both [4].  
The classification of DMO varies. The Early Treatment Diabetic Retinopathy Study (ETDRS) defined Clinically 
Significant Macular Oedema (CSMO) as DMO that threatens the centre of the macula (fovea) and was assessed by slit-
lamp biomicroscopy [5]. Diabetic maculopathy can be described as focal oedema, diffuse oedema, ischaemic 
maculopathy or mixed maculopathy depending on the blood–retinal barrier integrity and the macular perfusion in fundus 
fluorescein angiography (FFA) [5]. OCT is also commonly used to define DMO as centre-involving, if the central 1mm 
subfield is involved [6]. OCT may also provide a number of quantitative measures of severity, such as the retinal 
thickness, the extent of retinal thickening, and the macular volume, as well as qualitative measures such as the retinal 
morphology and co-existing disease of the vitreo-retinal interface [4, 7].  
DR and maculopathy, primarily driven by chronic hyperglycaemia, is the result of a complex pathway with a 
variety of sequential and related processes [8]. The pathophysiological pathways of DR and DMO implicate the 
upregulation of inflammatory mediators and vascular endothelial growth factor (VEGF). VEGF expression is induced 
T 
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directly by hypoxia or through inflammatory mediators [9]. Consequently, both VEGF and inflammatory factors including 
ICAM-1, interleukin-6 (IL-6) and MCP-1 affect the integrity of the blood–retinal barrier [10] [11-12]. Additionally, placental 
growth factor (PlGF), [13] tight junction proteins, and other vasoactive factors, including protein kinase C (PKC), 
histamine, angiotensin II (AII), matrix metalloproteinases (MMPs), pigment epithelium derived factor (PEDF), platelet-
derived growth factor (PDGF), and basic fibroblast growth factor (b-FGF) appear to play significant role in the 
development of DMO [10]. VEGF promotes retinal neovascularization acting as an endothelial cell mitogen, whilst 
inducing DMO due to its vasopermeability properties [14].  
There have been a variety of clinical trials investigating the efficacy and safety of intravitreal anti-VEGF, steroid 
intravitreal injections and macular laser as monotherapy or combination treatment for DMO [5, 11-12, 15-25]. 
Given that the anti-VEGF intravitreal agents have shown impressive results in the management of DMO and that the 
LASER has been shown to be effective, the combination treatment could augment the advantages of both. 
The main purpose of this study was to study real world outcomes of ranibizumab intravitreal injection in DMO, 
given alone and in combination with LASER, and to assess if patients’ lipid profile influences the clinical manifestations of 
DMO. 
 
 
Subjects, Material, Methods 
 
Study Design 
This was a prospective, one-center, interventional, parallel, two group study recruiting diabetic patients with CSMO in at 
least one eye. The patients were fully informed of the purpose of the study and all provided written informed consent. 
Institutional Review Board approval was obtained and the study adhered to the tenets of the Declaration of Helsinki. 
 
Outcome measures 
The primary outcome measure was change in BCVA from baseline to year 2. Secondary outcomes were change in CRT 
from baseline, the number of intravitreal injections in the combination treatment group during the first and the second year 
of monitoring and the proportion of LASER sessions in both groups at 2 years follow-up. The patients’ lipidemic profile 
was investigated in terms of total, low-density lipoprotein (LDL), high-density lipoprotein (HDL), cholesterol and 
triglycerides (TGL). 
 
Population 
The eye with the worst BCVA of one hundred patients with DMO from the Outpatient Medical Retina Clinic was included 
in the study.  Inclusion criteria were men or women aged ≥18 years, diabetes mellitus (DM) type I or II, glycosylated 
hemoglobin (HbA1C) between 6% and 9%, and the presence of CSMO in the study eye regardless of DR stage. 
Exclusion criteria were an unstable systemic condition (lack of glycemic control, systolic blood pressure 
[BP]>155mmHg or diastolic >95mmHg), history of local administration or systemic administration of corticosteroids in the 
last three months, pan retinal photocoagulation (PRP) or macular photocoagulation to the study eye in the last three 
months, intravitreal or sub-Tenon administration of triamcinolone in the last three months in the study eye, previous 
participation in a clinical study with anti-VEGF agents, history of macular surgery or other ophthalmic surgery for DMO in 
the eye study, previous retinal vein occlusion (RVO), any intraocular surgery in the last twelve months, active intraocular 
or periocular inflammation, and clinically significant peripheral vascular disease in the last twelve months. 
 
Interventions 
Patients were allocated to one of two treatment groups based on their baseline CRT, in accordance with the UK’s 
National Institute of Health and Care Excellence (NICE) guidance, which reserves ranibizumab for patients with a CRT of 
at least 400μm. 
Group 1: Fifty consecutive diabetic patients with CRT greater than or equal to 400μm underwent combination 
therapy with intravitreal ranibizumab and macular LASER. Group 1 received three monthly intravitreal injections (loading 
dose) of 0.5mg ranibizumab via pars plana injection and underwent macular LASER photocoagulation (focal or grid) on 
the third month. Further intravitreal injections were received on a pro re nata (PRN) basis if there was at least one of the 
following criteria: 1) CRT increase of more than 50μm on OCT, 2) BCVA loss of at least 5 EDTRS letters compared to last 
measurement, 3) presence of intraretinal or subretinal fluid on OCT, 4) as per investigator judgment, such as BCVA 
worsening in 2 consecutive visits even if the numeric criteria did not meet the 5 letter criteria.  
Macular LASER photocoagulation could be repeated every three months up to three times in total if required.  
Modified focal or grid LASER was performed as follows: Focal LASER was performed in all leaking micro 
aneurysms within 500 to 3000μm from the fovea with 50μm spot size and duration 0.05-0.1 seconds. Grid LASER was 
conducted between 500 to 3000μm from the center of the fovea and no LASER was applied to papilo-macular area. 
Group 2: Fifty consecutive diabetic patients with CRT less than 400μm underwent LASER monotherapy (Group 
2). Group 2 received a baseline macular LASER and then two more sessions (at least 3 months in apart), if there was 
residual leakage in FFA, increase in CRT as above or as per the investigator’s judgement.   
 
Study assessments 
All patients were evaluated for changes in BCVA (EDTRS letters) and changes in CRT were measured by OCT (Stratus, 
Model 3000, Carl Zeiss Meditec) at monthly intervals during the two year study period. Further assessment with FFA in 
order to estimate the fluorescein leakage and with colour fundus photography in order to estimate the size of hard 
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exudates were performed at baseline and 3 months following the macular LASER, if unresponsive to treatment. 
 
Quantitative measurement of hard exudates 
For patients who had hard exudates, we measured the area of hard exudates. Because of variability in fundus 
photography magnification due to corneal curvature, axial length, refractive error and depth of focus, we used fixed retinal 
landmarks to determine the area of the fundus within which hard exudates would be quantified. For each participant with 
hard exudates, one fundus image centred on the macula was chosen for measurement. If both eyes had hard exudates, 
the right eye was used. The images were cropped to circles centred on the fovea with a radius equal to the distance 
between the foveal centre and the temporal optic nerve margin. Hard exudate area was assessed with Image J software 
(National Institutes of Health, Bethesda, MD). The cropped images were split into three colour channels and the green 
channel was used for analysis because it highlights hard exudate well. We measured the cropped circle area in pixels. 
We measured the area of hard exudates using a semi-automated technique. First the Maxentropy function in Image J 
identified hard exudates in an automated fashion using an intensity threshold that was set to maximize capture of all 
possible hard exudates in the cropped circle. Then two masked ophthalmologist-investigators evaluated the images and 
decided independently whether the automated function had missed or incorrectly identified hard exudates and manually 
corrected the images. Images graded by the two readers were compared and disagreements were arbitrated by a third 
ophthalmologist-investigator. The hard exudate area for each cropped image was then measured automatically in pixels 
using the measure function in Image J. We calculated a relative area of hard exudate by dividing the hard exudate area 
by the total cropped image area (Figure 1). 
 
 
 
Figure 1. Measurement of the size of exudates using Image J programme. 
 
 
Statistical analysis 
The trial was evaluated for 100 patients subdivided equally into Group 1 and Group 2. Data were checked for 
reasonability and any figures that showed a significant fluctuation were re-checked. Missing values were calculated using 
linear interpolation. 
An association between baseline BCVA (≤60, 61-73 and >73 ETDRS letters) and CRT (≤250, 251-400, >401μm) 
was found for all collected data points (P<0.001, Chi-Square test applied on 1,759 data points).  
Accepting that the baseline characteristics varied, we compared Group 1 and Group 2 in terms of BCVA change, 
OCT CRT change and number of LASER treatments. The difference between the two groups with respect to the number 
of LASER treatments was tested using the Freeman-Halton extension of the Fisher Exact test by stratifying by baseline 
BCVA letter score (≤60, >60).  
Improvement could be defined as improvement over normal fluctuations or whether one group performed better than 
the other. This was measured at months 12 and 24 as the proportion with at least   
 1, 5 or 10 letter improvement in BCVA and 
 1 or 100µm OCT improvement. 
Normal fluctuations were considered to be a standard deviation of 10 letters and 80µm in change of BCVA and 
OCT over baseline values respectively at twelve and twenty four months. Any improvements were tested using a z-test 
for proportions.  
The statistical hypothesis of any better improvement was based on a stratified Cochran-Mantel-Haenszel test 
with stratifications according to baseline BCVA letter score (≤60, >60) and number of LASER treatments (1, 2 or 3) - 
resulting into six strata. Any comparisons within the sub-strata was been made using Fisher’s Exact test.  
 
Results 
 
From the total of 100 Caucasian patients with DMO recruited in the study, 65 were women and 35 were men. At baseline, 
the mean age of patients was 65.4±13.9 years (women 65.6±14.3 years, men 63.7±11 years). The mean disease 
duration at baseline was 108.3±101.5 months (women 114.4±103.3 months, men 109.3±72.4 months). Nine patients 
(16%) were treatment naïve. 
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 36 
The combination treatment group (Group 1) had a mean baseline BCVA of 54.80 (standard deviation±15.84) 
while the LASER monotherapy group had a mean BCVA of 55.48 (±14.87). There was no difference between the two 
groups with respect to baseline BCVA if subdivided in the groups ≤60, 61-73 and >73 (P=0.9157). 
During the first year, the mean change in BCVA was 3.08 (SD=±13.89) and 3.48 (SD=±12.45) for the 
combination treatment group and LASER monotherapy respectively. 70% of combination therapy and 56% of LASER 
monotherapy showed an improvement over one year and there was evidence of an improvement over normal fluctuations 
for combination therapy (at least 1 letter improvement in BCVA, P=0.0009). BCVA improvement was mainly experienced 
in the first three to four months and then BCVA was relatively stable throughout. 
The mean change from baseline BCVA after two years was +4.03 letters (13.21) and +2.36 letters (±17.87) for 
the combination treatment group and LASER monotherapy respectively. The majority of patients showed improvement 
over two years (62.50% of combination therapy and 51.28% of LASER monotherapy). There was evidence that the 
combination therapy group had an improvement over normal fluctuations (at least 1 letter improvement in BCVA, 
P=0.0222; at least 5 letter improvement in BCVA, P=0.0051, at least 10 letter improvement in BCVA, P<0.001). There 
was evidence of an improvement over normal fluctuations of at least a 10 letter improvement in BCVA for LASER 
monotherapy (P<0.001). 
There was no evidence of any group outperforming the other with respect to BCVA improvement over one or two 
years. Having applied Fisher’s Exact test to every possible sub-strata, only one case resulted in a superior outcome: the 
combination therapy group showed better improvement of at least 1 BCVA over one year for individuals with one LASER 
treatment irrespective of their baseline BCVA (P=0.0174).  
The change in BCVA over time for the two groups separately and combined is presented in Figure 2. 
 
 
 
Figure 2. Chart Mean Change in Best Corrected Visual Acuity (BCVA) (EDTRS letters) for the two groups (combination 
treatment with ranibizumab and macular LASER versus LASER monotherapy) with respect to time in months. Overall and 
subgroup analysis (1, 2, 3 LASER sessions, BCVA more than 60 letters, equal or less than 60 letters). 
 
 
As per the group allocation, all those in Group 1 had a baseline CRT of at least 400μm, with a mean of 
500.22±53.42μm. All those in Group 2 had a baseline CRT less than 400μm, with a mean of 326.90±58.35μm (P<0.001). 
All cases in the combination therapy group experienced an improvement from baseline in OCT at end of the first 
(mean -260.20±69.50μm) and second year (-263.47±80.20μm). The majority of the LASER monotherapy group showed 
an improvement from baseline OCT at end of each year (First year: 82% showed improvement, mean -70.33±88.78μm; 
Second year: 79.59%, -69.1±83.73μm). Both groups showed large improvements in OCT during the first four months. The 
LASER monotherapy’s improvement stabilised from this point with a slight deterioration, while combination treatment 
continued to improve, albeit at a slower rate. Both groups showed strong evidence of an improvement over normal 
fluctuations (P<0.001) at any time point or level of improvement (at least 1µm, at least 100µm). 
The combination therapy group outperformed the LASER monotherapy group. In examining sub-strata, the 
combination therapy group was significantly superior in the group with baseline BCVA ≤60 (all LASER treatments, 1 year 
improvement P=0.0133, 2 year improvement P=0.0120. 
In examining the relative proportions with improvements of over 100µm in OCT over one or two years, the 
combination therapy showed a superior improvement in many sub-strata if the total strata size over the two groups was 
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more than 20 individuals.  
The Chart of Mean Change in CRT for the two groups with respect to time for Overall and the subgroup analysis 
are presented in Figure 3. 
 
 
Figure 3. Chart of Mean Change in Central Retinal Thickness (CRT) from baseline for the two groups (Combination Treatment 
with Ranibizumab and macular LASER & LASER monotherapy) with respect to time in months. Overall and subgroup analysis 
(1, 2, 3 LASER sessions, BCVA more than 60 letters, equal or less than 60 letters). 
 
The combination treatment group showed a decrease over time of needed intravitreal ranibizumab injections 
from 3.86±1.37 during the first year to 2.02±1.93 during the second year of monitoring. All of the individuals in both of the 
groups underwent at least 1 macular LASER session but the group with LASER monotherapy had a higher proportion of 
individuals with 3 LASER treatments (28% versus 4% respectively, P=0.0222). Examining this by stratifying by baseline 
BCVA resulted in no significant evidence of a difference between the two groups with respect to the number of injections 
(baseline BCVA ≤60, P=0.1165; baseline BCVA >60, P=0.1873) but this is possibly due to the small sample sizes. 
No statistically significant increase in the intraocular pressure (IOP) from baseline was noted. At the end of the 2 
years of monitoring, there was no statistically significant difference between the two groups regarding the development of 
cataract. There were no cardiovascular adverse events. No serious adverse events were attributed to either LASER or 
ranibizumab. Ophthalmic complications were also limited to the presence of subconjunctival haemorrhage and subjective 
discomfort during injection. 
Participants with macular hard exudates had a longer duration of DM (17.4±10.3 years vs 11.5±10 years, P=1.3 
×10-10), higher average Hemoglobin A1C (HbA1c) (8.4±2.1% vs 7.4±1.7%, P=1.3×10-9) and higher mean systolic BP 
(145.0±26.8mmHg vs 133.5±21.2, P=1.3×10-8) compared to participants without macular hard exudates. 
In univariate analysis and multivariate analysis (Table 1) after controlling for other risk factors of retinopathy, the 
presence of hard exudates was associated with higher total cholesterol (P=0.004 and P=0.041 for Group 1 and 2 
respectively) and with higher LDL cholesterol (P=0.01 and  P=0.045 respectively). Neither HDL cholesterol nor 
triglycerides were found to be related to the presence of hard exudates. 
Similarly, in univariate analysis and multivariate analysis (Table 2) after controlling for other risk factors of 
retinopathy, the area of hard exudates was associated with higher total cholesterol (P=0.02 and P=0.03 for Group 1 and 2 
respectively) and with higher LDL cholesterol (P=0.003 and P=0.01 respectively). Neither HDL cholesterol nor 
triglycerides were found to be related to the area of hard exudates. 
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 Table 1. Association between serum lipid levels and presence of macular hard exudates 
 Univariate Multivariate* 
 OR (95% CI) P value OR (95% CI) P value 
Total Cholesterol  
(per 10mg/dL) 
1.05 (1.01-1.08) 0.004 1.04 (1.001-1.08) 0.041 
LDL Cholesterol  
(per 10mg/dL) 
1.05 (1.01-1.09) 0.01 1.04 (1.001-1.09) 0.045 
HDL Cholesterol  
(per 10mg/dL) 
1.03 (.92-1.14) 0.58 1.07 (0.96-1.2) 0.19 
Triglycerides 
(per 10mg/dL) 
1.01 (0.99-1.03) 0.13 0.99 (0.97-1.02) 0.56 
* Controlling for age, sex, duration of DM, HbA1C, and systolic BP. Abbreviations: OR=Odds Ratio, CI=Confidence Interval, 
LDL=Low Density Lipoprotein, HDL=High Density Lipoprotein, DM=Diabetes Mellitus, HbA1C=Haemoglobin A1C, BP=Blood 
Pressure 
 
 
Table 2. Association between serum lipid levels and the size of macular hard exudates 
 Univariate Multivariate* 
 Coef (95% CI) P value Coef (95% CI) P value 
Total Cholesterol  
(per mg/dL) 
0.001  
(0.0002-0.0019) 
0.02 
0.001  
(0.0001-0.002) 
0.03 
LDL Cholesterol  
(per mg/dL) 
0.001  
(0.0004-0.002) 
0.003 
0.001  
(0.0002-0.002) 
0.01 
HDL Cholesterol  
(per mg/dL) 
0.001  
(-0.0009-0.004) 
0.20 
0.0025  
(-0.0002-0.005) 
 
0.07 
Triglycerides 
(per mg/dL) 
0.0002  
(-0.0003-0.0008) 
0.5 
-0.0001  
(-0.0007-0.0004) 
0.66 
* Controlling for age, sex, duration of DM, HbA1C, and systolic BP. Abbreviations: OR=Odds Ratio, CI=Confidence Interval, 
LDL=Low Density Lipoprotein, HDL=High Density Lipoprotein, DM=Diabetes Mellitus, HbA1C=Haemoglobin A1C, BP=Blood 
Pressure 
 
 
Discussion 
 
Ranibizumab has been found to significantly reduce CRT in DMO, [20, 24] as does macular LASER. Therefore, 
theoretically, the combination may be synergistic or have additive benefit. Our analysis found that the combined 
ranibizumab and macular LASER treatment had positive results in terms of both BCVA and CRT. Whilst these results 
compared favorably to the LASER monotherapy group, differences in baseline characteristics make it difficult to directly 
compare the interventions in terms of discriminating the effect of each treatment regimen. Nonetheless, in pragmatic 
terms the data suggest that combined treatment is acceptable in terms of both safety and efficacy.  
 These results are in line with the results from the major studies of DMO. The differences that exist may arise from 
our relatively small sample size and differences in our eligibility criteria and in particular lower baseline BCVA. The main 
studies [16, 18, 21] included patients with mean baseline BCVA between 57.6 and 62.4 ETDRS letters in the LASER 
monotherapy group and only one study [19] had patients with a substantially lower baseline BCVA of 28.4 letters. In the 
combination treatment arm of these studies, mean baseline BCVA was between 63.4 and 66.0 ETDRS letters, [18, 21] 
while only one study had patients with poor baseline BCVA, of 28.9 letters [19]. Our study combination treatment group 
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measured 54.8 letters at baseline and the LASER monotherapy group measured 55.5 letters. Baseline CRT in the above 
studies was lower than our study (between 371.0 to 474μm for the combination therapy groups), but it was higher in the 
LASER monotherapy group (from 407 to 540μm). Our mean values were 500.22μm for the combination group and 
326.90μm for the LASER monotherapy group.  
 The Ranibizumab Monotherapy or Combined with LASER versus LASER Monotherapy for Diabetic Macular 
Edema (RESTORE) study, [21] the sub-group with CRT greater than 400μm showed the greatest benefit following 
intravitreal ranibizumab compared to LASER monotherapy, which agrees with our data. Conversely, in two other studies 
[26-27] where intravitreal bevacizumab (Avastin) was injected in eyes with CRT greater than 400μm, the results were not 
as good as ranibizumab. 
 DRCR.net protocol I [18] and the expanded DRCR.net protocol I study, [28] concluded that ranibizumab 
treatment with prompt versus deferred macular LASER were similarly effective. Deferred LASER referred to macular 
LASER applied at 6 months following the initiation of the intravitreal injections. In our study the first LASER session was 
applied in the third month after three induction injections of ranibizumab. 
 The three-year results from Protocol I [29] found that - following 2 years of treatment - only 1 and 2 injections of 
ranibizumab are required in conjunction with prompt or deferred LASER. In the extended 3 year results, there was a slight 
difference between the prompt and deferred LASER groups, with better BCVA in the group with ranibizumab and deferred 
LASER treatment. We also found that the combination of anti-VEGF and deferred LASER (at 3 months) resulted in a 
decrease in the average number of injections required over time, with 3.86 injections during the first year and 2.02 
injections in the second year. 
 None of our patients in either group showed worsening of DR, whereas, some patients displayed improvement. 
This observation is in accordance with several clinical studies in which treatment with anti-VEGF resulted in a transient 
improvement of PDR [30] and treatment with intravitreal ranibizumab resulted in reduction of the cumulative risk of 
worsening of DR [18], [31] in patients with or without PDR [32]. 
 Regarding eyes with macular hard exudates, we found that both the presence of hard exudates and their size 
were both associated with higher total and LDL cholesterol, after adjusting for other risk factors for DR. Other 
epidemiological studies, including the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) study [33], found 
similar associations between higher total and /or LDL cholesterol and the presence of hard exudate size [33-40]. Other 
studies found no association with lipids [41-42].  
 Our study investigated not only the relationship between lipid profile and the presence of macular exudates, but 
also the relationship between lipids and the size of hard exudates. As far as we are aware, there has been only one study 
to assess both of these parameters [41]. The study included 97 participants with DM type 1 and 2. Similar to our study, 
the researchers found that higher levels of total and LDL cholesterol were associated with increased total area of hard 
exudates in the univariate analysis. However, in multivariate analysis, total cholesterol was no longer associated with the 
increased total area of hard exudates. Furthermore, LDL cholesterol levels and triglyceride levels did not share the 
association. Other clinical trials correlated dyslipidaemia to macular hard exudates in DMO [43-43]. Oral treatment with 
atorvastatin in patients with type 2 DM and dyslipidemia reduces the severity of hard exudates [43].   
 DMO is a major cause of visual loss in diabetic patients [45-46]. Hard exudates are often seen in the posterior 
pole in patients with DMO and should they become center-involving, they can cause structural damage to the fovea and 
permanent loss of vision, even after resolution of DMO [47]. This risk of permanent vision loss highlights the importance 
of identifying the modifiable risk factors for the development of hard exudates [47].  
An important limitation of this study is that the patient groups were not comparable at baseline so, in addition to the small 
sample size, comparisons between groups must be interpreted with considerable caution, both in terms of observed 
differences and apparent similarities.  
 
 
Conclusions 
 
The combination of macular LASER and ranibizumab has acceptable safety and efficacy for the treatment of DMO 
greater than 400 microns. There appears to be an association between higher levels of total and LDL cholesterol and the 
presence and the extent of hard exudates. 
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Abstract 
Objective: Cardiac amyloidosis (CA) is an underestimated and underdiagnosed cause of cardiac insufficiency. Despite being 
often considered as a solitary entity attributable to extracellular deposition of fibrillary proteins, there exist at least two different 
pathophysiologic backgrounds, with different clinical course and treatment. a) In light-chain cardiac amyloidosis (immunoglobulin 
light-chain amyloidosis-AL) the fibrils consist of light-chain immunoglobulins produced by a clonal plasma cell population in bone 
marrow. b) In CA related to transthyretin (transthyretin-related amyloidosis – ATTR), whether familial amyloid cardiomyopathy or 
senile systemic amyloidosis, monomers or dimers of the normally tetrameric protein of transthyretin are deposited in the 
myocardium. Today, definitive diagnosis of cardiac amyloid disease is based on endomyocardial biopsy in conjunction with 
immunohistochemical parameters or, in ambiguous cases, with mass spectroscopy. Several radiotracers have been hitherto 
tried in the detection of CA. Subjects and Methods: In this pilot study technetium-99m pyrophosphate (
99m
Tc-PYP) was 
administered to patients suffering from CA, aiming to differentiate scintigraphically between AL and ATTR. Twelve patients (8 
males, aged [mean±SD] 70,6±13,2y; 4 females, aged 65,7±9,9y) were enrolled for the discrimination between AL and ATTR. 
Diagnosis was confirmed by biopsy combined with the clinical and laboratory evaluation of the patients. Myocardial scintigraphy 
(planar and tomographic imaging) was conducted at 1, 2 and/or 3h after intravenous administration of 555-925MBq 
99m
Tc-PYP. 
Myocardial radiotracer uptake was evaluated optically and also by a semiquantitative method. Two regions of interest (ROI) 
were drawn: one over the heart and another over the contralateral hemithorax, to calculate the corresponding heart-to-
contralateral (H/CL) count ratio. According to established reference standards, a cut-off H/CL value of 1.5 best discriminates 
between the two conditions. 
99m
Tc-PYP scintigraphy revealed diffuse intense myocardial uptake upon visual evaluation that was 
also verified semi-quantitatively in 6 patients, all of which had ATTR. Faint or no myocardial tracer uptake was found in 4 
patients who were diagnosed with AL. Two AL patients had a borderline positive scan on visual evaluation but their H/CL ratios 
did not exceed the value of 1.5. In three patients, we also attempted scintigraphy with the tracer pentavalent 
99m
Tc-
dimercaptosuccinic acid. Results and possible mechanisms of uptake are discussed. The sensitivity and specificity of 
scintigraphy with 
99m
Tc-PYP was high, albeit the small number of patients. In conclusion: These preliminary results are 
compatible with current international literature, and demonstrate that scintigraphy with 
99m
Tc-PYP may prove a simple, non-
invasive and widely available method in the identification of patients with the ATTR subtype, thus optimizing therapeutic 
decisions. 
HJNM 2015; 18(Suppl1); 42-50                                                                Published on line: 12 December 2015 
 
 
 
Introduction 
 
ardiac amyloidosis (CA) or "stiff heart syndrome" constitutes an underestimated and underdiagnosed cause of 
cardiac insufficiency. It is a progressive disorder caused by the deposition of an abnormal extracellular fibrillary 
protein, namely amyloid, in the heart tissue, leading to early death due to congestive heart failure and arrhythmias.  
Amyloidotic cardiac involvement can occur either as part of a systemic disease, or as a localized phenomenon. Amyloid 
deposition can occur in multiple organs (e.g. heart, liver, kidneys, skin, eyes, lungs, nervous system) resulting in a variety 
of clinical manifestations. The type of the primary pro-amyloidogenic protein is the major determinant of the pattern and 
the severity of organ involvement. Furthermore, treatment decisions are based on the type of the amyloid fibril 
composition. Thus, in primary light chain (AL) cardiac amyloidosis the fibrils consist of light chain immunoglobulins 
produced by a clonal plasma cell population in the bone marrow and treatment involves chemotherapy or autologous 
peripheral blood stem cell transplantation. In AL, the spectrum and pattern of organ involvement is very wide, including 
proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure, and autonomic or sensory 
neuropathy, but cardiac involvement occurs in more than half of the cases and is sometimes the only presenting feature 
C 
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[1]. 
In transthyretin-related cardiac amyloidosis (ATTR), further classified in familial amyloid cardiomyopathy 
(ATTRmutant or AATRm) and acquired senile systemic amyloidosis (ATTRwild-type or AATRwt), misfolded monomers or 
dimers of the normally tetrameric protein of transthyretin form amyloid fibrils that are deposited in the myocardium. 
Transthyretin-related cardiac amyloidosis constitutes by far the most common cause of non-AL cardiac amyloidosis; it is 
more common in men than in women [2], and rarely develops in people under the age of 40. In familial ATTR syndromes, 
an inherited mutation causes the production of a mutated protein which tends to produce amyloid fibrils; several 
mutations have been associated with cardiac ATTR. ATTRm has an autosomal dominant pattern of inheritance; however, 
a negative family history is not rare. Wild-type ATTR is an acquired amyloidosis, which is increasingly recognized in the 
past decade. Wild-type TTR amyloid deposits are found at autopsy in about 25% of individuals above 80 years of age. 
Wild-type ATTR is a predominantly cardiac disease and the only other significant extracardiac feature is a history of 
carpal tunnel syndrome, often preceding heart failure by 3 to 5 years. Extracardiac involvement is most unusual [1]. 
Transthyretin is produced in the liver and treatment may involve drugs that stabilize transthyretin and prevent disease 
progression or organ transplantation in ATTRm. Mutations in other genes, such apolipoprotein A1 may rarely result in 
amyloid formation affecting the heart.  
The diagnostic algorithm of CA encompasses hitherto biomarkers, electrocardiography (ECG), echocardiography 
(ECHO), cardiac magnetic resonance (CMR) and biopsy, which remains the reference standard. In current clinical 
practice, biopsy is required for older patients in order to accurately identify the cardiac amyloid fibril type as well as for 
patients with an echocardiographically thickened left ventricle who have no history of hypertension, valvular disease, and 
have a family history of hypertrophic cardiomyopathy, particularly if the patient is young. However, the identification of 
amyloid fibrils by Congo-red staining alone is not sufficient for the correct diagnosis of amyloidosis and the identification 
of the specific amyloid fibril type is required. The correct typing is demanding and requires additional 
immunohistochemical studies, genetic tests and may also require advanced technology such as mass spectroscopy, 
which is the reference standard for the identification of the amino acid sequence of the amyloid-forming protein. 
An important aspect of the diagnostic algorithm for the identification of amyloidosis and amyloid type is the 
requirement for an invasive procedure such as endomyocardial biopsy. Although relatively safe, tissue sampling is not 
always feasible and a small but real risk of complications exists. Thus, non-invasive methods that could aid in the 
diagnosis of cardiac amyloidosis and the differentiation between the AL and ATTR types of amyloid deposits can improve 
substantially our diagnostic algorithms. In this pilot study we applied myocardial scintigraphy with technetium-99m-
labelled pyrophosphate (
99m
Tc-PYP) aiming to discriminate AL from ATTR and optimize therapeutic decisions. We also 
attempted a preliminary comparison with another radiotracer, specifically pentavalent technetium-99m labelled 
dimercaptosuccinic acid [
99m
Tc(V)-DMSA], whenever feasible. 
 
 
Subjects and Methods  
 
Twelve patients (8 males, aged [mean±SD] 70.6±13.2 years; 4 females, aged 65.7±9.9 years) were enrolled in the 
context of discriminating AL from ATTR cardiac amyloidosis, in the nuclear medicine departments of two tertiary referral 
hospitals. The present study protocol was in agreement with the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by our Institutional Review Committees. Written informed consent was obtained from each 
patient. 
Myocardial scintigraphy (planar and tomographic imaging) was conducted with a single-head γ-camera in the 
first department (Sophycamera DS7, Sopha Medical Vision International, Buc Cedex, France) and a dual-head camera in 
the second (General Electric Optima NM/CT 640, GE Healthcare, Wauwatosa, WI, USA), equipped with high-resolution, 
parallel-hole collimators. Imaging was performed at 1, 2 and/or 3h after intravenous administration of 555-925MBq 
99m
Tc-
PYP. The photopeak was centered at 140keV, with a symmetric 10% window. Planar images were acquired for a total of 
500,000 counts, on a 128×128 or 256×256 matrix. Tomographic imaging (single-photon emission tomography, SPET) in 
a 64×64 matrix, 32 frames at 20sec/frame, followed in cases of 99mTc-PYP myocardial uptake on planar images. 
Myocardial radiotracer uptake was evaluated optically and also by the use of a semiquantitative method. Two 
rectangular or circular regions of interest (ROIs) were drawn: one over the heart and another (mirror) over the 
contralateral hemithorax, to calculate the corresponding heart-to-contralateral (H/CL) count ratio. According to published 
reference standards, a cut-off H/CL value of 1.5 is considered as best discriminating between AL and ATTR [3]. Three 
patients were additionally submitted to planar myocardial scintigraphy with 555-925MBq 
99m
Tc(V)-DMSA at 2h and 24h pi 
acquiring 250,000 counts, on a 256×256 matrix. The results of both scintigraphic modalities were compared with clinical, 
laboratory, other imaging and biopsy findings. 
 
Results 
 
99m
Tc-PYP scintigraphy revealed intense diffuse myocardial uptake on optical evaluation that was also verified 
quantitatively in 6 patients (5 males, 1 female), all of whom were diagnosed with ATTR (Figure 1). None or faint 
myocardial tracer uptake was found in 4 patients (1 male, 3 females), who were ultimately diagnosed with AL (Figures 2 
and 3). Two AL patients (males) showed a borderline positive scan with mild uptake on visual evaluation, but their H/CL 
ratios did not exceed 1.5 (Figure 4). Despite the small patient population, we estimated the sensitivity and specificity of 
myocardial 
99m
Tc-PYP scintigraphy at 100%, when applying the semiquantitative method of the H/CL ratio. Notably, the 
specificity decreased to 75% when relying solely on visual assessment. All three patients studied with 
99m
Tc(V)-DMSA 
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scintigraphy demonstrated persistent intense blood pool activity, particularly at 2h pi, hindering the differential diagnosis 
between AL and ATTR. Yet some diffuse circumscribed uptake was observed in the delayed 24h-images in these 
patients, who were ultimately diagnosed with AL (Figure 2). 
 
 
Figure 1a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b 
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Figure 1. A 71 years old male with NYHA class II heart failure demonstrates intense 
99m
Tc-PYP myocardial uptake in both planar 
(1a) and SPET imaging (1b). H/CL ratio=2.34. The echocardiographic findings were consistent with cardiac amyloidosis, without 
discriminating the specific subtype. Endomyocardial biopsy in conjunction with immunohistochemistry revealed ATTR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A case of a 58 years old female with hardly visible 
99m
Tc-PYP myocardial uptake in planar images. H/CL 
ratio=1.15.ATTR. 
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Figure  3. A case of a 60 years old female with biopsy-proven AL shows absent 
99m
Tc-PYP myocardial uptake in anterior and left 
anterior oblique planar images (upper row). Persistent 
99m
Tc(V)-DMSA blood pool, especially in the 2-hour planar images 
(middle row) prevents the differentiation between ATTR and AL, but the delayed circumscribed 24h-activity warrants further 
investigation. 
 
 
 
 
99m
Tc-PYP 
99m
Tc(V)-DMSA 
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Figure  4. A case of a 64 years old male with mild myocardial uptake in planar images; a ratio of H/CL=1.09 essentially rules out 
ATTR. 
 
 
Discussion 
 
The differentiation between AL and ATTR cardiac amyloidosis presents a diagnostic challenge, being essential due to its 
unequivocal impact on prognosis, treatment, genetic guidance, and patient follow-up. Of note, the coexistence of a 
monoclonal gammopathy with senile amyloidosis is not rare in patients older than 70 years [4], considering that the 
prevalence of monoclonal gammopathy of undetermined significance (MGUS) is more than 5% in this age group [5]. 
Measurements of brain natriuretic peptides (NTproBNP and BNP) and cardiac troponins are extremely 
informative in AL, providing major diagnostic and prognostic information. Their prognostic value in ATTR is less clear. In 
general, elevated NT-proBNP levels in systemic AL are a sensitive marker of cardiac involvement, with a cut-off value 
above 650ng/L (in the absence of renal dysfunction or other cardiac disease) considered to be associated with amyloid 
cardiac involvement. Elevated levels of NTproBNP are also associated with poor survival and early death. Increased 
levels of plasma troponin is also a marker of poor prognosis, but the underlying mechanism has not been elucidated. 
ECG can provide clues to the presence of cardiac amyloidosis (low QRS voltage, conduction abnormalities, non-
specific ST changes, pseudo-infraction patterns, LBBB or RBBB etc.), but cannot differentiate AL from TTR amyloidosis.   
Echocardiographic findings may be characteristic in advanced disease but are harder to elicit earlier on and do 
not have clear prognostic significance. Typical findings include concentric ventricular thickening with right ventricular 
involvement, poor biventricular long-axis function with normal (or near-normal) ejection fraction and valvular thickening, 
particularly in ATTR. Diastolic dysfunction is the earliest echocardiographic abnormality and may occur before cardiac 
symptoms develop. Nevertheless, as with all investigations, ECHO must be interpreted within the clinical context; a 
speckled or granular myocardial appearance (“sparkling”), although characteristic of amyloid, is an inexact finding, which 
is dependent on machine gain settings. 
In CMR, the appearance of global, subendocardial late gadolinium enhancement is highly characteristic of 
cardiac amyloid and correlates with prognosis, but may be atypical and patchy, especially in early disease, and does not 
distinguish the type of amyloid infiltration. Cardiac MR is particularly useful in patients with other causes of left ventricular 
thickening/hypertrophy because it can differentiate amyloidosis from hypertension, which may not be achievable by 
routine echocardiography. Thus, regarding all the aforementioned modalities, both sensitivity and mainly specificity as to 
the type of amyloid fibrils are considerably limited. 
Today, definitive diagnosis of cardiac amyloid disease is based on endomyocardial biopsy in conjunction with 
immunohistochemistry or, in ambiguous cases, with mass spectroscopy. Amyloid fibrils bind Congo-red stain, yielding the 
pathognomonic apple-green birefringence under cross-polarized light microscopy that remains the gold standard for 
identifying amyloid deposits. Complications such as cardiac wall perforation remain a small but real risk and may not be 
well-tolerated in restrictive cardiomyopathy. Moreover, the difficulties involved in performing the ultimate diagnostic 
confirmation with mass spectroscopy, which is conducted in very few centers in the world, propound the necessity for an 
improved diagnostic technique. 
This pilot study investigated the ability of 
99m
Tc-PYP scintigraphy to differentiate between ATTR and AL cardiac 
amyloidosis. Whole-body scintigraphy with 
99m
Tc-PYP has been used in the past as a diagnostic tool in the assessment of 
patients with rhabdomyolysis, acute myocardial infarction, soft tissue injuries, polymyositis and dermatomyositis. The 
mechanisms of increased tracer uptake in the inflammatory muscles probably include tracer binding in high calcium 
concentrations in necrotic cells as well as in crystalline hydroxyapatite and calcium phosphate in ischemic tissues [6]. 
99m
Tc-PYP was first used as a bone-seeking agent. It was also found to localize in acute myocardial infarction and other 
necrotic tissues. The mechanism that has been suggested is due to the formation of polynuclear complexes with 
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denatured macromolecules [7] or formation of intramitochondrial apatite-like crystals in damaged cells [8]. Earlier 
experimental studies, which produced intestinal infarction in dogs, had shown the utility of 
99m
Tc-PYP in evaluating 
ischemic bowels [9-11]. Barth et al. found that experimental small bowel infarction could be detected as early as five 
hours after the onset of ischemia [12]. Lin et al. reported a case of intestinal perforation in dermatomyositis demonstrated 
on a 
99m
Tc-PYP abdominal scan for evaluating abdominal vasculitis [13]. Using 
99m
Tc-PYP scan, colon necrosis was 
correctly detected as early as 1 hour after tracer injection in this presented case [14].  
As early as 1983, colleagues described that a persistent uptake at 2h post-injection in case of diffuse 
99m
Tc-PYP 
myocardial uptake in the early image, seems to be correlated with myocardial damage. In cardiac amyloidosis, the 
underlying mechanism of increased 
99m
Tc-PYP uptake has recently been postulated to be linked with the possible 
existence of higher calcium concentrations [15], specifically higher calcium-containing compounds in ATTR hearts. On 
these terms, different calcium concentrations seem to reside within the different amyloid subtypes [16]. The diffuse 
pattern of 
99m
Tc-PYP myocardial uptake in ATTR is also significant. It is well-known that focal tracer uptake may be 
attributed to myocardial infarction [17], whereby PYP is fixed intracellularly by binding with mitochondrial calcium 
deposits. In addition, a temporal and topographical relationship has been found between calcium accumulation and 
concentration of 
99m
Tc-PYP in acute myocardial infarcts [17]. We believe that the biochemical pathways involved in 
99m
Tc-
PYP affinity for ATTR cardiac amyloidosis may be far more complex. Other researchers have reached the general 
conclusion that uptake of 
99m
Tc-PYP and related phosphates in infarcted myocardium and other tissues is a multifactorial 
phenomenon, in which concentration of the agents results from complexing with various soluble and insoluble forms of 
tissue calcium stores, including amorphous calcium phosphate, crystalline hydroxyapatite and calcium complexed with 
organic macromolecules, possibly supplemented by calcium-independent complexing with tissue constituents [18]. 
Indeed the degenerative process is associated with electrolyte alterations resulting from altered membrane function, for 
instance myocardial degeneration and myocytolysis have been shown to be associated with elevated myocardial sodium 
and calcium levels [18]. It is possible, for example, that concentration of 
99m
Tc-PYP may be mediated by influx of the 
agent along with calcium ions, followed by formation of an intracellular calcium-PYP complex, incorporation of the 
radiopharmaceutical into foci of calcification, and/or binding of the agent by altered intracellular macromolecules [19]. 
In another relevant analysis, it is reported that the intensity of nonspecific binding of 
99m
Tc-PYP was determined 
as the successive decreasing sequence of calcium phosphate, soluble proteins and enzymes, dextran, myosin, and 
cellulose. It is thus stated that, if calcium phosphate is responsible for the uptake of Tc-PYP, we should see the uptake 
only in the presence of large amounts of calcium phosphate in soft tissue. However, uptake may also be observed in 
conditions in which calcium phosphate is present in minor amounts, like inflammatory diseases, unstable angina, 
cardioversion, after radiation therapy and amyloid disease. Thus, the binding of 
99m
Tc-PYP in the soluble muscle proteins 
and enzymes in different cardiac abnormalities probably plays a major role and calcium phosphate has only a minor role 
[20]. 
Pentavalent 
99m
Tc-DMSA scanning demonstrated diffuse uptake in the heart in a 71 years old woman with 
histologically confirmed primary amyloidosis [21]. On the other hand, researchers found 
99m
Tc(V)-DMSA to accumulate in 
myeloma cells unrelated with amyloidosis [22]. It has been postulated that pentavalent DMSA resembles phosphate ion in 
its distribution pattern, and that this is the mechanism by which pentavalent DMSA accumulates in tumors, particularly 
medullary thyroid cancer, where calcification and amyloidosis are a well-recognized phenomenon [23, 24]. Moreover, 
Denoyer and colleagues elucidated the exact mechanisms; notably, the tracer reflects phosphate ion (Pi) transport and 
metabolism, entering cancer cells specifically via the type III Na/Pi co-transporter, this uptake being driven by the cellular 
levels of phosphorylated (i.e. activated) focal adhesion kinase (FAK), a keystone of accelerated proliferation [25, 26]. 
According to our studies in breast cancer, the uptake of 
99m
Tc(V)-DMSA is related to cell proliferation, FAK activation, 
neo-angiogenesis and overexpression of several growth factors, including calcitonin gene-related peptide and platelet-
derived growth factor [27-36]. Calcitonin gene-related peptide (CGRP) is a member of the adrenomedullin-amylin family 
leading to formation of β-amyloid deposits. Thus, the potential affinity of 99mTc(V)-DMSA for primary AL rather than ATTR 
amyloidosis may be justified by its biochemical pathway of accumulation and propounds the need for further research. 
Several recent publications exist on the usefulness of specific radiotracers in the detection of cardiac amyloidosis 
[3, 15, 37]. Limited data involving small patient samples report that 
99m
Tc-3,3-diphosphono-1,2 propanodicarboxylic acid 
(
99m
Tc-DPD) scintigraphy can also differentiate AL from ATTR [37]. Other radiopharmaceuticals that have been applied in 
the detection of amyloid deposits include 
123
I-labeled serum amyloid P component (SAP) and 
99m
Tc-labeled aprotinin. 
Labeled SAP is not commercially available except for only a few centers worldwide, and displays a poor sensitivity in 
patients with ATTR [39, 40]. Some promising results have been observed with 
99m
Tc-labeled aprotinin [41, 42]. Our results 
are in accordance with a research study conducted by Bokhari and colleagues [3]. Besides confirming the prominent role 
of 
99m
Tc-PYP scintigraphy in the diagnostic armamentarium of CA, it would also be valuable to explore its potential utility 
in the context of disease follow-up, evaluation of response to treatment and prognosis of major adverse cardiac events, or 
even induction of relevant therapeutic agents. 
The small sample of patients definitely belongs to the limitations of our study. Another potential pitfall involves 
the procedure regarding the semiquantitative method, which should probably be modified in order to achieve higher 
sensitivity as well as specificity of the method. Therefore, further research is merited. 
In conclusion, our preliminary results demonstrate the efficacy of myocardial 99mTc-PYP scintigraphy in 
elucidating the diagnostic dilemma between ATTR and AL cardiac amyloidosis. The underlying pathophysiologic 
mechanism remains to be clarified. Myocardial scintigraphy with 
99m
Tc-PYP constitutes a simple, non-invasive, low-cost 
and widely available modality which may prove extremely useful in the identification of patients with the ATTR subtype. 
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Abstract 
Chemical modification of histones represents an important epigenetic mechanism critical for DNA metabolism including, 
transcription, replication and repair. A well-known example is maintenance of histone acetylation status by the opposing actions 
of histone acetyltransferase and histone deacetylase enzymes which add and remove acetyl groups on lysine residues on 
histone tails, respectively.  Similarly, histone methyltransferase and histone demethylase enzymes are responsible for adding 
and removing methyl groups on histone tails, respectively. Further, there is accumulated evidence indicating a histone code 
where combinations of different chemical modifications on histone tails act in concert to regulate DNA metabolic events. 
Although numerous compounds have been developed to specifically alter the function of chromatin modifying enzymes (for 
example, histone deacetylase inhibitors are relatively well-investigated), we are only at the early stages of understanding the 
epigenetic effects of dietary compounds. Here we used in silico molecular modeling approaches combined with known 
experimental affinities for controls, to identify potential chromatin modifying compounds derived from Olea Europaea. Our 
findings indicate that various compounds derived from Olea Europaea have the ability to bind to the active site of different 
chromatin modifying enzymes, with an affinity analogous or higher than that for a known positive control.  Further, we initiated 
the process of validating targets using in vitro binding and enzyme activity inhibition assays and provide initial findings of 
potential epigenetic effects in a clinical context. Overall, our findings can be considered as the first instalment of a 
comprehensive endeavour to catalogue and detail the epigenetic effects of compounds derived from Olea Europaea.     
HJNM 2015; 18(Suppl1); 51-62                                                                Published on line: 12 December 2015 
 
 
 
Introduction 
 
pigenetics which literally translates to as “above” or “upon” genetics, is broadly understood to involve mechanisms 
resulting in heritable changes in gene expression that are not due to changes in the underlying DNA sequence. 
Therefore, if the sum of genes in a cell makes up the genome of that cell, the epigenome is considered as the 
totality of epigenetic processes involved in regulating gene expression which are not associated with changes in the gene 
sequence. Further, the large-scale and systematic investigation of the epigenome, predominantly via experiments using 
next generation sequencing technologies (NGS), refers to epigenomics. Epigenomic analyses have been typified by the 
Encyclopedia of DNA Elements (ENCODE) project and are poised to be extended by the US National Institutes of Health, 
Roadmap Epigenomics Project [1-3]. For example, chemical modification of DNA with a methyl group (or DNA 
methylation) is a well-known epigenetic mechanism and has been widely investigated using NGS [4, 5]. Indeed, aberrant 
DNA methylation has now been associated with various malignancies and a host of other chronic diseases.   
Similarly, aberrant chemical modifications on chromatin have been linked to disease. Briefly, the approximately 2 
metres of DNA in each cell is organized into functional units known as nucleosomes (Figure 1) [6-8]. Each nucleosome 
consists of approximately 146 base pairs of DNA wrapped around two copies of each of the four core histones, H2A, 
H2B, H3 and H4. Predominantly the lysine residues of the protruding histone tails of the core histones undergo chemical 
modification, of which acetylation and methylation are amongst the most-investigated. The acetylation status of histones 
is regulated by the opposing actions of histone acetyltransferases (HAT) which add acetyl groups to lysine residues on 
core histones and histone deacetylase enzymes (HDAC) which remove acetyl groups [9].   
Numerous enzymes have been identified to possess HAT activity and are classified into the major Gnc5-related 
N-acetyltransferase and MYST families with the p300/CBP, nuclear receptor coactivators representing another important 
class [10]. In turn, the 18 mammalian HDAC enzymes are categorized into two major groups on the basis of their 
homology to yeast counterparts, 1) the metal-dependent classical HDAC enzymes which include (class I: HDACs, 1, 2, 3  
E 
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Figure 1. 3D chemical structure of a nucleosome core particle with DNA fragment (146 base pairs) wrapped around the histone 
core (PDB ID: 1AOI). Nucleosomes are comprised of two sets of each of the four core histones with histone tails (H3 tail 
depicted-not to scale) protruding from the structure enabling chemical modification. Acetylation status is maintained by the 
opposing actions of histone acetyltransferases (HAT) which add acetyl groups to lysine residues and histone deacetylases 
(HDACs) which remove acetyl groups. Similarly, histone methylases control methylation levels, where histone methyltransferase 
(HMT) add methyl groups to residues whilst histone demethylases (HD) remove methyl groups.    
 
 
and 8; class IIa: HDACs 4, 5, 7 and 9; class IIb: HDACs 6 and 10; class IV: HDAC11) and 2) the sirtuins 1-7 which are 
nicotinamide adenine dinuclotide-dependent [9, 11, 12]. Similarly, histone methylation status is maintained by histone 
methyltransferases (HMT) which add methyl groups and include histone-lysine N-methyltransferases (divided into SET 
[Su(var)3-9, Enhancer of Zeste, Trithorax] domain containing or non-SET domain containing enzymes), and histone-
arginine N-methyltransferases and histone demethylases (HDM) which remove methyl groups from core histones [10]. 
Importantly, it has been demonstrated that combinations of patterns of differential histone acetylation and methylation 
regulate work in concert to control chromatin architecture and gene expression providing evidence for the “histone code” 
hypothesis [13, 14]. This adds a layer of complexity to the genome with such a vast array of possible chemical 
modifications. To provide a general example, histone acetylation and methylation of histone 3 on lysine 4 is associated 
with active transcription whereas deacetylation and methylation of histone 3 on lysine 9 is associated with inactive 
chromatin. 
      Diverse classes of chromatin modifying compounds have now been developed for their clinical potential, 
particularly for various malignancies, either as standalone therapeutics or combined with conventional therapies.  Cases 
in point include the HDACi suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza; Merck) and depsipeptide 
(Romidepsin, Istodax; Celgene) which, were the initial HDACi approved by the US Food and Drug Administration (FDA) 
for the treatment of advanced cutaneous T-cell lymphoma [15]. In addition, there is excitement regarding the potential of 
diet and regulation of the epigenome, necessitating research in the new field of nutriepigenomics, with an accumulating 
list of dietary compounds that have been shown to alter the chromatin landscape and gene expression [16]. Although still 
at very early stages, well-known examples of dietary chromatin modifying compounds include the active constituent of 
turmeric, curcumin which has been identified to be an HDACi, as well as the red wine phenol, resveratrol which activates 
the class III HDAC, Sirt1 [17, 18].  
      Here, we explored the epigenome-modifying potential of a selected group of compounds derived from Olea 
Europaea. Our selection was based on the ability to easily quantitate the chosen compounds from standard olive pomace 
extractions by high performance liquid chromatography (HPLC), which represents distinct advantages for further 
characterization. For this first instalment, our partial list of compounds, includes hydroxytyrosol and oleuropein, which 
have extensively been shown to have wide-ranging beneficial health effects, and oleocanthal which has been shown to 
be a potent inhibitor of cyclooxygenase enzymes (Cox-1 and 2) and therefore, associated with pain relief [19, 20]. Our 
investigations predominantly involve in silico evaluation of the potential of Olea Europaea-derived compounds to bind in 
the active domains of target chromatin-modifying enzymes including HATs, HDACs and histone demethylases. The 
epigenetic targets were chosen on the basis of the lists compiled by commercial provider Reaction Biology Corp. An 
important advantage of this strategy is the public availability of known IC50 values or % inhibition values for positive 
controls for each of the target proteins, which can inform our molecular modelling in an iterative process. With a focus on 
hydroxytyrosol, our work includes experimental validation of an epigenetic target and an analysis of modulation of HDAC6 
in the context of a diabetic wound case study. 
 
Materials and Methods  
 
In silico molecular docking  
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Protein and ligand structure preparation 
Chemical structures for olive bioactive compounds were obtained from the NCBI PubChem Compound database [21] as 
sdf. files, and then converted to pdb. format with OpenBabel [22], as listed in Table 1. The experimental coordinates of 
the epigenetic structures were obtained from the Protein Data Bank (PDB) [23], where available, as listed in Table 2. All 
PDB crystal structures used had a resolution of less than 3.00Å, and all water molecules were removed, as well as any 
exogenous ligands prior to docking. The first protein chain (chain A) was used for subsequent docking calculations, and 
where present Zn atoms were retained in the structures. A comparative (homology) model of several HDACs and HATs 
(where their respective x-ray crystallographic structure was not available) were constructed using the SWISS-MODEL 
ExPASy server, where the human FASTA sequence for each protein was obtained from the UniProt database [24] (ID 
listed in Table 2). Three models were generated by the server, and the top ranked GMQE model was selected for each 
epigenetic target.  
 
Table 1. Olive bioactive compounds investigated 
Compound 
name 
MW 
(gmol
-
) 
Structure 
Tyrosol 
 
139 
 
Cinnamic acid 
 
149 
 
Vanillin 153 
 
Hydroxytyrosol 
 
155 
 
p-coumaric acid 
 
165 
 
Vanillic acid 
 
169 
 
Hydroxytyrosol 
acetate 
 
197 
 
Elenolic acid 
 
243 
 
Apigenin 
 
271 
 
Luteolin 
 
287 
 
Oleocanthal 
 
305 
 
Pinoresinol 
 
359 
 
1-Acetoxy-
pinoresinol 
 
417 
 
Oleuropein 
 
541 
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Table 2. Experimental coordinates and docking parameters for AutoDock Vina 
Protein PDB 
ID 
UniProtK
B # 
Vina 
Searchspac
e 
3D 
Representation 
HDAC1 4BKX - X:18.7535 
Y:22.7369 
Z:21.1327 
 
HDAC2 - Q92769 X:18.5247 
Y:20.6447 
Z:21.8525 
   
HDAC3 4A69 - X:26.8411 
Y:26.2011 
Z:20.8456 
 
HDAC8 1W22 - X:36.8727 
Y:18.0877 
Z:29.5576 
  
 
HDAC4 4CBY - X:39.2723 
Y:25.8957 
Z:37.7597 
 
 
HDAC5 - Q9UQL6 X:20.0911 
Y:27.3540 
Z:25.0000 
  
 
HDAC7 3C10 - X:25.7613 
Y:27.6917 
Z:15.2945 
  
 
HDAC6  - Q9UBN7 X:20.2066 
Y:20.2711 
Z:17.4606 
   
 
HDAC10 - Q969S8 X:27.5080 
Y:26.6923 
Z:15.2250 
  
 
SIRT1 4KXQ   X: 23.5588 
Y:25.4043 
Z:22.2533 
 
 
SIRT2 4RM
H 
-  X:20.1359 
Y:16.9719 
Z:19.7885 
 
SIRT3 3GLS - X:15.8738 
Y:16.1272 
Z:29.6833 
  
 
SIRT5 2NYR - X:16.9138 
Y:24.8714 
Z:27.9732 
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HDAC11 - Q96DB2 X:25.0000 
Y:15.8769 
Z:20.0130 
  
 
MYST2 - O95251 X:22.1647 
Y:25.0000 
Z:14.7616 
  
 
MYST4 - Q8WYB5 X:17.0837 
Y:23.1876 
Z:25.0000 
  
 
CBP/CR
EBBP 
- Q92793 X:23.8449 
Y:19.8348 
Z:17.0297 
 
 
p300 3BIY - X:25.2605 
Y:20.2350 
Z:17.1278 
  
  
pCAF 1CM0 - X:21.2596 
Y:18.2596 
Z:21.5758 
   
KAT2A 1Z4R - X:25.0000 
Y:13.0644 
Z:36.4100
  
 
KAT5 2OU2 - X:29.6444 
Y:27.7770 
Z:48.5760 
 
 
KDM4A 2QQS - X:20.6175 
Y:17.8001 
Z:18.3697 
  
 
KDM5B - Q9UGL1 X:17.1910 
Y:25.0000 
Z:31.3245 
  
 
 
 
 
Protein-ligand docking calculations 
The molecular docking program AutoDock Vina (The Scripps Research Institute, California, USA) was used to generate 
energetically favourable binding sites for the phenolic ligands onto the chosen epigenetic targets. AutoDock Vina 
combines the use of knowledge-based and empirical scoring functions, where the program draws on experimental affinity 
measurements and conformational predictions of the receptor-ligand complex. The binding pose of the ligand is then 
ranked based on an energy scoring function [25]. Epigenetic targets and ligand pdb. files were processed using PyRx 
(The Scripps Research Institute, California, USA) to create their corresponding pdbqt. files for use with AutoDock Vina. 
Rotatable torsions of the ligands were activated and all epigenetic protein structures were assumed rigid. The docking 
site of the ligand was defined by establishing a cube at the geometrical centre of the protein active or binding site with the 
dimensions for each macromolecule listed in Table 2. The best binding pose was saved, and its corresponding binding 
affinity value for each complex. The binding poses were then visualised and analysed using VMD version 1.9.2 [26].  
 
Demethylase inhibition assay  
The inhibitory activity of hydroxytyrosol against lysine specific demethylase 1 (LSD1) was estimated by the commercial 
provider, Reaction Biology Corp (RBC) (Pennsylvania, USA). Briefly, hydroxytyrosol was tested in ten doses with a three-
fold serial dilution starting at 100μM. Similarly, the positive control compound, tranylcypromine was tested in ten doses 
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with a three-fold serial dilution starting at 100μM.  A fluorescence coupling enzyme assay based on the production of 
FAD-dependent H2O2 as a result of demethylase activity of LSD1, using 10µM histone H3(1-21) K4me2 peptide as a 
substrate, was measured by coupling with horse radish peroxidase and Amplex Red. The IC50 values for each compound 
were then calculated. 
 
 
Immunofluorescence staining of epidermal tissue sections 
 
Tissue collection and processing 
Six tissue samples were obtained through therapeutic debridement procedures over several weeks, at Ashwood Medical 
Group, Melbourne, Australia with informed consent. The samples were collected from a 79 year old male patient whom 
suffered from a chronic diabetic venous ulcer of approximately 10cm
2
, located on the right inferolateral lower leg. The 
patient was treated with a commercial topical antimicrobial spray, containing the Olivamine 10
®
 formulation, which 
includes a hydroxytyrosol containing olive extract. Sections were paraffin embedded by Gribbles Pathology Veterinary, 
and subsequently, sections of 4μm were prepared at a clearance angle of 5° using the Leica Microsystems microtome. 
 
 
Immunofluorescence 
Expression of HDAC6 and acetylated α-tubulin were examined in the skin samples using anti-HDAC6 (1:500) (Epitomics, 
California, U.S.A) and anti-acetylated α-tubulin (1:250) antibodies. Samples were deparaffinised in xylene and hydrated in 
three washes of graded ethanol. Slides were subsequently microwaved on high power for 1 minute and low power for 10 
minutes before left to cool at room temperature for 20 minutes. Slides were then equilibrated with two washes in 0.1% 
Tween 20 with phosphate buffered saline (PBS) for 15 minutes on an orbital mixer at room temperature. Tissues on the 
slide were circled with a mini pap pen (Invitrogen, California, U.S.A) and were blocked with 100μL of 1% bovine serum 
albumin (BSA (v/v)) for 1 hour and blotted. Subsequently, 100μL of primary antibody in 1% BSA was added and slides 
were incubated overnight in a 4°C humidified chamber. Slides were then washed 3 times in 0.1% Tween 20 PBS for 10 
minutes at room temperature on an orbital mixer. Secondary antibody (100-300µL) anti-mouse 488 (1:500) and anti-rabbit 
546 (1:500) in 1% BSA was added for a 1 hour incubation in a dark humidied chamber on an orbital mixer at room 
temperature. TOPRO-3 (100-300µL; 1:1000) in PBS was the added for a further 10 minutes. Slides were then washed 
twice for 10 minutes in PBS on an orbital mixer. Excess PBS was blotted off the slides and samples were cover slipped 
with Permount before left to dry in a dark humid chamber for three days. Skin sections were examined and images were 
obtained using the A1r Nikon confocal microscope from Monash Micro Imaging set at x60 objective with oil. A Z-stacked 
imaged was acquired with a step size of 0.25μm. 
 
 
Results 
 
In silico docking studies and in vitro inhibition of LSD1 by hydroxytyrosol 
Molecular docking studies were performed on the 14 bioactive compounds to obtain insight into their binding pose onto 
the epigenetic target enyzmes. In turn, the calculated free energy of binding (ΔG) for each complex was also predicted. 
The binding affinities obtained for the bioactive compounds to each epigenetic target is presented in Figure 2. The values 
indicate the binding energy upon docking of the ligand to the known active site or binding site of the protein, as stipulated 
in the literature. The results demonstrate clear trends within the protein groups, and among the global dataset. Firstly, 
there appears to be an increase in binding affinity following docking with the higher weighted compounds, especially from 
apigenin through to oleuropein which all possess more than one phenyl ring. Secondly, there appears to be similarity 
between homologous epigenetic targets, whereby the first three HDAC classes produce comparable results within their 
respective cohort, while KAT2A and KAT5 share low binding affinities to the tested ligands. Thirdly, among the Class II, III 
and IV HDACs, HDAC4, 6, 7 & 11 as well as SIRT1 showcase a more homogenous spread of binding affinities, with 
some interesting higher docking affinities seen with the lower weight compounds hydroxytyrosol and cinnamic acid. Upon 
close inspection of the docked ligands to the above epigenetic targets, it was noticed that histidine residues were directly 
involved in ligand interactions among HDAC 4, 6, 7 and 11 as well as within LSD1 (Figure 3).   
The findings from the LSD1 demethylase profiling indicated inhibition of the enzyme by hydroxytyrosol with an 
IC50 of 3.57µM demonstrating more potent activity than the positive control and well-known LSD1 inhibitor, 
tranylcypromine (IC50 =17.7µM). 
 
Immunofluorescence expression of HDAC6 in a chronic diabetic ulcer  
The level of HDAC6 and acetylated α-tubulin expression was characterised in tissue sections obtained from the peri 
wound of a diabetic ulcer treated with a commercial topical product, containing the Olivamine 10
®
 formulation, which 
includes a hydroxytyrosol containing olive extract. The findings illustrate the time-dependent increase in expression of 
HDAC6 within the tissue sections examined, without a concomitant change in expression of acetylated α-tubulin from 
week 1 to week 3, Figure 5. 
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Figure 2. Heat map depicting free energy of binding (ΔG) for each complex. Red corresponds to the weakest binding affinity 
whilst green indicates strongest binding values. The selected bioactive compounds are in ascending order, based on molecular 
weight.   
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Figure 3. 3D structure of epigenetic targets complexed with hydroxytyrosol (HT), cinnamic acid (CA) or oleocanthal (OL). Depicts 
the binding mode of the highest bound affinity for each compound, and shows residues directly involved in the interaction, within 
3.5Å of the ligand.   
 
 
 
 
 
 
 
 
 
 
 
 
Compound IC50 (μM) 
Hydroxytyrosol 3.57 
Tranylcypromine 17.7 
A 
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Figure 4. LSD1 demethylase activity and binding of hydroxytyrosol and the control compound, tranylcypromine. (A) IC50 values 
for the two compounds, as produced by RBC. (B) 3D structure LSD1 (PDB ID: 2DW4) complexed with hydroxytyrosol (orange) 
and tranylcypromine (silver). Depicts the binding mode of the highest bound affinity for each compound, and shows residues 
directly involved in the interaction, within 3.5Å of the ligand.   
 
 
Discussion 
 
Using molecular docking, we propose models of the interactions between chosen epigenetic targets and bioactive olive 
ligands within the known active sites of the proteins. Firstly, our results generally indicate an increase in binding affinity in 
correlation with a higher ligand molecular weight. Similar patterns regarding molecular weight have emerged in a range of 
docking studies, due to limitations of unique algorithms in various programs [28-30]. Nevertheless, in general and in our 
case, false positives represent a better outcome than missing potential interactions. Overall, our studies identify specific 
interactions of the ligand and surrounding residues providing important insights into the potential unique ligand binding 
positions.  Inspection of the binding modes obtained from AutoDock Vina, it was found that the various bioactive ligands 
had effectively bound to the known active sites of the proteins, and specific residue interactions of the docked compounds 
were shown to be essential in effective binding (Figures 2-4). The active site containing the histidine residues directly 
involved in proton transfer of HDACs [31] is found to interact with the bioactive compounds HT, CA and OL among the  
HDACs 4, 6, 7, 11 and SIRT1. This indicates that the observed binding modes of these complexes, is probably an 
accurate representation of the ligands as inhibitors, and may be the cause for the relatively high ΔG values observed.  
Given the relatively high binding affinity of hydroxytyrosol to LSD1 in comparison to the other single phenyl-group 
compounds, further analysis of the binding mode of hydroxytyrosol and a known inhibitor was conducted for LSD1. 
Briefly, the discovery of LSD1 led to the identification of the first histone demethylase that specifically removes methyl 
groups from lysine 4 of histone H3 [32]. In vivo, LSD1 is a key histone modifier that maintains gene expression in human  
Β 
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Figure 5. Level of expression of HDAC6 and acetylated α-tubulin, as detected by immunofluorescence staining. Bar=200µm, 60x 
magnification. 
 
embryonic stem cells [33]. It has also been shown to be overexpressed in many cancer types [34], and its inhibition has 
been shown to mitigate cellular proliferation and invasion of neoplastic cells. As a histone demethylase, the catalytic 
centre of LSD1 is formed of both FAD-binding and substrate binding sub-domains [35]. From our findings, assessment of 
the binding mode generated by AutoDock Vina demonstrated direct binding of hydroxytyrosol into the catalytic core of the 
enzyme, interacting with the residues of the substrate binding subdomain (Figure 4). The binding of LSD1 and 
hydroxytyrosol suggests the possibility of π-π interactions between Tyr807, Phe560 and hydroxytyrosol (see Figure 4), as 
well as cation-π interactions between His812 and hydroxytyrosol, which may serve to stabilise bonds. In conjunction, the 
binding of the putative LSD1 inhibitor, tranylcypromine, was found to have a different binding position to hydroxytyrosol 
with fewer interactions with surrounding residues (see Figure 4). X-ray crystallography coordinates of LSD1 bound to 
tranylcypromine indicate the two residues intimately bound to the inhibitor found in our results, are likewise found in the 
confirmatory X-ray structure [36]. This demonstrates the binding mode predicted from our findings, may be a likely binding 
site of the inhibitor. Interestingly, the commercial demethylase assay found the predicted IC50 for LSD1 inhibition by 
hydroxytyrosol to be lower than the positive control tranylcypromine (see Figure 4). However, although in the positive 
range, hydroxytyrosol was not predicted to be the most potent LSD1 inhibitor calculated by our molecular docking studies 
compared with several other compounds of higher molecular weight and those ligands containing multiple phenyl rings. 
This highlights that predicting protein-ligand interactions is inherently challenging owing to the many forces that contribute 
to these interactions [37].  
Access to a specialised wound clinic provided us the opportunity to obtain human tissue samples that allow for 
the elucidation of the expressional changes of epigenetic targets in vivo. In an heterogenous group of patients, the 
presentation of a diabetic patient with an associated ulcer is commonplace, and suitable samples were obtained from one 
such patient treated at the clinic. The adverse effects of diabetes is orchestrated by hyperglycaemia and the resultant 
oxidative stress on endothelial health increases the risk of serious long-term complications, including the formation of 
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diabetic leg and foot ulcers [38]. Several studies have shown that epigenetic changes play a role in diabetic complications 
[39-41]. Specifically, underlying differences in the cellular phenotype of fibroblasts obtained from diabetic ulcers has been 
shown to be influenced by significantly lower global DNA methylation patterns as compared to fibroblasts from non-
diabetic wounds [42]. Activation and persistence of the proinflammatory M1 macrophage in diabetic wound tissue has 
also been indicated to be a result of altered H3K27 demethylase (KDM6B) activity [43].  
Following the relatively high binding affinity obtained from hydroxytyrosol bound to HDAC6, we further examined 
the change in HDAC6 and acetylated α-tubulin expression from tissue obtained from a diabetic wound, treated with a 
commercial topical antimicrobial, containing the Olivamine 10
®
 formulation, which includes a hydroxytyrosol-containing 
olive extract (Figure 5). The results showed an increase in expression of HDAC6 without any quantitative change in the 
acetylated α-tubulin levels. HDAC6 is an α-tubulin deacetylase and its over-expression has been demonstrated to 
promote chemotactic cell movement [44]. This indicates that although the expressional increase in HDAC6 is apparent 
over the time course, the analogous α-tubulin deacetylase activity of HDAC6 is not pronounced. Little work has been 
conducted on the effect of HDAC6 expression on wound healing, however a study on corneal epithelial cells, has shown 
the enhancement of HDAC6 activity results in the deacetylation of α-tubulin, effectively increasing cell migration [45, 46]. 
Indeed, given the dynamic and transient nature of protein acetylation, our findings require further clarifications with much 
greater n numbers and time points. Further, whether the expressional increase in HDAC6 within the tissue was due to 
hydroxytyrosol specifically or the synergistic effect of the Olivamine 10
®
 formulation must be further explored.  
Our in silico findings indicate that the predicted IC50 for LSD1 inhibition by hydroxytyrosol is lower than the 
positive control tranylcypromine. However, it should be noted that although in the positive range, hydroxytyrosol was not 
predicted to be the most potent LSD1 inhibitor on the basis of molecular docking compared with various compounds of 
higher molecular weight. This highlights the need to refine our in silico methodologies and to utilise algorithms designed 
to factor for differences in molecular weight. Given the above observations however, on the basis of the molecular 
docking prediction, we may assume a high inhibition activity of hydroxytyrosol against HDAC6, which, nevertheless must 
be validated both in vitro and in vivo. These observations are interesting in the context of our case study results which 
indicated a significant increase in the expression of HDAC6 with time without a concomitant change in the expression of 
acetylated α-tubulin. Taken together, reasonable hypotheses may be that 1) the increased expression of the enzyme in 
the wounded skin could be a compensatory response to inhibition by the olive-derived, hydroxytyrosol containing 
components of the formulation and 2) the potent inhibition of HDAC6 by components of the formulation supersedes the 
increased expression of the HDAC6 enzyme and hence the lack of significant changes in the acetylation of α-tubulin.  
 
 
Conclusion 
 
Overall, we provide the first instalment for the identification of potential chromatin modifying compounds derived from 
Olea Europaea. Our combined in silico and in vitro observations highlight various compounds that may regulate the 
function of enzymes that write (HATs) and erase (HDACs and HDM) chemical modifications on chromatin. A pertinent 
example arising from the current work is the finding that the extensively investigated phenolic compound, hydroxytyrosol, 
may have activity as an inhibitor of HDAC6 and LSD1. When considering our in silico findings, we observe a trend 
indicating that molecular weight is an important determinant of a positive result in terms of binding the target domain of 
the enzymes. This is a known caveat in the field and future work will aim at eliminating this bias. Our approach will involve 
both using alternative docking software with varying algorithms and if required developing our own algorithms to further 
consolidate the in silico and in vitro findings in an iterative process. Furthermore, we aim to extend our work to incorporate 
further chromatin modifying enzymes (for example, histone methyltransferases) and enzymes involved in DNA 
methylation. Finally, we plan to extend our database of compounds derived from Olea Europaea for exploration using our 
methodologies.   
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Abstract 
Objective: Very few studies have utilized specific criteria to assess mental disorders in brain tumor patients, and from them, they 
are mainly descriptive. The purpose of this study is to examine mental disorders in relation to tumor characteristics and patients’ 
psychosocial factors using DSM-IV (depression, sleep and mood) criteria, among brain tumor patients. Materials and Methods: 
From March 2009 to July 2011, 98 patients who surgically treated with intracranial neoplasm were included in this prospective 
study. The mean age of the patient group was 42.2 years with a range of 18-60 years with a male to female ratio of 1.2. The 
most common tumor type was glioblastoma multiform (30.3%), followed by meningioma (16.8%) and anaplastic glioma (12.3%). 
Results: In our study, the prevalence of mild depression was about 30% for males and 38% for females before surgery; however 
at 3 months after surgery, this amount decreased to the amount of 25.6% and 26% for male and female patients respectively. 
Before tumor operation, the prevalence of major depression was 10.4% for males and 19.7% for females. At 3 months after 
operation the prevalence of major depression was 12.8% for males, and 6.7% for females. Aggression or suicide attempts were 
not seen related to depression. Before operative intervention, severe anxiousness as well as severe Obsessive Compulsive 
Disorder (OCD) symptoms was present in 14.7% of males while at 3 months after operation, prevalence of severe anxiousness 
and severe OCD symptoms decreased to 4% and 9.3% respectively. In females, 28.7% of the subjects had reported to have 
severe anxiousness and 25.6% severe OCD symptoms. Three months after surgery, these amounts were 17.6% and 38.7% 
respectively. Conclusion: Depressive symptoms as well as anxious and OCD psychopathology were shown to be prevalent 
signs among patients with brain tumor. Diagnosis of the previous mentioned symptoms were totally based on DSM-IV criteria 
and these disorders and the percentiles don’t seem to be related to each other. Due to high variability of tumor stages, statistical 
analysis of whether the mentioned psychiatric symptoms get worsen at the later stages of the tumor genesis was not feasible. 
Although not measured directly, mentioned psychiatric symptoms seem to get worsen at the later stages of the brain tumor. The 
associated factors are tumor location, patient’s premorbid psychiatric status, cognitive symptoms and adaptive or maladaptive 
response to stress. 
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Introduction 
      
rimary brain tumor has a great, often dramatic impact on the life of patients and their families [1, 2]. Brain tumor, 
being both a malignancy and a progressive neurodegenerative disease, has a direct effect on the patient’s 
cognitive, neurological and psychic functions, causing focal cerebral dysfunction at the site of the tumor lesion [3]. 
In addition, treatment of the tumor, i.e. surgery, radiotherapy, chemotherapy and immunotherapy, may be neurotoxic and 
cause dysfunction of the sub cortical white matter [4]. The main literature in the field of neuropsychiatry symptoms for 
brain tumor patients has been based on individual case reports and retrospective case series [3]. In addition, studies 
focusing on psychiatric symptoms in brain tumor patients are mainly descriptive, and the number of cases in the study 
populations is small [5, 6]. Quality of life (QOL) in brain tumor patients has not yet been extensively studied; the first 
studies were initiated as recently as in the 1990’s [7, 8]. Since many studies of QOL in brain tumor patients are either 
retrospective or cross-sectional in nature, the effects of tumor characteristics and treatment as well as patients’ emotional 
and cognitive impairments are difficult to estimate over time [6]. This study is a prospective project in which mental 
disorders among brain tumor patients are evaluated. The purpose of this study is to examine mental disorders in relation 
to tumor characteristics and patients’ psychosocial factors among brain tumor patients. 
 
 
Materials and Methods 
 
In this study, 98 patients with intracranial brain tumor were referred to the clinic of neurosurgery from March 2009 to July 
2011 and were surgically treated. The mean age of the patient group was 42.2 years with a range of 18-60 years. Fifty 
five percent (55%) of the patients were male. Male to female ratio was 1.2. In terms of educational level, 51.8% had high 
school diploma or less, 38.5% had a college degree, and 9.7% held a post graduate degree. Most of the patients were not 
P 
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employed (67.9%) at the time of the interview and testing, while the remainders were employed full time (17.6%), or part 
time (24.5%). The majority of the patients (61.8%) were married, while the remainders were never married, 
separated/divorced, or widowed. Range of Karnofsky Performance Scale (KPS) ratings was from 60% to 100%. In our 
cases, 28% had KPS=100; 26% had KPS=90; 15% had KPS=80; and 31% had KPS=70. The majority of the patients in 
our study had frontal lobe tumors (42.6%) of the glioblastoma multiform (GBM) type (43.8%). The location and side of the 
tumors are summarized in table 1.  
 
Table 1. Olive bioactive compounds investigated 
Location 
No (%) 
Right 
No (%) 
Left 
No (%) 
Total 
No (%) 
Frontal 18 (20.7) 20 (23.0) 38 (42.6) 
Temporal 10 (11.5)  7 (8.0) 17 (19.1) 
Parietal  5 (5.7) 10 (11.5) 15 (16.9) 
Brain Stem      -       - 9 (10.2) 
Others  2 (2.3) 8 (8.9) 10 (11.2) 
 
 
The most common pathologic type was glioblastoma multiform (30.3%), followed by meningioma (16.8%). Table 
2 demonstrates the relative frequency of the pathologic tumor types of the patients. 
 
Table 2. The frequency of the pathologic type of brain tumors in the patients 
Pathologic Type No (%) 
Glioblastoma multiforme 27 (30.3) 
Anaplastic glioma 11 (12.3) 
Low grade glioma 9 (10.1) 
Meningioma 15 (16.8) 
Ependymoma 4 (4.5) 
Germinoma 2 (2.2) 
Hemangioma 2 (2.2) 
Lymphoma 3 (3.4) 
Medulloblastoma 3 (3.4) 
Pituitary Adenoma 8 (8.9) 
Metastasis 5 (5.6) 
Total 89 (100) 
 
 
In this study, the patients had received multiple and varied treatments. The treatments included: neurosurgical 
debulking (85%); regional radiotherapy (68%); chemotherapy (32.2%); whole brain irradiation (17.3%); and gamma knife 
radiotherapy (4.6%). In addition, 82.5% of the patients' group was on steroids at the time of their interviews. The 
prevalence of depressive symptoms was assessed with Beck Depression Inventory (BDI). The level of anxiety according 
to CCEI, and the level of obsessive-compulsive symptoms (OBS) in the CCEI were assessed separately for male and 
female patients. In the male patients, the prevalence of at least mild depression (BDI) prior to operation was 30%, while it 
was 25.6% (Figure 1) months after the operation. In the female patients, 37.8% were shown to be at least mildly 
depressed before tumor operation. However, at three months after operation, 26% of the females were found to have at 
least mild depression (Figure 2). Before tumor operation, the prevalence of major depression (BDI scores 14 or over) was 
10.4% for males and 19.7% for females. At three months after operation the prevalence of major depression was 12.8% 
for males, and 6.7% for females. Before tumor operation, 14.7% of the male patients were severely anxious, while the 
corresponding proportion was 4% at three months after the operation. In the female patients, 28.7% of the subjects had 
reported to be severely anxious before tumor operation. However, the rate of severe anxiety was 17.6 % in the female 
group three months after the operation. The level of anxiety differed significantly between the genders at three months 
(P=0.015) after tumor operation, but not before. 
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Figure 1. Bar diagram of the                 
frequency of depression in male 
patients before and 3 months 
after operation. 
 
 
 
In this study, 14.5% of the males were severely obsessive (OBS) before tumor operation. However, the 
proportion of severely obsessive males decreased to 9.3% at three months after tumor operation. Among females, the 
prevalence of severe obsession was 25.6% before tumor operation, and it increased at three months after tumor 
operation up to 38.7%. The gender difference was found to be statistically significant only at three months after operation 
(P=0.022). Considering the anxiety level according to CCEI which was assessed before the tumor operation, the patients 
with a tumor in the right hemisphere were shown to have higher anxiety scores (5.75±3.32) compared to those with a 
tumor located in the left hemisphere (3.59±3.12, 0.032) Corresponding differences in the level of anxiety were not found 
in three months and in one year after the operation. Furthermore, a statistically significant decline in anxiety levels from 
brain surgery to the follow-up assessments was found in patients with a right hemisphere tumor (P=0.015), while no 
significant difference between measurements was observed among patients with left hemisphere tumors. The changes 
over time in the level of obsession (OBS) by the CCEI were investigated according to lateralization and anterior/posterior 
location of the tumor. In the female patients who had a primary brain tumor in the left anterior hemisphere, a statistically 
significant increase was observed in the level of obsession between preoperative and three month postoperative 
measurements (P=0.007). No corresponding increase in the level of obsession was found in females or males if the tumor 
was located in any other region of the brain. Another finding was that at preoperative measurements, the level of 
obsession was notably high among patients with the tumor in the right anterior hemisphere (right anterior vs. left anterior 
P=0.021, right anterior vs. right posterior (P=0.055), and it remained notably high (the mean obsession scores >8.0) also 
in the subsequent measurements. Assessment of the depression association with tumor location showed that patients 
with a tumor located anteriorly in the hemispheres had a trend for higher depression (BDI) scores (9.4±8.7) before tumor 
operation compared to those with a tumor in posterior regions of the brain (5.7±6.0, P=0.057) This difference in the level 
of depression was, however, not found at three months after the surgery. The decrease of the depression level among the 
patients with an anterior tumor was statistically significant from the mean±SD scores 9.4±8.7 before surgery to the scores 
6.1±5.2 at three months after the operation (P=0.049). A corresponding decrease between preoperative and 
postoperative measurements was not found if the tumor was located in the posterior regions of the brain. (P=0.34) In the 
patients with a high-grade glioma in the right hemisphere, the decline of the anxiety scores by CCEI (4.7±2.0) was 
statistically significant between measurements before tumor operation and at three months after the operation (2.4±1.5, 
P=0.018). No differences in the level of anxiety were found in the patients with a glioma (low-grade or highgrade), those 
with a meningioma in the left hemisphere or those patients with a meningioma in the right hemisphere. The level of 
depression did not differ between the histological subgroups, being independent of the malignant or benign status of the 
tumor. However, an overtime change was observed in the depression level of the patients with a pituitary adenoma 
whose depression scores decreased significantly during the follow-up from to 6.7 to 2.4, (P=0.019). The prevalence of 
depression was studied in our patients. The mean (SD) BDI score for males was 6.9; the corresponding score for females 
was 8.9. At three months after tumor operation, the decrease of the mean of depressive scores were statistically 
significant in the whole database (P=0.031). 
 
 
Discussion 
 
In general, a human is a biopsychosocial entity in which psyche, soma and the social environment are in a subtle and 
complex interrelation between each other. The central nervous system is responsible for the regulation of this entity, and 
a brain tumor, causing brain dysfunction, has a direct, biological impact on all human functions [12]. Patients with a 
primary brain tumor can experience their disease in a more comprehensive way than indicated by their clinical symptoms 
due to the tumor [13]. This is because this serious illness causes a psychological reaction, a typical, individual response 
in each patient [12], and malignancy per se causes dysregulation of the hypothalamic-pituitary-adrenal axis and changes 
in immune system [14]. Although psychiatric symptoms are based on location of damage in the brain, psychiatric 
symptoms in brain tumor patients are different from those patients with infarct, injury or infection in the brain [15]. In stroke 
Figure 2. Bar diagram of the 
frequency of depression in female 
patients before and 3 months 
after operation. 
 
Figure 3. Bar diagram of the 
frequency of anxiety in male 
patients before and 3 
months after operation. 
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patients, psychiatric symptoms are more studied and destruction of neurons is seen, while in brain tumor patients deficits 
are mainly based on the more gradual displacement and plasticity of neuronal structures [16]. Psychiatric symptoms can 
be the first and only signs of primary brain tumor and between 1% and 2% of patients with a psychiatric disorder may 
have unrecognized brain neoplasm [17, 18]. Depressive symptoms as well as anxiousness and obsessive 
psychopathology were shown to be prevalent signs among neurosurgical patients with a primary brain tumor in our 
patients. 
 In our study, the prevalence of at least mild depression before tumor operation was as high as 30% for males 
and 38% for females. Although the proportion of depressed patients decreased significantly after tumor operation, the 
prevalence of at least mild depression was still notably high. Before tumor operation, severe anxiousness symptoms as 
well as severe obsessive compulsive symptoms were present in 14% of the male patients. In females, 29% had reported 
to have severe anxiousness and 25% severe obsessive symptoms. However, the prevalence of severe anxiousness 
decreased both in females and in males to 14% and 4% respectively during the follow-up. Contrary to anxiety symptoms, 
the prevalence of severe obsession increased significantly up to the three-month measurement point in female patients, 
while it decreased during the follow-ups in male patients. Assessment of the tumor lateralization association with the 
anxiety of patients before tumor operation showed that the level of anxiety was substantially higher in the patients with a 
tumor in the right hemisphere compared to those with a left hemispheric tumor. Furthermore, the level of anxiety 
decreased significantly three months after tumor operation in the patients with a right hemispheric tumor. While 
investigating the level of obsession in relation to tumor location, it was found that in the female patients with a tumor in the 
left anterior region of the brain the obsession scores were significantly increased three months after operation. However, 
in the patients with a tumor in the right anterior location, severe obsession was already present before tumor operation as 
well as at the follow-ups. The association of depression with tumor location and with the patients’ functional outcome was 
also investigated. The anterior location of the tumor of the patients was associated with higher preoperative depressive 
scores compared to the scores of the patients suffering from a posterior location of the tumor. In addition, depression was 
found to be significantly correlated with the patients’ decreased functional outcome before tumor operation and at follow-
ups. Among patients with a primary brain tumor, depression was shown to be a major psychiatric symptom, and in all 
likelihood it complicated the course of the disease before and after operation. In addition, obsessive and compulsive 
symptoms in females appeared to increase as early as at three months after operation among those with a tumor in left 
anterior location of the brain. Severe obsession was found especially in female patients with a tumor in the right anterior 
location of the brain at all the measurement points. In earlier literature, depression among cancer patients was considered 
to be a normal psychological reaction to a serious illness [19]. Nowadays, there is growing evidence that depression in 
cancer patients is not merely an appropriate psychological reaction, but that it has biological and biochemical bases [14]. 
 The pathophysiology behind the depression in cancer patients is most probably multifactorial in its origin. As 
suggested by several researchers, deregulations of the hypothalamic-pituitary-adrenal axis and changes in cytokine 
levels in the brain may lie behind the association between depression and cancer [14, 19]. Further, depression in cancer 
patients complicates coping with the disease, causes worsening the quality of life and interferes with adherence to 
medical treatment [20]. The prognosis of cancer patients may worsen particularly due to depression as depression often 
prevents patients from complying with treatment regimens and other health-promoting behaviors [21]. Both obsessive-
compulsive symptoms and depression are known to decrease the quality of life in the patients [22, 23]. Patients in 
psychiatric settings may present with such medical conditions as brain tumors, which may or may not be associated with 
neurological symptoms. In some cases, patients may only have psychiatric symptoms such as mood changes, psychotic 
symptoms, panic attacks, changes in personality, or memory difficulties. Brain tumors may be detected in patients at their 
first presentation to mental health services or sometimes in patients with well-established psychiatric diagnoses. In this 
study, we showed that in some cases brain tumors can be neurologically silent and only present atypical psychiatric 
symptoms. We emphasize the need for neuroimaging studies in patients with atypical changes in mental status, even 
without neurological signs or symptoms. Our findings remain exploratory due to small sample size, but they suggest that 
psychological problems develop over time and are due to a combination of neurological and psychosocial problems that 
ensure initial treatments. The factors suggested being associated with psychiatric symptoms among brain tumor patients 
are tumor location, patient’s premorbid psychiatric status, tumor-associated cognitive symptoms and adaptive or 
maladaptive response to stress, usually all in combination [3]. Treating these problems may reduce the complications in 
patients with brain tumors. 
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Abstract 
Objective: Using microsurgical procedures without intraoperative imaging, Gross Total Resection (GTR) has so far only been 
achieved in less than 30% of all cases. Radio-guided surgery was introduced in the clinical setting in 1985 in an attempt to 
facilitate intraoperative tumor detection. Because of few studies in literature about this subject, we decided to use gamma probe 
with the hypothesis that we could increase extent of tumor resection. Materials and Methods: From January 2013 till February 
2014, 22 patients with cerebral glioma were randomized equally into two groups and evaluated. In the first group, 370MBq of 
Technetiumc-99m was injected. The microsurgical resection of the tumor was performed as much as possible, and then the 
tumoral bed was examined, if the signal was more than 2 times of the background signal, more tissue resection performed if 
feasible until the signal was diminished. In the control group, conventional resection of the tumor was performed. The extent of 
tumor resection was assessed by contrast magnetic resonance imaging (MRI) study. Results: Before surgery the patients in the 
first group had average tumor volume of 81.68±9.78. In the second group the average tumor volume before surgery was 
82.63±10.06cc. There is no significant difference between preoperative tumor volumes in two groups. In the first group, in the 
post-operative MRI, the tumor volume was 5.04±2.69cc and in the second group it was 9.5±4.8cc. Eight patients (72.7%) in the 
radioguided group experienced radical resection (more than 95%), but in the control group radical resection was achieved in just 
3 patients (27.2%), radical resection was significantly higher in radioguided group (P<0.001). Due to the usage of the gamma 
detection probe, time of finding the tumor in the radioguided group was significantly less than control group (P=0.02). However 
total operation time in the radioguided group, was not significantly more than the control group (P=0.88). Conclusions: 
Neuronavigation system increases the percentage of gross total resection, but it is expensive, increases duration of surgery is 
not considered a real-time assessment, and is not accurate in determining the borders of glioma due to brain shift. In contrast, 
radio-guided surgery is easy to use, real time, not expensive, and increases the extent of tumor resection. 
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Introduction 
      
he surgery of brain tumors is one of the major concerns in the field of neurosurgery. These tumors constitute 
approximately 2% of all adult tumors. Unfortunately, more than half of these tumors are high-grade gliomas that are 
highly aggressive with a great probability of recurrence that makes median survival time 1-3 years after diagnosis. 
Finally, 50% to 75% of patients suffering from low-grade glioma pass away because of the disease [1].  
In the literature it is shown that extent of radical resection of malignant tumors is a predictor of survival; however, 
there is no randomized trial that compares simple debulking cytoreductive surgery with radical resection on survival [2-9]. 
Efficacy of radiotherapy and chemotherapy on these tumors are inversely related to the remaining of tumor after resection 
[10]. 
So, patients with extensive tumor resection, even with the same chemotherapy regimen, had significantly longer 
survival time than patients in whom just a biopsy was carried out [11]. On the other hand, aggressive resection also may 
increase the risk of neurological deficits which definitely affect on patient’s quality of life [12]. Obviously, the aim of 
surgery is to achieve maximum tumor resection with minimal neurosurgical complications. 
The most important and basically therapeutic management of malignant gliomas is microsurgical resection, [8, 9] 
however complete resection of these tumors has been achieved in less than 30% of all the patients [2, 5]. Preoperative 
imaging like CT and MRI can help define the location of brain tumors, but estimation of the exact spatial location of an 
intracranial lesion during surgery is usually difficult [13]. 
One of the important challenges in complete resection of gliomas is the obscure plane between the tumor and 
normal brain tissue. Also, surgery near the eloquent areas is hazardous and prevents aggressive resection [14]. Several 
preoperative and intraoperative techniques have been developed to make resection of these tumors more accurate and 
feasible. These techniques can determine the tumors position anatomically and differ it with functional nearby brain 
T 
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tissue. One of the innovative techniques in modern surgery is neuronavigation using image guided systems. This 
technique was used firstly by Robert et al. in 1986 [15]. 
In the late 20th century, neuronavigation system has been developed [16]. This technique is a frameless, image-
guaided system that is based on preoperative CT or MRI. It can increase the accuracy of the size and location of 
craniotomy and makes tailored tumor resection more feasible. Although neuronavigation shows the exact boundary of the 
tumor and other structure at the beginning of surgery, images were taken before the operation and don’t show changes in 
brain shape and location of its structure that would happen during surgery and so it is not considered as a real-time 
imaging procedure [16, 17]. 
Functional brain MRI is another modality that helps the surgeon to visualize eloquent areas of the brain. In this 
technique, active part of brain will be shown due to higher blood flow through them when the patients move their limbs or 
talk. MRI shows these parts in a different color. 
However, it is not very accurate in assigning tumor position but surgeon can avoid functional regions during 
surgery. This imaging technique is not available in operation room, so it’s not a real-time imaging technique [18]. Fiber 
tracking using diffusion tensor imaging (DTI) shows exact location of the eloquent white matter structures. Merged with 
neuronavigation data, the accuracy of surgery especially near the functional brain tissue is increased. This technique is 
not real-time too and it’s not available in most centers [18]. 
The functional brain tissues also can be determined intraoperatively with direct cortical stimulation. First time, 
Foerster reported “Direct Cortical Stimulation” and “Brain Mapping” technique in 1930, [19] and then Penfield et al. 
described it in details [20-22]. In this technique, after craniotomy with use of a bipolar or unipolar electrode touching the 
brain surface, motor responses will be recorded as MEP (motor evoked potentials) on limbs while the patient is just 
sedated without general anesthesia. The areas that caused MEP response will be marked with sterile papers to make a 
Brain Mapping in order to avoid during resection of tumor [8, 18]. 
Paramount benefit of this method is real-time detection of functional brain tissues, but it has some difficulties and 
complications. Anesthesia process is difficult and the operation time will increase [18]. On the other hand, operation on 
awake patient will cause some complications like respiratory dysfunction, hemodynamic instability (rising blood pressure 
and heart rate), seizure during surgery, neurological deficit, brain edema and hemorrhage, local anesthetizing drug 
toxicity, nausea and vomiting, aspiration, pulmonary emboli and even death [23]. 
Intraoperative imaging using ultrasonography is another technique for improving detection of tumors, especially 
in subcortical cystic glioma and adjacent ventricles and peritumoral vasculature with neuronavigation [24]. Koivukangas 
and Kelly introduced use of ultrasonography as an intraoperative imaging technique in 1986 [25]. The most important 
advantage of ultrasonography is the ability of real-time imaging during surgery. But it does not have adequate efficiency in 
non cystic tumors. Combination of ultrasonography with neuronavigation can increase the accuracy of glioma surgery [24, 
26]. 
Another technique for improving resection of glioma is fluorescence-guided surgery that uses fluorescent tumor 
markers in order to distinguish tumor from natural brain tissues. In this technique, after administration of oral 5-
aminolevulinic acid (5-ALA) that is nonfluorscent prodrug, this substance will be metabolized to protoporphyrin IX (PpIX) 
in tumor tissue through heme biosynthesis pathway [27]. So PpIX accumulate in malignant glioma and it has fluorescent 
nature. In normal brain tissue, PpIX level is very low. In the view provided by the special microscope that omits blue light 
(400nm wavelength), the tumor tissue is shown as a reddish material and the normal brain as a bluish tissue [27-29]. It 
has been shown that fluorescence-guided surgery increases tumor resection with less morbidity. The reported side 
effects of oral administration of 5-ALA has been skin photo sensitivity [30, 31]. 
However, 5-ALA is not FDA approved yet. This method needs a special microscope that is limited to a few 
centers. 5-ALA is now commercially available but it is extremely expensive [29]. The other real-time intraoperative 
imaging procedure is intraoperative MRI that allows surgeons to take MRI during surgery in the operation room. The first 
0.5 Tesla intraoperative MRI system was manufactured in Brigham’s Hospital in Boston in 1990 [32]. Sutherland et al. in 
1999 used intraoperative MRI in neurosurgery field. They used this system to operate brain tumors and vascular lesions 
[33]. This technique is almost real-time and the surgeon can use it for maximum resection of glioma with minimum 
neurological deficit; [34] however, it needs specially equipped operation theatre without any magnetic material device in 
either surgery tools or anesthetic equipments that is so expensive and right now, it exists in just 100 centers all over the 
world [18]. It does not exist in Iran too. Moreover, this technique will lengthen the operation time and is technically 
demanding [35]. 
Radio-guided surgery has been developed about 60 years ago [36]. Using gamma detection probe technology, 
radio-guided surgery has revolutionized the surgical management of many malignancies such as breast cancer, 
colorectal cancer, melanoma and parathyroid disease [37, 38]. This technique provides critical and real-time information 
about size, location and invasion of the tumor into the adjacent tissues, so as to help find surgical resection margins 
accurately. 
Moreover, this technique has enabled the surgeons to be able to perform maximal cytoreduction with fewer 
complications [38]. 
Morley and Jefferson used phosphorus-32 and a modified Geiger-Muller probe that detect beta radiation to map 
the tumor extent and locate the tumor to guide biopsy for the first time [39]. 
Desiatnikov et al. used this technique with similar purposes in 1968 [40]. The first radioguided brain tumor 
surgery with using a gamma probe was reported by Vilelha and Carneiro in 2002. They resect a metastatic renal cell 
carcinoma in the right parietal lobe of a 62 year old man with use of gamma probe after injection of Tc-99m [41]. 
Thereafter, just a few studies performed, using radioguided surgery. In 2004, Kojima et al reported resection of primary or 
secondary brain tumors in 13 patients, using gamma probe. They used Tc-99m as a radionuclide agent [42]. Then Gay et 
al used In-111(DTPA)-D-Phe 1 pentereotide (an analoge of somatostatin) as radionuclide to resect meningiomas in 10 
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patients [45]. In 2006, Serrano et al used Thallium-201 to resect an astrocytoma of right temporoparietal lobe with 
radioguided surgery [46]. They also reported resection of 6 patients’ malignant astrocytomas in 2008, using same 
technique [47]. Finally, Bhanot et al in 2007 reported radioguided surgery, using Tc-99m for resection of 13 patient’s 
glioma [48]. The efficacy of this approach in brain tumor surgery has not been properly investigated and there is no 
general comparison of this technique with conventional methods in the literature. The aim of this study is to determine the 
effect of radio guided surgery in cerebral gliomas in our series. 
 
 
Materials and Methods 
 
In this study all the patients who were diagnosed as cerebral glioma in our institute from January 2013 till February 2014 
referred to our neurosurgical clinic were evaluated. They did not receive any brain surgery, chemo or radio therapy 
before. The inclusion criteria were patients aged between 18-60 years that their neuroimaging were consistent with 
cerebral glioma. After performing MRI (in postgadolinium T1-weighted images), only cases with the potential for complete 
tumor resection (non eloquent lesions and not deep seated) were selected. Our exclusion criteria were as follows: deep 
lesions, involvement of the eloquent areas, gliomatosis cerebri, pregnant or lactating women. All the selected cases were 
randomized into two groups. 
Before the study, informed consent was obtained from all the patients and complete procedure of the study was 
explained to their family and themselves and our study was reviewed and accepted by Shahid Beheshti university ethical 
committee. 
Functional metabolic imaging modalities can provide information about metabolic status of brain tumors. 
However it seems that positron emission tomography (PET) has more sensitivity than SPET (single-photon emission 
computed tomography), but SPET is considered as a valuable alternative because of lower cost and wider availability 
[49]. 
In the first group, before the procedures, Tc-99m MIBI SPET was performed. A brain SPET was performed 40 
minutes after the injection of 111MBq of Tc-99m MIBI. Images were reported quantitatively and qualitatively. The patients 
who didn’t have enough uptakes in SPET were excluded from study. The others had acceptable uptake in SPET. 
With using of the open-source image processing software “ImageJ” developed by the National Institutes of 
Health (http://rsb.info.nih.gov/ij/index.html) in slice with maximum lesion uptake, relative tracer concentration was 
calculated in ROI (region of interest) and a second mirror region on the contra lateral normal side of the brain in the same 
slice (as normal background uptake). By dividing average signal in the lesion ROI by those in the mirror regions, T/N 
(tumor/normal) ratios were achieved [49]. These T/N ratios are shown in Table 2. 
A surgical gamma probe was used (SCINTIPROBE MR100) with the energy window manually ranged between 
60 and 180keV, including the 2 main photo peaks of Tc-99m MIBI. Tip of our probe diameter was 15mm. 
After all requisites had been fulfilled, an additional dose of 37MBq of Tc-99m MIBI chloride was injected at the 
same time as the craniotomy in the operating room. In the course of the surgery, the signal from skull, dura, cortex 
overlying the tumor and the tumoral bed after tumor resection was recorded with the use of hand held gamma probe and 
its related digital detector. The signal of the suspected tumoral area more than the index ratio of the background signal 
was considered significant. The time between the end of the bone flap resection and tumor identification were also 
determined in each case. Then surgical resection of the tumor was performed as much as possible considering the color 
and consistency and differentiation with surrounding tissue. Then the tumoral bed was examined, if the signal was more 
than T/N ratio of the background signal, more tissue resection performed (if feasible) until the signal was diminished. In 
the control group, conventional resection of the tumor was performed. After surgery, in all the cases, MRI with and without 
contrast were performed at first post-operative day and the tumor remnant was determined and compared with the 
preoperative MRI. The tumor volume was estimated using Cavalieri principle [50, 51]. The recorded variable were as 
follows: Age, sex, tumor location, pre op and post op tumor volume, the time between bone flap removal and tumor 
identification, and the signal recorded from skull, dura, cortex and tumoral bed. All the data were gathered in a data base 
using Excel software. For comparison of the data between the two groups we used Student T test and for the assessment 
of the intervening factors, Chi square test was performed. 
 
 
Results 
 
In this study all the patients who were diagnosed as cerebral glioma from January 2013 till February 2014 referred to our 
neurosurgical clinic were evaluated. According to our inclusion and exclusion criteria 22 patients were selected and 
randomized into two groups. The first group consisted of 11 patients who were considered for radio guided surgery. In this 
group 7 cases were male (63.7%) and 4 cases were female (36.3%). The average age of this group was 37.1y with the 
standard deviation of 10.9y. Maximum age was 54y and the minimum age was 32y with the median of 32y. The second 
group consisted of 11 patients who were considered as the control group. In this group 6 cases were male (54.5%) and 5 
cases were female (45.5%). The average age of this group was 41.3y with the standard deviation of 5.2y. Maximum age 
was 52y and the minimum age was 36y with the median of 40y. There is no significant difference between ages of these 
groups. (P=0.099) 
 In 8 cases of the first group, the site of the tumor was in the right hemisphere (72.7%) and in 3 cases (27.3%) the 
tumor was located in the left hemisphere. The location of the tumor was in frontal lobe in 2 patients (18.2%), occipital lobe 
in 1 case (9%), temporal lobe in 7 cases (63.8%) and insula in 1 case (9%). The most common chief complaint of the 
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patients in this group was headache, 6 cases (54.5%). Seizure occurred in 4 cases (36.4%), hemiparesis in 3 patients 
(27.3%). The detected gamma probe signals were recorded by the detector in each step of the surgery. But in the second 
group, site of the tumor in 8 cases was in the right hemisphere (72.7%) and in 3 cases (27.3%) the tumor was located in 
the left hemisphere. The location of the tumor was in frontal lobe in 2 patients (18.2%), occipital lobe in 2 cases (18.2%), 
temporal lobe in 6 cases (54.6%) and insula in 1 case (9%). Comparing the location of tumor in two groups did not show 
significant differences. (P=0.76) 
 In the operative field, the average signal over the scalp was 28.9±8.5. The maximum signal was 42 and the min 
value was 15 and the median was 28. Over the skull the average value of the signal was 30.5±8.3. The maximum value 
was 42, the min was 15 and the median was 32. The mean detected signal over the dura was 30.4±7.7, max signal was 
40, min was 15 and median was 30. The average signal detected over the tumor site was 38.18±6.4. The mean signal 
value after tumor resection was 13.6±5.8, maximum value was 25 and minimum signal was 6. 
 Details of gamma beam spectrometry are in Table 1. 
 
Table 1. Data of gamma beam spectrometry 
Patients Skin Bone Dura Tumor After Resection 
1 15 25 35 40 6 
2 20 25 20 30 15 
3 40 40 35 45 15 
4 35 40 40 45 25 
5 25 25 25 35 10 
6 20 15 15 25 8 
7 35 32 36 42 16 
8 28 34 30 38 21 
9 30 32 30 40 16 
10 42 42 38 45 10 
11 28 25 30 35 8 
 
 
In the first group, the time interval between dural opening and tumor recognition was 7.5±3.5 min and the 
average duration of operation in the first group was 4.8±0.7h, maximum value was 6h, minimum time was 4h and the 
median was 5h. In the second group, the time interval between dural opening and tumor recognition was 13.5±2.44min 
and the average duration of operation in this group was 5±0.6h, maximum value was 6h, minimum time was 4h and the 
median was 5h. 
Before surgery the patients in the first group had average tumor volume of 81.68±9.78. In the second group, the 
average tumor volume before surgery was 82.63±10.06cc. There is no significant difference between preoperative tumor 
volumes in two groups (P=0.71). In the first group, in the post-operative MRI, the tumor volume was 5.04±2.69cc and in 
the second group it was 9.5±4.8cc. 
Table 2 shows pre and post operation tumor volume and operation time for the patients in details. 
 
Table 2. Details of pre and post operation surgery tumor volume and resection extent in all cases 
Patients Using 
gamma 
probe 
Tumor volume 
before surgery (cc) 
Residual 
volume (cc) 
Amount of 
resection 
(percentage) 
Resection extent 
(Radical resection 
or not) 
Surgery 
duration 
(hour) 
T/N ratio 
(SPET) 
1 Yes 86 3.5 95.93 Y 5 3.6 
2 Yes 98 4 95.92 Y 4 2.9 
3* Yes 74 9.75 86.82 N 6 0.9 
4* Yes 68.5 3 95.6 Y 4.5 1.0 
5 Yes 77 9 88.31 N 5.5 3.8 
6 Yes 86.5 3.75 95.66 Y 5 3.3 
7* Yes 89.5 4.25 95.25 Y 4 1.2 
8 Yes 69 2.75 96.01 Y 6 3.6 
9 Yes 73 8.75 88.01 N 5 2.3 
10 Yes 87 3.5 95.98 Y 4.5 4.0 
11 Yes 90 3.25 96.38 Y 5.5 3.0 
12 No 88 14.5 83.52 N 5 - 
13 No 94.5 15.75 83.33 N 4 - 
14 No 74 11.25 84.79 N 6 - 
15* No 79.5 2.75 96.54 Y 5 - 
16 No 96 3 96.87 Y 5 - 
17 No 89 14 84.26 N 4 - 
18* No 92 3.75 95.92 Y 6 - 
19 No 66.5 9.5 85.71 N 4.5 - 
20* No 70 13.5 80.71 N 5.5 - 
21 No 82.5 10.25 87.57 N 5 - 
22 No 77 12.5 83.76 N 4.5 - 
* These patients had low grade glioma due to pathological examination after surgery 
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 After surgery the pathological report of the tumor were as follows: astrocyroma grade 2 in 1 case (9.1%), 
oligodendroglioma grade 2 in 2 patients, astrocytoma grade 3 in 2 cases and gliobalstoma multiform 6 cases. In the 
second group, pathological report of the tumor were astrocyroma grade 2 in 1 case (9%), oligodendroglioma grade 2 in 2 
patients (18.2%), astrocytoma grade 3 in 3 cases (27.3%) and gliobalstoma multiform in 5 cases (45.4%). The difference 
between these two groups was not significant (P=0.88). 
 
 
Discussion 
 
In most centers from all over the world, common imaging techniques like neuronavigation system, MRI or CT-scan with 
contrast is not available in the operating room [32]. So lack of realtime imaging technique in the operating room is 
noticeable. 
      MRI but these imaging techniques are not usually available in the operating room and if they were, they would be 
so expensive. 
 Differentiation between brain tumors and natural brain tissue during an operation is so important, because we 
need to remove as much as possible of tumor with less damage to the normal and especially functional brain tissues. 
Maximum removal of the brain tumor and cytoreduction increases the efficacy of adjuvant therapies (i.e. radiotherapy or 
chemotherapy) [42]. 
In this study, the mean residual tumor volume was 5.04cc in radioguided group and 9.5cc in control group. There 
was a significant difference between residual volumes in the 2 groups (P=0.01). 
 In our study, 8 patients (72.7%) in the radioguided group experienced radical resection (more than 95%), but in 
the control group radical resection was achieved in just 3 patients (27.2%) that our control group is similar to other studies 
using microsurgery. Radical resection was significantly higher in radioguided group (P<0.001). 
 In our study, extending the amount of tumor resection in the cases demonstrating significant signal did not 
increase the rate of postoperative neurological deficit (18% in both groups). This may be due to the fact that we only 
included patients with total resectability potential. 
 Time of finding the tumor in the radioguided group was significantly less than control group (P=0.02). This 
reduction in finding tumor time is because of using gamma probe. However, total operation time in the radioguided group, 
was not significantly more than the control group (P=0.88). 
 The annual exposure limit of radionuclide was set by The International Commission on Radiological Protection 
(ICRP) as a total dose equivalent of 100000μSv per year in five years that it has to not exceed 50000μSv in a year [52, 
53]. Radiation exposure from Tc-99m MIBI used for radioguided surgery of brain has been evaluated. The mean 
exposure time was 6.1 hours for all operation room personnel. The mean whole body exposure was 27.9μSv for 
surgeons, 25.8μSv for nurses and 14.9μSv for anesthetists [42]. 
 According to existing data microsurgery without any intraoperative imaging, resulted in gross total resection 
(GTR) in 27% to 38.2% of patients [54-57]. 
 Neuronavigation system increases the percentage of gross total resection, but it is expensive, increases duration 
of surgery and is not considered a real-time assessment, and is not accurate in determining the borders of glioma duo to 
brain shift [2]. Kurimoto et al. reported that GTR can be achieved in 64.3% of cases using using neuronavigation system 
[57]. 
 Our complication rate was 18%. In Kurimoto study the rate of complication after resection of cerebral glioma was 
17.6% in microsurgery group (similar to our results) and just 9.5% in neuronavigation group [57]. Nimsky reported 10.2% 
complications after surgery using neuronavigation and just 2.9% in their patients operated with iMRI [56]. 
 In a study performed by Enchev et al., they evaluated efficacy of intra-operative ultrasound combined with 
neuronavigation on operation of recurrent cystic glioma. Postoperation evaluation revealed 60% GTR, 20% near total 
resection and 20% subtotal resection of tumor. 
 Intraoperative ultrasonography is so useful in subcortical cystic tumors, it is real-time and economical; however it 
has not enough accuracy in operating of solid tumors and interpretation of these tumors images need more experience 
[24]. 
 In 2006, Muragaki reported that iMRI use in 96 cases with cerebral glioma, resulted in 0.025mL tumor residue 
whereas in the control group the average tumor remnant was 1.7mL. (P<0.001) [58]. They also reported that in patients 
with iMRI application, GTR achieved in 95% of their patients [58]. In Nimsky series, GTR was achieved in only 27% of 
their patients according to the results obtained by iMRI. After the iMRI evaluation, the overall GTR was achieved in 40% 
of the cases [54-56]. 
 Currently, just about 100 centers in all over the world have special operation room and surgery device, adapted 
for intraoperative MRI and these facilities are very expensive [18]. It is not worldwide and there is no such an operation 
room in Iran. The overall cost of polestar N20 iMRI was over 3 million dollars that mentioned in Makary study and it has 
about 120,000$ running cost each year [59]. As claimed by American Hospital Association Health Data Management 
Group guidelines in 2008, this system’s economic life is only 5 years without any end-of-life salvages value [60]. 
 As it was shown in the literature, iMRI elongates the operating time about 0.5 to 2 hours more than usual [61-63]. 
 Stummer et al., in their series compared fluorescence-guided surgery using 5-ALA with microsurgery. In 
fluorescence-guided group 65% of patients showed GTR, but in microsurgery group just 36% of their patients showed 
GTR in post-operative MRI.31 Also in 2014, Piquer et al. reported 79.3% GTR in their series using fluorescence-guided 
[64]. This microscope is expensive and using 5-ALA is costly for each patient, however it is commercially available 
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worldwide, it is not available in Iran. 
 Table 3 compares our study results with other studies with different methods. 
 
 
Table 3. Review of GTR in recent studies, comparing different modalities 
Study Imaging technique Number of patients Extent of resection 
Kurimoto (2004) [57] Neuronavigation 76 64.3% GTR with 
Neuronavigation 
38.2% GTR with 
Microsurgery 
Nimski (2006) [56] iMRI 137 40% GTR 
Enchev (2006) [24] Ultrasound + 
Neuronavigation 
16 60% GTR 
Stummer (2006) [31] Fluorescence-guided 
surgery 
322 65% GTR with FGS 
36% GTR with white light 
Muragaki (2006) [58] iMRI 96 91% GTR with 
microsurgery 
95% GTR with iMRI 
Solheim (2010) [65] Ultrasound 156 37% GTR 
Piquer (2014) [64] Fluorescence-guided 
surgery 
38 79.3% GTR 
Witt Hamer (2012) [66] ISM* 8091 75% GTR with ISM 
58% GTR without ISM 
Kuhnt (2011) [67] iMRI 117 41.9% GTR 
Our study Radio-guided surgery 22 72.7% Radical resection 
with RGS 
27.2% Radical resection 
without RGS 
*ISM: Intraoperative Stimulation Brain Mapping 
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Abstract 
Background: Many radionuclides have been used for several decades in cancer treatment. 
131
I, 
90
Y, 
89
Sr, 
111
In, 
177
Lu and 
223
Ra 
are some of the most widely used radioisotopes. Therapeutic results and side effects can be associated only if the absorbed 
dose is well estimated. Knowledge of the absorbed dose during radionuclide therapy is the only method that can compare 
therapeutic results between different therapeutic techniques such as external radiotherapy and radio immunotherapy. Accurate 
patient specific estimation of the absorbed dose to the tumor and normal tissue can be achieved with voxel based internal 
dosimetry. Objective: The aim of this study is to develop a computer algorithm that calculates absorbed dose at every voxel of 
quantitative SPET scintigraphy image and establish a general internal dosimetry protocol for therapy by radionuclides. Material 
and Methods: SPET scintigraphy images of known 
131
I activities were obtained. The known activity of 
131
I was contained in a 
cylindrical phantom of 16cm radius. A numerical factor was determined to convert the measured count rate from the SPET 
images to activity. The algorithm that calculate absorbed dose at every voxel of the scintigraphy image was developed by 
MATLAB. MATLAB is a high level computer language with interactive environment and performs mathematical calculations by 
matrices. The scintigraphy images were imported in MATLAB and were converted to 3-dimensional matrices. Every element of 
the matrix was assigned with the respective count rate. The matrix was multiplied with the conversion factor and the new 
elements represented the activity at every voxel. A cumulative activity matrix was made from activity matrices that were obtained 
at different time points. The absorbed dose at every voxel of the cumulative activity matrix was computed with the convolution 
method. A3- dimensional convolution matrix with size 5x5x5 was created. The elements of this matrix are numerical factors that 
convert cumulative activity to absorbed dose. The convolution between these two matrices was made using the ‘convn’ function 
of MATLAB. This function convolves the cumulative activity matrix with the convolution matrix and gives a new matrix with 
numeric elements that represent absorbed dose at every voxel. Furthermore, regions of interest can be drawn on the images 
and dose volume histograms and mean absorbed doses can be calculated. Results: SPET scintigraphy images were obtained 
for 64MBq 
131
I activity. A cumulative activity of 230GBq*s was calculated and the voxel convolution method showed that mean 
absorbed dose was 20.6Gy. Maximum dose of 50Gy was calculated for the central voxel in the activity. A region of interest was 
drawn and the dose volume histogram was calculated. The results were compared to MIRDOSE3.1 program. A mean dose of 
20.1Gy was calculated with MIRDOSE3.1 for the same cumulative activity in 0.85cm diameter. Conclusion: Patient specific 
voxel internal dosimetry can be performed accurately with MATLAB. Dose volume histograms and mean dose can be 
calculated.  
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Introduction 
 
adionuclide treatments have the advantage to deliver lethal dose to cancer cells while keeping low dose to healthy 
tissue [1]. Toxicity to the healthy tissue is the main problem during the radionuclide therapy. High absorbed dose 
to the kidneys may cause renal failure and high absorbed dose to bone marrow may cause myelotoxicity [2-13]. 
The accurate estimation of the absorbed dose to the tumor and the healthy tissue is essential for the efficiency of the 
treatment and the safety of the patient. Dosimetry studies have proved that great fluctuations occur in absorbed dose 
between patients that receive radionuclide therapy [14]. Dosimetric calculations must be done separately for every 
patient. The absorbed dose for each patient is affected by differences in anatomy and in pharmacokinetics. Patient 
specific dosimetry during radionuclide therapy allows accurate estimation of the absorbed dose to the tumor and healthy 
tissue. Therapeutic results can be predicted. Late biological effects can be assigned to the absorbed dose. Therapeutic 
results between different treatments techniques can be compared [15]. Voxel based internal dosimetry has many 
advantages. Complex activity distributions can be imaged. Inhomogeneous activities can be processed with a resolution 
of a few millimeters. The aim of this study is to develop a computer algorithm that calculates absorbed dose at every 
voxel of quantitative SPET scintigraphy image and establish a general internal dosimetry protocol for radionuclide 
therapy. 
 
 
Material and Method 
 
A dual head Siemens Symbia γ-camera was calibrated in order to obtain quantitative scintigraphy images. Siemens 
R 
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Symbia has two NaI(Tl) crystals of 9.5mm thickness each. The high energy low resolution collimator was used. The 
energy window was centered at 364keV with 15% window width. Tomographic scintigraphy images of known activities 
were acquired and the count rate was measured. A 
131Ι Theracap sodium iodide capsule was used at two time points that 
the capsule had activity of 166.5MBq and 64.01MBq respectively. The capsule was inserted into a polymethyl 
methacrylate PMMA cylindrical phantom. The phantom had 16cm diameter and the capsule was placed 1cm under the 
phantom surface. The tomographic scintigraphy images were acquired according to the following imaging protocol: step 
and shoot circular tomography, 3 degrees step, 32 steps, 5sec acquisition time per step, matrix 64x64 and zoom 1, 23cm 
constant circle radius. Uniformity corrections were applied. The images were processed with the Tomo SPET Only 
protocol. Butterworth filter with cutoff 0.4 and order 5 was applied. Attenuation correction was applied with the Chang 
method. The total counts in activity region were measured. The measured counts were assigned to the known activities 
respectively. Linear fit was applied between data. A first degree function was determined that converted total acquired 
counts to activity. The scintigraphy images were imported in MATLAB. MATLAB is a high level computer language with 
interactive environment and performs mathematical calculations by matrices. Every axial slice of the scintigraphy image 
was represented as a 64x64 matrix. Every element of this matrix had a numerical index that is equal to the number of 
counts measured for the specific voxel. Finally a 3 dimensional matrix, named Count matrix, with size 64x64x64 was 
obtained from the 64 axial slices of the tomography scintigraphy image. The voxel size of the matrix was 6.1mm.  
The Count matrix was multiplied according to the equation y=0.0001x-10.143.  
This equation was determined from the γ-camera calibration procedure as described above. The index of every 
voxel of the Count matrix was calculated according to the above equation and the result was a new 3 dimensional matrix 
64x64x64 size, named Activity matrix. The index of every voxel of the Activity matrix was a numerical value that was 
equal to the activity in MBq of each voxel. The Activity matrix represented the 3 dimensional activity distribution as 
acquired from the tomographic scintigraphy image.  
Cumulative activity must be known in order to calculate the absorbed dose. Cumulative activity distribution can 
be determined if scintigraphy images are acquired at several time points. The Activity matrices can be calculated for the 
time points respectively. The cumulative activity matrix can be calculated from the Activity matrices and the time intervals 
between image acquisitions. A simple method for cumulative activity determination is to calculate the area under the 
activity-time diagram. Linear fit can be assumed between the time points. Exponential fit between time points gives more 
accurate results. For this study we assumed a residence time of 3600sec. The cumulative activity was computed by 
multiplying the Activity matrix with 3600. The new 3 dimensional matrix that was obtained had voxels indexed with 
numerical values that represented cumulative activity in MBq*sec. This matrix was named Cumulative activity matrix. 
Every voxel of the Cumulative activity matrix contains a certain amount of cumulative activity. Due to this fact, every voxel 
gives a specific value of absorbed dose to itself and also it distributes absorbed dose to the adjacent and to the more 
distant voxels. The Cumulative activity matrix contains 64x64x64=262144 voxels, so 262144 dose distributions must be 
determined and summed in order to obtain the total absorbed dose distribution. The absorbed dose distribution for 
131
I is 
published in MIRD 17. The published data give absorbed dose distribution per cumulative activity in mGy/MBq*sec. The 
given numeric values were modified in order to agree with the 6.1mm voxel size of the Cumulative activity matrix. A new 3 
dimensional matrix with size 5x5x5 was created and was named Convolution matrix. The Convolution matrix had 6.1mm 
voxel size and every voxel was indexed with absorbed dose per cumulative activity value according to MIRD 17 published 
data [16]. The values of the central slice of the Convolution matrix are presented in Table 1. The absorbed dose 
distribution is calculated with the convolution method. The Cumulative activity matrix is convolved with the Convolution 
matrix. The result of the convolution is a new 3 dimensional matrix with size 64x64x64 named Dose matrix. Every voxel of 
the Dose matrix is indexed with a numeric value that is equal to absorbed dose to voxel in mGy. 
 
 
Table 1. Central slice of the Convolution matrix. The central element 0.129 converts the cumulative activity of the 
convolved voxel to absorbed dose. The peripheral elements define the dose distribution around the convolved voxel.   
0.0001 0.0001 0.0001 0.0001 0.0001 
0.0001 0.0029 0.0029 0.0029 0.0001 
0.0001 0.0029 0.129 0.0029 0.0001 
0.0001 0.0029 0.0029 0.0029 0.0001 
0.0001 0.0001 0.0001 0.0001 0.0001 
 
Using MATLAB, regions of interest can be drawn and dose volume histograms can be generated. Dose statistics 
as minimum, maximum and mean dose are available. The results were compared to the MIRDOSE3.1 program. 
MIRDOSE3.1 program was developed by the Oak Ridge institute and is used for internal dosimetry calculations in 
nuclear medicine according to the Medical Internal Radiation Dose (MIRD) schema. The program has the ability to 
compute mean absorbed dose from spherical cumulative activity distributions for many radionuclides. We assumed the 
same cumulative activity of 
131
I contained in a sphere of similar dimensions as the Theracap sodium iodide capsule. 
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Results 
 
SPET scintigraphy images were obtained for 64.01MBq and 166.5MBq 
131
I activities. The activity was contained in a 
cylindrical capsule 1cm length. Measured counts were assigned to the known activities respectively. A slice of the Count 
matrix is shown at Image 1. Counts from every voxel were converted to activity using the first degree equation shown at 
Table 2. A slice of the Cumulative activity matrix is shown at Image 2. A cumulative activity of 230GBq*s was calculated 
and the voxel convolution method showed that mean absorbed dose was 20.6Gy. Maximum dose of 50Gy was calculated 
for the central voxel in the activity. A slice of the Dose matrix is shown at Image 3. A region of interest was drawn and the 
dose volume histogram was calculated. The results were compared to MIRDOSE3.1 program. Calculations were 
performed for the same cumulative activity of 230MBq*sec. The cumulative activity was considered to be contained in a 
sphere of 0.85mm diameter. A mean dose of 20.1Gy was calculated by MIRDOSE3.1 program. 
 
Table 2. Counts-Activity diagram. Linear fit was applied between data. According to the linear equation, measured counts 
were assigned to activity, for each voxel.  
 
 
 
 
 
Discussion 
 
Radionuclide therapy is used for cancer treatment and new radiopharmaceuticals are developed during the last years 
[17]. Patient specific dosimetry studies give high quality to the treatment. The importance of accurate absorbed dose to 
the tumor and healthy tissue was recognized as soon as the radionuclide treatments begun. The first attempt for dose 
estimation by radionuclides was done with the MIRD schema. The MIRD schema was first used for dose estimation 
during diagnostic applications of nuclear medicine. Calculations are done assuming a standard human anatomy, standard 
pharmacokinetics and homogeneous activity distribution in certain human organs [18]. When the MIRD schema was first 
used for dose estimation at therapeutic applications with radionuclides many uncertainties were observed. Patient 
anatomy varies from patient to patient and the standard anatomy model is not suitable for calculations at therapeutic 
applications. Also pharmacokinetics differs between normal and pathological situation. Activity distribution is not 
homogeneous in patient’s organs. It has been proven that activity distribution is not homogeneous even inside the tumor 
mass [19-24]. The need of more detailed dose calculations is satisfied by voxel dosimetry. Inhomogeneous complex act 
tivity distributions can be imaged and absorbed dose can be calculated with resolution of some millimeters. The basis of 
voxel based internal dosimetry is the scintigraphy images. Tomographic scintigraphy images have the advantage of 
reduced overlapping regions. γ-camera has to be calibrated in order to acquire quantitative images. Absorbed and 
scattered photons in patient’s body, γ-camera dead time, image blurring and the partial volume effect must be 
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Image 1. Axial slice of the Count matrix.                                          Image 2. Axial slice of the Cumulative activity 
The index of every voxel is equal to the                                            matrix. The index of every voxel is equal to the 
measured counts for each voxel. The total                                       cumulative activity in MBq*sec for each voxel. 
measured counts for every voxel are indexed.  
 
 
Image 3. Axial slice of the Dose matrix. The index of every voxel is equal to the absorbed dose in mGy for each voxel. 
 
 
taken into account [25-31]. A standard imaging protocol must be followed for imaging a suitable phantom which contains 
known activities in order to determine a factor that converts measured counts to activity. The same imaging protocol must 
be followed later when imaging the patients. The imaging protocol is preferred to be fast and must have enough resolution 
for dosimetry calculations. The protocol introduced in this study needs about 3 minutes to be executed and gives 6.1mm 
resolution which we consider as a good settlement between imaging time and detailed activity definition. The constant 
radius circular orbit has the advantage of good reproducibility and also less scatter radiation reach the collimator. Typical 
administered activity for 
131
I therapy is 3700MBq. Patients that receive thyroid surgery have 24 hour uptake 1%-3%. 37-
117MBq 
131
I are expected to be localized at thyroid remaining tissue [32-34]. 64.01MBq and 166.5MBq were used for γ-
camera calibration and these values are close to the expected activities for the clinical practice. The whole image 
processing and dose calculations are executed with the MATLAB software. The total processing time is a few seconds 
and can be performed by common computers. The result for the mean absorbed dose is in excellent agreement with the 
MIRDOSE3.1 program. In conclusion voxel based internal dosimetry can be performed accurately with MATLAB 
software. Dose volume histograms and mean dose can be calculated. The method can be developed in the future for 
other therapeutic isotopes.  
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Abstract 
Objective: The aim of this study was to assess the value of 
18
F-fluorodeoxyglucose (
18
F-FDG) PET/CT in detection of liver 
metastases in patients with suspected recurrent colorectal carcinoma, as well as to compare diagnostic performance of 
18
F-FDG 
PET/CT with conventional imaging methods (MDCT). Subjects and Methods: This study included 73 patients with resected 
primary colorectal adenocarcinoma referred for 
18
F-FDG PET/CT to the National PET Center, at the Clinical Center of Serbia, 
Belgrade, from January 2010 to May 2013, with suspicion of recurrence. The patients underwent 
18
F-FDG PET/CT examination 
on a 64-slice hybrid PET/CT scanner (Biograph, TruePoint64, Siemens Medical Solutions, Inc. USA). Prior to 
18
F-FDG PET/CT 
all patients underwent contrast-enhanced MDCT. Findings of 
18
F-FDG PET/CT and MDCT were compared to findings of 
subsequent histopathological examinations or with results of clinical and imaging follow-up over at least six months. Final 
diagnosis of liver metastases of colorectal cancer was made either by histopathological examination of specimen after biopsy or 
surgery, or based on clinical, laboratory and imaging evaluation during first six months after PET/CT scan. Results: In detection 
of liver metastases 
18
F-FDG PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and 
accuracy of 83.3%, 95.3%, 92.6%, 89.1% and 90.4%, respectively. In addition, MDCT showed sensitivity, specificity, positive 
predictive value, negative predictive value and accuracy in detection of liver metastases of 60%, 88.4%, 78.3%, 76% and 76.7%, 
respectively. There was significant difference in sensitivity (83.3% vs 60%; P=0.045) between these two methods. In addition, 
significant difference was observed in accuracy between PET/CT and MDCT (90.4% vs 76.7%; P=0.016). The higher specificity 
in visualization of liver metastases was also achieved by 
18
F-FDG PET/CT compared to MDCT (95.3% vs 88.4%), but this 
difference was not significant (P=0.37). Conclusion: 
18
F-FDG PET/CT was highly sensitive, specific and accurate method in 
detection of liver metastases in patients with suspected recurrent colorectal carcinoma in our study. This hybrid imaging showed 
superior diagnostic performance in evaluation of suspected colorectal cancer liver metastases compared to conventional 
imaging. 
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Introduction 
 
olorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females in the 
world, and it represents the fourth cause of cancer-related deaths among men and third among women [1]. Most 
CRC survivors are enrolled in post-treatment surveillance programs, aiming to detect recurrent disease in an early 
stage, as this has been shown to improve overall survival [2]. Between 55% and 80% of patients will develop recurrence, 
which involves the liver in 35%-50% of patients. Isolated hepatic recurrence initially occurs in approximately 30% of 
patients, with authors reporting between 17% and 55% [3]. Overall, liver metastases represent leading cause of cancer-
related morbidity and mortality in colorectal cancer [4]. 
At present, whole-body fluorine-18-fluoro-deoxyglucose positron emission tomography/computed tomography 
(
18
F-FDG PET/CT) is an advanced diagnostic imaging technique in detecting loco-regional recurrence and metastases in 
postoperative patients with colorectal carcinoma for its higher sensitivity and specificity [5]. However, other authors 
reported on lower sensitivity and specificity of 
18
F-FDG PET/CT compared to multi-detector computerized tomography 
(MDCT) and magnetic resonance imaging (MRI) in detection of liver metastases [6, 7]. In addition, combined positron 
emission tomography/ magnetic resonance (PET/MR) imaging is proven to be more sensitive in the detection of 
colorectal cancer liver metastases compared to PET/CT [8]. 
According to previous, the aim of this study was to assess the diagnostic performance and added value of 
18
F-
fluorodeoxyglucose (
18
F-FDG) PET/CT in detection of liver metastases in patients with suspected metastatic recurrent 
colorectal carcinoma, compared to conventional imaging methods (MDCT). 
 
C 
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Subjects and Method 
 
Study population 
This study included 73 patients with resected primary colorectal adenocarcinoma referred for 
18
F-FDG PET/CT to the 
National PET Center, at the Clinical Center of Serbia, Belgrade, from February 2010 to May 2013, with suspicion of 
metastatic recurrent colorectal cancer. The patients underwent 
18
F-FDG PET/CT examination on a 64-slice hybrid 
PET/CT scanner (Biograph, TruePoint64, Siemens Medical Solutions, Inc. USA). Prior to 
18
F-FDG PET/CT all patients 
underwent contrast-enhanced MDCT, as well as serial measurements of serum levels of CEA. The inclusion criteria were: 
histopathologically confirmed colorectal adenocarcinoma, curative resection of the primary tumor, at least 3 months 
before PET/CT and availability for follow-up after 
18
F-FDG PET/CT for at least 6 months. After exclusion of patients with 
previous history of another type of malignancy and patients with insufficient follow-up data, 73 patients were finally 
eligible for the study.  
 
 
Procedures 
The indications for 
18
F-FDG PET/CT examination were: symptoms and signs suggesting recurrence; abnormal or 
equivocal contrast-enhanced MDCT findings; or elevated tumor marker levels. Findings of 
18
F-FDG PET/CT in the liver 
were retrospectively compared to results of MDCT. During follow-up clinical data, results of subsequent imaging tests and 
laboratory data were collected and evaluated every three months. Findings of imaging tests were compared with findings 
of histopathological examination or with results of at least 6 months of clinical and imaging follow-up. The study was 
approved by the Ethics Committee of the Faculty of Medicine of the University of Belgrade. 
 
Data acquisition and interpretation 
The patients underwent 
18
F-FDG PET/CT examination on a 64-slice hybrid PET/CT scanner (Biograph, TruePoint64, 
Siemens Medical Solutions, Inc. USA) at National PET Center, Clinical Center of Serbia, Belgrade. After fasting for 6h 
patients received an intravenous injection of 5.5MBq/kg of 
18
F-FDG. Blood glucose level over 11mmol/l was considered 
as exclusion criteria for PET/CT examination. Following injection of 
18
F-FDG, patients rested in quiet and darkened room 
for 60min, after which images of PET/CT were obtained. Low-dose non-enhanced CT scans (120kV with automatic, real-
time dose-modulation amperage, slice thickness of 5mm, pitch of 1,5 and a rotation time of 0.5s) and 3-dimensional PET 
scans (6-7 fields of view, 3min/field) were acquired from the base of the skull to the mid thigh. Non-corrected and 
attenuation-corrected CT, PET and fused PET/CT images were displayed for analysis on a Syngo Multimodality 
workplace (Siemens AG).  
18
F-FDG PET/CT findings were defined as positive for liver metastases if any abnormal 
18
F-FDG uptake was 
observed in the liver after exclusion of benign and physiological causes, with or without clearly visible corresponding CT 
malformation. Semi-quantitative analysis of 
18
F-FDG uptake was based on maximum standardized uptake value 
(SUVmax), which was corrected for individual body weight and dose injected, and calculated as follows: tissue activity 
(counts/pixel/s) multiplied by calibration factor divided by injected 
18
F-FDG dose (MBq/kg of body weight). Findings were 
interpreted separately by two nuclear medicine physicians. Consensus was reached in cases of discrepancy.  
Final diagnosis of liver metastases of CRC was made either by histopathological examination of specimen after 
surgery or biopsy, or based on clinical and imaging evaluation during first six months after PET/CT scan. Overall, liver 
metastases were definitely diagnosed in 29 patients, with histopathological confirmation of the metastases in the liver in 
18 cases. PET/CT study was defined as true-positive when 
18
F-FDG avid lesions were histopathologically confirmed to be 
malignant or lesions responded to therapy. The 
18
F-FDG PET/CT study without abnormal 
18
F-FDG uptake or with 
18
F-
FDG uptake regarded as physiological or benign, and no evidence of malignancy during follow-up was considered to be 
true-negative. A false-positive PET/CT study showed at least one lesion characterized as malignant, but without evidence 
of disease on follow-up. And, finally, false-negative studies had evidence of recurrence on further examination during the 
first six months after PET/CT, despite negative PET/CT findings.  
 
Statistical analysis 
The diagnostic performance of 
18
F-FDG PET/CT and MDCT was assessed by calculation of specificity, sensitivity, 
positive predictive value (PPV), negative predictive value (NPV) and diagnostic accuracy. The difference in sensitivity, 
specificity and accuracy between FDG PET/CT and MDCT in detection of liver metastases of colorectal cancer was 
assessed using McNemar’s test. A P value of less than 0.05 was considered significant.  
 
 
Results 
 
The demographic and clinical characteristics of patients included in this study, with reference to MDCT and 
18
F-FDG 
PET/CT findings regarding liver metastases of colorectal cancer are given in Table 1. 
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Table 1. Demographic and clinical characteristics of patients included in the study, N=73 
  Number  
Gender Male  42  
 Female  31  
Age Mean 60.1±11.1  
Localization of primary 
tumor 
Rectum  
Colon  
37  
36  
Time elapsed from 
surgery 
Median 22 mts 
≤12 
12-24 
>24 
 
18 
27  
28 
Chemo-radiotherapy 
before 
18
F-FDG PET/CT 
Preoperative 
Postoperative  
Pre + postoperative 
None 
5  
53  
3  
12  
CEA Normal  
Increased  
31  
42  
Liver metastases 
diagnosed on MDCT 
Yes  
No 
22  
51  
Liver metastases 
diagnosed on 
18
F-FDG 
PET/CT 
Yes 
No 
27  
46 
CEA: Carcinoembryogenic antigen; MDCT: Multi-detector computed tomography; 
18
F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron 
emission tomography/computed tomography. 
 
 
Diagnostic performance of 
18
F-FDG PET/CT and MDCT in the detection of liver metastases 
In our study patients 
18
F-FDG PET/CT showed sites of abnormal 
18
F-FDG accumulation in 57 patients overall, suggesting 
recurrent colorectal cancer. Areas of abnormally elevated glucose metabolism in the liver were found in 27 patients, 
suggesting CRC liver metastases. Out of those, local recurrence was observed in five patients as well, while extra-hepatic 
disease in terms of pulmonary, bone or other sites of distant metastases were suggested in 8 cases (Figure 2). In 25/27 
cases these findings were confirmed during follow-up (histopathological confirmation was available in 15 cases), so these 
cases were considered to be true positive regarding liver metastases. In two patients, although PET/CT suggested 
presence of the disease in the liver, biopsy was negative, suggesting that 
18
F-FDG PET/CT were false positive. There 
were five cases of false negative FDG PET/CT findings, with liver metastases being confirmed after surgery despite 
negative FDG PET/CT (Table 2). 
 
Table 2. Cross-table of 18F-FDG PET/CT and MDCT findings 
18
F-FDG PET/CT 
MDCT 
 TP FP TN FN Total 
TP 17   1 18 
FP  1 4  5 
TN  1 37  38 
FN 8   4 12 
Total 25 2 41 5 73 
MDCT: Multi-detector computed tomography; 
18
F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography/computed 
tomography; TP: True positive; FP: False positive; TN: True negative; FN: False negative 
 
     Overall, in the detection of liver metastases 
18
F-FDG PET/CT showed sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy of 83.3%, 95.3%, 92.6%, 89.1% and 90.4%, respectively (Table 3). 
Contrast-enhanced MDCT suggested CRC liver metastases in 23 patients, out of whom 18 were confirmed on 
follow-up (true positives), while in others no signs of spread of the disease in the liver was observed (false positives). Out 
of 51 patients who had no liver involvement on MDCT, there were 12 false negatives on follow-up. Accordingly, MDCT 
showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy in detection of liver 
metastases of 60%, 88.4%, 78.3%, 76% and 76.7%, respectively (Table 3).  
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Table 3. Comparison of diagnostic performance of  18F-FDG PET/CT and MDCT 
 FDG PET/CT (%) MDCT (%) 
Sensitivity 83.3 (25/30) 60 (18/30) 
Specificity 95.3 (41/43) 88.4 (38/43) 
Accuracy 90.4 (66/73) 76.7 (56/73) 
PPV 92.6 (25/27) 78.3 (18/23) 
NPV 89.1 (41/46) 76 (38/50) 
18
F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography; MDCT: Multi-detector computed 
tomography; PPV: Positive predictive value; NPV: Negative predictive value 
 
Comparison of 
18
F-FDG PET/CT and MDCT 
There was significant difference in sensitivity (83.3% vs 60%; McNemar’s test, P=0.045) between these two methods. In 
addition, significant difference was observed in accuracy between PET/CT and MDCT (90.4% vs 76.7%; McNemar’s test, 
P=0.016). The higher specificity in visualization of liver metastases was also achieved by 
18
F-FDG PET/CT compared to 
MDCT (95.3% vs 88.4%), but this difference was not significant (McNemar’s test, P=0.37). An example of 18F-FDG 
PET/CT in patients with CRC metastases confined on the liver, without clearly visible CT abnormalities, is shown in 
Figure 1. 
 
 
 
Figure 1. 
18
F-FDG PET/CT scan (trans axial CT, PET and fused image, and maximum intensity projection image) in patient 
showing area of increased 
18
F-FDG uptake in IV segment of the liver (cross-bars), without visible corresponding CT 
abnormalities 
 
 
Impact of 
18
F-FDG PET/CT findings on treatment  
Liver metastases were confirmed in 29/73 patients. Out of those, in three patients surgical treatment of the liver was 
performed based on newly diagnosed liver metastases on 
18
F-FDG PET/CT (one left hepatectomy and two 
segmentectomies). In two cases chemotherapy was introduced based on 
18
F-FDG PET/CT finding of hepatic and extra-
hepatic disease, while in another two patients surgical treatment of the liver was canceled due to disseminated disease 
seen on 
18
F-FDG PET/CT. 
18
F-FDG PET/CT scan in patient with extra-hepatic disease in terms of pulmonary and 
abdominal lymph-node metastases is shown in Figure 2. Overall, 
18
F-FDG PET/CT induced treatment changes in 7/29 
(24.1%) patients with colorectal liver metastases (Table 4). 
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Table 4. Treatment changes after 18F-FDG PET/CT scan in patients with colorectal liver metastases (N=29) 
 n 
Switch to surgical treatment of liver metastases 3 
Switch from surgery to chemoradiotherapy 2 
Switch from surgery to palliative 2 
No treatment changes 22 
18
F-FDG PET/CT: Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography 
 
 
 
 
Figure 2. 
18
F-FDG PET/CT scan (trans axial CT, PET and fused image, and maximum intensity projection image) in patient 
showing liver (cross-bars), pulmonary and abdominal and pelvic lymph nodes metastases 
 
 
Discussion 
 
This study compared the diagnostic performance of 
18
F-FDG PET/CT and MDCT in detection of liver metastases of 
colorectal cancer. Our results showed high sensitivity, specificity and accuracy of 
18
F-FDG PET/CT in detection of 
metastases in the liver in patients with suspected metastatic recurrent colorectal carcinoma, with superior sensitivity and 
accuracy compared to MDCT. 
Although MDCT represents the mostly used imaging tool in postoperative surveillance of patients with colorectal 
cancer, 
18
F-FDG PET/CT is becoming the modalitiy of choice in detection of recurrent colorectal cancer with the highest 
accuracy confirmed in many studies [9, 10]. In addition, when it comes to detection and identification of hepatic and extra-
hepatic lesions, 
18
F-FDG PET/CT is thought to be the most sensitive method [11, 12]. This has been proven for other 
types of malignant diseases as well [13].  
Regarding liver metastases of the colorectal cancer, magnetic resonance imaging (MRI) has been regarded as 
the most sensitive method for visualisation of hepatic involvement [14, 15]. However, other studies showed similar 
sensitivity of 
18
F-FDG PET/CT and MRI in detection of hepatic lesions [16]. Moreover, it has been shown that 
18
F-FDG 
PET/CT can identify unusual sites of metastatic disease in this region; such is massive portal vein tumour thrombosis 
[17]. In another systematic review, lower sensitivity with higher specificity of 
18
F-FDG PET compared to contrast-
enhanced CT and MRI was reported [7]. In contrast with these results, our study showed significantly higher sensitivity of 
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F-FDG PET/CT over MDCT in detection of hepatic metastases.  
In a systematic review and economic evaluation, which included six studies and 362 patients, the estimates of 
sensitivity and specificity of 
18
F-FDG PET/CT for liver metastases in patient-based analyses ranged from 87%-100% and 
from 75%-100%, respectively, with pooled sensitivity of 91% and specificity of 76%. In the same study, the sensitivity and 
specificity of contrast-enhanced CT ranged from 75%-98% and 25%-100%, respectively [18]. Although our study 
confirmed superiority of 
18
F-FDG PET/CT over MDCT, we reported lower sensitivity of 
18
F-FDG PET/CT compared to 
above study, because of number of cases with false negative results. This can be explained with the cystic presentation 
of the lesions in two patients, which were subjected to surgery due to accelerated growth and confirmed to be metastatic 
disease. 
In our study, the specificity of 
18
F-FDG PET/CT, although it was higher, did not differ significantly from MDCT. 
This complies with the results of other researchers [11]. The reason can be found in very few false positive findings due to 
inflammatory and/or postoperative changes, because 
18
F-FDG PET/CT was performed at least three months after any 
kind of surgical treatment.  
The agreement of various preoperative and intra-operative imaging modalities, including 
18
F-FDG PET/CT, with 
operative findings in patients with colorectal liver metastases, assessed in the study of Bonanni et al., showed good 
correlation of 
18
F-FDG PET/CT with histopathological results and very good correlation with AJCC/UICC stage of 
metastatic liver disease. The only modality showing better correlation was intra-operative ultrasound [19]. In our study, 
among 18 patients with CRC liver metastases subjected to histopathological examination during follow-up, 
18
F-FDG 
PET/CT finding was confirmed in 15 cases. 
18
F-FDG PET/CT affected treatment in 24.1% of our patients with liver metastases. This completely complies 
with the results of meta-analysis [7]. The treatment changes included cancellation of intended surgical treatment of liver 
metastases, when extra-hepatic disease was observed and switch to surgical treatment in cases when 
18
F-FDG PET/CT 
identified metastases confined to liver, which were not observed with MDCT.  
The limitations of the study were retrospective comparison of 
18
F-FDG PET/CT findings with MDCT results, 
relatively small sample and the presence of the liver metastases in a little less than half of our patients, but enough to 
determine the benefit of 
18
F-FDG PET/CT in evaluation and management of these patients. Although histopathological 
confirmation of colorectal cancer metastases to the liver was made not in all patients, this was overcome with long and 
detailed follow-up.  
In conclusion, 18F-FDG PET/CT was highly sensitive, specific and accurate method in detection of liver 
metastases in patients with suspected recurrent colorectal carcinoma in our study. This hybrid imaging showed superior 
diagnostic performance in evaluation of suspected colorectal cancer liver metastases compared to conventional imaging 
and induced treatment changes in approximately one-quarter of our patients with proven colorectal liver metastases. 
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Abstract 
A pathway to the procedure of interpreting radiology images or pathology slides is presented. This simplified mnemonic can be 
used as a memory aid determining the order in which diagnosis should be approached. First, before we place the radiology 
image in front of the lightbox or the slide under the microscope we have to be sure that it is adequately labelled and prepared 
(Correct). It is also necessary to have or gather all available information concerning the patient and if possible his full medical 
history (A, Available Information). Once we come across the image, two fundamental questions should be answered: which part 
of the body does the image concern and-where applicable-if the image is adequate (B, Body). Next, we proceed to answer if we 
have a neoplastic tissue or not (C, Cancer). We then either form a differential diagnosis list or we reach to a final diagnosis (D, 
Diagnosis), which is followed by the writing of the report (E, Exhibit). These series of steps followed as an ad hoc procedure by 
most specialists, are important in order to achieve a complete and clear diagnosis and report, which is intended to support 
optimal clinical practice. This ABCDE concept is a generic standard approach which is not limited to specific specimens and can 
lead to faster diagnosis with less mistakes. 
HJNM 2015; 18(Suppl1); 88-94                                                                Published on line: 12 December 2015 
 
 
Introduction 
 
atient management is conducted by a multidisciplinary team, including radiologists, pathologists, surgeons, 
radiation oncologists, and medical oncologists, all of whom should communicate effectively. The correct diagnosis 
and complete report of radiologists and pathologists are cornerstones to disease diagnosis, treatment and follow-
up of patients. 
The diagnostic pathway begins when a test is indicated and a request is generated; it progresses via the 
diagnostic process and ends when a report is acted upon by the requester. 
1
Minimum standards for the identification of 
patient and his radiology image or tissue sample must be produced by the corresponding laboratory. All relevant clinical 
information should accompany the sample on the appropriate request form. Trained laboratory staff should follow a 
process of generating a radiology image or a pathology slide (rad-path image) according to local protocols. The 
generated images are interpreted by professionals-radiologists, pathologists. The final report should include radiology or 
pathology findings and ideally a final conclusion. Where ancillary studies are performed, the findings should be included 
in the body of the report. 
Even though protocols and proforms can orientate radiologists and pathologists when creating a report, there is a 
need for a clear and standardized diagnosis pathway that identifies the order in which a rad-path image should be 
evaluated. This article proposes a systematic framework for bridging the above gap. The proposed algorithm provides a 
step by step approach to rad-path image diagnosis primarily to medical students as well as to biomedical scientists, 
residents, radiologists and pathologists. In particular, the present article describes a practical and systematic ABCDE 
approach that can be used as a guide to rad-path image diagnosis pathway. The proposed procedure is a generic 
standard approach which is not limited to specific specimens and can help improve both diagnoses and the quality of the 
final report being issued to clinicians. 
The procedure consists of six sequential steps. The underlying idea is that every step should be cleared before 
proceeding to the following one. If a step has not been cleared, additional clarifications that need to be taken into 
consideration are provided. The first three steps (Correct, A, B) are considered as prerequisite checkpoints before 
reaching the diagnosis phase (C, D). Cited data are meant to provide a uniform framework of thinking and reporting (E) 
across all health care professionals that use the relevant information. A detailed discussion of the general principles of 
image quality, collection, submission, preparation and staining of samples is outside the scope of this document. The 
proposed ABCDE algorithm has been inspired from the Cytology ABCDE algorithm. 
2
To the best of our knowledge such a 
generic ABCDE approach has not emerged in the open literature. 
  
 
 
P 
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A comprehensive ABCDE procedure for accurate interpretation of radiology and patholoy 
images and data 
 
The proposed ABCDE pathway for the radiology image or pathology slide (rad-path image) diagnosis is summarized in 
Table 1. 
 
Table 1. The ABCDE of radiology image or pathology slide diagnosis 
Correct Correctly labelled and prepared rad-path image 
(same name - number of patient on rad-path image and request form, correct 
preparation) 
A Available information 
(gender, age, medical history of the patient) 
B Body 
Rad: (is the image compatible with the expected radiological findings according to 
topography of the lesion? 
& do we have an adequate image?) 
Path: (are the microscopic elements compatible with the expected histopathological 
findings according to topography of the lesion? 
& do we have an adequate sample?) 
C Cancer 
(is it a neoplasm or a non-neoplastic lesion?) 
D Diagnosis 
(we assess what we saw) 
E Exhibit findings 
(we write a report) 
Note: rad-path image = Radiology or Pathology generated images 
 
 
A flowchart of the suggested algorithm is depicted in Figure 1 
 
The procedure follows six-step process, which commences with the “Correct” step. 
 
Correct: At this stage, we ensure that the rad-path image corresponds to patient and we look for optimal image 
preparation technique. 
      When receiving a rad-path image for diagnosis and prior to having it examined in front of the lightbox or under 
the microscope, we need to confirm that the name on the image or the number slide matches the one on the request form 
(correctly labelled). Correct stage is a safeguard. Regarding quality, radiology images and pathology slides should be 
prepared as documented in laboratory standard operating procedures (correctly prepared). 
 
Available Information (A): At this stage, we establish the basis for our diagnosis. 
      Note that all relevant available information is a prerequisite for an accurate diagnosis. The first thing we need to 
register is the personal data and clinical information of the patient and in particular, the name, gender, age, medical 
history, previous rad-path images if any, previous tumors if any, relevant treatment given (such as radiotherapy or 
chemotherapy), as well as all accompanying radiologic information (when examining a pathology slide) and laboratory 
results. Patient history is the key in many cases. 
Do we already have this data (best case scenario is that clinicians provided us all relevant information)? 
     If the answer is Yes, then we directly move on to step B. 
     If the answer is No, then we must gather all necessary information. We can communicate with the managing clinician 
for clarification; or, if we are in a clinical setting, we can search the medical records. Some may skip this step rushing 
forward with the radiologic image interpretation or the microscopic examination of the slide. However, it is of paramount 
importance to acquire the missing data in order to correctly and rapidly form a complete and accurate differential 
diagnosis or a definitive diagnosis.      
Note that current guidelines recommend that the clinician, radiologist, and pathologist work together towards 
establishing a diagnosis. Clinical and imaging information play a critical role to a pathology diagnosis. 
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YES 
NO 
YES 
CORRECT 
Fix Error 
A 
Do we already know available information? 
YES 
YES 
YES NO 
NO 
NO 
Gather all patient data 
C 
B 
Are the figured elements compatible with the expected 
anatomical - histological findings according to the 
topography of the lesion? 
 
 
Ectopic tissue 
Mistake 
Do we have an adequate image - sample? 
Is it a neoplasm? 
NO 
Is it benign, suspicious or malignant? 
If malignant: Is it a primary malignancy or a 
secondary one? 
Is it completely negative? OR 
Is it a non-neoplastic abnormal condition? 
 
Consider morphology and -if needed- any ancillary techniques 
comment @ E 
D 
Figure 1. A Systematic Approach to Radiology Image and Pathology Slide Diagnosis. 
 
C D E 
D 
E 
E 
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Body (B): At this stage, we check if the rad-path image is in accordance with the information provided in the lesion field on 
the request form. We also question the adequacy of the rad-path image-where it applies. 
      It is essential to know what to expect, from an anatomy point of view for Radiology and from histological point of 
view for Pathology. We need to know the topography of lesion, the part of the body that the sample comes from. For 
example, in a mammogram we expect to see a pair of breasts depicted symmetrically, in a Pap smear we expect to see 
squamous and endocervical cells. 
Are the figured elements compatible with the expected anatomical or histological findings according to the topography of 
the lesion? 
     If the answer is Yes, then we proceed to the next question, which is “Do we have an adequate image-sample?” 
     If the answer is No, then we either consider it as a mistake that needs to be clarified before proceeding to C or 
consider the possibility of ectopic tissue and proceed to step C. Awareness of possible ectopic tissue in erratic locations 
can help radiologists and pathologists make the correct interpretation of rad-path images. 
      Assessment of adequacy of the sample is a prerequisite for reducing the incidence of false results and in 
particular, false negatives. In case of a mammogram for example, pectoral muscle should be properly depicted. 
3
In case 
of sputum, if we do not see any pulmonary macrophages it is a superficial expectoration and we cannot have a 
representative image of the possible underling lesion. 
4
 
Do we have an adequate image-sample? 
     If the answer is Yes, then we move on to step C. 
     If the answer is No, then we move to C, keeping in mind that at stage E a comment needs to be added, pointing out the 
inadequacy of the rad-path image. The reason of inadequacy should be clearly stated in the report. 
5
 
 
Cancer (C): At this stage, we decide about the neoplastic or not character of the lesion. 
      The radiological and histopathological examination of a lesion is the basis of cancer diagnostics. Morphology can 
confirm malignancy, as opposed to a reactive or infectious process. For most cases a morphologic examination is 
sufficient for conclusive determination of a lesion. However, sometimes, we need further diagnostic work-up in order to 
reach a definitive decision. 
      Reaching stage C, we examine morphology and the following question is posed: 
Is it a neoplasm? 
     If the answer is Yes, then we have to differentiate between benign, suspicious and malignant conditions by looking for 
hallmark features that will enforce our decision. In case of malignancy, we must deduce if the morphology defines a 
primary malignant tumor or a metastasis. Note that if morphology isn’t straight-forward, we need to consider the use of 
additional imaging modalities or the use of ancillary techniques e.g. immunohistochemistry. Subsequently, we move on to 
step D. 
     If the answer is No, we need to examine the following complementary questions. Is it completely negative or do the 
features imply a non-neoplastic abnormal condition (e.g. infection, atrophy, dysplasia)? After answering the above 
question, we move on to step D. 
 
Diagnosis (D): At this stage, we make our decision. 
      We have collected all clinical information (stage A), macroscopic description of specimen-if any-and radiologic or 
microscopic findings (stages B and C). It is the right time to formulate a diagnosis in our mind. Sometimes, we may arrive 
at this stage only to form a differential diagnosis list, while we wait for ancillary studies to take place and lead us to a 
definitive diagnosis. 
      An accurate, specific and sufficiently comprehensive diagnosis will enable the clinician to develop an optimal 
plan of therapeutic intervention. If we are not able to completely identify the lesion, we provide a differential diagnosis list. 
Then, we move to the final step E. 
 
Exhibit (E): At this stage, we exhibit our findings by writing a report. 
      Good formatting of the report is essential in order to optimise our communication with the clinician. 
Standardization, uniformity and consistency in the presentation of results between laboratories greatly facilitate the 
clinicians to read and understand reports coming from different laboratories. It is therefore of considerable importance the 
adoption of a systematic reporting procedure regarding diagnosis of cancer. 
5
For this reason, there are standard protocols 
that can be followed to present the required data elements in many of the eligible cancer radiology or pathology reports. 
6
The final report should include patient, doctor and specimen identification, a gross description of the specimen-if any-, 
radiologic or microscopic findings and ideally a final conclusion
7,8
.  
      Note that in case of an inadequate specimen, an adequacy statement needs to be added in stage E of the report. 
Any notes and suggestions are also included here. 
5
 
      In Tables 2 and 3, we present two examples on the application of the proposed ABCDE algorithm to radiology 
and pathology diagnosis procedure accordingly. 
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Table 2. The ABCDE diagnosis pathway for radiology-case of a mammogram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. The ABCDE diagnosis pathway for pathology-case of a fine needle aspiration of breast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correct Correctly labelled mammogram (confirm patient) 
Correctly prepared mammogram (exposure dose and time, the entire breast parenchyma is 
included on the image) 
A Available  
information 
Gender: woman 
Age: 42-year-old 
Medical history: clear 
Physical examination findings: palpable lump in the right breast 
Previous films for comparison: none 
B Body 
 
Breast 
Being adequate: Pectoral muscle is properly depicted 
C Cancer Suspicious abnormality, hyperdense mass with irregular shape and 
spiculated margins, that significantly disturbs the surrounding parenchymal 
architecture of the breast 
D Diagnosis Suspicious for invasive breast carcinoma 
E Exhibit Identifications, exposure, views 
Imaging findings: narrative description of what we saw 
Conclusion: BIRADS 4 
Correct Correctly labelled slides (confirm patient) 
Correctly prepared slides (stain, slides covered without air) 
A Available  
information 
Gender: woman 
Age: 42-year-old 
Medical history: clear 
Physical examination findings: palpable lump in the right breast 
Radiological findings: BIRADS 4 
B Body Breast 
Being adequate: Solid lesions: No specific requirement for a minimum 
number of epithelial cells. 
11 
Cystic lesions: There are no criteria for a minimal cell count. 11 
C Cancer YES 
Smears are hypercellular, with sheets and cords of malignant cells. 
Cells are crowded and enlarged. Nuclei are hyperchromatic with occasional 
prominent nucleoli. Myoepithelial cells are lacking. Abundant large cellular 
fragments with slender, well-formed papillary structures with narrow 
avascular stalks and wide bulbous ends = micropapillary form. 
ICC: ER+(2+) , PR+(2+) , c-erb-B2+(3+), Ki-67>20% 
D Diagnosis Ductal carcinoma 
E Exhibit Identifications 
Macroscopic: FNA of palpable mass ±2cm, close to areola of right breast; 3 
slides: 1 prepared with liquid-based cytology method and 2 prepared with 
conventional method; Pap stain. 
Microscopic: narrative description of what we saw, plus ICC findings 
Conclusion: Ductal carcinoma 
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 93 
Discussion 
 
To the best of our knowledge and after a careful search of all relevant literature, there are two ABCDEF and an 
ABCDEFGHI guide in Radiology, all three for chest radiograph assessment. In Pathology the only worldwide “ABCDE 
criteria” currently available is a heuristic procedure for detecting melanoma. There is also the “ABCD scheme”, the so-
called Whitmore-Jewett prostate staging that has been replaced by the TNM staging system. The Diagnostic Medicine 
ABCDE has been inspired from the Cytology ABCDE algorithm(2).  
The described Diagnostic Medicine ABCDE procedure is a well-structured and systematic way of thinking when 
examining a radiology image or a pathology slide. The originality of this work is that all these steps have been structured 
to comply to an ABCDE algorithm that provides a consistent set of steps for reliable diagnosis. It should be noted that it is 
a generic concept, not limited to specific specimens or imaging modalities. The proposed pathway is in its first edition and 
has not been through a full cycle of use, review and further refinement. 
These sequential steps are followed as an ad-hoc procedure by most specialists, but as a new standardized and 
systematic method they can be a useful, practical and educational tool for all medical professionals. For students, it 
should add an element of fun and guidance to the learning process. In addition, if all medical students are acquainted with 
this generic ABCDE algorithm, in their follow-up professional years they will be more inclined to provide all relevant 
information to radiologists and pathologists, which can potentially lead to faster diagnosis, and they can better understand 
and appreciate Diagnostic’s Medicine role. It can also set the basis of a common language among doctors of different 
specialties. 
Medical instructors can use this practical ABCDE guide to facilitate teaching. They can use it to present a case, 
to write a case report or to embed it to their lectures. 
Professionals who teach residents could also make use of the generic ABCDE philosophy when they 
simultaneously view an image in front of the lightbox or the slides under the teaching microscope. They can communicate 
their observations in a more coded way. For example, “what’s the A?”, “what did you find in C?”, “what’s your opinion 
about D?” 
Everyone who processes radiology images or pathology specimens can probably find it useful, practical and 
educational as well. It could also help improve outcomes in reports by ensuring that all important elements for a complete 
diagnosis will be included. 
We believe that by using this ABCDE step-by-step approach a medical professional cannot deviate from the right 
course of action when interpreting a medical image. Furthermore, the use of the Diagnostic Medicine ABCDE procedure 
can potentially lead to faster diagnosis with less mistakes. Thus, we conclude that the generic ABCDE algorithm for 
radiology image and pathology slide interpretation is of great value to diagnosis field and it can give birth to other ABCDE 
algorithms on medical diagnosis in the future. 
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Advances in knowledge 
 
Diagnostic Medicine ABCDE algorithm: 
 is a new structured way to orientate radiology image or pathology slide assessment 
 describes a generic systematic procedure in radiology and pathology diagnosis, not limited to specific specimens 
or imaging modalities 
 is a useful practical and educational tool for all medical professionals i.e. students, residents, specialists, 
professors and researchers 
 is an approach towards integrating Radiology and Pathology. 
  
Implication for patient care 
Diagnostic Medicine ABCDE algorithm can potentially lead to faster diagnosis with less mistakes. 
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Abstract 
Objective: A serious complication of joint replacement surgery is infection, which results in prolonged invalidity as well as 
removal and subsequent re-implantation after lengthy antibiotic therapy. In terms of diagnostic imaging, nuclear medicine has 
presented several tracers and imaging modalities over the years to be used in prosthetic joint infection. The PubMed/MEDLINE 
literature database was systematically examined for publications on infection, arthroplasty, joint replacement, prosthetic joint, 
gallium, labeled leukocytes, sulfur colloid, antimicrobial peptides, Fluorine-18-fluorodeoxyglucose (
18
F-FDG), positron emission 
tomography/computed tomography (PET-CT), and single-photon emission (SPET-CT). This was determined to be a 
comprehensive review, not a meta-analysis of prosthetic joint infection and diagnostic imaging in the field of nuclear medicine. 
Prosthetic joint replacement is more frequently being employed as a way of improving the quality of life in an ever-ageing 
population. Complications following joint replacement surgery include aseptic or mechanical loosening, as well as polyethylene 
wear and prosthetic joint infection. The rate of infection is estimated to be between 1%-3%. The therapeutic management of 
these complications lies in the ability to differentiate between infection and aseptic mechanical loosening. Given that plain 
radiographs are neither sensitive nor specific to infection and computer tomography, as well as magnetic resonance imaging are 
limited due to metal-induced artifacts, radionuclide imaging has come to aid in the diagnostic imaging in the failed joint 
replacement. However, each modality has its advantages and disadvantages, thus there is no gold standard technique of 
radionuclide imaging. Nevertheless, radiolabelled leukocyte scintigraphy has proven itself to be the gold standard in neutrophil-
based infection processes. Several studies have examined the role of PET using radiotracers such as 
18
F-FDG, gallium-67 and 
18
F, as well as SPET-CT in diagnosing prosthetic joint infections. Other radiotracers, such as antigranulocyte antibodies and 
fragments, as well as radiolabeled antibodies and antimicrobial peptide have yet to confirm their role in diagnostic imaging of the 
failed joint replacement. Nuclear medicine plays a vital role in diagnosing prosthetic joint infections. WBC/bone marrow imaging 
is the best available diagnostic imaging test. Newer imaging modalities, such as SPET-CT may in the future, play a larger role in 
diagnosing prosthetic joint infections. The roles of 
18
F-PET and 
18
F-FDG-PET have yet to still be determined. 
HJNM 2015; 18(Suppl1); 95-102                                                                Published on line: 12 December 2015 
 
 
Introduction 
      
rosthetic joint replacement is being more frequently employed as a way of improving the quality of life in an ever-
ageing population, given that life expectancy is steadily increasing [1]. However, as with every surgical procedure, 
there are certain risks and complications. Common complications following joint replacement surgery are aseptic or 
mechanical loosening, as well as polyethylene wear [2]. While not often observed, prosthetic joint infection is a serious 
complication that can result in significant morbidity, decrease in joint function, prolonged invalidity and hospitalization, 
often leading to explantation and subsequent re-implantation following several weeks of antibiotic therapy [1, 3]. In 
addition, the financial, clinical and psychological factors of such an infection must be taken into consideration [4]. There is 
a 1% rate of infection following primary hip implantation and 2% for knee prostheses [5]. Following revision surgery, these 
numbers increase to about 3% for hip replacements and 5% for knee replacements [5].  
Prosthetic joint infections can be grouped into “early” (within three months after surgery), “delayed” (between 
three months to two years) and “late” (after two years) [6]. The two most common organisms found are Staphylococcus 
epidermidis (31%) and Staphylococcus aureus (20%) [2]. Whereas Staphylococcus aureus is typically isolated in “early” 
infections, coagulase-negative Staphylococci, Streptococci, Enterococci and Anaerobes are seen in “late” infections [6]. 
Some factors that predispose individuals to prosthetic joint infections are higher age, obesity, underlying joint infection 
(rheumatoid arthritis, psoriasis), poor nutritional status, diabetes mellitus, remote infection and prior joint infection, as well 
as immune suppression [7, 8]. 
P 
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 Between the patient’s bone and the prosthesis material is a thin layer of reactive fibrous tissue, also known as a 
membrane [1]. In prosthetic joint infection, either as a result of microbial colonization that occurs at time of implantation or 
haematogenous seeding leads to inflammatory cells, collagen and blood vessels thicken this membrane [1]. Furthermore, 
the pathogens attach to the membrane by means of capsular polysaccharide-associated adhesins and a proteinaceous 
cell wall, subsequently secreting a biofilm that protects them from the host immune response and antibiotics [1]. 
Therefore, diagnosis and subsequent treatment of joint infections are quite difficult.  
It is a known fact that bacteria secrete chemotactic factors, such as histamine and prostaglandins that recruit 
leukocytes, induce endothelial activation and cause edema. Therefore, the incessant recruitment of leukocytes from the 
blood to the periprosthetic tissue is typical of acute or sub-acute bacterial infection. Due to active migration into an 
infected tissue by means of adherence to vascular endothelium followed by migration, autologous radiolabelled white 
blood cells have a high specificity [9]. A subtype of white blood cells (WBC), neutrophils, are present in the infected joint 
and are the predominantly labeled circulating cell in labeled leukocyte scintigraphy (LS) with tracers, such as 
111
In-oxine 
and 
99m
Tc-hexamethyl propyleneamine oxime (HMPAO) [1]. Leukocyte labeling in infection imaging was first introduced in 
1976 by McAfee and Thakur [10]. Labeled leukocytes do not accumulate at sites absent of infection or where there is 
increased bone turnover [1]. Therefore, LS is considered to be a valuable tool in diagnosing prosthetic joint infections [1]. 
In addition, given that neutrophils are typically absent in aseptic loosened prosthesis, LS should be able to distinguish 
between an infected prosthesis and an inflamed aseptic prosthesis [5, 11, 12]. However, bone marrow displacement or 
activation by surgery can result in a secondary uptake of leukocytes around prostheses [1]. Therefore, a combination of 
LS and bone marrow scintigraphy (BMS) with 
99m
Tc-sulphur-/nanocolloid has been introduced [1]. Within 48 hours of 
bacterial seeding, an acidic pH, low oxygen tension, increased intraosseous pressure and vascular insufficiency suppress 
the uptake of sulfur-/nano colloid [13]. Given that infection stimulates the uptake of leukocytes, but suppresses the uptake 
of sulfur-/nanocolloid, LS and BMS in infections are spatially incongruent [5]. If however, the uptake of the two 
radiopharmaceuticals is similar or spatially congruent, the labeled leukocyte activity is attributable to bone marrow uptake 
[5].  
 In terms of diagnostic imaging, nuclear medicine has offered various tracers and imaging modalities over the 
years to be used in diagnosing infected joint replacements. This review will discuss those most widely used. 
 
 
Preoperative work-up in suspected prosthetic infections 
 
Prosthetic joint infection is defined by major and minor criteria. Major criteria include: a) presence of a sinus tract 
communicating with the prosthesis or b) two positive periprosthetic cultures with phenotypically identical organisms [14]. 
Minor criteria include: 1) raised serum erythrocyte sedimentation rate (ESR) and serum C-reactive protein concentration 
(CRP), 2) raised synovial WBC count change on leucocyte esterase test strip, 3) raised synovial polymorphonuclear 
neutrophil percentage, 4) positive histological analysis of periprosthetic tissue or 5) a single positive culture [14]. One of 
the most perplexing diagnostic situations involves a persistent marginally elevated CRP or tenacious pain after surgery 
[1]. Therefore, diagnosis involves a variety of different factors. Firstly, thorough clinical histories, including medical, 
surgical and physical examinations deliver excellent initial diagnostic and aid in subsequent diagnostic evaluation [1]. 
Further diagnostic evaluation of prosthetic joint infection includes hematological tests with inflammation markers (C-
reactive protein (CRP), WBC count, ESR and interleukin-6). A study by Glithero et al. (1993) [15] examining CRP values 
in patients with suspected prosthetic infections reported a sensitivity, specificity and accuracy of 83%, 74%, and 77%, 
respectively. In a study currently under review, the sensitivity of CRP was 57%, specificity 28%, with an overall accuracy 
of 33% [16]. A review by Yuan et al. (2014) [17] demonstrated that CRP had good diagnostic accuracy for periprosthetic 
infections with a sensitivity of 82% and specificity of 77%. Overall, it appears that CRP alone is not very accurate in 
prosthetic joint infections. In terms of WBC count, a study by Berbari et al. (2010) [18] that demonstrated that WBC count 
has the lowest diagnostic accuracy for prosthetic joint infections. While this analysis only investigated serum CRP and 
WBC count, a study by Claassen et al. (2014) [19] that assessed 46 patients with knee arthroplasty and aspiration in 77 
cases, demonstrated an increase in WBC count in only 7 cases and normal levels in the remaining patients. In addition, 
CRP was increased in 33 cases and normal in 44 cases [19]. In a study currently under review, they demonstrated a 
sensitivity of 0%, specificity of 92% and overall accuracy of 82% [16]. Similar to this study, Claassen et al. (2014) [19] also 
concluded that CRP and WBC are not accurate in diagnosing ongoing infection.  
 A normal CRP or ESR cannot completely rule out a low-grade infection, given that false negative results can 
occur following long-term antibiotic treatment or in patients with delayed-onset infection [18]. Therefore, additional 
diagnostic examinations, such as joint aspiration with a WBC count and differential, gram stain and culture, as well as 
numerous imaging modalities may be required [1, 18]. 
 
 
Well-established tracers in infection 
 
67
Gallium-citrate 
Gallium-67 (
67
Ga) is an analog of iron that can bind to circulating transferrin in its ionic form and thus uses transferrin 
receptors to enter cells and become highly stable [20, 21]. Roughly 90% of 
67
Ga-citrate is transferrin-bound and found in 
the plasma [22]. It is believed that 
67
Ga-citrate can seep through the vascular endothelium and attach to lactoferrin, which 
is released by leukocytes or siderophores expelled by the infectious microorganisms at infection foci [23]. Given that the 
siderophores have a high affinity for 
67
Ga, they readily bind and are transported into the microorganism, to later be 
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phagocytized by macrophages [24]. 
67
Ga is normally distributed within the liver, bone marrow, bone, soft tissues, 
gastrointestinal- and genitourinary tracts [21, 24]. In the past, 
67
Ga has been used for accessing prosthetic joint infection. 
The reported accuracy lies between 50% [25] and 95% [26]. Gomez-Luzuriaga et al. (1988) [27] demonstrated a 
sensitivity, specificity and accuracy of 70%, 90% and 80%, respectively. Mountford et al. (1986) [28] and McKillop et al. 
(1984) [29] also reported the accuracy of gallium scintigraphy in prosthetic joint infection to be 80%. Conversely, Kraemer 
et al. (1993) [30] exhibited a low sensitivity of 38% but a high specificity of 100% and overall accuracy of 81%. In addition, 
Aliabadi et al. (1989) [31] demonstrated a sensitivity of 37% and specificity of 100%. Merkel et al. (1986) [32] presented a 
study showing 66% sensitivity, 81% specificity and 77% accuracy in 
67
Ga diagnostic testing of infection in the painful 
prostheses. Similar results have been seen in 
67
Ga testing in animals. Merkel et al. (1984) [33] reported a sensitivity, 
specificity and accuracy of 61%, 71% and 67%, respectively in loose and infected canine arthroplasty. While diagnostic 
testing with 
67
Ga in prosthetic joint infections has been carried out at one time, its accuracy was not acceptable when 
trying to determine an infected prosthetic joint from an inflamed one. It is now typically limited to diagnosing chronic 
osteomyelitis, fever of unknown origin (FUO) and lung infections. 
 
111
In-oxine 
111
In-oxine is characterized by its ability to diffuse through the cell membrane and detach itself from the lipophilic complex, 
thus leading to an irreversible binding to the nuclear and other intracellular components [21, 34]. Some advantages of 
using 
111
In-oxine include a 67h half-life with a constant distribution limited to the bone marrow, liver and spleen, which is a 
great benefit, especially in infections of the prosthetic joint and musculoskeletal system [22]. Disadvantages include not 
being able to use this radiotracer in inflammatory bowel diseases, as well as a 24h-interval requirement between injection 
and imaging [22]. The sensitivity of indium-111 LS lies within 38%-100%, specificity between 15%-100% and accuracy 
60%-96% [15, 35-37]. However, in combination with technetium-99m sulfur colloid, it is possible to increase sensitivity, 
specificity and accuracy. Mulamba et al. (1983) [38] demonstrated a sensitivity, specificity and accuracy of 92%, 100% 
and 96%, respectively. Furthermore, Palestro et al. (1991) [39] exhibited a sensitivity of 86%, specificity of 97% and 
accuracy of 95% in 41 patients with knee prostheses suspected of being infected. In addition, Palestro et al. (1990) [40] 
reported a sensitivity, specificity and accuracy of 100%, 97% and 98%, respectively in 92 cemented total-hip 
arthroplasties. Finally, a study by Joseph et al. (2001) [41] in 58 patients before reoperation of total knee or hip 
arthroplasty demonstrated a sensitivity of 46%, specificity of 100% and overall accuracy of 88%. Typical indications of 
using 
111
In-oxine include diagnostic imaging for prosthetic joint infections, chronic osteomyelitis and in certain cases of 
fever of unknown origin/occult fever [23].  
 
99m
Tc-hexamethylpropyleneamine oxine (HMPAO) 
Labeling of leukocytes with 
99m
Tc-HMPAO was first introduced in 1986 by Peters et al (1999) [42]. The 
99m
Tc-HMPAO 
complex is able to enter the cell, transform to a hydrophilic state and then becomes trapped in the cell [23]. Some 
advantages of using this tracer include low radiation burden, continuous availability, cheapness and ideal γ-ray energy 
[43]. It also has a higher proton flux, which permits the imagining of body parts such as feet [23]. Given its low radiation, 
this tracer can easily be used in children. However, this tracer is less stable than 
111
In-oxine, eluting from cells up to 7%/h, 
which requires imaging to occur within 2-4h after injection of the tracer [23, 43, 44]. 
99m
Tc-HMPAO accumulated in the 
gastrointestinal tract, bone marrow, spleen, liver and kidneys [23]. It is commonly used in the imaging of bone/joint 
infection, irritable bowel disease and soft tissue infection.  
 
Leukocyte labeling with 
111
In-oxine or 
99m
Tc-HMPAO 
The reported accuracy of WBC-labeling combined with bone marrow imaging ranges from 86-98% of patients [39-41, 45-
54]. One of the earliest studies with 30 patients examining labeled leukocytes with bone marrow imaging and hip 
arthroplasty by Mulamba et al. (1983) [38] observed a 92% sensitivity and 100% specificity for diagnosing hip infections. 
Another study of labeled leukocytes and bone marrow scans in 72 patients with hip arthroplasty by Palestro et al. (1990) 
[40] demonstrated 100% sensitivity and 97% specificity in diagnosing infection. A review examining 59 patients with failed 
hip- and knee arthroplasties by Love at al. (2004) [53] reported the sensitivity, specificity and accuracy of combined 
leukocyte/bone marrow scanning to be 100%, 91%, and 95%, respectively. In addition, a study by El Espera et al. (2004) 
[52] determined 80% sensitivity, 94% specificity and 91% accuracy in 60 patients with knee or hip arthroplasty that 
received combined leukocyte/bone marrow scanning. While most studies show that combined leukocyte-and bone 
marrow scanning is highly specific, the sensitivity of this method can vary. A study by Pill et al. (2006) [55] reported only 
50% sensitivity in combined leukocyte/bone marrow scan. Furthermore, while Joseph et al. (2001) [41] reported 100% 
specificity in their patient population of 58 patients with total knee or hip arthroplasty, they observed only 46% sensitivity 
for combined leukocyte/bone marrow imaging.  
It has been argued that poor sensitivity can be attributed to chronicity of an infection, as well as non-specific 
inflammation [29, 56-58]. While chronic infections are typically characterized by less distinct neutrophil recruitment and 
edema [59], a study by Datz et al. (1986) [11] that examined the labeled leukocytes in acute and chronic infections found 
no significant statistical difference in sensitivity. In non-specific inflammation, neutrophils are generally absent [60]. Given 
that LS is most sensitive in imaging neutrophil-dominate responses [60], aseptic inflammation may lead to false negative 
results and a decrease in sensitivity [61]. While it was once discussed that false negative results could be due to prior 
antibiotic treatment, several studies have shown this not to be the case [62, 63]. However, one must keep in consideration 
that both the activity and uptake can vary, as well as the normal distribution of WBC in the bone marrow [64]. For 
example, one would expect to see fewer WBC migrating to the joints of chronic infection. Furthermore, uptake depends 
on the number of WBC that migrate to the site of infection [64].  
Despite the high accuracy of this technique, LS does have its disadvantages, which have to be considered 
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before performing this test. Firstly, the procedure is labor intensive. Given that two to three technologists are involved in 
the labeling and imaging processes, it can be estimated that a total of 8-10 hours is required from them for this technique, 
over two days. Furthermore, this technique is routinely available in only a few hospitals worldwide. In addition, it involves 
contact with blood products, which requires strict protocols, such as the use of a laminar flow hood [51, 53, 60, 65]. The 
indications for the combination imaging LS/BMS include prosthetic joint infection, musculoskeletal infections, and 
neuropathic joint [64]. Leukocyte scintigraphy has also been implemented in patients with fever of unknown origin, 
postoperative infections, as well as systemic infections [64].  
 
18
F-deoxyglucose (FDG) 
The first studies investigating the role of 
18
F-FDG in infection imaging were first introduced in 2006 [66-68]. Cells with 
increased glucose requirements, such as inflammatory cells and tumor cells readily take up 
18
F-FDG [43]. Given that 
deoxyglucose cannot leave the cell after it has been taken up, it can be used in the imaging of the above-mentioned cells 
[69, 70]. Some of the advantages of this tracer include easy preparation and imaging [43]. On the other hand, 
disadvantages include a short half-time of 110 minutes, as well as a low labeling efficiency when compared to 
111
In-oxine 
and 
99m
Tc-HMPAO [59]. Given the negative aspects of the tracer, two to three times more activity must be used in the 
labeling process, which ultimately results in a higher activity being injected into the patient [71]. In addition, given its short 
half-life, late images required in prosthetic joint infection imaging are not possible [59]. Physiological uptake of 
18
F-FDG is 
seen in the brain, heart, kidneys and bladder [59]. Infection imaging with 
18
F-FDG has shown high sensitivity, but low 
specificity, mainly due to the fact that imaging is based on increased metabolic activity [72, 73]. Thus, its role in 
diagnosing osteomyelitis and infected prosthetic joints is limited. One major drawback with 
18
F-FDG in infection imaging 
are the artifacts adjacent to prostheses [74]. In addition, healing tissues up to 6 months following surgery, bone fractures, 
varicose veins and atherosclerotic lesions can all demonstrate non-specific 
18
F-FDG uptake [75, 76]. As shown in a recent 
study by Aydin et al. (2015) [77] 
18
F-FDG uptake was confined to the proximal segment of the prosthesis in 62 
asymptomatic patients who underwent total hip replacement, whereby the femoral segment showed no uptake. Thus, a 
positive 
18
F-FDG-scan in infection must be interpreted with caution given the various reasons that can produce false 
positive results [78]. Several studies have investigated 
18
F-FDG in infection imaging. Zhuang et al. (2001) [79] 
demonstrated 89.5% increase in 
18
F-FDG uptake along hip arthroplasties and 77.8% in knee arthroplasties. Chacko et al. 
(2002) [80] exhibited 92% sensitivity and 97% specificity in infection of hip arthroplasty. In both of these studies, intensity 
was not able to differentiate between aseptic inflammation versus infection. As seen in a study by Delank et al. (2006) 
[81] they were able to demonstrate that 
18
F-FDG-PET was able to positively diagnose evidence of loosening in 76.4% of 
patients and detect periprosthetic inflammation in 100% of septic cases. However, only 45.5% of cases were positive for 
increased abrasion and aseptic inflammation, thus, 
18
F-FDG-PET was not able to deduce the difference between 
abrasion-induced versus inflammation due to bacteria [81]. Similar results were seen in a study by Garcia-Barrecheguren 
et al. (2007) [82] who reported a low sensitivity (64%) and specificity (67%) of 
18
F-FDG-PET in hip replacement infections. 
In regards to accuracy, Cremerius et al. (2003) [83] and Gravius et al. (2010) [84] reported roughly 89% accurate in 
infection of hip arthroplasties, while Manthey et al. (2002) reported 96% accuracy [85]. On the other hand, Stumpe et al. 
(2004) [86] demonstrated an accuracy of only 69%, with bone scintigraphy being more accurate (80%) than 
18
F-FDG-PET 
in their study. Pill et al. (2006) [55] exhibited 95% sensitivity and 93% specificity in infected hip replacements, versus 50% 
sensitivity and 95.1% specificity of WBC/marrow imaging in a subgroup of these patients. Regardless of the different 
criteria on how to interpret 
18
F-FDG uptake in infection, it has been exhibited in several studies that 
18
F-FDG-PET is less 
accurate when compared to labeled WBC/bone marrow imaging in diagnosing prosthetic joint infection [53, 87, 88]. In a 
meta-analysis, the overall sensitivity and specificity of 
18
F-FDG-PET in prosthetic joint infection was 82% and 87%, 
respectively [89]. Thus, its role in diagnosing prosthetic joint infection still needs to be determined. However, it has been 
shown to be important in diagnosing spondylodiscitis [79, 90, 91].  
 
 
Future outlook 
 
Recently published papers assessing future directions in leukocyte labeling include using monoclonal antibodies, SPET-
CT as an adjunct to scintigraphy, as well as 
18
F-FDG PET. The use of monoclonal antibodies such as Sulesomab for 
infection diagnostics has also been recently discussed and reported sensitivity and specificity lie between 75% to 93% 
and 65% to 86%, respectively [92-94]. Its role in infection diagnostics has, however, yet to be determined. On the other 
hand, the additional role of SPET-CT is a promising direction in infection diagnostics. In a study by Graute et al. (2010) 
[95] they were able to increase sensitivity from 66% to 89% and specificity from 60% to 73% by combining planar images 
with SPET-CT. Furthermore, a recently published study by Kim et al. (2014) [96], which assessed adding SPET-CT to 
99m
Tc-HMPAO-labeled leukocytes, demonstrated an increase in sensitivity from 82% to 93.3%, specificity 88% to 93.3%, 
PPV from 89% to 94.3% and NPV 80.5% to 92.1% and diagnostic accuracy from 84.8% to 93.3%. Additionally, a study by 
Bar-Shalom et al. (2006) [97] demonstrated the additional role of SPET/CT in patients with 
111
In-WBC, as it is able to 
provide exact localization, as well as the extent of the infection, thus improving diagnosis. In addition, Filippi et al. (2006) 
[98] demonstrated 100% accuracy when using SPET/CT with 
99m
Tc-exametazime labeled leukocytes in patients with 
suspected musculoskeletal infection, compared to 64% when using solely scintigraphy. Horger et al. (2003) [99] exhibited 
97% accuracy when using 
99m
Tc-labeled anti-granulocyte antibody and SPET/CT in the diagnosis of bone infection versus 
59% accuracy of scintigraphy alone. It is believed, in accordance with other studies that the CT component increases the 
sensitivity by precisely localizing the anatomical site of infection [98]. Lastly, the role of 
18
F-FDG PET has showed great 
potential for infection diagnostics and for studying bone metabolism. A study by Sterner et al. (2007) [100] was able to 
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demonstrate that the sensitivity, specificity and accuracy of 
18
F-FDG PET, 100%, 56%, and 71%, respectively, were 
higher when compared to radiographs with 43%, 86%, and 64%, respectively, when assessing for aseptic loosening in 14 
patients with painful knee arthroplasties. Kobayashi et al. (2011) [101] exhibited sensitivity 95%, specificity 88% and 
overall accuracy 91% of 
18
F-PET in 49 patients following total hip arthroplasty with significant differences shown between 
the maximum standardized uptake value (SUVmax) values for aseptic and septic loosening. Several studies by Ullmark et 
al. (2012, 2013) [102, 103] demonstrated the promising role of 
18
F-FDG PET in analyzing bone formation. While SPET-CT 
increases sensitivity through the CT component, an increase in sensitivity leads to a decrease in specificity. In conclusion, 
until the roles of SPET-CT and 
18
F-FDG PET in diagnostic infection imaging can be determined, the combination of LS 
with bone marrow imaging is an accurate technique in diagnosing prosthetic infections.  
 
 
Conclusion 
 
Nuclear medicine plays a vital role in diagnosing prosthetic joint infections. This review has shown that currently, 
WBC/bone marrow imaging is the best available diagnostic imaging test. Newer imaging modalities, such as SPET-CT 
may in the future, play a bigger role in diagnosing prosthetic joint infections, especially given that it can provide us with 
important additional information, such as exact anatomical location. The roles of 
18
F-FDG PET and 
18
F-FDG PET/CT have 
yet to be determined. 
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Abstract 
Objective: Extracorporeal shock wave lithotripsy (ESWL) is highly effective for the treatment of uretral lithiasis and remains the 
first treatment option for the majority of patients when ureteral lithiasis can not be treated otherwise for more than two decades. 
In the present study we aim to evaluate the levels of serum tumor necrosis factor a (TNF-a) and interleucin 6 (IL-6) in patients 
undergoing ESWL and investigate whether preESWL levels of serum TNF-a and IL-6 correllate with any possible infectious 
complications after ESWL. Subjects and Methods: Thirty patients (17 males and 13 females), with a mean age of 43 who 
underwent ESWL for ureteral stones and 10 healthy volunteers serving as the control group were enrolled in this study. Serum 
samples for TNF-a and IL-6 were obtained before ESWL and after ESWL, 1, 24, and 48 hours and 2, 24, and 48 hours, 
respectively. The preESWL and postESWL serum TNF-a levels and IL-6 were compared and correlated with possible tissue 
damage and infectious complications. Results: We found that serum TNF-a levels were significantly decreased one hour 
(P<0,001) and increased 24 hours (P=0.007) after ESWL. Furthermore IL-6 was also significantly increased 2 hours (P<0,001), 
24 and 48 hours after ESWL (P=0,003 and 0,002 respectively). In 3 patients we observed fever (39°C) postESWL procedure 
with negative urine culture and high serum values of TNF-a and IL6 preESWL. In conclusion: A high specific markers such as 
serum TNF-a levels (15-25pg/ml) and IL-6 (25-35pg/ml) might be useful to identifying patients with possible infection following 
ESWL lithotripsy. However, further studies are needed to get more accurate results. 
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Introduction 
 
xtracorporeal shock wave lithotripsy (ESWL), could be considered the first-line therapy for ureteral stones that 
cannot be treated otherwise. In recent years, after the conservative treatment has failed, ESWL is universally 
adopted for the treatment of ureteral stones [1, 2].  
Proinflammatory cytokines are a group of peptides that regulate the humoral and cellular components of immune 
system and in vivo inflammatory responses. Interleukin-6 (IL-6) is an inducer of activation and differentiation of B and T 
cells during inflammatory response and activates the vascular endothelium in the process of inflammation. Tumor 
Necrosis Factor-a (TNF-a) is produced by many kidney cells: glomerular mesangial, epithelial and endothelial cells, and 
tubular epithelial cells. It activates monocytes-macrophages and increases the release of other cytokines, chemokines, 
growth factors, and acute phase proteins. Increased and prolonged release of TNF-a is harmful and may cause 
inflammation and tissue damage [3, 4]. In our study, we investigated serum markers related to the acute injurious effects 
of ESWL on ureter by using serum cytokines as IL-6 and TNF-a in 1, 2, 24 and 48 hours. 
 
 
Subjects and Methods 
 
Patients and control group characteristics are summarized in Table 1. Thirty patients (17 males and 13 females), mean 
age of 43 (range: 21-65 years) with ureteral lithiasis treated with ESWL and 10 healthy blood donors as the control group 
were studied. None of the patients had received any other treatment for urinary stones like percutaneus nephrolithotripsy, 
ureteroscopy or ESWL or had a history of systemic or immunosuppressive disease. Other exclusion criteria included age 
less than 18 or more than 80, previous insertion of a ureteral stent or nephrostomy tube, neoplasmatic disease, and renal 
insufficiency. Urine cultures, before and after ESWL were routinely obtained in all patients in order to exclude the 
presence of urinary tract infection. 
Patients were admitted 1 day prior to ESWL procedure. A prophylactic dose of an intravenous broad-spectrum 
antibiotic was administered at the same day of the procedure. 
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The ESWL procedure was undertaken at the lithotripsy unit of Urology Department of General University Hospital 
of Alexandroupolis Greece via electromagnetic bathless lithotripter of Dornier lithotripter SII (Dornier Medtech
®
 Germany). 
Approximately 3000-4000 shock waves at the range of 80-95 shock waves per minute were applied to every individual. 
Tumor necrosis factor-a was measured 1, 24 and 48 hours before and after ESWL, while IL-6 levels were 
measured at 2, 24 and 48 hours. The measurements at one and two hours post ESWL were obtained in order to evaluate 
the possible acute effect of the procedure. The blood samples were centrifuged as soon as possible at 4000/rpm for 
10/min at 4
o
C. The serum samples were divided into aliquots and stored at -85
o
C until analysis. Cytokine concentrations 
were measured using the commercial Biosource Europe SA IL-6 and TNF-a immunoradiometric assay (IRMA) (Rue de 
l’Industrie 8 B-1400 Nivelles, Belgium). The reference range for IL-6 normal values was 6-31pg/mL and for TNF-a 
5pg/mL, respectively. 
 
Table 1. Clinical characteristics of 30 patients with ureter lithiasis treated with ESW lithotripsy and 10 health controls 
 Patients Control group 
Age years Mean (-) 43 (21-65) 51,05 (31-72) 
Gender ♀ / ♂ 17/13 6/4 
Size of stone (cm)   
0-0,6 8 (24%)  - 
0,6-1.00 21 (63%)  - 
>1.01 1 (13%)  - 
Stone  location   
Upper ureter  17 (57%)  - 
Median ureter 1 (43%)  - 
   
 
 
Statistical analysis 
Statistical analysis was performed using the statistical package SPSS V.20. Statistical analyses of serum TNF-a and IL-6 
values of the control group and 1 hour (or 2 hours samples for IL-6), 24h, 48h postures were performed using paired 
samples T-test with confidence interval 95%. A P value of less than 0.01 was considered statistically significant.  
 
 
Results 
 
Serum TNF-a levels of our patients were statistical significantly correlated with the control group at 1h post ESWL 
(P=0,001) and were not significantly correlated at 24h and 48h postESWL. Serum levels of IL-6 were no significant in 2h 
but were significant at 24h and at 48h postESWL (P<0,001) (Table 2). 
 
Table 2. Serum IL-6 and TNF-a. Paired samples T test with confidence interval 95%. Independed variable: the Control 
Group of IL-6 and TNF-a before and 1h or 2h, 24h, 48h hours after ESWL 
 Paired 
Differences 
Std.  
Deviation 
Std.  
Error  
Mean 
95% Confidence  
Interval of the   
Difference 
 
t df Sig.  
(2-tailed) 
 
 Mean   Lower Upper    
Interleukine 6         
Before ESWL - CG 4.14400 6.22842 1.96960 -0.31155 8.59955 2.104 9 ,065 
2h after ESWL - CG 18.6310 8.72011 2.75754 12.3930 24.8689 6.756 9 ,000 
24h >>     >>        >> 27.5290 8.11295 2.56554 21.7253 33.3326 10.73 9 ,000 
28h >>     >>        >> 16.7070 6.35297 2.00899 12.1623 21.2516 8.316 9 ,000 
TNF-a         
Before ESWL - CG 8.83200 5.45179 1.72401 4.93202 12.7319 5.123 9 ,001 
1h after ESWL - CG 0.20000 2.97317 0.94020 -2.10687 2.14687 0.021 9 ,983 
24h >>     >>        >> 1.29200 3.51234 1.11070 -1.22058 3.80458 1.163 9 ,275 
28h >>     >>        >> 4.20800 5.25937 1.66316 0.44567 7.97703 2.530 9 ,032 
IL-6: serum interleukin 6; TNF-a: serum tumor factor a; ESWL: extracorporeal shock wave lithotripsy; CG: control group 
 
 
In Figure 1 and 2 we show the time distribution of serum TNF-a and IL-6 respectively in our patients and in 10 
healthy volunteers who represent the control group. Some changes in serum cytokine levels were observed in bivariate 
linear correlation between the groups of interest (Pearson’s test) and are shown in Table 3.  
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 105 
 
Figure 1. The distribution of serum TNF-a before and after ESWL and the control group of the study 
 
Figure 2. The distribution of serum IL-6 before and after ESWL and the 10 healthy volunteers which represents the control group 
 
 
Serum TNF-a levels were significantly decreased 1h after (P<0,001) and increased 24h (P=0.007) after ESWL. 
Furthermore, IL-6 was also significantly increased 2h (P<0,001), 24h and 48h after ESWL (P=0,003 and 0,002 
respectively). All patients developed postESWL microscopic haematuria and were successfully treated conservatively 
with drinking lots of fluids and antibiotics. Post ESWL fever (>39°C) was developed in 3 patients (10%) and was managed 
with i.v antibiotic (ciprofloxacin 1gr/day for 7 days). All those patients had negative urine culture pre ESWL and serum 
values for TNF-a were 22 to 24.51pg/mL, and 24-25.42pg/mL for IL6. PostESWL at 1 hour for TNF-a the serum values 
decreased to 14-15.84pg/mL (from 22 to 24.51pg/mL) and at two hours for IL increased to 69-73.56pg/mL (from 24-
25.42). Other complications such as stone or stone fractions migration, ureteral or renal injury and haematomas were 
absent. 
. 
 
Discussion  
 
The method of ESWL was introduced in 1980 as a minimally invasive treatment for patients with upper urinary tract 
stones. Prior to the introduction of this new method, the only treatment available for calculi that could not pass through the 
urinary tract was open surgery. Since then, ESWL has become the preferred tool in the urologist’s armamentarium for 
treatment according to the size and localization of renal and ureter stones [5, 6]. The comminution of the calculus by 
ESWL is due to mechanical forces generated by the shock waves. These mechanical forces are not innocuous and may 
result in damage of the kidney, ureter and vascular injury [7].  
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Table 3. Bivariate linear correlation between the groups of interest (Pearson’s test). Serum TNF-a and IL-6 values before 
and 1h or 2h,24h,48h after ESWL 
Tumor necrosis 
factor a 
 Before URS 1h after URS 
2h for IL6 
24h after URS 48h after URS 
 
Before URS 
PC 
P value  
N 
, 
 
   
 
1h after URS 
PC 
P value  
N 
 261 
,164 
  30 
   
 
24h >>     >> 
PC 
P value  
N 
,132 
.487 
   30 
,863  
,000 
   30 
  
 
48h >>     >> 
PC 
P value  
-.018 
 ,924 
,376* 
,041 
 ,482** 
,.007 
 
 N    30    30    30  
Interleukine 6      
 
Before URS 
PC 
P value  
N 
    
 
2h after URS 
PC 
P value  
N 
,738** 
,000 
   30 
   
 
24h >>     >> 
PC 
P value  
N 
,528** 
,003 
   30 
,665** 
,000 
   30 
  
 
48h >>     >> 
PC 
P value  
,540* 
,002 
,598 
,000 
,723** 
,000 
 
 N    30    30    30  
** Correlation is significant at the 0.01 level (2-tailed),* Correlation is significant at the 0.05 level (2-tailed), PC: 
Pearson Correlation, P value: Sig. (2-tailed) 
 
 
Emergency treatment for stone removal should be considered for stones with a diameter of ≥7mm, when 
adequate pain relief cannot be achieved and in cases that stone causes obstruction associated with infection, especially 
in cases of a single stone [8]. 
The whole ESWL procedure requires a well equipped department and some follow-up time in order to reach a 
satisfactory stone-free situation. It also requires more patient’s visits to the clinic. Retreatment may be necessary in 
ESWL more than in other ureter lithiasis treatments. The advantages of ESWL are noninvasiveness and no need of local 
or general anesthesia [9]. 
Absolute contraindications for ESWL include urosepsis, uncontrolled hypertension, distal obstruction of stone 
passage and pregnancy. Other relative contraindications are morbid obesity [10] and cystine stone is well known for its 
resistance for ESWL [11].  
Shock waves destroying stones in soft tissues are through to have harmful effects on the surrounding tissues or 
may induce inflammation [12]. The most common complication for renal and uper ureter ESWL is perirenal, intrarenal, or 
subcapsular hemorrhage caused by direct tissue damage. Acute pancreatitis is an additional, although rare, complication 
[13]. 
Secretion of IL-6 and TNF-a activates several other reactions exacerbating the host inflammatory response. In 
vitro human blood monocytes produce IL-6 and TNF-a when exposed to 25-50pg/mL of endotoxin. Such endotoxin levels 
have been reported in the bloodstream of patients during septic shock [14]. 
Reports in the literature suggest that the intensity of tissue damage can be measured by cytokines and acute-
phase proteins [4, 15-17]. After tissue damage, local neutrophils granulocytes and macrophages activate the cytokine 
cascade and lead to subsequent production of IL-6 with following local or systemic acute phase reaction. Other 
investigators have shown that 30 to 60/min after injury, IL-6 can be detected and peak serum levels are reached within 6h 
[18]. 
For urine IL-6 and IL-1 levels Goktas C et al. (2012) found that before ESWL, there was no significant elevation. 
In early phase, 24h after ESWL, there was a strong inflammatory response that could be detected by measuring urine IL-
6. For IL-1 the inflammatory response continued at a slower rate, up to 14 days after and finally they conclude that urine 
IL-6 and IL-1 may be used to measure the severity of inflammation [18].  
Perez-Fentes (2015) demonstrate that tissue damage caused by the percutaneous nephrolithotomy (PCNL) on 
40 patients is low. This damage increases significantly in those cases showing postoperative complications. IL-6 at 
24hours has been shown to be a good predictive tool for the development of complications after PCNL. On the other hand 
the group treated with ESWL (50 patients) didn’t show significant changes in any of the studied serum cytokines such IL-
1β TNF-α and IL-6 [19]. 
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Earlier in 2000 serum cytokines levels were measured by Fornara et al. in 145 patients who underwent various 
laparoscopic procedures, open surgical procedures and ESWL.Cytokines showed less marked elevation during 
laparoscopy and ESWL when compared to an open surgery [20].  
In a clinical study to assess acute ESWL-induced inflammation, Dundar et al. (2001) detected no change in 
plasma and urine levels of the inflammatory cytokines TNF-α and IL-6 in patients 2 h after ESWL [4].  
Bantis et al. in 2014 demonstrated that serum IL-6 and TNF-a levels were affected by simple tissue injury under 
aseptic conditions at the time of minimal invasive surgery as ureteroscopy and laser lithotripsy [6]. 
In conclusion, in this study we found significant differences between the cytokine TNF-a levels before and 1h 
(P<0,001) and 24h (P=0,007) after ESWL and the IL-6 at 2h, 24h and 48h (P<0,001, P=0,003 and P=0,002). This 
increase postESWL may be the result of the ESWL method on soft tissues and/or the irritation caused by the stone itself. 
This finding supports that cytokines are produced locally. The significance of the increase of serum TNF-a and IL-6 levels 
may be related to its early collection, as indicated in Table 4.  
 
 
Table 4. Contribution of TNF-a and Interleukine 6 serum values in control group and in patients with lithiasis before and 
after ESWL in 1h or 2h, 24h and 48h (pg/mL) 
TNF-a/ILl6     
(pg/ml) 
CG 
(N10) 
Patients  ESWL   (N30) 
  Before ESWL After 1 hour 
After 2 hours for  
IL-6 
After 24h After 48h 
TNF-a      
MD  
(min-max) 
      5.58 
(2.78-12.03) 
      24.51 
(3.90-24.51) 
     15.84 
(3.70-15.84) 
     18.16 
(4.40-18.16) 
      20.72 
(4.45-20.72) 
      
IL-6      
MD  
(min-max) 
      17.48 
(6.17-30.12) 
      37.16 
(13.16-25.42) 
      45.91 
(19.37-73.56) 
      53.33 
(24.14-77.23) 
       41.65 
(23.59-53.27) 
TNF-a: serum tumor factor a; IL-6: serum interleukin 6; MD: median definition; min-max: minimum and maximum levels of serum 
TNF-a and IL-6; CG: control group 
 
 
These results support a definitive role of the production of pro inflammatory cytokines after ESWL. Of course 
more elaborate studies should be performed to support the above findings. 
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Abstract 
Aim: This study aimed at examining the direct and indirect, via cognitive control and emotion recognition, effects of advancing 
age on adults’ social cognition, and especially, on complex forms of it such as indirect speech, faux pas, and social mental verb 
understanding. Method: The sample comprised a total of 70 adults, aged from 18 to 83 years. Participants were almost equally 
distributed in each one of three age-groups (young, middle-aged, and older adults), according to their gender and educational 
level. Three tasks measuring the ability to interpret indirect speech, the ability to understand faux pas, and social mental verb 
understanding, respectively, were administered as measures of social cognition. Cognitive control, as inhibitory control, task 
switching, updating-monitoring, and planning, as well as basic emotion decoding from visual cues, were measured by four and 
one task respectively. Results: After the confirmation of the factor structure of each one of the dimensions of social cognition, 
and the examination of the direct effects of age on them, the all-inclusive path model finally confirmed showed that age has a 
significant negative indirect effect, via cognitive control, on social cognition as ability to interpret indirect speech and faux pas. 
Conclusion: The decreased performance that cognitively healthy older adults exhibit, as regards specific complex dimensions of 
social cognition, could be attributed to negative effects of age on cognitive control. However, it is likely that some other complex 
dimensions of social cognition are not affected by frontal aging.   
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Introduction 
      
ocial cognition includes automatic and voluntary cognitive processes applied for decoding and encoding the social 
world [1]. It is defined as the ability to represent mentally the relations between ourselves and other people, as well 
as the use of these representations to guide social behavior [2]. In fact, social cognition is a higher-order cognitive 
process that serves interactions [3] and leads to coherent interpersonal relationships [4]. As such a complex process, it 
comprises a set of abilities. Theory of Mind (ToM), namely the ability to attribute the full range of mental states, is the 
most representative and most studied dimension of social cognition [5]. At the theoretical level, a distinction is made 
between two broad dimensions of ToM: a. the cognitive dimension that refers to the ability to make inferences about 
cognitive states, such as beliefs, thoughts, and intentions [6]; b. the affective dimension that represents the ability to infer 
the feelings, affective states and emotions of others [7]. Recent studies in the field of social and cognitive neuroscience 
have identified a number of specific components of ToM. 
A core component is called ‘first-order’ ToM and concerns the ability to draw conclusions about a person's mental 
states, like beliefs and thoughts (e.g., I think that Mr. X thinks that...) [8]. ‘Second-order’ ToM, a more complex form of 
ToM [9], corresponds to more internal representations about ourselves, and involves the ability of simultaneously 
adopting two perspectives (e.g., Mr. X thinks that Miss Y thinks that…) [10]. Higher metarepresentations are involved in 
more advanced ToM components, such as the comprehension of ‘indirect speech’ and ‘faux pas’.  
Indirect speech is ubiquitous in ‘everyday’ social interactions, when people make jokes or speak ironically or 
sarcastically [11]. The indirect meaning arises from the fact that there is a discrepancy between the literal meaning of the 
words and the social context [12]. In order to understand indirect speech, someone should comprehend speaker’s 
intentions and other mental states, such as beliefs and feelings [13]. Specifically, understanding indirect speech requires 
first-order ToM as regards the speaker’s belief, to avoid interpreting it as a mistake, as well as second-order ToM as 
regards the speaker’s belief about the listener’s belief, to avoid interpreting it as a lie [14].  
Faux pas is a particular case of a non-intentional action. A faux pas occurs when a speaker says something 
without considering if it is something that the listener might not want to hear or know, and which typically has a negative 
outcome on the listener that the speaker never intended. It implies both the ability to refer to other’s state of mind and the 
appreciation of the emotional impact of their statement on their listener [15]. Faux pas involves both cognitive and 
affective ToM, as faux pas understanding requires the ability to infer epistemological mental states, intentions and 
emotions. Specifically, in order for a faux pas to be identified, one should understand that the speaker did not realize that 
the statement should not have been said and that the listener may feel sad or upset [16]. The understanding that the 
speaker’s intention was not malicious is also required [13]. 
Mental verbs are claimed to contribute to ToM [17]. From the semantic point of view, mental verbs relate to the 
S 
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‘language of mind’ [18] and assist the understanding of our own and other’s mental states. Philosophers of language 
distinguish some subclasses within the general class of mental verbs, like cognitive mental verbs (know, remember, 
understand etc.) and social mental verbs (promise, agree, suggest, etc.), with cognitive mental verbs denoting a true 
event (factive) described in the complement clause, and social mental verbs denoting an obligation or intention, stating 
reasons, arguments and communications [19]. Hence, by definition, it is obvious that social mental verbs are very strongly 
interconnected with social cognition and ToM. In any case, in order to judge a mental verb about the factivity or 
nonfactivity, it is necessary one to be able to separate mind content (mental representation) from reality [20].  
Moreover, emotion recognition, which is an important but somehow instinctive and primitive social skill, is 
suggested to be interlinked with social cognition and empathy [21]. In particular, the ability to decode emotions from facial 
expressions seems to be related with the affective ToM, as it was found that the brain areas which are activated during 
these functions are overlapped [5]. In addition, in a recent study where older participants performed lower that younger 
ones, in faux pas discrimination, it was found that emotion recognition fully mediated age effects, [22]. These results 
provide evidence for the role of emotion recognition in a range of important social deficits.       
As regards the pattern of social cognition’s changes with age, there is still no clear research conclusion. This is 
true in particular for ToM, as the number of empirical studies is limited, and although most of them have concluded that 
there is a decline, there are contradictory findings in the literature. The first study aiming to investigate ToM in aging [23] 
found that older adults were more efficient than younger ones, in terms of their performance on the ‘Strange Stories test’. 
This is a ToM task in which participants have to make inferences about what one character thinks about the mental state 
of another character, by decoding sarcasm, irony or social rule violation. Conversely, in a recent study, it is reported that 
young–old and old–old adults performed more poorly than young participants on a similar task, except when cognitive load 
was reduced. These findings show that older adults are impaired only on ToM tasks with high cognitive processing 
demands [24]. In the same vein, age-related declines in ToM were found, when second-order ToM tasks requiring 
participants to consider the thoughts of two different characters, were used, while less complex first-order ToM was not 
impaired with age. This could indicate that, rather than showing a specific deficit in the ability to represent mental states, 
older adults show a decline in the domain-general resources required for complex ToM judgments [25]. However, such a 
conclusion is also debatable, as preservation of more complex forms of ToM, like faux pas, has been supported by other 
studies [26].These discrepancies may have arisen from methodological limitations, such as ceiling effects, small samples 
or the use of tasks with different demands for assessing the same ToM component. In particular, the older studies tended 
to examine a single ToM component or use only one type of task to measure it [10]. Nevertheless, recent research 
suggests that different dimensions of social cognition and ToM follow different developmental trajectories [27].  
Regardless of the uncertainty about the identification of social cognition’s dimensions that appear to be impaired 
in normal aging, another important issue concerns the relation between these impairments and deterioration of other 
cognitive functions. Aging is known to be accompanied by irreversible changes at a cellular level that evolve progressively 
with age [28]. As regards central nervous system during normal aging, many changes occur in brain’s structure and 
function [29]. As a result, cognitive functions seem to be affected to a greater or lesser extent [30]. Neuropsychological 
research demonstrates a cognitive profile of contrasts in aging, as some main functions display deficits, while others 
remain intact [31]. Impairments in functions that are supported by frontal lobe, such as cognitive control or as it is usually 
called, ‘executive functions’, are well documented [32]. It has been suggested that executive functions are strongly 
required during the production of a social inference, and therefore, are involved in ToM, throughout lifespan development 
[33]. Thus, it is interesting to examine their contribution in ToM performance in aging. Previous studies showed conflicting 
results. Some of them concluded that the deterioration in cognitive ToM components observed in healthy older adults is a 
result of an age-related decline in executive functions, like inhibitory control, rather than an impairment of the actual 
system for representing mental states {34-35}. However, at least one recent study clearly shows that age-related decline 
in ToM is not attributable to age-related impairment in executive functions [24]. 
Based on the theoretical framework, it seems that despite the fact that, recently, research interest has shifted to 
the investigation of social cognition in aging, clear conclusions about which are the dimensions of social cognition that are 
affected by age,  as well as about the role of other cognitive functions in the developmental trajectory of ToM have not 
been formulated. In this light, the present study was designed to examine adults’ ability to understand higher-order 
dimensions of social cognition and ToM, which are less studied formerly, and explore the effects of age, gender and 
education on these abilities. The study aimed also at examining the relations among social cognition, emotion 
recognition, cognitive control, and individual - demographic factors. 
Τhe hypotheses of the study were formulated as follows: 
1. Although deficits in less complex dimensions of social cognition in older adults than the abilities selected to be 
examined in this study have been confirmed by previous research, the effects of executive functions on social cognition 
decrements seem to be decisive. Therefore, it was assumed that age would not have any direct effect on any one of the 
dimensions of social cognition that the present study aimed to examine.  
2a. According to several studies, impairments in social cognition with age are mediated by executive functions, which are 
also impaired. Thus, it was suggested that there would be an indirect negative effect of age on social cognition, through 
cognitive control.   
2b. Apart from the hypothesized indirect effect of age on social cognition via cognitive control, this study aimed also at 
examining potential effects exerted by age on social cognition, via the ability of emotion recognition. Data in this field are 
limited. Only one study found that age affect indirectly and negatively, via emotion recognition, the ability to understand 
faux pas [22]. Hence, it was assumed that there would be indirect negative effects of age on the dimensions of social 
cognition involving affective elements, like understanding of faux pas where empathy is required, and understanding of 
indirect speech, which requires, among others, inferring the feelings of the speaker.  
3. The effects of individual - demographic factors, like gender and educational level, on adults’ social cognition have 
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attracted little research interest. For this reason, a specific aim of the present study was to examine their direct effects on 
social cognition’s dimensions. According to one study [36], older adults’ impaired performance on social cognition was not 
affected by educational level. Hence, it was assumed that there would not be direct effects of this factor on social 
cognition's dimension. 
   
 
Method 
 
Participants  
The sample comprised a total of 70 adults (34 women) from Greece, who participated voluntarily in the study. As regards 
the age of the participants, the sample consisted of three age-groups: young, middle-aged, and older adults. Participants 
belonged to three different educational levels (EL): middle EL (n=25, 10-12 years of education), upper EL (n=19, ≥13 
years of education–vocational/technical school), and high EL (n=26, ≥13 years of education-university and technological 
educational institute). Participants in each one of the three age-groups were almost equally distributed in terms of their 
gender, F (2, 67)=0.046, P>0.05, and educational level, F (2, 67)=0.076, P>0.05, with no statistically significant 
differences between the age-groups (Table 1). The sample of the 70 participants was the final one, after the exclusion of 
persons who met the exclusionary criteria used in the study. Exclusionary criteria for all possible participants were the 
presence of uncorrected hearing or visual loss, and a history of mental illness (depression symptoms and/or a history of 
psychosis) or substance abuse. The presence of depressive symptoms in the older adult group was examined with the 
Geriatric Depression Scale-15 (GDS-15). Taking into account the financial crisis in Greece, a relatively flexible criterion 
for exclusion (a score more than 8) of the older adult participants on the basis of their GDS–15 score was adopted, 
considering that the GDS-15 score ‘6-7’ was confirmed as a valid cutoff level for the diagnosis of older adult depression in 
Greece [37]. To investigate the existence of depressive symptomatology in young and middle-aged adults, the Beck 
Depression Inventory (BDI) was administered. Potential participants who scored over ‘30’ were excluded, as this rating is 
an indication of serious clinical depression [38]. Additional exclusionary criterion for the older adult participants was the 
existence of cognitive decline. A score lower than ‘23-24’ in the Mini Mental State Examination (MMSE) is considered 
indicative of cognitive impairment [39]. However, in this study, to ensure that older participants were cognitively healthy, a 
more stringent criterion was used, as a score lower than 27 excluded the potential participant.  
 
 
Table 1. Participants’ distribution according to age, gender, and educational level 
*GDS = Geriatric Depression Scale; **MMSE = Mini Mental State Examination; ***BDI= Beck Depression Inventory 
Measures 
 
Social cognition 
 
Indirect Speech Understanding Task: Irony, Humor, Sarcasm (ISUT). Based on ‘’Strange Stories test” [23], the ISUT was 
developed by Natsopoulos, for the purposes of the present study, as a part of a battery of tasks aiming at examining 
different complex dimensions of social cognition. The ISUT contains nine stories (three of each form of indirect speech, 
namely of irony, humor, and sarcasm), in which the protagonists say something that are not meant literally. Every story is 
read by the examiner. Initially, the participant is asked to answer a series of control questions, in order to examine 
whether they cognitively understand the story. This is a prerequisite to proceed with the following step. Then, the 
participant’s task is to answer the main two questions developed to examine ToM. In the first, the participant has to 
answer if the protagonist’s statement is true. Only if the answer to this question is ‘’no’’, suggesting that the non-literal 
meaning of the story is understood, the second question, that is ‘’Why did he/she say that?’’, is given. In order for the 
interpretation of the indirect speech to be considered “correct”, it is necessary the participant to understand the 
motivations and various mental states of the person who expresses something not literally. As regards scoring for the 
ISUT, every correct answer, for the main two questions, is credited with ‘1’ and every incorrect answer is taking ‘0’. An 
example item of the task is the following:  
Philip is reliable worker. His employer cuts a significant amount of his fixed fee. Philip disappointed says: “I did not expect 
 
Adult participants 
Age-group 
Age 
Range 
(years) 
Mean 
 
SD  
Gender 
 Male 
 
Female 
 
Middle 
Education 
Upper  
(years) 
High 
GDS* 
Mean  
(SD) 
MMSE**       BDI*** 
Mean            Mean 
(SD)             (SD) 
 
Young (n=26) 
 
18-30 
 
23.4 
 
4.0 
 
14 
 
10 
 
10 
 
5 
 
11 
   
 
4.8 (5.9) 
 
4.0 (4.2) Middle-aged (n=20) 35-58 45.8 6.7 10 10 7 7 6                                        
Older (n=24) 65-83 71.6 5.8 12 12 8 7 9 1.4  
(1.4) 
28.8  
(1.6) 
Total sample (N=70) 18-83 47.1 21.2 36 34 25 19 26   
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such a consistency! I am very willing to work with you in the future!’’  
Faux Pas Understanding Task (FPUT). This task, consisting of three stories, was developed on the basis of a 
test described in Stone, Baron-Cohen, and Knight (1998) [40].The stories contain scenarios that tell about a faux pas. 
After the reading of each story by the experimenter, the participant is asked six questions about important details of the 
story, as a control for story comprehension. This step is a prerequisite to proceed with the next questions related to ToM. 
Then, the participant is asked a faux pas detection question: “Did anyone say something that it shouldn’t have been said? 
Did anyone say something awkward?” If the participant answers ‘’yes’’, they are asked “Who said something that it should 
not have been said?” Then three more demanding -in terms of ToM- questions are asked: “Why shouldn’t the individual in 
the story have said what they did?” This question examines whether the participant is able to understand that the listener 
would be hurt or insulted. In fact, this is an inference about affective mental states. The next question is “Why do you think 
they did say it?” This question examines whether the participant is able to understand that the faux pas was unintentional. 
This is an inference about epistemic mental states and intentionality. The final question is “How do you believe that the 
person who listened something that it shouldn’t have been said, felt?” Again, an inference about affective mental states is 
needed. Each correct answer, only for the questions related to ToM, scores “1” point. Every incorrect answer is taking ‘0’. 
An example item of the task is the following:  
Fotini rents new apartment and buys new curtains... Her friend, Elpida, visits her to see the apartment. She says “curtains 
are crap! I hope to buy soon new!”  
Social Mental Verb Understanding Task (SMVUT). To examine adults’ ability to understand the social factor 
together with the indeterminate (nonfactive) ‘nature’ of social mental verbs, the SMVUT was used [41]. The SMVUT 
includes three  social mental verbs (promise, propose, agree), each one from which is contained in four, very short, main 
clauses, and is given half the time in affirmative and half the time in negative form. This task examines the ability to make 
inferences from social nonfactive mental verbs. As regards scoring for the SMVUT, every correct answer is credited with 
‘1’ and every incorrect answer is taking ‘0’. In order to compare adults' performance as regards social mental verb 
understanding with the respective performance regarding cognitive (factive) mental verb understanding, a cognitive 
mental verb understanding task was also administered [41]. This task was designed to examine a person’s ability to draw 
inferences from factive mental verbs. It includes three cognitive mental verbs (know, remember, forget), which are 
contained in four, very short, main clauses, and are given half the time in affirmative and half the time in negative form. An 
example item of the task is the following: 
Anthimos proposed to Pericles to play basketball with the school team.  
Who is going to play basketball: A. Pericles? B.  Anthimos? C. I can’t decide’’. 
  
Emotion recognition 
 
The ‘TASIT- PART I: Emotion Evaluation Test (EET – PART 1 – FORM A) [42]. The EET was designed to examine a 
person’s ability to identify six basic emotions, namely happiness, pleasant surprise, sadness, anger, anxiety, and disgust, 
and discriminate these from neutral expressions, when they are portrayed dynamically by professional actors. 
Specifically, it comprises 28 alternative forms of a series of short (15-60 seconds) videotaped vignettes of people 
interacting in everyday situations. After viewing each scene, the participant is asked to choose the emotion displayed by 
the actor from a list of six emotional categories and one non-emotional category (neutral) displayed in random order on 
one of five Response Cards. All scripts are neutral in content and do not lend themselves to any specific emotion. 
However, considering that the test was developed in English, for the purposes of the present study, we decided to 
administer it with the sound turned off, so as to focus on the person’s ability to read dynamic visual cues. As regards 
scoring, a total score for correct decoding of each one of the six emotions and the neutral condition is calculated. Thus, 
the score for every emotion and the neutral condition could range from ‘0’ to ‘4’. 
 
Cognitive control 
 
Delis - Kaplan Executive Function System (D-KEFS) [43]. This battery provides a standardized assessment of higher-
order cognitive functions supported by the frontal lobe (executive functions). It is composed of nine stand-alone tests. In 
the current study, the following tests were administered: a) the Verbal Fluency Test which assesses main executive 
functions (inhibitory control, task switching), long term memory, verbal intelligence, attention, reaction time and the ability 
to use strategies; b) the Design Fluency Test which assesses the same executive functions (inhibitory control, task 
switching) plus cognitive flexibility, nonverbal creativity, the ability to create optical patterns, as well as simultaneous 
processing of stimuli; c) the Tower Test which assesses forward planning of a sequence of steps, as the participant tries 
to move a pattern of discs efficiently from a start configuration to a goal configuration to match a target pattern, the ability 
to apply specific rules,  inhibitory control, rule switching, and updating-monitoring. As regards scoring, in Verbal and 
Design Fluency Test, a total score for the correct answers for the three conditions that composed each one of the tests, is 
calculated. In Tower Test, the total achievement score is based on how many towers were correctly completed in the 
allotted time and how many moves were required to complete them.  
Example items: 
In one condition of the Verbal Fluency Test is requested the following; ‘’Say as many animals as you can in one minute’’. 
In one condition of the Design Fluency Test is requested the following; ‘’Draw as many patters as you can in one minute, 
by linking the black dots with four lines”.      
Working memory task: Short-Term Retention and Processing Task: Central Executive (STRPT: CE). The task 
involves listening recall and it was designed based on the working memory battery of Pickering and Gathercole (2001), to 
test the functions of the central executive. This task is a dual-processing task and is administered in order to assess 
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storage capacity and dual processing [44]. Participants are asked to listen to a sentence, then state whether its content is 
true or false. After doing so for all sentences in the set, they have to repeat the last word of all sentences in the set. Each 
memory span includes six trials, and if they answer four correctly, they advance to the next span level. If they answer 
three or fewer out of six trials incorrectly, the test must be discontinued. The variable of interest is the largest memory 
span achieved, which is calculated by the range of the previous span level where the test was disconnected. The memory 
span could be ranged from ‘2’ – ‘9’.   
 
Statistical analyses 
 
Confirmatory factor analysis (CFA), the technical construction of multiple indicators equations - multiple causes (Multiple 
Indicators Multiple Causes Modelling - MIMIC), and path analysis (Path Modelling) that will be presented below were 
conducted in EQS Version 6.1. [45]. Because of kurtosis, all the aforementioned SEM techniques were performed on 
covariance matrices using Robust Maximum Likelihood estimation procedure. Model fit was evaluated based on the 
Satorra-Bentler scaled chi-square statistic as well as on the root mean squared error of approximation (RMSEA); a rule of 
thumb is that RMSEA < 0.05 indicates close approximate fit, and RMSEA ≥0.06 & ≤0.08 indicates good fit. The Comparative 
Fit Index (CFI) was also used; CFI values greater than 0.90 indicate reasonably good fit of the model [46]. 
 
Procedure 
 
The examination process began with the completion of the individual – demographics information. Thereafter, the tests which 
ensured that the participants met the inclusion criteria were administered. During the first session of the examination, the 
tests of social cognition were administered in random order, and during the second session, the tasks of cognitive control 
and emotion recognition wee administered in random sequence. Before the examination, participants gave written informed 
consent for their participation in the research. 
 
 
Results 
 
Structural validity of the Indirect Speech Understanding Task (ISUT): Irony, Humor, Sarcasm 
 
In order to examine whether there are any underlying, broad dimensions based on which indirect speech understanding is 
achieved, the data were subjected to confirmatory factor analyses (CFAs). Two alternative CFA models for the structure of 
the ISUT were examined. According to the existing literature, we firstly tested a two-factor model of the ISUT. Three 
observed variables, which were obtained from the answers to the first question in each form of story (namely the question 
examining the ability to understand the non-literal meaning of the speech), were set to load on a factor labelled ‘First-order 
Theory of Mind’. Three observed variables, which were obtained from the answers to the second question in each type of 
story (namely the question examining the interpretation of the indirect speech and requiring the discrimination of the correct 
form –irony, humor, sarcasm- of the indirect speech), were set to load on a factor labelled ‘Second-order Theory of Mind’ 
(measurement model ‘A’). This model was not confirmed, showing that the two factors as they were defined represented a 
model that did not fit the data. The next CFA model tested was a single factor model in which all observed variables were 
set to load on a factor labeled ‘Understanding of Indirect Speech’ (measurement model ‘B’). The model yielded an 
excellent fit. The chi-square goodness of fit test was not statistically significant, resulting in the acceptance of the null 
hypothesis of good fit, Satorra-Bentler scaled χ2 (1, Ν=70)=0.16, P=0.90. The CFI was 1.00, indicating strongly 
reasonable fit, and the RMSEA was 0.00 (90% CI: 0.00-0.19), indicating close approximate fit for the structural model ‘B’ 
(see Figure 1). However, it is important to mention that the variables found to load on the factor concerned only three of 
the nine stories, in particular one from each form of indirect speech examined (irony, humor, sarcasm). As regards 
internal consistency of the latent variable of the model, this was found to be low, as Cronbach’s alpha was 0.54 for the 
‘Understanding of Indirect Speech’ factor.  
 
Indirect speech understanding task performance  
 
To find out the extent to which adults can distinguish the indirect speech from a sincere exchange, but also their ability to 
understand the intention for irony, humor and sarcasm, frequency analysis was performed. The best possible score was 
‘6’, given that only the scores from the answers to the questions of the stories that load on the factor ‘Understanding of 
Indirect Speech’ were considered as valid ones. The results showed that there is not any person credited with the best 
possible score. The best performance which was observed was ‘5’ and only 20% of the participants (n=14) were credited 
with it. To identify whether the participants’ greater difficulty was in the ability to distinguish indirect speech from a sincere 
exchange, or in the understanding of speaker’s intention, analysis of frequency was performed separately for each of the 
two questions of the stories, and separately for the three forms of indirect speech. Regarding irony, 90% of the 
participants (n=63) responded correctly to the first question and understood that what was said was false. However, only 
12.9% of the same participants (n=9) answered correctly to the second question and understood that what was said was 
ironic. In regards to sarcasm, participants understood that what was said was not true in a percentage of 91.4% (n=64), 
but only 11.4% (n=8) understood correctly speaker’s intent for sarcasm. In fact, 47.1% of the participants (n=33) 
appeared to misunderstand sarcasm as irony. Similar difficulties were not found regarding humor, as the 91.4% of the 
participants (n=64) answered correctly the first question and 62.9% of them (n=44) understood correctly the speaker’s 
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Indirect Speech 
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intention. 
 
 
 
 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The underlying structure of the Understanding of Indirect Speech latent factor (standardized solution). 
*All loadings drawn indicate significant associations (P0.05). **e = measurement error 
 
 
Structural validity of the faux pas understanding task (FPUT) 
 
Although similar tests have been used in several studies previously, there is no evidence for the factorial structure of such 
a test. Based on what is theoretically examined via the questions that constitute the FPUT, we firstly tested a single factor 
model of the FPUT. Six variables, which were resulted from the summative scores of the answers to the ToM-related 
questions of the three stories of the FPUT, were set to load on a factor labeled ‘Faux Pas Understanding’ (measurement 
model A). This model was not confirmed, showing that the latent factor as it was defined was responsible for the 
misspecification of the model. Inspection of the standardized solution revealed that the variable-indicator ‘Did anyone say 
something that it shouldn’t have been said?’ (Faux pas identification question) had a non-significant loading on the factor. 
Therefore, we tested a single factor model, where five of the ToM-related questions of the FPUT set to load on a latent 
factor labeled ‘Understanding the commit conditions of Faux Pas’, while the observed variable ‘Identification of Faux Pas’ 
was set to be free (measurement model B). The Wald and the Lagrange tests, which represent frequently used statistics 
to identify focal areas of misfit in a CFA solution, showed that three of the five variables had to be kept to load on the 
latent factor. Moreover, the latent factor and the free observed variable in the model should be allowed to correlate with 
each other. The modified model yielded an excellent fit. The chi-square goodness of fit test was not statistically 
significant, resulting in the acceptance of the null hypothesis of good fit, Satorra-Bentler scaled χ2 (2, Ν=70)=1.13, P=0.57. 
The CFI was 1.00, indicating strongly reasonable fit, and the RMSEA was 0.00 (90% CI: 0.00-0.20), indicating close 
approximate fit for the modified model (see Figure 2). At this point, it is important to mention that the three variables kept 
corresponded to the answers to the questions: ‘Why shouldn’t the individual in the story have said what he/she did?’, 
‘Why do you think he/she did say it?’, ‘How do you believe the person that listened something shouldn’t have been said, 
felt?’ (see Figure 2). The internal consistency of the latent variable was found to be good, as Cronbach’s alpha was 0.78 
for the ‘Understanding the commit conditions of Faux Pas’ construct. 
   
Faux pas understanding task performance 
 
In order to examine adults’ performance in this task, analysis of frequency was performed. The results showed that 
participants had a well-formulated ability both to identify the Faux Pas and to understand the commit conditions of Faux 
Pas. The best possible score as regards the ability to identify Faux Pas was ‘three points’ and 81.4% of the participants 
(n=57) were credited with this. Regarding the ability to understand the commit conditions of Faux Pas, 21.4% of the total 
sample (n=15) responded correctly in the three questions for each one of the three stories (score = ‘9’), while the same 
proportion answered correctly in eight and seven questions (score = ‘8’ or ‘7’). Looking in more detail the performance, 
participants appeared to have in a greater extent the ability to identify correctly the feelings of the person that listened 
something shouldn’t have been said, as 71.4% of the participants (n=50 ) responded correctly in the respective questions. 
 
 
 
 
 
 
 
 
 
Irony 
Is this true? 
Why it was said? 
 
 0.47 0.88e 
0.98 
Humor 
Is this true? 
Why it was said?   0.22e 
0.25 
Sarcasm 
Is this true? 
Why it was said? 
 
0.97e 
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Figure 2. The structural model of the Faux Pas Understanding Task (standardized solution). 
*All loadings and correlations drawn indicate significant associations (P0.05). **e = measurement error 
 
 
Structural validity of the Social Mental Verb Understanding Task (SMVUT) 
 
According to the extant literature, it is supported that the processing of affirmative and negative sentences differs, as each 
of them is mediated by distinct brain regions [47]. For this reason, we tested a two-factor model of the SMVUT. Three 
observed variables referring to social verb understanding, when the verbs are given in affirmative form, were set to load 
on a factor labelled ‘Understanding of Social Verbs in Affirmative Form’. The remaining three variables referring respectively 
to understanding of each one of the same social verbs, when the verbs are given in negative form, were set to load on a 
second factor labeled ‘Understanding of Social Verbs in Negative Form’ (measurement model ‘A’). The Lagrange test 
showed that the two factors in the model should be allowed to correlate with each other (structural model ‘A’). This 
structural model yielded an excellent fit. The chi-square goodness of fit test was not statistically significant, resulting in the 
acceptance of the null hypothesis of good fit, Satorra-Bentler scaled χ2 (7, Ν=70)=5.64, P=0.58. The CFI was 1.00, 
indicating strongly reasonable fit, and the RMSEA was 0.00 (90% CI: 0.00-0.13), indicating close approximate fit for the 
structural model ‘A’ (see Figure 3). As regards internal consistency of the two latent variables, Cronbach’s alpha was 0.70 
and 0.78 for the ‘Understanding of Social Verbs in Affirmative Form’ and the ‘Understanding of Social Verbs in Negative 
Form’ factor respectively. 
  
Social Mental Verb Understanding Task performance 
 
The results from the analysis of frequency showed that adults did not possess a well-formulated level of social mental 
verb understanding. There was not any person credited with the best possible score as regards the ability to draw 
inferences from social - nonfactive verbs given in affirmative form, while only 7.1% of the participants (n=5) were credited 
with the best score for their ability to draw inferences from social - nonfactive verbs given in negative form. In fact, 51.4% 
(n=36) and 37.1% (n=26) of the participants were found to mistakenly attribute the meaning of all three verbs in 
affirmative and negative sentences, respectively. In sharp contrast, adults were found to posses the ability to draw 
inferences from cognitive - factive mental verbs, as 77.1% (n=54) and 42.9% (n=30) of the participants were credited with 
the best score, when the cognitive mental verbs were given in affirmative sentences and in the negative form 
respectively. 
 
Direct effects of age, gender and educational level on understanding of indirect speech, faux pas, and social mental verbs 
 
To examine the effects of age, education, and gender on the ISUT, FPUT and SMVUT, the Multiple Indicators Multiple 
Causes (MIMIC) modelling technique was used. In MIMIC models, both the latent factor and its indicators are regressed 
onto exogenous variables added to a CFA model established previously. MIMIC models were not confirmed, a finding 
that indicates that there was not any effect of age and the other two individual-demographic factors on the ability to 
understand indirect speech, on faux pas understanding, as well as on the ability to understand the indeterminate ‘nature’ 
of social mental verbs.  
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Figure 3. The structural model of the Social Mental Verb Understanding Task (standardized solution). 
*All loadings and correlations drawn indicate significant associations (P0.05). **e = measurement error 
 
 
Directed relations of age, gender, cognitive control, emotion recognition, and social cognition 
 
In order to examine the directed relationships between age, gender, cognitive control, emotion recognition, and social 
cognition, all the latent variables were transformed to new observed variables. Cognitive control, as resulted from the 
respective CFA, was loaded by the following variables - indicators: design fluency (0.45), planning-tower test (0.56), 
working memory (0.51), semantic fluency (0.89), semantic fluency, after rule switching (0.80), and rule switching score 
(0.84). Basic emotion decoding was loaded from the variables - indicators: happiness decoding (0.39), pleasant surprise 
decoding (0.50), sadness decoding (0.42), anxiety decoding (0.52), and disgust decoding (0.55). In the same CFA model, 
neutral expression decoding and anger decoding represented observed variables allowed free.     
Each one of the newly created variables represented the summative score for the answers to questions - 
indicators that were found to load on the respective latent variable. After that, all relevant variables were subjected to 
recursive path analysis. The all-inclusive path model finally confirmed (path model 1), Satorra-Bentler χ² (68, 
N=70)=74.70, P=0.27, CFI=0.96, RMSEA=0.04 (90% CI: 0.00-0.08), showed that age affected directly, negatively, and 
moderately emotion recognition, and indirectly, negatively, and moderately, through cognitive control, the recognition of 
emotionally neutral expression (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4. The final path model displaying the relations among age, gender, emotion decoding variables, cognitive control, and 
social cognition’s dimensions (standardized solution). 
*All paths and correlations drawn indicate significant associations (P0.05). **e = measurement error. ***Gender: 1=female, 2=male 
 
With regard to complex social cognition, age was found to affect indirectly, negatively, and moderately, and only 
via cognitive control, the ‘Understanding of Indirect Speech’, the ‘Understanding the commit conditions of Faux Pas’ and 
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the ‘Detection of Faux Pas’ dimensions of social cognition. The direct effect of cognitive control on the same tasks was 
found to be positive and relatively low. Gender was found to affect negatively and low anger recognition. However, no 
relation was confirmed between emotion recognition and social cognition or between gender and complex social 
cognition. Moreover, educational level was not found to relate with any one of the other variables in the model (see Figure 
4). 
 
 
Discussion 
 
Indirect speech understanding in adults 
 
The finding that ISUT consists of one factor, namely the 'Understanding of Indirect Speech' factor, indicates that young, 
middle-aged and older adults use a common mental mechanism - pattern to process indirect speech. However, the way 
that this pattern is formulated was not totally expected. According to the relevant theory, understanding of irony, humor 
and sarcasm, as forms of indirect speech, requires two discrete levels of ToM. The ability to go beyond the literal meaning 
of a sentence mentally, in order to understand that the speaker is not lying but is intending to express something in an 
indirect way, implies first-order ToM. In order for the speaker’s intention either for irony, humor or sarcasm, to be 
understood, second-order ToM is required [12].The findings of the present study are partially in agreement with the above 
theory. The model which was confirmed shows that in order to understand these three forms of indirect speech, the 
abilities to distinguish them from a sincere exchange or a lie and to infer the speaker’s correct intention are indeed the 
ones needed but they are processed in the same level of ToM complexity, as parts of a single dimension - ability of 
indirect speech understanding in adults, independently of their age.  
As regards the development of indirect speech understanding during the lifespan, this ToM component first 
appears at about six to eight years of age [48], that is, relatively lately in comparison to other abilities of social cognition. 
The findings of the present study indicate that adults, at least as regards written forms of indirect speech, have the 
capacity to distinguish irony, humor and sarcasm from a sincere exchange or a lie, but they find it difficult to properly 
convey the speaker’s intention and understand which specific form of indirect speech is expressed. Specifically, it seems 
that between the three forms of indirect speech, adults face difficulties in the attribution of irony and sarcasm intention. In 
particularly, the greatest difficulty lies in the understanding of sarcasm, as the intention for sarcasm was correctly 
attributed by a very low percentage of participants in this study. Moreover, a large proportion was found to confuse 
sarcasm with irony. This finding is not surprising, and, despite the fact that sarcasm is a more caustic form of indirect 
speech and is used to exert a strong criticism, it is a form of irony [49]. Hence, the sarcasm stories used in this study are 
possibly not the most appropriate tasks to properly reflect the 'stinging' nature of sarcasm.  
Regarding the ability to understand irony, the most of the participants gave a completely wrong answer for the 
intention of the speaker. In a smaller percentage, participants correctly understood the intention of irony, while the same 
number of participants was found to confuse irony with humor. Moreover, despite the fact that the findings of this research 
show that adults have a satisfactory level of understanding humor, many of the participants who answered wrong in this 
case, confused humor with irony. According to the literature, irony and humor are theoretically considered different forms 
of indirect speech. However, it has been found that adults often recognize humor elements in ironic statements [50]. In 
conclusion, it seems that adults, independently of their age, recognize indirect speech but face serious difficulties in 
understanding the discrete forms of indirect speech [51].  
 
Faux pas understanding in adults 
 
Through the single-factor model, which was confirmed in this case, it seems that in order for a faux pas to be understood, 
not only the ability to identify a faux pas is required but also the ability to understand the commit conditions of faux pas. 
Furthermore, it was found that from the five questions that theoretically examine the understanding of commit conditions 
of faux pas, only three contribute to the understanding of this form of inappropriate speech, in adults. Thus, it seems that 
young, middle-aged, and older adults process a faux pas in a common way, and the ability to comprehend a faux pas is 
reflected in understanding the reason for which the inappropriate statements did not have to be said, in the ability to 
attribute the speaker’s intention and in understanding the listener’s feelings. Moreover, as the observed variable 
'Identification of Faux Pas' and the latent factor 'Understanding the commit conditions of Faux Pas', were found to 
correlate strongly and positively, it is indicated that the identification ability and the ability to understand a faux pas in 
depth are distinct but strongly interconnected processes in adults. 
The ability to understand a faux pas in typically developing children is firstly observed around nine to eleven 
years of age [15], and it has been reported that it may still develop during adolescence and adulthood [7]. The 
performance of the participants in this study demonstrates that adults posses the ability to understand the social blunders 
in a high level. More specifically, at a much higher rate than average, the participants recognized in all three stories that 
something awkward was said. Moreover, on the basis of the percentage of participants answered correctly to the 
questions which load on the factor 'Understanding the commit conditions of Faux Pas', it is indicated that adults have the 
capacity to infer the listener’s feelings and also to understand the reason why the speaker did not have to say this 
causerie. To a lesser extent, however satisfactory, adults appear to properly understand the speaker’s intentions. 
Although faux pas understanding is considered a complex social cognitive ability, on the basis of the extant literature the 
performance of healthy adults is expected to be good, as it has been reported that the same ability is maintained even in 
patients with neurological disorders [16, 52]. Furthermore, it has been found that in studies in which healthy adults 
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participated as a control group, their performance was very high [53-54]. 
 
Social mental verb understanding in adults 
 
Considering the model which was confirmed for the SMVUT, it seems that this complex ToM ability consists of two 
interconnected dimensions, namely the abilities to understand social verbs in affirmative form and in negative form. The 
findings show that young, middle-aged, and older adults process social mental verbs in a common way, which, however, 
varies depending on the form in which the verb is given. Such a conclusion corroborates the suggestion that the 
processing of affirmative and negative sentences differs, as it has been observed that during their processing different 
brain areas are activated. Christensen (2009) [47], on the basis of the findings of an fMRI study, has claimed that, through 
a negation, left premotor cortex exhibits an increased activation, whereas affirmation causes an increased activation in 
the right supramarginal gyrus. In this vein, it is likely that since these two types of clauses are mediated by different brain 
areas, they could also be processed in a different way, at the cognitive – behavioral level [47]. 
      Although language significantly affects the quality of social interactions and the performance on tasks that 
measure various dimensions of social cognition [17], the empirical studies examining the ability to understand social 
mental verbs in adulthood are considerably limited. In this context, the present study tried to fill the gap that exists as 
concerns adults’ ability to understand the social factor and the ‘indeterminate’ nature of social verbs. The results indicated 
that adults do not possess a well-formulated level of social mental verb understanding during the lifespan. This does not 
mean that they do not understand the semantics or the meaning of social mental verbs. However, it seems that, when 
they have to make inferences about these verbs, they are based on heuristics or/and pragmatological schemes. 
Generally, discourse comprehension could occur through top-down processing and also by using the ‘real world’ 
knowledge [55]. Furthermore, in order to understand a text, complex representations are used, which are formed by text 
information and also by the accumulated knowledge [56]. Moreover, in order to comprehend a text, people tend to use 
situation models, which are multi-dimensional representations of the topic of the text that include information such as 
space, time, and causal relationships [57]. According to the findings of this study, it seems that adults, due to their need to 
eliminate uncertainty involved in the information processing system about a social mental verb [58], tend to ‘treat’ social, 
nonfactive verbs as factive ones. On the other hand, the high-level performance of the participants, as regards cognitive 
mental verb understanding, indicates that adults have the ability to understand the factivity and the true event that these 
verbs denote. Knowing the way in which adults organize their mental lexicon, this finding is not surprising. As mentioned, 
they seem to be more able to process mental verbs of low uncertainty such as the factive ones, because of their lower-
level demands in terms of inference and information processing resources [59]. 
 
Age and social cognition: Is there any direct relationship? 
 
One of the main aims of the current study was to examine the direct effects of age on higher-order abilities of social 
cognition. Although the findings of the existing studies are controversial, the majority argue that older adults exhibit 
deficits even in simpler forms of social cognition, such as the ability to understand false beliefs [27, 60]. However, in most 
of the studies it was found that the factor of age does not explain these deficits, as they seem to be mediated fully or 
partially by other factors, such as executive functions or fluid intelligence [10, 61]. In this line, in the present study it was 
hypothesized that age would not affect any complex ability of social cognition. This hypothesis (1
st
) was confirmed, 
supporting previous findings according to which age is considered simply a time axis, along which various developmental 
phenomena emerge, and not an interpretive factor for the impairments that older adults face in various cognitive domains 
[62]. According to the first study examining social cognition in relation to age, it was found that older adults, due to their 
greater experience, exhibit an improvement in their ability to infer mental states [23]. However, in this study the possible 
effect of other factors on social cognition performance was not examined. This is a methodological limitation that 
controverts the validity of the results, as it seems that some factors, such as vocabulary, provide information for the 
interpretation of older adults' performance. Indeed, in a subsequent research, where older adults did not show deficits in 
ToM, it was found that the maintenance of this function was attributed to their superior vocabulary abilities. Thus, it has 
been argued that any deficits that could demonstrate older adults in ToM, are not specific ToM deficits but could emerge 
due to a general cognitive decline [25]. 
  
Gender, educational level, and social cognition 
 
In the present study, the examination of the direct effects of educational level and gender on social cognition confirmed 
the relevant hypothesis (3
rd
), as neither educational level nor gender directly affected social cognition. As regards 
educational level, this result is in line with previous research findings, which showed that this factor does not contribute to 
the observed older adults' deficits in their ability to infer mental states [36]. However, according to another study, the 
differences in the performance on social cognition’s tasks, which were observed between older adults with high and low 
educational level, indirectly indicated that high educational level implies higher crystallized intelligence. Hence, this 
probably constitutes a protective factor for the difficulties that may occur in social cognition across lifespan development 
[63]. The participants of the current study, as in a recent research of Cavallini et al. (2013) [36], had middle, upper and 
high educational level. Perhaps, this is a main reason why there was not observed any effect from educational level on 
complex social cognition examined in this study.  
As regards gender, it has been reported that in participants with autism spectrum disorder, it was observed that 
women performed better on ToM. This superiority of women was claimed that it possibly exists, because women’s 
empathy is in a superior level than men’s [64]. In a recent study, where high-school students participated, it was found 
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that gender affects directly and indirectly, through empathy, the performance in a ToM task, with women to display higher 
performance [65]. As far as we know, the factor of gender has not been examined in relation to its' possible direct effect 
on social cognition in adults. The results of the current study confirm the respective hypothesis (3
rd
), demonstrating that 
gender does not affect directly the complex abilities of social cognition. It is therefore likely that, regardless the differences 
observed between the two genders in social behavior in “everyday” life [64], men and women in experimental conditions 
process the respective tasks in a common way. 
 
Age, gender, educational level, cognitive control, emotion recognition, and social cognition: are there any indirect 
relations between individual-demographic factors and social cognition? 
 
The path model confirmed, shows that age affects directly and negatively the ability to recognize basic emotions, and 
indirectly and negatively, via cognitive control processes, the ability to recognize the emotionally neutral expressions. 
These findings are in line with previous research, as in several studies it was found that older adults are less able to 
recognize emotions from visual stimuli [66-67]. These difficulties are attributed to the general cognitive function, as it is 
suggested that the advance of age, accompanied by cognitive decline, causes deficits in recognizing emotions, 
regardless of their valence [68]. Moreover, this model shows that gender affects directly the ability to recognize anger, as 
women’s performance was significantly better. Differences between the two genders in favor of women are observed 
since childhood and continued in the period of adulthood [69]. It has been supported that these differences are probably 
interlinked with gender differences observed in the functional organization and architecture of the brain structures, which 
are involved in the control of emotions [70, 71].  
Interestingly, as regards social cognition, age appears to affect indirectly and negatively the abilities to identify 
and understand indirect speech and faux pas, through its' effect on cognitive control. Hence, it could be suggested that 
cognitive control mediates the relation between age and social cognition, and, specifically, between age and the 
dimensions associated with affective ToM (2
nd
 hypothesis). This finding contradicts those of another study, according to 
which age was found to affect only those abilities that are related to cognitive ToM [60]. However, at least one study had 
similar results. In this case, age was found to negatively affect only the dimensions of social cognition in which processing 
of affective elements was needed. It has been suggested that possibly such a finding was observed due to the 
association of these abilities with higher memory load [65]. Moreover, it could be argued that as affective dimensions of 
ToM overlap with cognitive empathy [35], it is likely that the negative effects of age on those abilities could be attributed to 
deficits in cognitive empathy observed in normal aging [72].  
In conclusion, the present study contributes to the literature in terms of providing findings about the difficulties 
which adults have in sarcasm, irony and social mental verb understanding. Moreover, the findings confirm the 
conclusions of the existing research, in terms of revealing the important role of cognitive control in social cognition: it was 
found that the higher-level abilities of social cognition that combine cognitive and affective ToM components, are 
negatively affected by age, but this effect is fully mediated by the difficulties that older adults face in cognitive control 
tasks.  
 However, there are some limitations in the study. The restricted nature of the sample should be noted with 
regard to the number of participants in each age-group. The limited number of dimensions of social cognition examined, 
the non-dynamic tasks used, the inability to associate behavioral performance with more objective indices of cognitive 
performance and neuroimaging data should be also mentioned. Moreover, a main limitation is the cross-sectional design 
of the study. It is unknown if the same pattern of results would be obtained if the same persons had repeatedly been 
measured at different age. Generally speaking, more rigorous methods and longitudinal design are needed to examine in 
depth the effects of age on social cognition.       
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Abstract 
Objective: The aim of the present study was the comparison of the general cognitive ability (g) between young children and older 
adults through the investigation of the latent structure qualitative changes in [R] Educational Coloured Progressive Matrices 
(CPM) from age to age, using Confirmatory Factor Analyses (CFA) and testing a conventional unidimensional model. Method: 
The sample consisted of 42 kindergarten and 56 elementary school students (age range: 5-8 years) and 118 new-old adults and 
27 old-old adults (age range: 61-88 years). The participants’ cognitive abilities were examined in: (a) the Raven’s Educational 
CPM test, and (b) the Mini-Mental State Examination (MMSE). Results: CFA applied to data of the total sample, elementary 
school students subsample and new-old adults subsample, indicating that individual variability across [R] CPM measured 
variables (total scores for each of the three sets) can be modeled by one latent variable (a single underlying factor). The same 
pattern of [R] CPM latent structure was not verified for the subsamples of kindergarten students and old-old adults, since the 
variance of a single underlying factor was not found to be statistically significant. Conclusion: The results support the existence 
of a different factor structure in [R] Educational CPM between first- to second- grade elementary school students and new-old 
adults, on the one hand, and kindergarten students and old-old adults, on the other. This difference could possibly reflect the 
underdevelopment of inductive reasoning and executive functioning in the group of kindergarten students and the 
disorganization of them in the group of old-old adults.  
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Introduction 
      
esearchers in the field of cognitive aging seem to agree that, on average, cognitive functioning declines with aging. 
Among the cognitive abilities that seem to be more affected by age is fluid intelligence, the capacity to solve 
problems in novel situations, independent of acquired knowledge [1, 2]. On the contrary, crystallized intelligence, 
i.e. the ability to use skills, knowledge, and experience, seems to remain intact [2].  
Moreover, researchers have observed the general relationship between aging and development as findings in 
gerontological research have indicated that the collapse of intelligence in dementia patients causes retrogression to 
childhood and/or appears to reverse Piaget’s developmental stages [3-5]. As stated by the retrogenic models, there is an 
inverse and progressive pattern of functional and cognitive decline observed in Alzheimer’s Disease (AD) patients 
compared to the developmental acquisition of these capacities in children. Retrogenesis has been defined as the process 
by which degenerative mechanisms reverse the order of acquisition in normal development [6-8].  
       The findings regarding the retrogenic models suggest that comparisons should be made between the cognitive 
ability of these two groups of population, namely the developing children and the retrograding elderly people. This 
suggestion has been taken into account in the limited use, in assessing cognition in moderate and severe AD patients, of 
several screening instruments available for cognitive examination in infancy and childhood. For example, the application 
of the adapted and modified Ordinal Scales of Psychological Developmental (OSPD), developed by Uzgiris and Hunt for 
cognitive testing in infants, has been found to be superior to the use of traditional tests, such as the Mini-Mental State 
Examination (MMSE), in evaluating the cognitive capacity of patients with moderately severe and severe AD [9]. It was 
also reported that the use of test measures previously applied to infants and young children, based on Piagetian tradition, 
demonstrated residual cognitive capacity in subjects with severe AD previously considered untestable [6, 10]. 
Furthermore, childhood intelligence test measures, such as the Japanese version of the Binet scale, namely the Tanaka-
Binet intelligence scale, has been found to be useful in evaluating cognition in moderate to severe AD patients [9]. 
Since there is a loss of cognitive abilities acquired during childhood before the appearance of clinically detectable 
dementia [5], comparisons of cognitive ability should also be made between the aforementioned groups of population, 
R 
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namely the developing children and the normal older adults or preclinical Alzheimer Disease (AD) patients.  
As regards the preclinical AD patients with neurological changes it was reported that they do not demonstrate 
measurable cognitive decline on standard tests [11, 12]. More sensitive tests to detect early or preclinical stages of AD 
are desired, such as the Mini-Mental State Examination (MMSE), Wechler Adult Intelligence Scale-Revised (WAIS-R) and 
Wechler Memory Scale-Revised (WMS-R) which are evidence-based test batteries for memory decline and intelligence. 
However, these scales can be administered (have been developed and standardized) only to persons between 16 and 74 
years of age [5].      
In order for an approximate comparison between children’s and older adults’ cognitive ability to be correctly 
conducted, the administration of the same screening instruments to the two groups should be available [5, 13]. In 
addition, throughout the many attempts that have been made to develop test batteries for the early detection of dementia, 
it is also possible that the detection of preclinical AD could be more accurate through neuropsychological tests focused on 
the detection of developmental disturbances both in young children and older adults. Therefore, simple screening 
instruments, available for cognitive examination in infancy and childhood, are needed to allow the assessment of the 
cognitive ability in older adults, in a short period of time, which would assist in early detection of cognitive impairment. 
 
Raven’s progressive matrices 
Raven’s Progressive Matrices–Standard Progressive Matrices (SPM) and Coloured Progressive Matrices (CPM)–have 
commonly been employed in such investigations of group comparisons as they are considered to be among the best 
measures of general intelligence. Moreover, they have, both, been widely used in research, educational and clinical 
settings [14-18]. 
Raven’s Progressive Matrices have been used for more than 70 years. In specific, J. C. Raven published the first 
version of his progressive matrices test in 1938 with a subtitle Perceptual Intelligence Test. The revised version, which 
was published in 1956, is known today as Standard Progressive Matrices (SPM). The test is non-verbal and was 
originally constructed as a test of eductive ability (from the Latin root “educere”, meaning “to draw out’), which can be 
described as the ability to make “meaning out of confusion” or the ability to go “beyond the given to perceive that which is 
not immediately obvious” [19]. Most of us today would call it inductive reasoning or general reasoning.  
Later, the original Standard Progressive Matrices (SPM) were supplemented by two more main versions -namely 
the easier Coloured Progressive Matrices (CPM) and the more difficult Advanced Progressive Matrices (APM)-, which 
followed the concept of standard matrices in all respects. Since then the three versions of the test (Standard, Coloured 
and Advanced Progressive Matrices) have been among the best-known and the most widely-used instruments for 
studying intelligence [20, 21].    
Coloured Progressive Matrices (CPM) first appeared in 1947 as an alternative form of the Raven’s Standard 
Progressive Matrices (SPM) and was revised in 1956. The CPM test was intended for children aged 5 to 11, special 
populations, and those who do not speak English. It comprises 36 items divided into three sets of 12 (Set A, AB and B). In 
each item subjects are presented with an incomplete design and six alternatives among which one must be chosen that 
best completes the design. The items increase in difficulty, and so do the three sets, with set B containing the most 
challenging items. Knowledge acquired by answering previous items is necessary in order to answer a subsequent item, 
which implies that the respondent is expected to learn from items. The items of the CPM test are arranged to assess 
mental development up to the stage when a person is sufficiently able to reason by analogy and to adopt this way of 
thinking as a consistent method of inference [19]. 
The first standardization of CPM occurred in 1949 in the UK town of Dumfries. The sample consisted of 627 
children between the ages of 5–11 years, representing 25% of the total school population. The test was sensitive to 
fluctuations in intellectual function, demonstrating good test–retest reliability (r=0.80) [22]. In 1982, a follow-up normative 
study was conducted in Dumfries with a sample of 598 children. In 1998, the parallel version of CPM (CPM-P) was 
developed in conjunction with the SPM+ and included the creation of a parallel version of Set AB. The newest edition of [R] 
CPM is the Raven’s Educational CPM [19]. It has not incorporated any change in the items of the test but provided new 
normative data based on its U.K. standardization. The [R] Educational CPM standardization was conducted with a nation-
wide stratified sample based on census data for geographical region, gender, race/ethnicity and parental educational 
level, a total of 608 children [19]. 
Apart from the UK normative studies, standardization of the CPM test has occurred in many countries around the 
world, such as the United States, France Argentina, Canada, Hong Kong, Germany, Romania, Slovenia, Lithuania, 
Turkey, Kuwait, South Africa, Pakistan, India (in nine Indian tribal groups) etc. Furthermore, a study aiming at providing 
normative data in older populations was conducted in the Netherlands with a representative age and gender stratified 
sample of 2.815 individuals aged from 55 to 85 years [23]. 
According to the [R] Educational CPM Manual [19], criterion-related validity report, there have been conducted a 
lot of studies that investigated the test’s ability to predict performance in educational, cross-cultural and clinical settings. 
As regards the clinical settings, some studies have looked at the use of CPM with healthy adults and AD patients. It was 
reported that among normal subjects CPM loaded .66 on a factor described as the ability to achieve perceptual 
organization and among pre-operative dementia patients CPM loaded 0.88 on a factor including low verbal Wechsler 
scores, poor EEG patterns, emotional instability and lack of social interest [19]. Furthermore, a strong association was 
found between the drawing impairment of AD patients and their CPM score (r=-0.59). Diagnostic differentiation between 
AD-type patients and those with vascular dementia, based on the use of their primitive responses to CPM, has also been 
reported. A correlation of 0.59 of the CPM scores with verbal WAIS scores and an internal consistency of the CPM test of 
0.68, were also reported in studies with older adults [19]. Reliability measurements were also calculated from the [R] 
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Educational CPM standardization sample. The constructors of Raven’s Educational CPM [19] report a split–half reliability 
of 0.97 (N=608) They also found a parallel forms reliability of 0.87 between the CPM and the CPM-P, the former edition of 
the test, in an equating study on a sample of 83 children [19]. 
With regard to their factorial validity, although Raven’s Progressive Matrices were initially developed as 
measures of the eduction of relations, they have been regarded by many researchers as appropriate measures of general 
intelligence (g-factor) according to the classic Spearman terminology [24-26]. However, this contention of a 
unidimensional nature of the ability measured by Raven’s Progressive Matrices has been debated, with no signs of an 
end in sight.  
Some researchers [27] found that APM measure two different processes, namely verbal-analytical and visual-
spatial. Other researchers [28] found some sets in SPM to be unidimensional and some not. They applied a Rasch 
analysis on sets A to E of [R] PM and they found that Set A and the first half of Set B measured the perceptual process, 
while the second half of Set B and Sets C to E measured the analytic process. Furthermore, they concluded that other 
processes were probably involved in the solution of half the items in Set E [28].  
A lot of researchers [16, 29] identified in the factor structure of SPM three first-order factors that have been 
organized on the second-order g-factor. In specific, they confirmed the aforementioned [28] identification of a perceptual 
factor measured by Set A and the first items of Set B, and they also observed that the aforementioned [28] analytical 
factor could be separated in two distinct factors. These findings were also supported by researchers who argued that, 
although it is sometimes claimed that [R] Matrices provide an almost pure measure of g, there is evidence that the easier 
items in SPM and APM measure a perceptual or Gestalt factor distinct from the more analytic items in the rest of the tests 
[22].  
Principal component analyses and nonlinear factor analyses both provided qualified support for both the 
multidimensional and the unidimensional models. Some researchers found that Rasch analyses more strongly suggest 
that APM are best described as being multidimensional [30], while other researchers concluded that, although the test 
yielded several specific first-order factors, it seems to be unifactorial as regards the second order [31].   
As regards the factor structure of the CPM test in specific, from its inception, it has been acknowledged that the 
CPM test has a high g loading, with a visuo-spatial ‘k’-factor involved to some degree [19]. Carlson noted a development 
in the reasoning process required for CPM solutions from perceptual to conceptual. This notification led him to relate 
CPM to Piagetian conservation concepts and found high loadings for both perceptual and conceptual items on the factor 
defined as simultaneous processing [32]. Further development of this work has led to the identification of three factors 
within the CPM items, namely, closure and abstract reasoning by analogy, pattern completion through identity and 
closure, and simple pattern completion [33, 34]. In a sample 180 first-to third-grade children, these factors were found to 
account for 36% of the total variance [34]. The aforementioned German findings were also confirmed in American studies 
[15, 35]. Principal component factor analyses were applied on data from 783 primary-grade children in California and the 
same three factors were found to account for 28% to 41% of the total variance [15].  
However, other researchers analysed the findings of a sample of 166 gifted children on a little different way: They 
concluded that the CPM measures one factor, which has three related facets [36]. This position seems to support that 
probably the “most distinctive feature” of Raven’s test “is its very low loading on any factor other than g” [26]. 
Furthermore, the authors of the Raven’s Educational CPM manual [19] also claimed that the Item-Response-Theory-
based item analysis demonstrates the scientific value of “general cognitive ability”.     
More recently, some researchers [31] suggest that it is crucial the possible constructive elements that form g (the 
cognitive processes, such as memory, learning, perception, metacognition etc., that the participants use during solving 
intelligence tests) to be taken into account in the discussion about the factor structure of intelligence tests, such as [R] 
PM. For them, the solutions with three or four factors identified in the items of CPM are also optimal. In their confirmatory 
factor analyses of the test, in the models with the explicitly introduced higher-order general factor the correlations of the 
primary factors with the general factor were between 0.50 to 0.90. However, both the models with and without the higher 
order factor were found to fit data equally well. As regards the findings provided from the application of factor analysis by 
age, they found that factor solutions are practically stabilized after the age of five when a factor pattern that is later 
repeated at all ages is already form. This factor pattern reflects the difficulty of the CPM’s items. On the contrary, at the 
age of four, the factors do not resemble the factors obtained at older ages [31].  
 
 
Aim of the study 
 
Based, firstly, on findings in the field of cognitive aging, supporting that fluid intelligence (inductive reasoning) increases 
rapidly in the early years of life and declines with aging [1, 2], and, secondly, on the hypothesis of “retrogenesis”, the aim 
of the present study was the comparison of the, highly correlated with fluid intelligence [37], general cognitive ability (g) 
between the developing children and the healthy older adults. The comparison has been conducted through the 
investigation of the latent structure qualitative changes in [R] Educational CPM from age to age, using Confirmatory 
Factor Analyses (CFA).    
 Comparing pair-wise the four groups of our sample (first-to second-grade elementary school students with new-
old adults) and (kindergarten students with old- old adults), the latent structure in [R] Educational CPM is expected to 
differentiate between first-to second-grade elementary school students and new-old adults, on the one hand and 
kindergarten students and old-old adults, on the other (Hypothesis 1).  
 In specific, we expected to find similar latent structure in [R] Educational CPM for first-to second-grade 
elementary school students and new-old adults (Hypothesis 2a), and similar latent structure in [R] Educational CPM for 
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kindergarten students and old-old adults (Hypothesis 2b).   
 
 
Method 
 
Participants and procedure 
The total sample consisted of four groups of individuals: a group of kindergarten students, a group of first- to second- 
grade elementary school students, a group of new-old adults, and a group of old-old adults.  
The first group comprised 42 kindergarten students 5 to 6 years old (mean age=68.1 months, age range: 61-75 
months). Of the 42 participants, 16 were boys (38.1%) and 26 were girls (61.9%). The second group included 56 first- to 
second- grade elementary school students 6 to 8 years old (mean age=85.45 months, age range: 74-98 months). Of the 
56 participants, 22 were boys (39.3%) and 34 were girls (60.7%). All the children attending regular classrooms, without a 
history of learning difficulties (based on the school records and student reports) in two preschool institutions (one public 
and one private) and three primary schools (two public and one private) of medium and high socioeconomic status, in the 
city of Ioannina in Epirus (a province in the West of Greece). All the young participants, additionally to the [R] Educational 
CPM, completed the Greek version of the Mini Mental State Examination [MMSE; 38, 39] in order for a brief estimate of 
their overall cognitive functioning to be provided [for the kindergarten students: M=22.67 (SD=3.66), and for first-to 
second-grade elementary school students: M=26.95 (SD=2.28)]. These means are consistent with previous findings [5, 
13]. In collaboration with the school committees, parents gave their written statement of consent prior to the participation 
of their children in this study and then they completed an individual–demographics form. Children’s testing in [R] 
Educational CPM and MMSE was performed in their school environment, by trained interviewers under the surveillance of 
a psychologist. No time limit was assigned for the completion of the tests and all young participants were informed that 
they were free to withdraw from testing at any time. 
Given that the [R] Educational CPM test was also intended for use with older adults, two groups of older adults 
were tested. In specific, one group comprised 118 new-old adults (mean age=71.33 years, age range: 61-79 years). Of 
the 118 participants, 45 were men (38.1%) and 73 were women (61.9%). The second group of older adults included 27 
old-old adults (mean age=83.04 years, age range: 80-88 years). Of the 27 participants, 10 were men (37.0%) and 17 
were women (63.0%).  
Exclusion criteria for both groups were history of neurological conditions or psychiatric diseases, alcohol or drug 
abuse, severe head trauma, profound visual impairments, and verbal incomprehension. Moreover, all the participants 
additionally completed the Greek version of the Mini Mental State Examination [MMSE; 38-39]. In specific, the subsample 
of older adults consisted of 122 normal participants (103 new adults & 19 older adults), who had MMSE scores between 
25 and 30 points, and 23 participants (15 new adults & 8 older adults), who had MMSE scores between 20 and 24 points 
falling in the Mild Cognitive Impairment (MCI) to mild dementia range [38-39], although they had not been diagnosed by 
consultant neurologists and psychiatrists as meeting diagnostic criteria for possible dementia. All the participants were 
community dwelling adults–volunteers recruited by the researchers through seniors’ centers. They were residents of 
Thessaloniki and Kozani (a town in the province of West Macedonia in Greece). Participants were examined at an 
individual basis, either at the center recruited, or in their own home. No time limit was assigned for the completion of the 
examination and the participants were informed that they were free to withdraw from testing at any time. For all the 
participants informed consent was obtained and then they completed an individual–demographics form. It should be noted 
that the subsample of older adults included an overrepresantation (57.2%) of persons with 9 years of formal education or 
fewer. 
 
Instrument 
 
Raven’s educational coloured progressive matrices (R-CPM).  
Raven’s Educational Coloured Progressive Matrices are designed to assess the intellectual processes of young children 
ranging in age from 4 to 11 years [19]. The book form of the [R] Educational CPM contains three sets (A, AB, and B) of 12 
items of coloured large-print drawings each. In each item subjects are presented with an incomplete design and six 
alternatives among which one must be chosen that best completes the design. Every correctly solved item results in 1 
point. Sum scores may be used for every set (score range 0-12) or for the total [R] CPM test (score range 0-36).   
 
Statistical analysis 
As has already been mentioned the aim of the present study was the investigation of the latent structure qualitative 
changes in [R] Educational CPM from age to age, using Confirmatory Factor Analyses (CFA).  
 According to the aforementioned findings in the introduction section, it is obvious that previous empirical works 
have implied several a priori competing models for CPM dimensionality. It should be also noted here that the present 
study did not aim to test extensively the constructive validity and the rest psychometric properties of [R] Educational CPM 
in Greek population, since the Greek standardization of [R] Educational CPM is in progress [40]. Furthermore, the sample 
size of the present study was inadequate for the conduction of CFA models testing the dimensionality of the [R] 
Educational CPM (including the 36 items of the test) in every one of the four groups of the sample. It is recommended that 
the sample size requirements, for SEM techniques, would be at least five observations per estimated parameter [41]. 
Hence, in order for the sample size to be adequate, at least 180 persons should participate in every group. 
Because of the relatively small sample size of each group, analyses were not run at the item level. Instead, the 
covariance matrix was based on three total scores (measured variables), namely, total raw score for Set A, total raw 
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score for Set AB and total raw score for Set B. Hence, the sample size for the conduction of CFA had to exceed 15. Thus, 
the sample size of each one of the four groups exceeded the minimum recommended level for performing confirmatory 
factor analysis. 
 Considering CFA–a structural equation modeling (SEM) technique for analyzing structural models with observed 
variables, is adequate for examining the latent factor structure of the [R] Educational CPM test for every group of our 
sample, using sum scores of each one of the three observed variables (sets of the test). Hence, we used CFA in order to 
test the hypothesis that individual variability across CPM measured variables (total raw scores of each of the three sets) 
can be modeled by one latent variable (a single underlying factor). Confirmatory factor analysis was conducted in EQS 
Version 6.1 [42] and performed on the five covariance matrices, which stemmed from the total sample and each one of 
the four groups of participants, using the Maximum Likelihood (ML or ML ROBUST) estimation method. The Wald test 
was used to test the need for the estimated parameters and to suggest a more restricted model. 
      The indices of each one of the five models, which were provided from the application of CFA in each of the five    
covariance matrices, were the following: χ2=0.00, df=0, P=undefined, NFI=1.00, while NNFI, CFI and RMSEA were not 
computed because the degrees of freedom were zero. These models have been solved and should be considered as 
just-identified [43]: “In fact because the numbers of knowns equals the number of unknowns, in just-identified models, 
there exists a single set of parameter estimates that perfectly reproduce the input matrix.” The input matrices of the 
aforementioned models consist of 6 knowns (3 variances, 3 covariances), and the models consist of 6 freely estimated 
parameters: 3 factor loadings and 3 indicator errors, with the variance of the latent variable to be fixed to 1.0. Thus, 
although just-identified CFA models can be fit to the sample input matrix, goodness-of-model-fit evaluation does not apply 
because, by nature, solutions such the aforementioned, always have perfect fit [43]. 
 
 
Results 
 
Testing latent structure of [R] educational CPM in the total sample 
Initially, we tested the one-factor CFA model [the one-factor model in which all three measured variables loaded on a 
single latent variable] in the total sample (Model A). Confirmatory factor analysis fully verified the one-factor structure-
based on 3 measured variables/summated items-of [R] Educational CPM for the total sample [χ2(0, Ν=243)=0.00, 
P=undefined, NFI=1.00]. NNFI, CFI and RMSEA were not computed because the degrees of freedom were zero. 
According to the suggestions of the Wald test all the parameters’ loadings of the Model A were statistically significant. 
Thus, we derived one factor (latent variable), that probably explains the variance of participants’ performance on [R] 
Educational CPM. For the total sample, Cronbach’s α coefficient was 0.86.                                                                                                                              
                                                                                                          
 
                                                                                                                                              
                                                                                                       
                                                                                                                               
 
 
 
  
 
 
 
 
 
 
      
 
 
 
 
 
 
Figure 1. The underlying structure of the single g latent factor in the total sample (standardized solution). 
*All loadings drawn indicate significant associations (P0.05). **e = measurement error 
 
 
Testing latent structure of [R] educational CPM in the subsamples of elementary school students and new-old adults 
In order to compare the latent structure in [R] Educational CPM between elementary school students and new-old adults, 
we tested the one-factor CFA model [the one-factor model in which all three measured variables loaded on a single latent 
variable] in the group of first-to second-grade elementary school students (Model B). Confirmatory factor analysis verified 
the one-factor structure -based on 3 observed variables/summated items-of the [R] Educational CPM for the group of first- 
to second-grade elementary school students [χ2(0, Ν=56)=0.00, P=undefined, NFI=1.00]. NNFI, CFI and RMSEA were 
not computed because the degrees of freedom were zero. According to the suggestions of the Wald test, all the 
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parameters of the Model B were statistically significant, except for the residual of one of the measured variables, namely 
the residual of the total raw score for Set B (P=0.19). Thus, we derived one factor (latent variable), that probably explains 
the variance of the elementary school students’ performance on [R] Educational CPM. For the group of first-to second-
grade elementary school students, Cronbach’s α coefficient was 0.80.   
 Then, we tested the one-factor CFA model [the one-factor model in which all three measured variables loaded on 
a single latent variable] in the group of new old adults (Model C). Confirmatory factor analysis fully verified the one-factor 
structure -based on 3 latent variables/summated items- of the [R] Educational CPM for the group of new-old adults [χ2(0, 
Ν=118)=0.00, P=undefined, NFI=1.00]. NNFI, CFI and RMSEA were not computed because the degrees of freedom were 
zero. According to the suggestions of the Wald test all the parameters’ loadings of the Model C were statistically 
significant. Thus, we derived one factor (latent variable), that probably explains the variance of the new old adults’ 
performance on [R] Educational CPM. For the group of new-old adults, Cronbach’s α coefficient was 0.89.   
 The comparison of the CFA Model B with the Model C indicates a similar latent structure in [R] Educational CPM 
for first- to second- grade elementary school students and new-old adults and verified Hypothesis 2a. 
 
 
 
 
      
 
 
 
 
   
        
  
 
 
 
 
 
 
 
 
 
 
Figure 2. The underlying structure of the single g latent factor in the subsamples of elementary school students and new-old 
adults (standardized solution). 
*All loadings drawn indicate significant associations (P0.05). **e = measurement error 
 
 
Testing latent structure of [R] educational CPM in the subsamples of kindergarten students and old-old adults 
In order to compare the latent structure in [R] Educational CPM between kindergarten students and old-old adults, at first 
we tested the one-factor CFA model [the one-factor model in which all three observed variables loaded on a single latent 
variable] in the group of kindergarten students (Model D1). Due to the statistically significant excess kurtosis of this group 
of the sample, Model D1 was computed using the Maximum Likelihood (ML ROBUST) estimation method. However, 
during our trial to test Model D1, the EQS program [42] warned that corrected chi-square could not be calculated due to 
numerical difficulties. Since the Satorra-Bentler chi-square was impossible to be computed as well as the rest goodness-
of-model-fit indices, because of the nature of the model [43] (see also Model A, B, & C), the provided solution was not 
acceptable. Hence, despite the distributional misspecification (significant excess kurtosis), the confirmatory factor 
analysis was re-performed on covariance matrix using the Maximum Likelihood (ML) estimation procedure (Model D2) 
[42]. According to its indices [χ2(0, Ν=42)=0.00, P=undefined, NFI=1.00], it seemed that Model D2 should be also 
considered as just-identified (see Models A, B, & C) [43], and fits the data better than Model D1 of this set of analysis. 
However, according to the suggestions of the Wald test, the one-factor structure-based on 3 latent variables/summated 
items-of the [R] Educational CPM was not confirmed for the group of kindergarten students because, although the rest of 
the parameters’ loadings of Model D2 were statistically significant, the variance of the single latent variable (factor) was 
not found to be statistically significant (P=0.07). Thus, we did not derive one factor, that could explain the variance of the 
kindergarten students’ performance on [R] Educational CPM. For the group of kindergarten students, Cronbach’s α 
coefficient was 0.71.   
 Finally, we tested the one-factor CFA model [the one-factor model in which all three measured variables loaded 
on a single latent variable] in the group of old-old adults (Model E). According to its indices [χ2(0, Ν=27)=0.00, 
P=undefined, NFI=1.00], it seemed that Model E should be also considered as just-identified (see Models A, B, C, & D2) 
[43] and fits the data perfectly. However, according to the suggestions of the Wald test, the one-factor structure-based on 
3 latent variables/summated items-of the [R] Educational CPM was not confirmed for the group of old-old adults because, 
although the rest of the parameters’ loadings of Model E were statistically significant, the variance of the single latent 
variable (factor) was not found to be statistically significant (P=0.07). Thus, we did not derive one latent factor, that could 
explain the variance of the old-old adults’ performance on [R] Educational CPM. For the group of old-old adults 
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Cronbach’s α coefficient was 0.72.   
 The comparison of the CFA Model D2 with Model E indicates a similar pattern of structure in [R] Educational 
CPM for kindergarten students and old-old adults and verified Hypothesis 2b. 
 To summarize, the aforementioned findings confirm Hypothesis 1 and support the existence of a different factor 
structure in [R] Educational CPM between  first-to second-grade elementary school students and new-old adults, on the 
one hand, and kindergarten students and old-old adults, on the other. 
  
 
Discussion 
 
Although we stuck to the standard methodology of confirmatory research, the present study should not be understood as 
testing the hypothesis of unidimensionality in [R] Educational CPM. The aim of the present study was the comparison of 
the general cognitive ability between the developing children and the retrograding older adults through the investigation of 
the latent structure qualitative changes in [R] Educational CPM from age to age, using Confirmatory Factor Analyses 
(FCA) and testing a conventional unidimensional model.    
 With regard to dimensionality, for the groups of elementary school students and new-old adults, the results of 
CFA seem to support the existence of a single latent g-factor measured by [R] Educational CPM. For the groups of 
kindergarten students and old-old adults the existence of a single latent g-factor measured by [R] Educational CPM was 
not confirmed, since its variance was not found to be statistically significant.  
 The aforementioned findings are consistent with previous findings [31] indicating that the factor solutions are 
stabilized after the age of 5-6. Until then, the factor structure of [R] CPM does not resemble much the factor structure 
obtained in older ages. Since inductive reasoning or general reasoning (the current name of eductive ability) is one of the 
main possible constructive elements that form g, a possible explanation for these findings could be that inductive 
generalization is not a unitary cognitive operation, but it is possible to start with perception and only in the end to develop 
pure induction [44,45]. Some researchers [31] provided another explanation, taking also into account a possible 
component of g, namely the executive functioning. According to them, the delay of stabilization of the CPM factor 
structure at earlier ages (before the age of 5-6) could reflect lack of metacognitive and self-regulative processes–two of 
the main components of executive functioning–and could be attributed to the inflexible solving strategy, the poor 
management of goal activity and the weak mechanisms of control [31,4 6-51].    
 The similar, not unidimensional structure of the [R] Educational CPM test that was observed, in the present 
study, between the group of kindergarten students and the group of old-old adults, is possible to indicate a qualitative 
change, perhaps a start of disorganization, either in the inductive reasoning, and/or in the executive functioning of the old-
old adults comparing to that of the new-old adults [46-51]. This finding is consistent with the general admission in the field 
of cognitive aging, stating that cognitive functioning declines with aging and fluid intelligence –which is highly related to 
inductive reasoning– is among the cognitive abilities that seem to be more affected by age [1, 2]. 
 In general terms, the different pattern in the latent factor structure of the [R] Educational CPM test, that was 
found in the present study, between the groups of kindergarten students and old-old adults, on the one hand, and the 
groups of first- to second- grade elementary school students and new-old adults, on the other, is a supporting finding with 
regard to the hypothesis of “retrogenesis”.  It should be also noted that the disorganization of general cognitive ability as 
regards two of its components, namely inductive reasoning and executive functioning [46-51], was found to be present 
before the appearance of clinically detectable dementia in the majority of the participants in the subsample of old-old 
adults. This finding seems to be in line with recent findings indicating that a large proportion of healthy old-old adults show 
memory decline which may represent the early stages of a potentially more severe cognitive impairment [5, 11-12]. 
Furthermore, the concept that normal old-old adults, as well as MCI patients, retrograde to the levels of early childhood, 
regarding their general cognitive ability, simplifies the understanding of them and contributes to their appropriate care 
from their family and caregivers.     
 In conclusion, this is a pilot study of [R] Educational CPM conducted in a Greek population of young children and 
older adults. More research is also needed to further validate and refine, in other cultural contexts, the different pattern in 
the structure of g, -as it is measured by [R] Educational CPM-, that was found in the present study, between the groups of 
kindergarten students and old-old adults, on the one hand, and the groups of first- to second- grade elementary school 
students and new-old adults, on the other. The results of our findings, with the size of the sample used, support the 
usefulness of [R] Educational CPM as a sensitive neuropsychological test for the detection, in the old-old adults, of the 
differentiation and/or the decline of the general cognitive ability acquired during childhood. In order for the applicability of 
[R] Educational CPM to be assessed in Greek older adults, normative data have to be provided for this population. This 
would permit us to test further the quality of the [R] Educational CPM test as an appropriate neuropsychological 
instrument for screening general cognitive ability in normal older adults and/or preclinical dementia patients as well.  
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Abstract 
Our research is implementing high quality next generation services for the Prediction, Early Diagnosis, Monitoring, and Support 
of patients with Cognitive Impairment (Subjective Cognitive Impairment –SCI-, Mild Cognitive Impairment –MCI-, Mild Dementia) 
and Education and Training for all stakeholders. Prediction, Early Diagnosis and Monitoring: The first idea was to Research and 
Develop a novel System using motion detection devices, depth cameras, and intelligent objects of everyday use (ranging from 
cooking implements such as kitchen to furniture (e.g. sofa, bed, etc.) which are appropriately adapted in order to capture 
changes of subject’s Activities of Daily Living –ADL- and behavioural patterns (including mobility, nutrition, exercising and 
medication schedule). We also demonstrated the potential of a virtual supermarket (VSM) cognitive training game as a 
screening tool for patients with MCI in a sample of older adults. We have indicated that this VSM application displayed a correct 
classification rate (CCR) of 87.30%, achieving a level of diagnostic accuracy similar to standardized neuropsychological tests, 
which are the gold standard for MCI screening http://www.en-noisis.gr/ Support of patients: Cognitive tasks and cognitive 
exercises for patients suffering from Alzheimer’s Disease (AD) through web-based applications. These exercises have been 
developed in such a way in order to exploit rich interactive multimedia interfaces (including music) based on human computer 
interaction principles. To this direction we are implementing a web based portal with supportive services such as (a) on-line 
monitoring of patient’s progress by health care professionals, (b) statistical representation of patients’ progress. Multimedia 
enriched cognitive exercises in virtual reality form (i.e. 3D Serious Games) use suitable modalities for such activities through the 
creation probable of new brain cells and by assisting the brain to find out alternative methods to execute functions, which are 
controlled by damaged brain regions. Another program the “robot-programming-as-cognitive-training” approach aims to explore 
the impact that the activity of programming a friendly robot might have on AD and MCI patients’ condition.  
http://aspad.csd.auth.gr. Another study aimed at investigating the benefits of combined physical and cognitive training on global 
cognition while assessing the effect of training dosage and exploring the role of several potential effect modifiers. The results 
indicate that combined physical and cognitive training improves global cognition in a dose-responsive manner but these benefits 
may be less pronounced in older adults with mild dementia. The long-lasting impact of combined training on the incidence and 
trajectory of cognitive disorders in relation to its severity should be assessed in future long-term trials. 
www.longlastingmemories.eu. Finally, Symbiosis is a revolutionary system aiming at providing integrated solutions to a series of 
problems related with MCI and AD. It is the first integrated AD support system that takes into account patient’s response in an 
adaptive way that fulfills each patient’s special needs and provides to caregivers and doctors considerable facilitations, 
unlocking the potential of innovative supporting role. www.youtube.com/watch?v=BDkLz-T-jYE. Education and training for all 
stakeholders (i.e. health professionals and informal and formal caregivers) through distance education platforms and e-
collaboration services. To augment this effort, the research team integrates biofeedback modules for stress measurement in 
teleconferences in order to support the emotional awareness of the participants. The depression, anxiety and burden of 
caregivers were reduced significantly in the same way as in a face to face intervention. http://aspad.csd.auth.gr. In conclusion 
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ICT can help health professionals and caregivers to support in a better wy the patients with cognitive, functional and behavioral 
problems.  
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Introduction 
 
mong the 10 more important medical topics on AGEING the first is dementia. The prevalence of dementia is rising 
all over the world, with considerable socio-economic impacts that are creating an imperative need for finding 
effective means of treatment. According to WHO report in 2015 47,47 million people suffer from dementia,  while 
this number will increase in 2030 and 2050 to 75,63 and 135,46 million respectively [1]. In Europe, it is estimated that 
between six to ten million people suffer from dementia [2]. In Greece, according ADI-2015 report [3], the number of 
patients is about 197.000. According to our epidemiological studies in North Greece the prevalence rate is between 7,2%-
9,6% in elderly more than 70 years old, that means between 144.000 to 192.000 [4, 5]. The prevalence of dementia 
increases with age, from approximately 1.5% in persons aged 60–69 years to 40% in persons 90 years and older [6] and it 
is found to be higher in nursing home residents in the Western countries [7].  
Neurodegenerative dementias are chronic, progressive, devastating disorders which in early stages are usually 
characterized only by cognitive problems. In addition dementia influences activities of daily living and patients have 
behavioral and psychological problems, also known as Behavioral and Psychological Symptoms in Dementia (BPSD) [8]. 
Caregivers of patients with dementia have great levels of anxiety, burden and depression. The most frequent dementia is 
Alzheimer’s disease (AD). There are different stages of AD: Asymptomatic, Mild Cognitive Impairment, early AD, 
moderate AD and severe AD. The diagnosis of asymptomatic and mild cognitive impairment based on medical history, 
neuropsychological and medical examinations is difficult even today and even in best memory clinics in the world. In 
current clinical practice, management of dementia begins with its diagnosis, which is based on criteria and assessments 
with tests that highlight quantitative and qualitative changes in cognitive functions, behavior and ADL. There are only 
symptomatic medications for AD until today.  
Therefore there are needs which are unmet in Dementia and we need contribution from other sciences in order to 
succeed better and earlier diagnosis and also to find methods for management the disease in order both the patients and 
caregivers have better quality of life.  
 
Prediction, Early Diagnosis and Monitoring: Computerized tests 
 
Prediction and early diagnosis 
With the rise of the aging population the risk for cognitive impairment leading to dementia increases drastically. The 
international scientific community seeks to find early disease markers and assessment tools for these markers that allow 
to identify earlier people at risk to develop dementia so that they can receive intervention earlier. All these require early 
monitoring and evaluating precisely and accurately the patient’s behaviour and symptoms remotely and on a continuous 
base.  
Until now, the assessment of patients with cognitive impairment was mainly based on clinical interviews for which 
clinicians use scales or questionnaires to evaluate cognitive functions, behavior, and daily life activities. However, with 
these methods certain problems can arise such as 1. Patients and caregivers can have a confusing awareness of the own 
condition and 2. Assessor can be Subjective of Biased. The question is how can we measure behavior more objectively? 
Currently, there are several diagnostic tools for assessing dementia, but the sensitivity for the early detection of 
dementia is very low [9]. Furthermore, the majority of these tests are complex and need highly trained personnel and 
specialized equipment, which is not usually available at primary care level. Because of this, MCI and mild AD are often 
unrecognized in primary care centers [10]. Therefore, there is a need to develop screening tests oriented to the general 
practitioners that allows them to differentiate with high accuracy MCI and mild AD patients, and that is easily applicable in 
daily practice in primary care centers. 
The relationship between neuropsychology and technology dates back to the introduction of the first personal 
computers. Neuropsychologists and test designers have always monitored technological progress and were quick to 
implement new technologies in neuropsychological testing and evaluation [11]. One could argue that test designers 
adopted new technology with a high degree of enthusiasm and saw technology as a means that would lead to improved 
testing and evaluation. 
The first computers provided the opportunity for automatic scoring and record keeping which led to the 
development of lengthy batteries. Test designers, freed from the need for manual scoring, designed batteries that could 
cover every possible diagnostic situation from performance testing to dementia diagnosis and evaluating the effects of 
chemical agents on the brain. Ongoing technological progress opened up many new possibilities. Since test batteries 
were already quite comprehensive the use of new technology focused more on the test interface. Technologies such as 
multimedia, voice instructions and touch screens led to tests that were easier to administer while being more pleasant for 
A 
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the examinee. Ongoing technological developments led to further development and diversification of computerized tests. 
Tablet PCs allow for the administration of tests without using office space in a hospital or health center. These small 
devices enable administration in the waiting room and even in the patients’ home for patients who cannot visit a hospital. 
At the same time web-based administration and scoring lowers costs and overcomes issues of hardware and software 
compatibility. 
Currently, computerized tests are being used in various aspects of neuropsychological evaluation. There is a 
diverse range of tests designed either for in-depth evaluation or screening. At the same time a number of tests are often 
specific to certain conditions such as MCI while others cover a large spectrum of cognitive dysfunction. Recently test 
designers have shifted their focus to the design of short screening tests aiming to detect cognitive impairment at its 
earliest stages and there is a general tendency towards reducing administration time and making the tests more user-
friendly. There is a wealth of research activity on the subject ranging from the evaluation of existing tests and batteries to 
the design of new ones. Our recent review has identified 18 tests currently used in the neuropsychological evaluation of 
older adults and another 3 tests that are still in the development phase [9].  
The wealth of computerized instruments could lead one to believe that computerized testing is well established, 
perhaps to the same extend as traditional pencil and paper instruments. Unfortunately the current situation is a lot more 
complicated. 
Computerized tests are not as well established as traditional instruments. There is currently no “gold-standard” 
as far as computerized testing is concerned. Lack of normative data and psychometric standards is often cited [12] and 
the volume of relevant research literature remains lower than that available for pencil and paper tests. Data on concurrent 
validity with pencil and paper instruments are often inconclusive even when these tests measure the same cognitive 
domains. It is worth noting thought that some researchers argue that concurrent validity should not be used to judge the 
quality of a computerized test since traditional tests often exhibit poor construct validity themselves. The use of 
discriminant validity as an indicator of the test’s quality is proposed since their unique format can render comparison with 
pencil and paper instruments redundant [13]. 
 
Our work on computerized tests 
1. We demonstrated the potential of a virtual supermarket cognitive training game as a screening tool for patients with 
MCI in a sample of older adults. So far virtual reality game–based applications and especially virtual supermarkets have 
been used as cognitive training applications and as measures of cognitive functions, although it has been shown that they 
can detect MCI only when used in combination with standardized neuropsychological tests. We succeeded in making the 
shift to MCI screening via robust virtual reality game applications that can be used on their own for accurate MCI 
detection. We have indicated that the virtual supermarket (VSM) application displayed a correct classification rate (CCR) 
of 87.30%, achieving a level of diagnostic accuracy similar to standardized neuropsychological tests, which are the gold 
standard for MCI screening [14]. Under the same project (http://www.en-noisis.gr/ennoisis/) we have prepared a virtual 
garden and a virtual laundry.  
2. Custom Serious Games with dual-task walking (DTW) "motor signatures" performance data provided an ecological and 
reliable approach for cognitive assessment across multiple sessions and thus can be used as a useful tool for tracking 
longitudinal change in observational and interventional studies on amnestic MCI (aMCI) [15]. 
3. Diadohokinetic (DDK) SPEECH tests were also used by speech-language pathologists for assessment of motor 
speech impairment. Quick and accurate production of rapid, alternating sound tokens involving different parts of mouse, 
e.g. “puh-tuk-kuh-puh-tuh-kuh-”. The DDK test may challenge both motor and cognitive control over speech production. Is 
the DDK regularity useful in distinguishing between Control/MCI/AD groups [16]? We have to go on our research with 
more patients. 
4. To provide a solution to this problem the European FP7 project Dem@care was created, which stands for Dementia 
Ambient Care: Multi-parametric monitoring for timeless assessment and self-independence of PwD which had the goal 
was to develop a system consisting of different sensors allowing continuous, more complete and remotely monitoring of 
PwD, their condition, lifestyle, their symptoms and illness progression. One potential solution for this problem may be the 
use of new Technologies such as sensors which can measure certain parameters. One potential solution for this problem 
may be the use of new Technologies such as sensors which can measure certain parameters such as movement 
intensity or walking speed which in turn can be related to certain changes in behavior. For example GPS tracking 
technologies for assessing loss of orientation. The advantage of such devices is that they enable the patients’ 
performances and actions to be captured in real time and real life situations. Some exmaples are actigraphy, automatic 
speech analyses and automatic video analyses.  
 
Monitoring 
Typical questionnaire-based assessment approaches tend to introduce a high level of subjectivity, while lacking the 
comprehensive view of the person’s life and status that only continuous monitoring can provide. Using ICT is a framework 
that provides objective observations regarding the completion of daily tasks of the person with dementia, focusing on the 
differences between MCI and AD patients. More specifically, a sensor-based framework is proposed as a remedy to 
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support clinicians’ assessments and eventually patients by semantically integrating and analyzing multi-sensory data. 
However, approaches with more than one sensor had three main problems until now: (i) how we can analyze the raw data 
from the sensors, (ii) how clinicians can use all the sensors efficiently during interventions and (iii) how results could be 
visualized in order to be valuable for the clinicians’ assessments. Our project dem@care (http://www.demcare.eu). The 
proposed system in this project tries to address the above problems by employing knowledge-driven interpretation 
techniques based on Semantic Web technologies to analyze the sensors’ recorded data, visualizing it through a simple 
clinician interface. In order to evaluate the system, a pilot study was conducted with patients with cognitive problems. The 
main goal of this pilot study was to identify whether the system is able to identify differences between MCI and AD 
patients and eventually verify the results of the clinical assessment.  
 
Sensors 
The sensors currently included in the framework support a variety of data formats and are non-intrusive, whether ambient 
or wearable. In this scenario, an ambient depth camera
1
 is placed to survey the whole room, collecting both image and 
depth data. The Plug sensors
2
 are attached to electronic devices, i.e. to the tea kettle and radio in this intervention, to 
collect power consumption data. Tags
3
 are attached to objects of interest, i.e. tea cup, kettle, drug-box, watering can, 
folder of bills and phone, capturing motion events and consequently, providing information about the objects used during 
the protocol. Regarding wearable sensors, the intervention employs the wristwatch
4
 that measures moving intensity 
during directed and semi-directed activities, and a wearable wireless microphone to record the participant’s voice during 
directed activities and vocal tasks.  
 
Data retrieval and storage  
One of the main technical obstacles in concurrent AAL systems, is to unify and timely coordinate sensor data retrieval, 
synchronicity and homogeneity. Indeed, the sensors used in our intervention present various data forms and especially 
both real-time and asynchronous data transfer. A dedicated module interfaces with each sensor, complying with its own 
API and platform dependencies. The ambient camera module continuously stores image and depth frames from the 
device’s live feed. In addition, the module developed for Tags is push-based, sending certain sensor events to the system 
for storage, such as motion detection. The plugs on the other hand, are pull-based. Therefore, the module for plugs 
constantly polls them for power consumption data. The module for the microphone is also able to start and retrieve a 
recording on-demand. While, the aforementioned sensors are always online to the system, the wristwatch has to be 
connected to start the data transfer. However, this process is also aided by the system, as the wristwatch module is able 
to automatically retrieve and process wristwatch data upon connection.  
 
The clinician interface  
One of the main limitations of the systems presented in the related work section is that they require the presence of a 
technician during a protocol. Considering this issue, we designed and developed the clinician interface based on the 
following main principles and goals: (i) The system should be easily operated by a novice computer user, (ii) The 
clinicians should be always informed about the current status of the protocol and the relevant instructions, (iii) The 
clinicians should easily operate the sensors and they should be informed about potential problems with the sensors, (iv) 
The clinicians should be informed about the results of each patient in a comprehensive way after the completion of the 
protocol, (v) They could easily conduct a diagnosis based on the system and correlate data from the system with 
neuropsychological assessment. In order for the human computer interaction to be efficient, the tasks, procedures and 
methods that the clinician may perform with the system need to be structured in a logical and consistent manner. This 
means that the interface should be intuitive and the system should address the clinician’s goal and objectives. Moreover, 
the number of actions that a user has to perform in accomplishing a task (even for technologically demanding tasks, like 
the operations of the sensors) should be minimized. 
 
Our intervention  
The intervention was conducted in a lab environment in the above day care center. Each participant started with a regular 
consultation with a general practitioner, and then undergoes the ecological assessment, which is followed by a 
neuropsychological assessment. During the consultations, demographical and medical characteristics are gathered by 
means of widely used and generally recognized assessment tools. Using an instruction sheet, participants had to 
complete 8 daily-living-like activities in 15 minutes: Make a phone call, Water a plant, Boil water to prepare tea, Turn on 
the radio, Read a magazine and write some answers, Establish account balance, Check the pill box, and Exit the room. 
The intervention consists of monitoring persons with cognitive impairment using the system’s technology in order to 
                                       
1
 Xtion Pro: http://www.asus.com/Multimedia/Xtion_PRO/ 
2
 Plugwise sensors: https://www.plugwise.nl/ 
3
 Wireless Sensor Tag System: https://www.plugwise.nl/ 
4
 DTI-2, provided by Philips, www.philips.com 
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provide a brief overview of their health status during consultation (cognition, behavior and function), and to correlate the 
system data with the data collected using typical dementia care assessment tools. (Figure 1). 
 
Figure 1: Smart lab 
 
The clinician could make different kind of comparisons using different sensors to see if one activity influences 
another. For example, the clinician can make correlations between moving intensity and sleep in order to see if the 
gymnastic and physical interventions actually helps patient’s sleep. Rapid eye movement sleep Behavior Disorder (RBD), 
affects one third of patients with Parkinson disease (PD) [17]. RBD is even more common (80%-90%) in patients with 
multiple system atrophy and dementia with Lewy body disease [18] and other neurodegenerative diseases characterized 
on postmortem examination, as is PD, by deposit of alpha-synuclein protein in t brain neurons [19]. In addition, as many 
as one third to two thirds of patients with a diagnosis of idiopathic RBD may, in the subsequent decade after diagnosis, 
develop signs of parkinsonism [20, 21]. In contrast, RBD was reported to be rare in a series of patients with Alzheimer’s 
disease, progressive supranuclear palsy (PSP), frontotemporal dementia, and corticobasal degeneration [22]. 
Also under another project (http://www.en-noisis.gr/ennoisis/) we had the opportunity to develop methods to 
monitor patients at the their homes using ambient smart home sensors and depth cameras (Figure 2). 
FOLLOWING THE 
MOVEMENTS
Bedroom
Living Room
Master
Bedroom
Bedroom
Kitchen
Eating
 
Figure 2: Smart Home 
 
Today new ICT tools like GPS, Actigraphy, Automatic speech analyses, Automatic video analysis are used in 
research for the assessment of dementia patients next to current tools and we have to find out at which extent they can 
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provide additional information.  
 
  
Management 
 
Patients support 
Mild cognitive impairment and non-pharmacological interventions 
There is no medication for MCI or asymptomatic AD. There are data in many studies confirming the effectiveness of 
cognitive training in MCI patients [23-26]. Cognitive training is the most appropriate method to practice and enhance 
specific cognitive abilities, such as language, memory, attention. Some of them [27], have shown that cognitive training 
can also improve the activities of daily living. 
We used both programs which are provided free by internet –such as brain workout- but also we created cognitive 
exercises under five different projects:  Long Lasting Memories project, Brain B^right,  Symbiosis, ASPAD,  En-NOHSHS. 
  
Long lasting memories project (www.longlastingmemories.eu) 
We provided evidence that combined training –physical and cognitive) induces dose-responsive improvement in global 
cognition, especially in individuals with mild cognitive disorders. Whether effects on global cognition through combined 
training may reduce the incidence and the trajectory of cognitive disorders in relation to its severity must be assessed in 
future long-term randomized controlled trials [28]. 
 
Brain^Bright 
Brain B^right is a serious game application developed by students of the International Faculty of the University of 
Sheffield, CITY College. The application is developed for Alzheimer Hellas as part of the "Industrial Software Project" 
module of the Computer Science curriculum and it offers a collection of memory strengthening serious games in the 
Greek language.  Brain B^right provides an individualized experience, since it records the personal progress of its users 
and presents games of different levels of difficulty. The cooperation between CITY College and Alzheimer Hellas and the 
development of the application initiated in 2012. The first version was available in June 2013 and the second in June 
2014. Both versions have been evaluated very positively by users visiting the care units of Alzheimer Hellas. The project 
continues this year (2015-2016) with the goal to enhance the application with visual games based on photos and pictures. 
 
Symbiosis 
We run this computerized project at Alzheimer Hellas with 11 patients with MCI amnestic or of multiple domains, 54-78 
years old and 6-18 years of education, without depression and MMSE=24-29, FUCAS:42-49 and FRSSD: 1-6. The 
duration of the session was 60min, 3x/week, for 4 weeks. Two specialists were with patients at every session. At every 
session patients had to finish three exercises. We needed a PC, a TV and a kinect of Microsoft. At the end of the program 
we had improvement in the speed of visual execution Trail B (p.033), in visual attention ΤΕΑ (P=0.005), ΤΕΑ (P=0.021), 
comprehension of guidelines of movement CAMCOG (P=0.020), ADL, FUCAS (P=0.25), and global cognitive function, 
MMSE (P=0.039). (This paper is under preparation) 
 
ASPAD 
Sensory Stimulation interventions such as Music therapy, Massage therapy, Multi-Sensory environment/Snoezelen, 
Acupuncture, Bright Light Therapy and Aromatherapy have been used for different behavioral problems in dementia. We 
have finished a program of Music Therapy on PC under the umbrella of the project ASPAD.  
In the framework of the same program we have prepared 1000 exercises for language improvement. This study 
showed significant results and we try to compare the results of this online study with the study we have finished also on 
paper and pencil. 
Another program the “robot-programming-as-cognitive-training” approach aims to explore the impact that the 
activity of programming a friendly robot might have on AD and MCI patients’ condition.  All the above efforts have finished 
and the studies are in preparation. 
There is a strong need for effective and cheap caregiver interventions in order to efficiently support the informal 
dementia caregivers. So far, the psychological interventions seem to have a positive impact on the self-esteem of the 
dementia caregivers [29] depression and anxiety [30]. Under the ASPAD project we prepared a platform for support the 
caregivers of patients with dementia in Greece. The results showed that both programs on site and online have the same 
benefit on depression, anxiety and burden of caregivers. Our study is under preparation. 
 
Obstacles  
There are not yet well organized health nets for patients with dementia. A well structured net is consisted of ICT system 
with a technician-coordinator, general practitioners, specialists, pharmacist, community nurses, social workers, 
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occupational therapists, physiotherapist, dietitians, day centers, nursing homes. 
Even using ICT services, which are cheaper, we’ll meet the problem that many elderly have no idea of ICT 
solutions. In 2013, 77%, 59% and 47% of Americans more than 65 years old use mobile phone, internet, and broadband 
respectively. (Table 1) 
 
In Greece, during 2013, only 9,5% of seniors 65-74 years old  use internet, while 60,4% of people 16-74 years old have  
PC and 59,9% use Internet [31].  
Another important issue, especially in the current economic climate, is cost. Currently most computerized 
batteries are quite costly and the use of advanced technology can raise the cost even further when specialized equipment 
such as dedicated input devices or tablet PCs is required. High costs can pose a barrier to small hospitals and private 
practices and even to larger hospitals and organizations in less affluent countries leading to a “two-speed” healthcare 
where only the richest could benefit from technological advances. It is worth noting that apart from a computerized visuo-
spatial memory test designed to be used as a supplementary screening test for dementia [32] no computerized test is 
public domain or free for use. At the same time, no national health service has developed a computerized test that could 
be used freely in public healthcare while the cost of computerized testing is not always covered by state or private health 
insurance. 
Furthermore increased costs have to be justified by increased efficiency. Since computerized testing is still not 
well established and integrated in health care its efficiency cannot be judged easily, making the investment in equipment 
and personnel seem risky and unjustified. Indeed some researchers argue that sometimes computerized tests appear to 
be either no more accurate or even less accurate than pencil and paper tests [33]. Whether the increased practicality of 
computerized administration, scoring and record keeping along with the ongoing research and validation of computerized 
instruments will be enough to offset their high cost remains to be seen. 
Closely related to the issue of cost is the question of whether the implementation of the latest and more 
advanced technology offers a significant advance. One could argue that the test designers’ enthusiasm about 
technological progress has led them to adopt new technologies as they emerge without stopping to think if that level of 
technology is really necessary or indeed represents an actual step forward in testing. Researchers have recently begun to 
re-evaluate even those technologies that were universally considered advantageous. A good example is touch-screens 
which are often praised as an easy and intuitive method of response [34] but have also been criticized for being less 
sensitive in simple and choice reaction time tasks and for inducing muscle fatigue in older adults. Such questions have 
started to appear only lately as technological progress has accelerated to an impressive pace. It is often argued that the 
lower cost and increased accessibility offered by the use of a standard PC outweighs the advantages offered by more 
advanced technological solutions [35]. A critical attitude towards technology and a re-evaluation of the suitability of 
various technological offerings could lead to better use of the available resources while dealing with the issue of cost to 
some extent. 
In conclusion, we would like to say a few words about acceptability and future impact of these technologies in 
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clinical practice: If we want them to be successfully integrated and used in clinical routine, the perceived benefits for the 
end-user, must be stronger present than perceived efforts to use the technology, this increases motivation which is an 
important factor and the key to acceptability. The technology has to be easy to use and should not interfere too much with 
daily life activities, should be not too intrusive. Clinician who uses the technology needs to take the time and the effort to 
explain to the patients the possible benefits of using a device, explain why are using it and what is it measuring. So the 
device alone is useless, and it is useful to underline the Importance of personal social interaction between the patient, the 
clinican and the technology (mixed approach). We have not to forget that there is a need for immediate 
feedback/visualization of the recorded data and measurements – enhance feeling of safety. In order to develop a 
technology that is successfully used afterwards, we need a maximum of end-user involvement, which means the clinican 
and the patients should be Involved in the design from the beginning on.  Finally, monitoring by sensors is only beneficial 
if it is followed by an intervention/prompting/support to the user. 
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Abstract 
Objective: Cleft lip and palate (CLP) is comprised within the wide range of congenital deformities of the maxillofacial region with 
an overall incidence on the increase from 1:1000 to 1:700 live births thus being the most common congenital birth error. Failure 
of the lateral and medial nasal processes to fuse with the anterior extension of maxillary processes and of the palatal shelves 
between the 4
th
 and 8
th
 gestational week results in cleft lip and palate.  Clefts include different types with variable severity, 
confirming the complexity and unpredictable expression of cleft modality and have a multifactorial aetiology. Functional 
impairment, aesthetic disturbances and psychosocial effects are common sequalae in patients with cleft lip and palate. The main 
long-term morbidity of this condition may include dysfunctional speech, impaired hearing and communication, as well as dental 
problems. These complications are followed by unfavourable surgical outcome and aesthetic appearance, which all seem to 
affect this group of patients significantly and have an impact significantly both quality of life and healthcare. Treatment 
requirements of cleft patients are multifactorial and a multi-disciplinary approach and intervention at multiple levels is necessary. 
Yet, in this country, resources available to parents and consistent publicity given to this issue and its treatment are still 
inadequate in spite of the introduction of “Centres of Excellence” and Unified Hospitalization Coding or DRG equivalents to 
optimize health management. The multi-disciplinary approach to cleft management has been a reality for over a century while 
cleft treatment protocols are still being evaluated in order to optimise standards of cleft care. According to relevant guidelines 
primary surgical management of lip and palate defects is performed during the first 3 to 9 months of life. Secondary operations in 
the form of revisional lip and nose procedures are performed at later stages aiming with an aesthetically improved outcome. 
Indications for surgery include widened scars, lip contour deformities, shortened lips, poorly defined and flattened nasal tip, short 
columella and irregularities of the nostrils (narrow or high-riding) and cartilages. Wound dehiscence, contractures, vermilion 
notching, white roll malalignment and orovestibular fistulas are possible unfavourable results after cleft lip repair. The 
psychological status of children and adults with repaired cleft lip and palate has been the subject of extensive research 
especially regarding the way of their evaluation facial appearance, satisfaction and need for secondary corrective surgical 
procedures in the hope of increasing their self-esteem and self-confidence. Conclusion: The aim of this study was to assess 
secondary CLP deformity management in an accredited present-day tertiary hospital facility with an existing infrastructure of a 
specialist teams however not formed in a multidisciplinary group. Equally, to answer questions of specific operation indications 
and choice as related to prior surgeries, hospitalization time and cost, provision of adequate preoperative information, 
correlation between paediatric and plastic surgeons and effect of post-plastic surgical care on patients’ health and well-being. It 
also aims at presenting, beyond our current primary cleft lip and palate repair approach, appropriate indications and timing of 
secondary repair and achieved results. 
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Abstract 
Objective: The aim of this retrospective study was to evaluate role of 
18
F-DOPA PET/CT and 
131
I-MIBG planar scintigraphy in 
patients with pheochromocytoma. Methods: The patients with diagnosis of pheochromocytoma based on radiological and 
biochemical markers were retrospectively selected for the study. These patients had undergone both 
131
I-MIBG scintigraphy and 
18
F-DOPA PET/CT. The imaging findings were compared to patient histopathology reports, biochemical markers and clinical 
follow up whenever available to establish the diagnosis. Results: 
131
I-MIBG showed a sensitivity of 68% and specificity of 100%. 
18
F-DOPA PET/CT showed a sensitivity of 82% and specificity of 100%. 
18
F-DOPA was better at localizing and finding more no 
of lesions as compared to 
131
I-MIBG scintigraphy. 
18
F–DOPA also is a better study in evaluation of paragangliomas. Conclusions: 
18
F-DOPA PET/CT seems to be a better modality in comparison to 
131
I-MIBG scintigraphy in the evaluation of 
pheochromocytoma/paraganglioma. At this point both these tracers seem to have mutually additive role in these patients and 
essential investigations with diagnosis and follow-up of this disease. 
 
 
HJNM 2015; 18(Suppl1); 141                                                                Published on line: 12 December 2015 
 
 
 
 
 
 
 
 
 
 
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 142 
 
 
 
 
 
 
In-111 polyclonal HIG identifies patients but not atherosclerotic lesions 
at risk - a 5 years follow-up 
 
Robert Berent
1
 MD, Johann Auer
2
 MD, Susanne Granegger
3
, Helmut Sinzinger
3
 MD, PhD 
 
 
1. HerzReha Bad Ischl, Center for Cardiovascular Rehabilitation, Bad Ischl, Austria, 2. Department of Internal 
Medicine, Hospital Braunau/Inn, Austria, 3. Isotopix, Institute for Nuclear Medicine, Vienna, Austria 
 
 
Correspondence adress: 
Professor Helmut Sinzinger,  
Isotopix, Institute for Nuclear Medicine,  
Vienna, Austria,  
Email: helmut.sinzinger@meduniwien.ac.at 
 
 
 
Abstract 
 
There is a strong need for non-invasive detection of human atherosclerotic lesions. One of the radioisotopic approaches using 
Indium-111-HIG has been shown to accumulate in oxidized LDL-rich foam cells and inflammatory vascular lesions. Earlier 
human studies in 200 patients, 100 with peripheral vascular disease and 100 with carotid artery disease comparing In-111-HIG 
scintigraphy with sonographic data revealed a high sensitivity (70%-77%) but a very low specificity (33%-41%). At this time we 
concluded the approach “not promising” for human studies. However, clinical follow-up over 5 years now shows that those 
patients with positive In-111-HIG scintigraphy exhibited a significantly higher vascular morbidity (P<0,01) and mortality (P<0,01), 
especially in the immediate follow-up period. Retrospective analysis discovered higher CRP and isoprostane (8-epi-
prostaglandin (PG) F2) levels in HIG-positive patients at the time of scintigraphy. These findings indicate that In-111-HIG 
reflecting vascular lesions with a high inflammatory component, probably more prone to rupture, may identify a population at 
high vascular risk rather than a lesion at risk. The clinical impact of this finding should be assessed in prospective studies. 
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Abstract 
 
Diuretic nephrogram is important diagnostic tool in the postnatal follow-up of asymptomatic antenatally detected hydronephrosis 
(HN). In the last decades, two quantitative indices of renal excretion, output efficiency and the residual kidney counts normalized 
to the 1-2min counts (normalized residual activity, NORA) have been proposed, that enhance the accuracy of technique to 
detect kidneys with obstruction. Unfortunately, in many nuclear medicine departments in developing countries the obsolete 
computer systems do not give the opportunity of sophisticated analysis of nephrogram. Almost a decade ago, the Nuclear 
Medicine Section of the International Atomic Energy Agency (IAEA) has developed non-commercial software for nephrogram 
processing on a simple p-computer, which allows access to the developments in this field. However, till now, the software has 
not been widely implemented in the nuclear medicine institutions in developing countries. Furthermore, the accuracy of 
numerical outputs of the software has not been assessed in comparison with commercial software. The aims of this study in 
children were: a) to calculate, by means of the International Atomic Energy Agency (IAEA) software, the values of the 
technetium-99m mercapto-acetyl-triglycine (
99m
Tc MAG3) parameters in three categories of kidneys: normal kidneys, obstructed 
kidneys and hypotonic unobstructed kidneys and b) to assess the accuracy of the obtained numerical parameters by comparing 
with the values published by other authors. Investigation was carried out on a sample of 62 children: 43 boys and 19 girls 
(median age: 16 months) with antenatally detected HN attributed to pelviureteric junction (PUJ) stenosis. Neither of kidneys had 
undergone pyeloplasty prior to our investigation. 130 nephrogram curves were analyzed. 22-minutes acquisition with 132 10sec 
images was applied. Furosemide was administered after 2min (F+2). Post-void static image was acquired at 60min. Two 
observers analyzed each study and classified kidneys into three categories. Group 1: 84 kidneys contralateral to hydronephrotic 
kidney, without structural abnormality on previous diagnostics; Group 2: 30 hypotonic non-obstructed kidneys; Group 3: 16 
obstructed kidneys. Parameters analyzed were: output efficiency (OE), residual kidney counts at 20min normalized to the 1-2min 
counts (NORA20) and residual kidney counts on post-micturition acquisition normalized to the 1-2min counts (NORAPM). Results 
were presented as mean±SD. For group 1 they were: OE: 95±1.5%; NORA20: 0.25±0.06; NORAPM: 0.02±0.007. Results for 
group 2 were: OE: 87±7.8%; NORA20: 0.57±0.19; NORAPM: 0.03±0.02. For group 3: OE: 56±9.6%; NORA20: 2.16±0.33; 
NORAPM: 0.27±0.13. Linear regression analysis showed significant inverse linear correlation between NORA20 and ROE20 (R=-
0.982; y=99.6–21.1x) at 0.01 level. ROC analysis revealed cutoff values of predicting obstruction at 71%, 1.62 and 0.11 for OE, 
NORA20 and NORAPM, respectively. Conclusion: We have calculated in children by means of the IAEA software the values of 
three advanced parameters of the 
99m
Tc MAG3 F+2 diuresis nephrogram for normal kidneys, hypotonic non-obstructed and 
obstructed kidneys. The overall results provided evidence of excellent agreement of obtained results with previously reported 
values of the quantitative parameters of renal washout. The parameters of IAEA software has been shown to be reliable in 
assessing kidney drainage. The nuclear medicine section of the IAEA should be encouraged to produce final version of the 
software and to release it through IAEA Web site. 
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Abstract 
 
The 2013-5 global outbreak of Ebolavirus disease brought to sharp focus the need for diagnostic capacity to be equitably 
available on a global scale: from the most under-developed areas of resource-limited countries in West Africa to high volume 
international travel hubs in Europe and the USA. Quick detection of the causal agent of disease is pivotal to containment, 
contact tracing and clinical action to protect healthcare workers, communities and patients. 
      Nucleic acid testing (NAT) by real time reverse transcription quantitative polymerase chain reaction (RT-PCR) has 
emerged as the preferred method for reliable patient status confirmation. Presently, this is served through advanced clinical 
molecular laboratory testing in a <8hr manual process that requires 3.5ml venous blood samples. To meet the demand in West 
Africa, this has necessitated large-scale mobile laboratory and volunteer biomedical scientist deployment: a solution that has 
proven eventually adequate, albeit temporary against future re-emergence of this and other haemorrhagic fever disease agents 
prevalent in the region.  
      The EbolaCheck consortium was formed in August 2014 to address the need for delivering NAT at the point of care. 
We have developed a novel platform technology that can QUantitatively, RAPidly IDentify (QuRapID) known RNA or DNA 
targets in viruses, bacteria, or eukaryotic cells directly in crude biofluids, including whole blood, in under 40min using a 5 
microliter sample. The portable, battery-operated system lacks microfluidics, pumps or other sensitive/high cost parts making it 
suitable for the environmental and economic challenges of resource-limited countries.  The simple, safe, 5-step sample-to-
answer process requires minimal training and informs frontline healthcare workers of diagnostic status, whilst reporting remotely 
epidemiologically relevant results. Data on biosafety level 2 surrogate Ebolavirus templates presented in encapsulated or 
enveloped viruses indicate performance comparable to clinical laboratory testing and utility beyond filoviruses. Emerging 
performance data on live Ebolavirus, non-human primate disease model and patient samples, as well as future development 
plans will be discussed. 
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Abstract 
 
The Island of Crete was the place where the use of herbal medicine has its roots since the Bronze Age period. Although, the 
consumption of aromatic plants as component in curing common diseases is still on population’s practices, a new interest was 
appeared on the basis of studies with a focus on illness behavior as a mutual collaboration between the University of Crete and 
the University of Leiden, The Netherlands. The antioxidant activity of certain Cretan plants has been documented and it has 
been shown and reported that herbal extracts are possible to decrease lipid per oxidation in cultured lung cells exposed to iron 
or ozon. The biological effects and bioactivity of essential oils as well as their antibacterial properties have been previously 
discussed in the literature. However, it was the first attempt in Europe when a double blind randomized controlled trial examined 
the effectiveness of an essential-oil extract of three Cretan aromatic plants (Origanum Dictamnus, Coridothymus Capitatus, 
Salvia Friticosa) designed and implemented in rural Crete on patients with upper respiratory tract infection. Descriptive 
differences were recently reported in favorable direction especially in the virus-positive population, while these results guide at 
the moment a series of actions for further research and discussion on the potentialities in the therapeutic medicine. An over-the-
counter drug under the name of “Cretan Iama” and as soft-gel capsules has recently circulated in Greece by the Olvos Science 
SA. A recent joint attempt (Clinic of Social and Family Medicine and Department of Experimental Endocrinology at the School of 
Medicine, University of Crete) under the support of the National Strategic Reference Framework Program focused on the 
effectiveness of functional extract of Mentha Spicata encapsulated in yogurt with honey on lipids profile of health patients in rural 
Crete. The first reported results of a cross-over study which was designed and implemented recently were in a favorite direction 
and it was in agreement with the animal based study that was carried out in the frame of this project. In conclusion, the two first 
studies on the Cretan medicinal and aromatic plants support the potentialities of the use of Ethno botanical methodology to 
move the needle of innovation on viral infections and lipids metabolism. 
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Abstract 
 
Objective: The quantification of the morphology of the parafoveal capillary network (PCN) in fluorescein angiography (FA) 
images using a novel semi-automated computerized method. Material and Methods: Using the MatLab R2011 a software we 
developed an algorithm that detects automatically the parafoveal capillary bed and its branch points as depicted in FA images 
creating simultaneously an one-pixel-wide skeleton of it. The detection process starts after delineating manually the foveal 
avascular zone in a cropped 1500μm*1500μm subimage resulting from the original FA image. Thereafter the algorithm 
calculates the capillary density and the branch points in a circle area with 1000μm radius. The method was also applied on FA 
images from subjects without diabetes mellitus, diabetics without diabetic retinopathy (DR) signs, patients with non-proliferative 
DR and patients with proliferative DR in order to assess the PCN morphology metrics for the studied groups. Results: The PCN 
density and the parafoveal capillary branch points were estimated for the mentioned subject groups and any significant 
differences among them were assessed as well. Conclusions: The described method could serve as a potential tool for the 
diagnosis and monitoring of PCN diseases and subclinical abnormalities. The assessed metrics reflect the capillary 
abnormalities in the central 1000μm area across different DR stages.  
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Abstract 
 
Objective: Fetuin-A is an acidic glycoprotein produced in the liver, as an inhibitor for cysteine protease. Its gene is founded in 
chromosome 3 (3q27). It is involved in various physiological and pathological conditions. These include vascular decalcification, 
bone metabolism, insulin resistance, protease function control, neurological illnesses and multiplication of breast cancer cells. 
Vascular calcifications predict cardiovascular disease which can be a major cause of death. So, fetuin-A is a potent circulating 
calcification inhibitor. Studies on individuals with clinical cardiovascular disease supported that lower levels of fetuine-A are 
released with coronary artery circulation (CAC) and the function of the heart valve. Our aim was to evaluate fetuin-A values of 
the patients with coronary artery disease, as a prognostic factor of the disease, in correlation with SPET myocardium 
scintigraphy. Patients and Methods: We studied 40 patients, 25 male and 15 female, with a mean age 48±8 years (range 36 to 
69), with coronary heart disease. All were subjected to myocardium scintigraphy, in the Nuclear Medicine Department of 
University Hospital of Alexandroupolis. Simultaneously, blood samples were drawn for the determination of fetuin-A. Serum 
fetuin-A levels were measured by a commercially available sandwich ELISA (Epitope Diagnostics, Inc., San Diego, CA). 
Results: The average values of fetuin-A range between 140-297mg/L, as it is derived from the current bibliography and our 
laboratory tests. In normal individuals, pathological values were considered to be under 140mg/L. Twenty five patients with 
positive SPET imaging for myocardium necrosis (scars) had  low fetuin values (45-148mg/ L), 10 of them passing away within 6 
months, while the rest of them were showing an encumbered clinical condition (P<0.005). Ten patients with reversible ischemia 
showed relatively low values (125-302mg/L) (P<0.005). Five patients with a normal myocardiac scintigraphic imaging showed 
normal values of fetuin-A (165-508mg/L) (P<0.005). Conclusions: Patients with myocardium necrosis demonstrated very low 
values of fetuin. Patients with ischemia show low amounts while patients with negative Scintigraphy for ischemia showed normal 
results of fetuin. The 10 patients that passed away in 6 months showed very low amounts of fetuin. Fetuin-A is supported to be a 
reliable prognostic factor in monitoring patients with coronary heart disease. 
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Abstract 
 
Objective: The burden of cardiac disease in childhood is unknown. It will be a sum of 1% of living births in  the general 
population, suffering from Congenital Heart Disease (CHD) + approximately 2.5% of the general population suffering from 
bicuspid aortic valve diseases + an unknown higher prevalence of acquired  diseases. Cardiomyopathies, arrhythmias - sudden 
cardiac death (SCD), rheumatic heard disease, hypertension and accelerating atherosclerosis are among the most frequent. 
Adding on, genetic syndromes including cardiac defects, endocarditis and myocarditis we can address a large pediatric 
population worldwide, suffering from heart disease. Diagnosis and treatment of these diseases are not afforded in many 
countries worldwide due to luck of human and material resources. The aim of this paper is to describe how some of the above 
mentioned diseases can be either early detected or prevented. The working Group “Cardiovascular Prevention” of the 
Association of European Pediatric and Congenital Cardiology (AEPC) focused on some forms of them since its formation in 
2011. These areas are: 1) some forms of critical CHD, 2) sudden cardiac death linked to sport activities and 3) detecting- 
preventing cardio vascular diseases CVD in the young. Methods-Populations: Measurements of pre and post ductal saturation of 
oxygen using pulse oximeters, after the first day from birth, can early and cheaply detect critical Ductal Arteriosus dependent 
pulmonary or systemic and cyanotic CHD, saving lives and decreasing significantly the cost of medical care. This screening test 
can be applied to all neonates as late as possible after their birth and before released to their homes. A combination of detailed 
medical history, physical examination and 12 lead ECG, during a pre-participation in sport activities medical screening test can   
prevent SCD, related to a variety of nosology. This combined screening test can be applied to all children before they are 
exposed to school or leisure sport activities. Screening to early detect and treating existent risk factors (RF) for CVD as well as 
preventing obesity and hypertension, contributes in lowering the burden of CVD. Specific screening tests as laboratory 
measurements of lipids, fasting glucose or regular measurements of Blood Pressure and waist to hip ratio in children with a 
family history of CVD or other co-morbidity that provokes accelerating atherosclerosis must be done on a regular basis. Results: 
Since 2010, four European studies reporting the test accuracy of routine pulse oximetry screening, in over 150.000 babies, have 
delivered new data.  A systematic review and meta-analysis of 230.000 screened babies, reported high specificity, moderate 
sensitivity and a low false-positive rate. Routine screening for critical CHD using pulse oximetry is being increasingly supported 
and was added to the recommended uniform screening panel in the USA in 2011. Evaluating children with CHD before their 
involvement in sport activities, so a clear view in what they can and what they can’t to is vital for their safety.  For children 
involved in competitive or leisure sport activities, an initial evaluation and a yearly F/U is vital. In cases of near SCD events an 
additional thorough investigation and appropriate management is required. Investigating the severity of the existing RF and 
cooperating with Pediatricians in their treatment (e.g. heredity forms of hyperlipidemias, existing hypertension) of them is 
essential. Furthermore preventing acceleration of atherosclerosis in patients with: Diabetes Mellitus I, II, chronic renal disease, 
post Kawasaki disease, post heart transplantation patients, Cardio-Metabolic Syndrome patients, by eradicating RF primordially 
or by alternating them by opposing a healthy life style or by medicine treatment, has sown in many studies to post pone clinical 
events in adulthood. Discussion: As many studies have proved the role of preventive measures that can alternate the outcome 
of cardiac diseases in childhood. AEPC/Preventive Cardiology working group is in the process to publish in the near future 
guidelines on this topic. 
 
 
HJNM 2015; 18(Suppl1); 148                                                                Published on line: 12 December 2015 
 
www.nuclmed.gr                                                                                 Hell J Nucl Med Suppl, September-December 2015 149 
 
 
18F-FBPA as a tumor specific tracer of L-type amino acid transporter 1 
(LAT1): PET evaluation in tumor and inflammation compared to 18F-
FDG and 11C-methionine 
 
Tadashi Watabe
1,2
 MD, PhD, Jun Hatazawa
1,2
 MD, PhD 
 
1. Department of Nuclear Medicine and Tracer Kinetics, 2. PET Molecular Imaging Center, Osaka University 
Graduate School of Medicine, Japan 
 
 
Correspondence adress: 
Tadashi Watabe MD, PhD,  
2-2 Yamadaoka, Suita, Osaka 565-0871, 
JAPAN. 
Email: watabe@tracer.med.osaka-u.ac.jp 
 
 
 
Abstract 
 
Objective: 
18
F-FDG-PET is used worldwide for oncology patients. However, we sometimes encounter false positive cases of 
18
F-
FDG PET, such as moderate uptake in the inflammatory lesion, because 
18
F-FDG accumulates not only in the cancer cells but 
also in the inflammatory cells (macrophage, granulation tissue, etc). To overcome this limitation of 
18
F-FDG, we started to use 
(4-borono-2-[
18
F]fluoro-L-phenylalanine) 
18
F-FBPA, an artificial amino acid tracer which is focusing attention as a tumor specific 
PET tracer. Physiological accumulation of 
18
F-FBPA is limited in the kidney and urinary tract in humans, which enable preferable 
evaluation of uptake in the abdominal organs compared to 
11
C-methionine (
11
C-MET). The purpose of this study was to evaluate 
18
F-FBPA as a tumor specific tracer by in vitro cellular uptake analysis focusing on the selectivity of L-type amino acid 
transporter 1 (LAT1), which is specifically expressed in tumor cells, and in vivo PET analysis in rat xenograft and inflammation 
models compared to 
18
F-FDG and 
11
C-methionine. Subjects and Methods: Uptake inhibition and efflux experiments were 
performed in HEK293-LAT1 and LAT2 cells using cold BPA, cold 
18
F-FBPA, and hot 
18
F-FBPA to evaluate LAT affinity and 
transport capacity. Position emission tomography studies were performed in rat xenograft model of C6 glioma 2 weeks after the 
implantation (n=9, body weight=197±10.5g) and subcutaneous inflammation model 4 days after the injection of turpentine oil 
(n=9, body weight=197±14.4g). Uptake on static PET images were compared among 
18
F-FBPA at 60-70min post injection, 
18
F-
FDG at 60-70min, and 
11
C-MET at 20-30min in the tumors and the inflammatory lesions by maximum standardized uptake value 
(SUVmax). Results: Cellular uptake analysis showed no significant difference in inhibitory effect and efflux of LAT1 between cold 
18
F-FBPA and cold BPA, suggesting the same affinity and transport capacity via LAT1. Uptake of 
18
F-FBPA via LAT1 was 
superior to LAT2 by the concentration dependent uptake analysis. Position emission tomography analysis using SUVmax 
showed significantly higher accumulation of 
18
F-FDG in the tumor and the inflammatory lesions (7.19±2.11 and 4.66±0.63, 
respectively) compared to 
18
F-FBPA (3.23±0.40 and 1.86±0.19, respectively) and 
11
C-MET (3.39±0.43 and 1.63±0.11, 
respectively) (P<0.01 by Tukey test). No significant difference was observed between 
18
F-FBPA and 
11
C-MET. Conclusions: 
18
F-
FBPA showed high selectivity of LAT1 by in vitro cellular uptake analysis, suggesting the potential as a tumor-specific substrate. 
In vivo PET analysis showed significantly lower uptake of 
18
F-FBPA and 
11
C-MET in the inflammatory lesions compared to 
18
F-
FDG, suggesting comparable utility of 
18
F-FBPA PET to 
11
C-MET PET in differentiating between the tumor and the inflammation. 
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Abstract 
 
Objective: Subarachnoid haemorrhage is responsible to a great extend for the death rate of patients who are hospitalised in 
intensive care units (ICU) with haemorrhage. The early detection of its severity plays an important role for the resulting health of 
the patients. Neurohormone Copeptin  is the C-end of pro-arginine vasopressin in plasma has been used as a prognostic marker 
in a number of various illnesses (acute myocardial infarction, heart and renal failure, acute dyspnoea, intracerebral and 
subarachnoid haemorrhage, ischaemic stroke, liver cirrhosis, acute pancreatitis). However, its prognostic value in subarachnoid 
haemorrhage has yet to be valued.  The aim of our study was to evaluate copeptin plasma values of patients with subarachnoid 
haemorrhage hospitalised in the ICU, as a prognostic factor for the severity of this disease. Patients and Methods: We studied 
32 patients, 21 male, 11 female, (average age 59±7 years), who were hospitalised in the ICU of Univ. Hospital of 
Alexandroupolis. Plasma Copeptin values were measured in the Nuclear Medicine Laboratory, with the Radioimmunoassay 
(RIA) method. The appropriate kit, from Phoenix Pharmaceuticals Inc. (USA), was used. Statistical Analysis: The x
2
 student test 
was used for statistical analysis. Results: The cut-off value  of copeptin ranged between 0.4-4.4 pmol/L. 19 patients showed 
gradual increase of copeptin values, (125-578 pmol/L), with a bad prognosis of the illness (P<0.005). Four of them with 
extremely high copeptin values died. Decrease of copeptin values for the rest 15 patients were correlated with the improvement 
of their clinical condition (P<0.005). Eleven patients appeared to have high values, followed by the gradual decrease by a range 
of 85-12pmol/L, and had a good prognosis of the condition. Two patients with normal values demonstrated to have a good 
clinical condition. Conclusion: Patients with a gradual increase of copeptin values showed to have bad prognosis of the disease. 
Four with extremely high copeptin values passed away, while patients with a gradual decrease or a normal amount of copeptin 
values had good prognosis. It is supported that copeptin values are a reliable prognostic factor in monitoring patients with 
intracranial haemorrhage. 
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Abstract 
Objective: Following radionuclide therapy, patients usually must remain hospitalised in special “restricted access area” 2-5 days, until radiation 
in their body drops below a certain level. During this period medical personnel can be faced with some challenges. Based on our previous 
experience, we used telemedicine approach as solution for it. We have developed comprehensive telemedicine system, which cons ists of three 
own developed hardware & software modules which are accessible remotely. Subjects and Methods: Challenge #1 Some of patients can 
experiencing serious complications related to radionuclide therapy or related to co-morbidities, if they have any of it. In some of those cases 
audio-visual contact with patients and follow-up their vital functions can be of high importance in case of patient needs urgent intervention. 
Solution #1 System for on-line remote monitoring of patients’ vital functions registered with bed side monitor and video surveillance of area 
which use patients during hospitalisation. This system is established by IP cameras and bedside patient monitor, equipped with appropriate 
network card and software. Using remote connection (LAN or internet), a physician can watch at personal computer or mobile phone the waves 
and vital signs patterns from the bedside monitor, as well as live video from surveillance cameras. It provides prompt intervention in case of 
emergency. Challenge #2 Having in mind the overall costs of radionuclide therapy and patients hospital stay on the one hand, and limited 
capacity of the hospital premises for radionuclide therapy, on the other, it is of high importance to estimate as early as possible the time period 
after which the radiation in a patient's body will drop below the limit imposed by the law. Solution #2 On-line remote radiation monitoring system, 
which measures the radiation exposure rate by means of a pancake probe, which is connected to a PTZ (Pan-tilt-zoom) device and DVR (Digital 
video recorder). Those devices enable precise positioning of the detector on target region of the patient's body. The positioning of the detector 
can be visually controlled by a micro camera, placed at the center of detector's plane. Furthermore, there are three LASER po inters placed 
around the detector in order to mark the area where it is directed. In addition, two ultrasound sensors placed on the edge of the detector holder 
in order to estimate the exact distance between the probe and the patient’s body. All those devices are controlled by the DVR . The data 
collected by the detector are acquired and processed by a PC, using customized hardware/software system developed by Italian Theremino
R
 
group. Using remote connection, a physician can watch on-line radiation exposure rate in any time and can use commands of PTZ and DVR 
device for proper positioning of probe during measurement and control it by micro camera, LASER pointers and US sensors. Physician demands 
from the patients to take the same position for 5 minutes on each hour, during first 10 hours. Those data we use as reference points for further 
processing by our software. Based on two exponential matematical model, our software estimates the whole process of elimination of 
radioactivity from the patient’s body, using reference points collected during the first day after  radionuclide therapy. Based on that, physician can 
predict (on first day after therapy!) when patient will be able to leave the restricted access area“. Challenge #3 Despite strict instructions given to 
them by physician and nurse before administration of radionuclide therapy, some patients sometimes try to leave “restricted access area”. 
Solution #3 We have developed a system which continuously monitors the corridor which a patient must use in case of an attempt to leave the 
“restricted access area”. Our system consists of a survey meter equipped with pancake probe directed towards the corridor. The survey meter is 
connected to a trigger circuit which gives signal in the case when the measeured count rate exceeds previously adjusted value . Trigger circuit is 
connected to the programmable siren, blinking light, alarm device unit with SIM card and IP surveillance camera. On the siren  we previously 
recorded the voice alarm. In the case when the system is triggered, the patient will hear warning message and see blinking light. When the alarm 
device is triggered it will call responsible physician and nurse on mobile phone and IP camera simultaneously records this event. System also 
sending via email appropriate data about each event, when it happens. Conclusion: From our experience gained over the past 4 years, our 
telemonitoring system dedicated for patients receiving radionuclide therapy ensures a high level of safety for the patient and medical staff.  
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Abstract 
Alzheimer’s disease is the most common cause of irreversible dementia, affecting mostly the presenile and senile age, shaping 
a tragic profile in the epilogue of the life of the suffering people. Due to the severity and the social impact of the disease an 
ongoing research activity is in climax nowadays, associated with many legal, social, ethical, humanitarian, philosophical and 
economic considerations. From the neuropathological point of view the disease is characterized by dendritic pathology, loss of 
synapses and dendritic spines, affecting mostly selective neuronal networks of critical importance for memory and cognition, 
such as the basal forebrain cholinergic system, the medial temporal regions, the hippocampus and many neocortical association 
areas. Tau pathology consisted of intracellular accumulation of neuroﬁbrillary tangles of hyperphosphorilated tau protein and 
accumulation of Aβ-peptide’s deposits, deﬁned as neuritic plaques, are the principal neuropathological diagnostic criteria of the 
disease. The neurotoxic properties of the oligomerics of the Aβ-peptide and tau mediated neurodegeneration are among the 
main causative factors of impaired synaptic plasticity, neuronal loss, dendritic alterations and tremendous synaptic loss. The 
gradual degeneration of the organelles, particularly mitochondria, smooth endoplasmic reticulum and Golgi apparatus, 
visualized clearly by electron microscopy (EM), emphasize the importance of the oxidative stress and amyloid toxicity in the 
pathogenetic cascade of the disease. The vascular factor may be an important component of the whole spectrum of the 
pathogenesis of AD. It is of substantial importance the concept that the structural alterations of the brain capillaries, may 
contribute in the pathology of AD, given that the disruption of the BBB may induce exacerbation of AD pathology, by promoting 
inflammation around the blood capillaries and in the neuropile space diffusely. From the morphological point of view, silver 
impregnation techniques revealed a marked tortuosity of the capillaries in early cases of AD. In addition, the distance between 
two branch points is longer in capillaries of AD brains, whereas the branch point density as well as the ratio of the branch point 
density to astrocytic density is substantially decreased in AD in comparison with age matched normal controls. EM revealed, that 
the most frequent morphological alterations of the brain capillaries in AD consist of thickness, splitting and duplication of the 
basement membrane, reduction of the length of tight junctions, decrease of the number of tight junctions per vessel length, 
associated as a rule, with morphological alterations of the mitochondria of the endothelial cells, the pericytes and the 
perivascular astrocytic processes. The number of the pinocytotic vesicles is substantially increase in the endothelium of the 
brain capillaries in AD in comparison with age matched normal controls. Endothelial cells play a very important role in the 
transport systems in the brain. Subsequently, the dysfunction of the endothelial cells and the disruption of the BBB may induce 
serious impairment in the transport system. The dysfunction of the brain capillaries may result in releasing neurotoxic factors, 
such as thrombin, pro-inflammatory cytokines, nitric oxide and leukocyte adhesion molecules, and in abnormal regulation of Aβ-
peptide homeostasis in the brain. The impairment of the brain capillaries in structures of the brain, which are crucial for the 
homeostatic equilibrium, such as the hypothalamic nuclei, may induce autonomic dysfunction, which usually occur in the 
advanced stages of AD, affecting dramatically the viability of the patients. Degeneration of the pericytes is also observed 
emphasizing even more the importance of the vascular factor in AD.  Pericytes may serve as integrators, coordinators and 
effectors of blood-brain barrier structure and maintenance, and play a key role in microvascular stability, capillary density and 
angiogenesis. The correlation between AD pathology and vascular pathology, at the level of brain capillaries and BBB, raises 
the rational question, whether the efficient treatment of the vascular factor might be beneficial for the patients who suffer from 
AD. It is reasonable that any protection of the brain capillaries at the initial stages of the disease might contribute in the 
abbreviation of the long chain of pathological alteration, which occur following the disruption of the BBB, which serves as the 
essential interface between the vascular system and the brain. 
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Abstract 
 
Objective: Diabetic nephropathy (DN) is a clinical syndrome characterized by persistent albuminuria, increasing arterial blood 
pressure and progressive decline in glomerular filtration rate (GFR). When persistent albuminuria is established, 
antihypertensive treatment becomes most important factor in slowing the progression of diabetic glomerulopathy. Aim of this 
study was to examine if renoprotective response to losartan therapy, in patients with diabetic nephropathy, depends on 1166 
A/C gene polymorphism for its target receptor, angiotensin II type 1 receptor (AT1R). Subjects and Methods: The study included 
35 patients with diabetes mellitus type 1 and high urinary albumin excretion rate (>30mg/24h) genotyped for the 1166 A/C gene 
polymorphism for the AT1R. The participants were segregated into three genotype groups according to combinations of A or C 
allele: AA-16, AC-15 and CC-4 patients. The patients received losartan 50mg daily for 4 weeks, following 100mg daily for 8 
weeks. At baseline and after losartan therapy period, blood pressure, GFR (Gates method) and filtration fraction (FF) were 
calculated. FF was calculated by dividing GFR by ERPF (Schlegels method). Results: GFR remained unchanged in all genotype 
groups. FF was significantly reduced from baseline by 0.018±0.024 (P=0.012) only in the AC group. In the AA genotype FF was 
reduced from baseline by 0.017±0.03 (P=0.052) and in the CC group by 0.01±0.008 (P=0.092). In the AA group, systolic blood 
pressure declined from 136±24mmHg at baseline, to an average of 121±18mmHg at the end of the study (P=0.001). The AC 
group achieved reduction from 131±10mmHg at baseline to 115±7mmHg (P=0.001) during the investigation period. In the AA 
genotype group losartan reduced diastolic blood pressure from 86±13mmHg at baseline to 78±8mmHg (P=0.004), and in the AC 
genotype from 88±5mmHg at baseline to 11.7±5.6mmHg during the investigation period (P=0.001). In the CC genotype diastolic 
blood pressure reduction remained nonsignificant (P=0.066). Conclusion: The results of our small sample size study provide the 
evidence that 1166 A/C AT1R polymorphism could be associated with the renoprotective response to losartan therapy. 
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Abstract 
 
Objective: The term Diabetic kidney disease (DKD) refers to any disease of the kidney that is a result of long-term 
hyperglycemia caused either by diabetes mellitus type 1 (DT1) or type 2 (DT2). When DKD coexists with macro albuminuria or 
proteinuria the condition is called diabetic nephropathy. DKD is the primary cause of renal failure since it is responsible for the 
44% of new cases presented in the U.S.A. in 2008. Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase and is used as a 
treatment for diabetes since 2006. Through the inhibition of the enzyme’s action sitagliptin prevents the degradation of GLP-1 
which is an endogenous peptide with significant hypoglycemic actions, particularly postprandial. The proven hypoglycemic 
actions of sitagliptin led the researchers to further study the possible effects sitagliptin may have on the complications of 
diabetes mellitus such as diabetic nephropathy. The purpose of the study is to examine the effect of sitagliptin on diabetic 
nephropathy using biochemical parameters for assessment. Methods: 27db/db mice were used in total. They were about 4 
weeks old. The mice were randomly divided into 3 groups each one consisting of 9 mice, the first 2 groups received sitagliptin 
treatment over a period of 32 weeks while the third did not receive any treatment. In the first group the mice received 200mg 
sitagliptin per Kg of body weight and in the second 10mg per Kg. At the end of the 32 weeks period the serum glucose, urea, 
creatinine, cholesterol, LDL, HDL, hsCRP and triglycerides as well as the urinary creatinine and microalbumin were measured in 
all 3 groups. Results: The first group (received 200mg/kg) in comparison to the third group (control group) exhibited a reduction 
in the biochemical parameters measured: glucose -12.35% (P=0.16), urea -17.18% (P=0.61), creatinine -0.81% (P=0.95 ), 
cholesterol -19.28% (P=0,09), HDL -12,25% (P=0.26), LDL -31.2% (P=0.25), triglycerides -13,9% (P=0.37), hsCRP -49.8% 
(P=0.06), microalbumin -37.8% (P<0.0001). Conclusion: The administration of sitagliptin reduces in a statistically significant 
manner the urinary microalbumin. In addition, hsCRP was greatly reduced but the reduction did not reach the required 
significance level. The other biochemical data presented a reduction which could not be considered as statistically significant. 
However, it should be mentioned that the exact mechanisms by which sitagliptin achieves this reduction in the biochemical 
parameters measured, except for the glucose reduction, remain unclear. Although it is suggested that the reduction of 
glucotoxicity due to sitagliptin treatment is the main reason for those results, the effects of sitagliptin on inflammation, protection 
of the endothelium and reduction of arterial blood pressure might play a facilitating role. 
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Abstract 
Objective: IgG4-related disease (IgG4-RD) is a systemic mass-forming fibro-inflammatory condition which can affect nearly 
every organ system [1]. Its pathophysiology remains incompletely understood, but affected tissues are characterized by a 
lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells which cause chronic inflammation, storiform fibrosis and phlebitis. 
These findings on histopathological specimens are considered the gold standard for the diagnosis [2]. Clinical signs and 
symptoms largely depend upon organ involvement which can be singular or multiple, synchronous or metachronous. The organs 
most frequently involved are the pancreas (autoimmune pancreatitis (AIP), salivary and lacrimal glands (Mickulicz disease and 
sclerosing sialadenitis), biliary tree (sclerosing cholangitis or cholecystitis), retroperitoneum (retroperitoneal fibrosis), aorta 
(periaortic fibrosis), kidneys (interstitial nephritis) and thyroid (Riedel thyroiditis) [3]. Presentation is mostly subacute and general 
symptoms such as weight loss, asthenia or fever are moderate, but more prevalent in multi-organ disease [4]. Lesions often 
mimic malignancy, but most respond well to steroid therapy. Conclusion: In this contribution we present a rare entity of IgG4-RD 
and discuss the utility of fluorine-18-fluorodeoxyglucose (
18
F-FDG) Positron emission tomography/computed tomography 
(PET/CT) in the diagnosis and treatment of this condition. 
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Presentation of the disease 
 
 35 year old Caucasian woman, G2P2, presented with vague right abdominal pain for over one month. The pain 
was most prominent when walking or moving and not linked with meals or defecation. The patient reported some 
fatigue although no weight loss, fever or night sweats were experienced. Apart from a recent episode of 
gastroenteritis her medical history included an episode of dyspepsia and an anal fissure bleeding. Family history 
noted colon carcinoma in her grandfather. At presentation the patient took acetaminophen pro re nata and oral 
contraceptives. Physical examination of the abdomen showed tenderness in the epigastric and right hypochondriac 
region. No mass was palpated. No signs of peritoneal irritation were present. Cardiopulmonary examination was normal. 
 
Investigations 
Laboratory analysis showed a C-reactive protein of 57.3mg/L (normal <5.0mg/L) and a mild leukocytosis 10,500/µL 
(normal <10,000/µL). Red blood cell and platelet counts were normal. Lactate dehydrogenase, liver and renal function 
tests were normal. Protein concentration was normal but protein electrophoresis showed hypoalbuminemia (48.6%, 
normal 55.8-66.1) and increased alpha 1 (5.6%, normal 2.9-4.9) and alpha 2 (15.8%, normal 7.1-11.8) globulin fractions. 
Abdominal ultrasound revealed a multilocular mass resembling necrotic lymph nodes in the right hemiabdomen. CT-scan 
confirmed a partly cystic mass in the mesenterium of the proximal colon transversum with local thickening of the colon 
wall and few swollen para-aortic lymph nodes. Because of the location and the patient’s age a lymphoma was ranked 
highest on the differential diagnostic list. Other diagnoses considered were metastasis of a gastro-intestinal malignancy, 
neuro-endocrine tumor, sarcoma, sarcoidosis or an infectious abscess. 
Gastroscopy and colonoscopy showed no abnormality. Subsequently a full body PET/CT scan (Discovery 
Lightspeed ST, General Electric Medical Systems, Milwaukee, Wisconsin, USA) was performed 1 hour after intravenous 
injection of 176MBq of 
18
F-FDG (Figure 1). Substantial tracer uptake was found in the mass in the ventral right abdominal 
area. No retroperitoneal lymph nodes were detected. A laparoscopic exploration with partial resection of the mass was 
scheduled.  
A 
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Figure 1. Axial slices through the midabdomen. PET with 18F-FDG (A and D), CT (B and E) and combined PET/CT (D and F), 
both at diagnosis (A, B, C) and 3 months later (D, E, F), after resection and glucocorticoid treatment. On the initial scan, an 
FDG-avid mesenteric mass (arrow) is seen to the right of the midline. On the later scan, the mass disappeared. 
  
Diagnosis and Treatment 
 
Histopathology of the tissue obtained was characterized by a dense lymphoplasmacytic infiltrate and diffuse storiform 
fibrosis (Figure 2). Staining of immunoglobulins showed up to 50 IgG4 cells per high power field and an IgG4/IgG cell 
ratio of 45%. These findings together with the clinical presentation, the biochemistry and the imaging results described 
the mass as an IgG4-related mesenteritis in accordance with the consensus statement of pathology for IgG4-RD [5]. 
 
Figure 2. Hematoxylin and eosin stained mesenterial tissue section (magnification 25X) characterized by paucity of fat cells, 
diffuse storiform fibrosis and dense infiltration by lymphocytes and plasma cells.  
One month after the initial presentation, C-reactive protein was back to normal levels of 2.7mg/L (normal 
<5.0mg/L). Screening for lupus anticoagulant, anti-cardiolipin antibodies, rheumatoid factor and anti-nuclear factor was 
negative. Eosinophils were 1% (normal 0-6%). Total protein count was normal, though with minimally raised 
gammaglobulin fraction of 15.5g/L (normal 7.0-15.0g/L). The IgG4 level was 155mg/L (normal 3-200mg/L). C3c and C4 
values were normal. Remarkably, three weeks after histopathological diagnosis, repeat ultrasound before initiating 
therapy could not distinguish the mass anymore. Nevertheless the abdominal pain was still present. Daily 
methylprednisolone 64mg was initiated. One month later MRI confirmed the remission of the mesenterial mass, though 
the abdominal discomfort was still present. Because of steroid intolerance (agitation, sweating, tremor) a tapering 
schedule was outlined. A repeat PET/CT scan one month later (50 minutes after intravenous injection of 178MBq 
18
F-
FDG) verified the remission. Abdominal discomfort was reduced to acceptable levels and biochemistry was normal. The 
patient will be followed up by biochemical and ultrasonic evaluation. 
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Discussion 
 
Up to a decade ago sclerosing mesenteritis was generally considered a rare, idiopathic fibro-inflammatory disease 
characterized by fat necrosis, fibrosis and chronic inflammation of the mesenterium [6]. Small bowel mesenterium was 
predominantly affected though cases of mesocolon and mesorectum involvement have been described [7]. Over the past 
few years sclerosing mesenteritis has been linked increasingly with IgG4-RD [8]. A retrospective analysis of 
histopathology specimens of seven patients diagnosed with sclerosing mesenteritis identified five patients meeting the 
diagnostic criteria of IgG4-RD [9]. Nevertheless sclerosing mesenteritis remains rare in the clinical spectrum of IgG4-RD; 
it is documented in about 1.6 percent of the IgG4-patients [10]. Commonly presenting symptoms are abdominal pain, 
bloating/distension, nausea and vomiting although a variety of gastro-intestinal and even extra-intestinal symptoms have 
been described [9].  
The vague and non-specific presentation of IgG4-RD can delay diagnosis and treatment and so cause damage 
to vital organ functions. Based on clinical suspicion, laboratory abnormalities and image findings a diagnostic IgG4-RD 
algorithm for non-specialists has been developed recently [11]. Clinical suspicion for IgG4-related disease should arise 
when a patient presents with a tumefactive lesion affecting at least 1 organ in combination with one or more of following 
laboratory findings: eosinophilia, elevated serum IgE levels, hypergammaglobulinemia or hypocomplementemia. Only a 
slight hypergammaglobulinemia was observed in our patient. Image confirmation of the lesion(s) justifies further 
exploration by serum IgG4 levels, flow cytometry and histopathology. The morphological finding of a lymphoplasmacytic 
infiltrate causing storiform fibrosis and phlebitis remains the corner stone to provide the definitive diagnosis. Elevated 
levels of IgG4 (>135mg/dL) in serum and raised IgG4+ cells (>10/high power field) or IgG4+/IgG+cell ratio (>40%) in 
immunohistochemical evaluation can be indicative but also appear in non-IgG4-RD conditions [11, 12]. Moreover, a 
substantial subset of patients with biopsy-proven IgG4-RD does not have elevated serum IgG4 concentrations [10, 13]. 
This makes high serum IgG4 concentrations neither adequately sensitive nor specific for diagnosis. In the patient 
described here, IgG4 was within the high normal range for the laboratory, although it was higher than cutoff of 135mg/dL 
[11]. 
The imaging techniques referred to in this diagnostic algorithm are ultrasound, X-ray or CT-scan. Current 
research, however, also describes multiple applications for 18F-FDG PET/CT in IgG4-RD [14-17].  
First, 
18
F-FDG PET/CT might be useful in assessing local disease extent and distant organ involvement. 
Approximately 60 percent of IgG4-RD patients have multi-organ involvement [3, 10, 18, 19]. One group used a criterion of 
FDG uptake equal to or higher than that in the liver for possible IgG4-lesions [16]. In the patient presented here, 
18
F-FDG 
PET/CT did not reveal additional disease locations, but in a prospective cohort study 
18
F-FDG PET/CT found more 
extensive organ involvement than originally determined by physical examination, ultrasound and CT in 25 out of 35 
patients; mostly in the aorta, lymph nodes and salivary glands. In that study, multi-organ involvement was present in 34 of 
the 35 patients and 9 out of 10 patients enrolled with single organ disease turned out to have multi-organ involvement 
[17]. A retrospective study found multi-organ involvement in 16 out of 19 non-treated patients [14]. In that study, 14 of 31 
patients showed the same number and sites of involvement on PET and other radiologic examinations. Eleven other 
patients had additional lesions on PET, again mainly in arteries, salivary glands and lymph nodes. Eight patients had 
lesions on radiological studies that were not distinguished on PET: a small area of pachymeningitis, pulmonary 
micronodules, involvement of the lacrimal glands, kidney lesions in 2 patients, pulmonary micronodules, and 
retroperitoneal fibrosis in 4 patients. These discrepancies have been ascribed either to limited spatial resolution, to 
nearby physiological uptake in the brain or kidney, or to inactive disease after treatment in 3 of the 4 instances of 
retroperitoneal fibrosis [20, 21]. So, 
18
F-FDG PET/CT is a sensitive technique for delineation of active disease locations in 
IgG4-RD. 
The clinical value of accurate determination of disease extent is twofold. Foremost, 
18
F-FDG PET/CT may identify 
locations which are still asymptomatic but potentially can lead to severe complications. Timely medical treatment may 
then prevent these complications. Aortic involvement is one example [22]. In the prospective study on 35 patients, 
18
F-
FDG PET/CT uncovered asymptomatic aortic involvement in 8 patients. Furthermore, in the same study 
18
F-FDG PET/CT 
gave evidence of acute ureteral obstruction in 5 out of 12 patients with retroperitoneal fibrosis, allowing for stenting before 
irreversible kidney damage was present [17]. In the retrospective study, increased 
18
F-FDG accumulation was found in 31 
asymptomatic lesions in 17 out of 19 patients [14]. Additionally, staging at diagnosis may help in risk-stratification of the 
disease, since it is known that involvement of multiple organs is associated with an increased risk of relapse [23-26]. 
Secondly, image patterns on 
18
F-FDG PET/CT can contribute to the differential diagnosis with other inflammatory 
diseases or malignancies. From the prospective study on 35 patients it was determined that diffuse uptake in exocrine 
organs such as the pancreas, prostate gland or salivary gland is likely to be IgG4-related. Patchy hypermetabolic lesions 
seen in the retroperitoneal region, vascular wall, bile duct, lungs, liver or kidneys are also suspicious for IgG4-RD [17]. In 
the pancreas heterogeneous accumulation of the tracer and multiple localizations are suggestive for AIP, in which they 
were observed in 8 of 15 patients, rather than pancreatic cancer, in which they were present in only 1 patient out of 19. 
Hilar adenopathy was significantly more frequent in AIP (9 of 15 patients) than in pancreatic cancer (3 of 26 patients). 
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Concomitant uptake of 
18
F-FDG in the lacrimal gland, salivary gland, biliary duct, retroperitoneal space and prostate were 
seen exclusively in AIP [27]. 
Thirdly, 
18
F-FDG PET/CT can identify foci with maximal uptake to determine the ideal biopsy site for 
histopathological diagnosis, taking into account activity as seen on the PET and accessibility. In the prospective study 
mentioned above, findings on 
18
F-FDG PET/CT resulted in the selection of a more accessible lesion for biopsy in 7 
patients out of 35 patients [17]. 
A fourth application of 
18
F-FDG PET/CT is in monitoring treatment. At present no randomized clinical trials 
investigating treatment of IgG4-RD have been published. Several retrospective evaluations - mostly on autoimmune 
pancreatitis - report excellent results using glucocorticoids [18, 28, 29]. Accordingly, glucocorticoids are recommended as 
current first-line treatment for all IgG4-related diseases. This treatment strategy is recently confirmed by an international 
expert panel in research and clinical practice on IgG4-related disease [30]. There is no consensus on tapering regimes or 
maintenance therapy. Despite rapid clinical remission in most patients, relapse is not uncommon, though less observed in 
patients who received initial steroid treatment. In case of failure of steroid treatment, immunosuppressants (e.g. 
azathioprine, methotrexate, cyclophosphamide) and B cell depletion (e.g. rituximab) are used with varying success rates 
[31-35]. Spontaneous remission as in the present patient has been observed in up to 74% of patients with autoimmune 
pancreatitis, but no data for spontaneous remission in IgG4-mesenteritis were available [36]. 
For lack of a standardized method to qualify disease activity or response to treatment, treatment has been mainly 
guided by alterations in clinical, laboratory and image findings. 
18
F-FDG PET/CT may be used to evaluate treatment 
response [16, 25, 37]. The standardized uptake value (SUV) on 
18
F-FDG PET may serve as a semiquantitative guide to 
inflammatory activity [15]. In the retrospective study cited above, it was found that in 7 out of 12 patients, 
18
F-FDG uptake 
disappeared after 3 to 24 months of treatment; in 2 more patients treated with rituximab only, 
18
F-FDG uptake remained 
stable whilst IgG4 normalized. In 3 patients, some lesions improved while either new sites or increased uptake in previous 
sites were detected; 1 of these patients was finally diagnosed as Castleman's disease. It was concluded that in most 
cases a good correlation exists between 
18
F-FDG PET evolution and treatment response and disease activity [14]. In the 
prospective study, 29 patients underwent 
18
F-FDG PET/CT follow-up after 2 to 4 weeks steroid-based therapy (40 to 
50mg prednisone/day). Complete metabolic remission was observed in 21 of these patients whereas the others showed 
strong partial responses. IgG4 declined in only 31 of 35 patients and less dramatically than the FDG uptake [17]. 
Moreover, documenting this early response to glucocorticoids further confirms diagnosis and excludes malignancy.  
Fifthly, IgG4-RD may relapse [24, 26, 36]. In AIP, the relapse rate is reported be 10%-53% [38]. A role for 
18
F-
FDG PET/CT in surveillance for relapse may be envisaged, although it is not clear which would be the optimal timing or 
frequency [15, 20, 25, 37]. 
Previously, gallium-67 (
67
Ga) imaging has been described in IgG4-RD [39, 40]. It has been shown to correlate 
with activity of disease and with IgG4 levels [40]. Advantages of 
18
F-PET over 
67
Ga may include the more rapid imaging 
and better spatial resolution. In conclusion, IgG4-related disease is an increasingly recognized fibro-inflammatory 
disorder which can affect virtually any organ. Untreated it may lead to failure of vital organ functions. 
18
F-FDG PET/CT is 
able to assess disease extent both locally and in other organs. It may be helpful in the differential diagnosis with other 
inflammatory diseases or malignancy and can determine the ideal biopsy site for histopathological diagnosis. Finally it is 
useful to monitor treatment. We report a patient in whom the diagnosise of IgG4-related mesenteritis was established on 
the basis of histopathologic findings. In this patient, 
18
F-FDG PET/CT was used in diagnosis and treatment monitoring. 
This confirms that 
18
F-PET/CT can be a useful addition to current imaging techniques for IgG4-RD, also in rare 
presentations.  
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extracorporeal shock wave lithotripsy for ureteral stones? 
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Abstract 
Objective: Ureteroscopic lithotripsy (URS) and Extracorporeal shock wave lithotripsy (ESWL) are highly effective for the 
treatment of uretral lithiasis and remain the treatment option for the majority of patients for more than two decades. In the 
present study we aimed to evaluate the levels of serum tumor necrosis factor A (TNFa) and interleucin 6 (IL6) in patients 
undergoing ESWL and URS. Subjects and Methods: A total number of seventy patients were involved in our study. Thirty 
patients (17 males, 13 females), with a mean age of 43 had underwent ESWL and thirty patients (19 males, 11 females), with a 
mean age of 47 (range: 26-68) underwent URS lithotripsy. Ten healthy volunteers serving as the control group were enrolled in 
this study. Serum samples for TNF-a and IL-6 were obtained before URS and ESWL and after the procedure at 1, 24, and 48 
hours and at 2, 24, and 48 hours, respectively. The pre ESWL/URS and post ESWL/URS levels were compared and correlated 
with possible tissue damage. According to ESWL procedure we found that serumTNF-a levels were significantly increased after 
one hour (P<0,001) and after 24 hours (P=0.007). Furthermore, IL-6was significantly increased at 2 (P< 0,001), 24 and 48 hours 
post ESWL (P=0,003 and 0,002) respectively. For URS serum TNF-a levels were statistical significantly correlated 
preoperatively with one hour (P=0,0083) and 48 hours (P<0,001) after URS and IL-6 with 2 and 24 hours (P<0,001). In 3 
patients for URS and 1 for ESWL we observed post procedure fever (>38.5C0). All those patients had preoperatively high values 
of TNF-a and Il-6 that increased at 1 and 2-hours respectively. In conclusion, high pre ESWL/URS levels of serum TNF-a and IL-
6 may indicate a predisposition for post ESWL/URS inflammation and infection following URS lithotripsy or ESWL procedure. 
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